id	sid	tid	token	lemma	pos
ijassa-493	1	1	2017	2017	NUM
ijassa-493	1	2	г	г	PROPN
ijassa-493	1	3	adv	adv	PROPN
ijassa-493	1	4	syst	syst	PROPN
ijassa-493	1	5	sci	sci	PROPN
ijassa-493	1	6	appl	appl	PROPN
ijassa-493	1	7	2018	2018	NUM
ijassa-493	1	8	;	;	PUNCT
ijassa-493	1	9	1	1	NUM
ijassa-493	1	10	;	;	PUNCT
ijassa-493	1	11	59	59	NUM
ijassa-493	1	12	-	-	SYM
ijassa-493	1	13	84	84	NUM
ijassa-493	1	14	published	publish	VERB
ijassa-493	1	15	online	online	ADV
ijassa-493	1	16	at	at	ADP
ijassa-493	1	17	http://ijassa.ipu.ru	http://ijassa.ipu.ru	ADV
ijassa-493	1	18	.	.	PUNCT
ijassa-493	2	1	analytical	analytical	ADJ
ijassa-493	2	2	study	study	NOUN
ijassa-493	2	3	of	of	ADP
ijassa-493	2	4	the	the	DET
ijassa-493	2	5	antitumor	antitumor	PROPN
ijassa-493	2	6	viral	viral	ADJ
ijassa-493	2	7	vaccine	vaccine	NOUN
ijassa-493	2	8	introduction	introduction	NOUN
ijassa-493	2	9	regimens	regimen	NOUN
ijassa-493	2	10	based	base	VERB
ijassa-493	2	11	on	on	ADP
ijassa-493	2	12	mathematical	mathematical	ADJ
ijassa-493	2	13	modeling	modeling	PROPN
ijassa-493	2	14	nina	nina	PROPN
ijassa-493	2	15	a.	a.	PROPN
ijassa-493	2	16	babushkina1	babushkina1	PROPN
ijassa-493	2	17	,	,	PUNCT
ijassa-493	2	18	ekaterina	ekaterina	PROPN
ijassa-493	2	19	a.	a.	PROPN
ijassa-493	2	20	kuzina1	kuzina1	PROPN
ijassa-493	2	21	1	1	X
ijassa-493	2	22	)	)	PUNCT
ijassa-493	2	23	v.a	v.a	PROPN
ijassa-493	2	24	.	.	PROPN
ijassa-493	2	25	trapeznikov	trapeznikov	PROPN
ijassa-493	2	26	institute	institute	PROPN
ijassa-493	2	27	of	of	ADP
ijassa-493	2	28	control	control	PROPN
ijassa-493	2	29	sciences	sciences	PROPN
ijassa-493	2	30	of	of	ADP
ijassa-493	2	31	russian	russian	ADJ
ijassa-493	2	32	academy	academy	PROPN
ijassa-493	2	33	of	of	ADP
ijassa-493	2	34	sciences	sciences	PROPN
ijassa-493	2	35	,	,	PUNCT
ijassa-493	2	36	117997	117997	NUM
ijassa-493	2	37	,	,	PUNCT
ijassa-493	2	38	profsoyuznaya	profsoyuznaya	NOUN
ijassa-493	2	39	street	street	PROPN
ijassa-493	2	40	,	,	PUNCT
ijassa-493	2	41	65	65	NUM
ijassa-493	2	42	,	,	PUNCT
ijassa-493	2	43	moscow	moscow	PROPN
ijassa-493	2	44	,	,	PUNCT
ijassa-493	2	45	russia	russia	PROPN
ijassa-493	2	46	e	e	NOUN
ijassa-493	2	47	-	-	NOUN
ijassa-493	2	48	mail	mail	NOUN
ijassa-493	2	49	:	:	PUNCT
ijassa-493	2	50	babushkina_na@mail.ru	babushkina_na@mail.ru	PROPN
ijassa-493	2	51	,	,	PUNCT
ijassa-493	2	52	kate_k93@mail.ru	kate_k93@mail.ru	ADV
ijassa-493	2	53	abstract	abstract	ADJ
ijassa-493	2	54	.	.	PUNCT
ijassa-493	3	1	the	the	DET
ijassa-493	3	2	paper	paper	NOUN
ijassa-493	3	3	presents	present	VERB
ijassa-493	3	4	the	the	DET
ijassa-493	3	5	algorithm	algorithm	NOUN
ijassa-493	3	6	for	for	ADP
ijassa-493	3	7	calculating	calculate	VERB
ijassa-493	3	8	the	the	DET
ijassa-493	3	9	maximal	maximal	ADJ
ijassa-493	3	10	effective	effective	ADJ
ijassa-493	3	11	antitumor	antitumor	PROPN
ijassa-493	3	12	viral	viral	ADJ
ijassa-493	3	13	vaccine	vaccine	NOUN
ijassa-493	3	14	introduction	introduction	NOUN
ijassa-493	3	15	regimens	regimen	NOUN
ijassa-493	3	16	,	,	PUNCT
ijassa-493	3	17	using	use	VERB
ijassa-493	3	18	a	a	DET
ijassa-493	3	19	computing	compute	VERB
ijassa-493	3	20	experiment	experiment	NOUN
ijassa-493	3	21	method	method	NOUN
ijassa-493	3	22	(	(	PUNCT
ijassa-493	3	23	in	in	ADP
ijassa-493	3	24	silico	silico	NOUN
ijassa-493	3	25	)	)	PUNCT
ijassa-493	3	26	based	base	VERB
ijassa-493	3	27	on	on	ADP
ijassa-493	3	28	the	the	DET
ijassa-493	3	29	software	software	NOUN
ijassa-493	3	30	implementation	implementation	NOUN
ijassa-493	3	31	of	of	ADP
ijassa-493	3	32	two	two	NUM
ijassa-493	3	33	mathematical	mathematical	ADJ
ijassa-493	3	34	models	model	NOUN
ijassa-493	3	35	in	in	ADP
ijassa-493	3	36	the	the	DET
ijassa-493	3	37	matlab	matlab	PROPN
ijassa-493	3	38	-	-	PUNCT
ijassa-493	3	39	simulink	simulink	NOUN
ijassa-493	3	40	system	system	NOUN
ijassa-493	3	41	.	.	PUNCT
ijassa-493	4	1	the	the	DET
ijassa-493	4	2	first	first	ADJ
ijassa-493	4	3	model	model	NOUN
ijassa-493	4	4	of	of	ADP
ijassa-493	4	5	antitumor	antitumor	PROPN
ijassa-493	4	6	vaccine	vaccine	NOUN
ijassa-493	4	7	therapy	therapy	NOUN
ijassa-493	4	8	describes	describe	VERB
ijassa-493	4	9	a	a	DET
ijassa-493	4	10	two	two	NUM
ijassa-493	4	11	-	-	PUNCT
ijassa-493	4	12	stage	stage	NOUN
ijassa-493	4	13	mechanism	mechanism	NOUN
ijassa-493	4	14	of	of	ADP
ijassa-493	4	15	the	the	DET
ijassa-493	4	16	tumor	tumor	NOUN
ijassa-493	4	17	cells	cell	NOUN
ijassa-493	4	18	’	’	PART
ijassa-493	4	19	death	death	NOUN
ijassa-493	4	20	as	as	ADP
ijassa-493	4	21	a	a	DET
ijassa-493	4	22	result	result	NOUN
ijassa-493	4	23	of	of	ADP
ijassa-493	4	24	the	the	DET
ijassa-493	4	25	immune	immune	ADJ
ijassa-493	4	26	response	response	NOUN
ijassa-493	4	27	.	.	PUNCT
ijassa-493	5	1	the	the	DET
ijassa-493	5	2	effectiveness	effectiveness	NOUN
ijassa-493	5	3	of	of	ADP
ijassa-493	5	4	immune	immune	ADJ
ijassa-493	5	5	response	response	NOUN
ijassa-493	5	6	is	be	AUX
ijassa-493	5	7	measured	measure	VERB
ijassa-493	5	8	in	in	ADP
ijassa-493	5	9	the	the	DET
ijassa-493	5	10	number	number	NOUN
ijassa-493	5	11	of	of	ADP
ijassa-493	5	12	antibodies	antibody	NOUN
ijassa-493	5	13	formed	form	VERB
ijassa-493	5	14	by	by	ADP
ijassa-493	5	15	the	the	DET
ijassa-493	5	16	immune	immune	ADJ
ijassa-493	5	17	system	system	NOUN
ijassa-493	5	18	against	against	ADP
ijassa-493	5	19	virus	virus	NOUN
ijassa-493	5	20	-	-	PUNCT
ijassa-493	5	21	infected	infect	VERB
ijassa-493	5	22	tumor	tumor	NOUN
ijassa-493	5	23	cells	cell	NOUN
ijassa-493	5	24	.	.	PUNCT
ijassa-493	6	1	the	the	DET
ijassa-493	6	2	second	second	ADJ
ijassa-493	6	3	model	model	NOUN
ijassa-493	6	4	of	of	ADP
ijassa-493	6	5	antitumor	antitumor	PROPN
ijassa-493	6	6	therapy	therapy	NOUN
ijassa-493	6	7	with	with	ADP
ijassa-493	6	8	discontinuous	discontinuous	ADJ
ijassa-493	6	9	trajectories	trajectory	NOUN
ijassa-493	6	10	of	of	ADP
ijassa-493	6	11	tumor	tumor	NOUN
ijassa-493	6	12	growth	growth	NOUN
ijassa-493	6	13	is	be	AUX
ijassa-493	6	14	designed	design	VERB
ijassa-493	6	15	to	to	PART
ijassa-493	6	16	evaluate	evaluate	VERB
ijassa-493	6	17	the	the	DET
ijassa-493	6	18	rate	rate	NOUN
ijassa-493	6	19	of	of	ADP
ijassa-493	6	20	the	the	DET
ijassa-493	6	21	tumor	tumor	NOUN
ijassa-493	6	22	cells	cell	NOUN
ijassa-493	6	23	’	’	PART
ijassa-493	6	24	death	death	NOUN
ijassa-493	6	25	after	after	ADP
ijassa-493	6	26	the	the	DET
ijassa-493	6	27	introduction	introduction	NOUN
ijassa-493	6	28	of	of	ADP
ijassa-493	6	29	the	the	DET
ijassa-493	6	30	viral	viral	ADJ
ijassa-493	6	31	vaccine	vaccine	NOUN
ijassa-493	6	32	.	.	PUNCT
ijassa-493	7	1	the	the	DET
ijassa-493	7	2	effectiveness	effectiveness	NOUN
ijassa-493	7	3	of	of	ADP
ijassa-493	7	4	the	the	DET
ijassa-493	7	5	therapy	therapy	NOUN
ijassa-493	7	6	is	be	AUX
ijassa-493	7	7	measured	measure	VERB
ijassa-493	7	8	in	in	ADP
ijassa-493	7	9	the	the	DET
ijassa-493	7	10	number	number	NOUN
ijassa-493	7	11	of	of	ADP
ijassa-493	7	12	dying	die	VERB
ijassa-493	7	13	tumor	tumor	NOUN
ijassa-493	7	14	cells	cell	NOUN
ijassa-493	7	15	after	after	ADP
ijassa-493	7	16	the	the	DET
ijassa-493	7	17	introduction	introduction	NOUN
ijassa-493	7	18	of	of	ADP
ijassa-493	7	19	a	a	DET
ijassa-493	7	20	viral	viral	ADJ
ijassa-493	7	21	vaccine	vaccine	NOUN
ijassa-493	7	22	.	.	PUNCT
ijassa-493	8	1	keywords	keyword	NOUN
ijassa-493	8	2	:	:	PUNCT
ijassa-493	8	3	mathematical	mathematical	ADJ
ijassa-493	8	4	model	model	NOUN
ijassa-493	8	5	,	,	PUNCT
ijassa-493	8	6	experimental	experimental	ADJ
ijassa-493	8	7	oncology	oncology	NOUN
ijassa-493	8	8	,	,	PUNCT
ijassa-493	8	9	tumor	tumor	NOUN
ijassa-493	8	10	cells	cell	NOUN
ijassa-493	8	11	,	,	PUNCT
ijassa-493	8	12	kinetic	kinetic	ADJ
ijassa-493	8	13	curves	curve	NOUN
ijassa-493	8	14	of	of	ADP
ijassa-493	8	15	tumor	tumor	NOUN
ijassa-493	8	16	growth	growth	NOUN
ijassa-493	8	17	,	,	PUNCT
ijassa-493	8	18	tumor	tumor	NOUN
ijassa-493	8	19	growth	growth	NOUN
ijassa-493	8	20	delay	delay	NOUN
ijassa-493	8	21	,	,	PUNCT
ijassa-493	8	22	virus	virus	NOUN
ijassa-493	8	23	,	,	PUNCT
ijassa-493	8	24	vaccine	vaccine	NOUN
ijassa-493	8	25	therapy	therapy	NOUN
ijassa-493	8	26	,	,	PUNCT
ijassa-493	8	27	immune	immune	ADJ
ijassa-493	8	28	response	response	NOUN
ijassa-493	8	29	,	,	PUNCT
ijassa-493	8	30	number	number	NOUN
ijassa-493	8	31	of	of	ADP
ijassa-493	8	32	antibodies	antibody	NOUN
ijassa-493	8	33	,	,	PUNCT
ijassa-493	8	34	vaccine	vaccine	NOUN
ijassa-493	8	35	efficacy	efficacy	NOUN
ijassa-493	8	36	,	,	PUNCT
ijassa-493	8	37	time	time	NOUN
ijassa-493	8	38	-	-	PUNCT
ijassa-493	8	39	frame	frame	NOUN
ijassa-493	8	40	for	for	ADP
ijassa-493	8	41	recurrent	recurrent	ADJ
ijassa-493	8	42	vaccine	vaccine	NOUN
ijassa-493	8	43	introductions	introduction	NOUN
ijassa-493	8	44	,	,	PUNCT
ijassa-493	8	45	in	in	ADP
ijassa-493	8	46	silico	silico	NOUN
ijassa-493	8	47	.	.	PUNCT
ijassa-493	9	1	1	1	X
ijassa-493	9	2	.	.	X
ijassa-493	9	3	introduction	introduction	NOUN
ijassa-493	9	4	vaccine	vaccine	NOUN
ijassa-493	9	5	therapy	therapy	NOUN
ijassa-493	9	6	is	be	AUX
ijassa-493	9	7	one	one	NUM
ijassa-493	9	8	of	of	ADP
ijassa-493	9	9	the	the	DET
ijassa-493	9	10	methods	method	NOUN
ijassa-493	9	11	of	of	ADP
ijassa-493	9	12	immune	immune	ADJ
ijassa-493	9	13	therapy	therapy	NOUN
ijassa-493	9	14	of	of	ADP
ijassa-493	9	15	the	the	DET
ijassa-493	9	16	oncological	oncological	ADJ
ijassa-493	9	17	diseases	disease	NOUN
ijassa-493	9	18	.	.	PUNCT
ijassa-493	10	1	it	it	PRON
ijassa-493	10	2	implies	imply	VERB
ijassa-493	10	3	vaccination	vaccination	NOUN
ijassa-493	10	4	against	against	ADP
ijassa-493	10	5	the	the	DET
ijassa-493	10	6	malignant	malignant	ADJ
ijassa-493	10	7	cells	cell	NOUN
ijassa-493	10	8	formed	form	VERB
ijassa-493	10	9	in	in	ADP
ijassa-493	10	10	the	the	DET
ijassa-493	10	11	body	body	NOUN
ijassa-493	10	12	.	.	PUNCT
ijassa-493	11	1	as	as	ADP
ijassa-493	11	2	with	with	ADP
ijassa-493	11	3	any	any	DET
ijassa-493	11	4	vaccination	vaccination	NOUN
ijassa-493	11	5	,	,	PUNCT
ijassa-493	11	6	the	the	DET
ijassa-493	11	7	introduction	introduction	NOUN
ijassa-493	11	8	of	of	ADP
ijassa-493	11	9	viral	viral	ADJ
ijassa-493	11	10	vaccines	vaccine	NOUN
ijassa-493	11	11	stimulates	stimulate	VERB
ijassa-493	11	12	the	the	DET
ijassa-493	11	13	body	body	NOUN
ijassa-493	11	14	's	's	PART
ijassa-493	11	15	immune	immune	ADJ
ijassa-493	11	16	system	system	NOUN
ijassa-493	11	17	and	and	CCONJ
ijassa-493	11	18	causes	cause	VERB
ijassa-493	11	19	the	the	DET
ijassa-493	11	20	formation	formation	NOUN
ijassa-493	11	21	of	of	ADP
ijassa-493	11	22	antibodies	antibody	NOUN
ijassa-493	11	23	specific	specific	ADJ
ijassa-493	11	24	to	to	ADP
ijassa-493	11	25	the	the	DET
ijassa-493	11	26	tumor	tumor	NOUN
ijassa-493	11	27	type	type	NOUN
ijassa-493	11	28	.	.	PUNCT
ijassa-493	12	1	experiments	experiment	NOUN
ijassa-493	12	2	in	in	ADP
ijassa-493	12	3	tumor	tumor	NOUN
ijassa-493	12	4	immunotherapy	immunotherapy	NOUN
ijassa-493	12	5	can	can	AUX
ijassa-493	12	6	be	be	AUX
ijassa-493	12	7	traced	trace	VERB
ijassa-493	12	8	back	back	ADV
ijassa-493	12	9	to	to	ADP
ijassa-493	12	10	ehrlich	ehrlich	NOUN
ijassa-493	13	1	[	[	X
ijassa-493	13	2	1	1	NUM
ijassa-493	13	3	]	]	PUNCT
ijassa-493	13	4	,	,	PUNCT
ijassa-493	13	5	and	and	CCONJ
ijassa-493	13	6	since	since	SCONJ
ijassa-493	13	7	the	the	DET
ijassa-493	13	8	middle	middle	NOUN
ijassa-493	13	9	of	of	ADP
ijassa-493	13	10	the	the	DET
ijassa-493	13	11	twentieth	twentieth	ADJ
ijassa-493	13	12	century	century	NOUN
ijassa-493	13	13	the	the	DET
ijassa-493	13	14	studies	study	NOUN
ijassa-493	13	15	aiming	aim	VERB
ijassa-493	13	16	to	to	PART
ijassa-493	13	17	find	find	VERB
ijassa-493	13	18	the	the	DET
ijassa-493	13	19	viruses	virus	NOUN
ijassa-493	13	20	that	that	PRON
ijassa-493	13	21	are	be	AUX
ijassa-493	13	22	able	able	ADJ
ijassa-493	13	23	to	to	PART
ijassa-493	13	24	affect	affect	VERB
ijassa-493	13	25	malignant	malignant	ADJ
ijassa-493	13	26	tumors	tumor	NOUN
ijassa-493	13	27	without	without	ADP
ijassa-493	13	28	causing	cause	VERB
ijassa-493	13	29	any	any	DET
ijassa-493	13	30	harm	harm	NOUN
ijassa-493	13	31	to	to	ADP
ijassa-493	13	32	the	the	DET
ijassa-493	13	33	humans	human	NOUN
ijassa-493	13	34	commenced	commence	VERB
ijassa-493	13	35	in	in	ADP
ijassa-493	13	36	the	the	DET
ijassa-493	13	37	soviet	soviet	PROPN
ijassa-493	13	38	union	union	PROPN
ijassa-493	13	39	and	and	CCONJ
ijassa-493	13	40	were	be	AUX
ijassa-493	13	41	further	far	ADV
ijassa-493	13	42	continued	continue	VERB
ijassa-493	13	43	in	in	ADP
ijassa-493	13	44	russia	russia	PROPN
ijassa-493	14	1	[	[	X
ijassa-493	14	2	2	2	NUM
ijassa-493	14	3	-	-	SYM
ijassa-493	14	4	6	6	NUM
ijassa-493	14	5	]	]	PUNCT
ijassa-493	14	6	.	.	PUNCT
ijassa-493	15	1	one	one	NUM
ijassa-493	15	2	of	of	ADP
ijassa-493	15	3	approaches	approach	NOUN
ijassa-493	15	4	to	to	ADP
ijassa-493	15	5	developing	develop	VERB
ijassa-493	15	6	effective	effective	ADJ
ijassa-493	15	7	antitumor	antitumor	PROPN
ijassa-493	15	8	vaccines	vaccine	NOUN
ijassa-493	15	9	implies	imply	VERB
ijassa-493	15	10	using	use	VERB
ijassa-493	15	11	the	the	DET
ijassa-493	15	12	viruses	virus	NOUN
ijassa-493	15	13	that	that	PRON
ijassa-493	15	14	are	be	AUX
ijassa-493	15	15	able	able	ADJ
ijassa-493	15	16	to	to	PART
ijassa-493	15	17	identify	identify	VERB
ijassa-493	15	18	malignant	malignant	ADJ
ijassa-493	15	19	cells	cell	NOUN
ijassa-493	15	20	and	and	CCONJ
ijassa-493	15	21	do	do	AUX
ijassa-493	15	22	not	not	PART
ijassa-493	15	23	cause	cause	VERB
ijassa-493	15	24	any	any	DET
ijassa-493	15	25	damage	damage	NOUN
ijassa-493	15	26	to	to	ADP
ijassa-493	15	27	the	the	DET
ijassa-493	15	28	normal	normal	ADJ
ijassa-493	15	29	tissues	tissue	NOUN
ijassa-493	15	30	.	.	PUNCT
ijassa-493	16	1	the	the	DET
ijassa-493	16	2	viruses	virus	NOUN
ijassa-493	16	3	selected	select	VERB
ijassa-493	16	4	for	for	ADP
ijassa-493	16	5	therapy	therapy	NOUN
ijassa-493	16	6	should	should	AUX
ijassa-493	16	7	be	be	AUX
ijassa-493	16	8	clinically	clinically	ADV
ijassa-493	16	9	harmless	harmless	ADJ
ijassa-493	16	10	and	and	CCONJ
ijassa-493	16	11	epidemiologically	epidemiologically	ADV
ijassa-493	16	12	safe	safe	ADJ
ijassa-493	16	13	.	.	PUNCT
ijassa-493	17	1	therefore	therefore	ADV
ijassa-493	17	2	,	,	PUNCT
ijassa-493	17	3	oncotropic	oncotropic	ADJ
ijassa-493	17	4	viruses	virus	NOUN
ijassa-493	17	5	must	must	AUX
ijassa-493	17	6	have	have	VERB
ijassa-493	17	7	a	a	DET
ijassa-493	17	8	genetically	genetically	ADV
ijassa-493	17	9	fixed	fix	VERB
ijassa-493	17	10	absence	absence	NOUN
ijassa-493	17	11	of	of	ADP
ijassa-493	17	12	pathogenic	pathogenic	ADJ
ijassa-493	17	13	properties	property	NOUN
ijassa-493	17	14	and	and	CCONJ
ijassa-493	17	15	be	be	AUX
ijassa-493	17	16	unable	unable	ADJ
ijassa-493	17	17	to	to	PART
ijassa-493	17	18	cause	cause	VERB
ijassa-493	17	19	an	an	DET
ijassa-493	17	20	acute	acute	ADJ
ijassa-493	17	21	infectious	infectious	ADJ
ijassa-493	17	22	disease	disease	NOUN
ijassa-493	17	23	in	in	ADP
ijassa-493	17	24	a	a	DET
ijassa-493	17	25	human	human	ADJ
ijassa-493	17	26	body	body	NOUN
ijassa-493	17	27	.	.	PUNCT
ijassa-493	18	1	among	among	ADP
ijassa-493	18	2	the	the	DET
ijassa-493	18	3	viruses	virus	NOUN
ijassa-493	18	4	that	that	PRON
ijassa-493	18	5	meet	meet	VERB
ijassa-493	18	6	these	these	DET
ijassa-493	18	7	criteria	criterion	NOUN
ijassa-493	18	8	are	be	AUX
ijassa-493	18	9	the	the	DET
ijassa-493	18	10	venezuelan	venezuelan	ADJ
ijassa-493	18	11	horse	horse	NOUN
ijassa-493	18	12	encephalomyelitis	encephalomyelitis	NOUN
ijassa-493	18	13	virus	virus	NOUN
ijassa-493	18	14	(	(	PUNCT
ijassa-493	18	15	vee	vee	PROPN
ijassa-493	18	16	)	)	PUNCT
ijassa-493	19	1	[	[	X
ijassa-493	19	2	5	5	NUM
ijassa-493	19	3	-	-	SYM
ijassa-493	19	4	7	7	NUM
ijassa-493	19	5	]	]	PUNCT
ijassa-493	19	6	and	and	CCONJ
ijassa-493	19	7	rat	rat	NOUN
ijassa-493	19	8	parvovirus	parvovirus	NOUN
ijassa-493	19	9	h-1	h-1	NOUN
ijassa-493	20	1	[	[	X
ijassa-493	20	2	15	15	NUM
ijassa-493	20	3	-	-	SYM
ijassa-493	20	4	23	23	NUM
ijassa-493	20	5	]	]	PUNCT
ijassa-493	20	6	.	.	PUNCT
ijassa-493	21	1	both	both	PRON
ijassa-493	21	2	are	be	AUX
ijassa-493	21	3	not	not	PART
ijassa-493	21	4	harmful	harmful	ADJ
ijassa-493	21	5	to	to	ADP
ijassa-493	21	6	humans	human	NOUN
ijassa-493	21	7	because	because	SCONJ
ijassa-493	21	8	they	they	PRON
ijassa-493	21	9	do	do	AUX
ijassa-493	21	10	not	not	PART
ijassa-493	21	11	affect	affect	VERB
ijassa-493	21	12	healthy	healthy	ADJ
ijassa-493	21	13	tissues	tissue	NOUN
ijassa-493	21	14	since	since	SCONJ
ijassa-493	21	15	they	they	PRON
ijassa-493	21	16	can	can	AUX
ijassa-493	21	17	not	not	PART
ijassa-493	21	18	replicate	replicate	VERB
ijassa-493	21	19	in	in	ADP
ijassa-493	21	20	the	the	DET
ijassa-493	21	21	non	non	ADJ
ijassa-493	21	22	-	-	ADJ
ijassa-493	21	23	dividing	dividing	ADJ
ijassa-493	21	24	cells	cell	NOUN
ijassa-493	21	25	[	[	X
ijassa-493	21	26	16	16	NUM
ijassa-493	21	27	-	-	SYM
ijassa-493	21	28	18	18	NUM
ijassa-493	21	29	]	]	PUNCT
ijassa-493	21	30	.	.	PUNCT
ijassa-493	22	1	thus	thus	ADV
ijassa-493	22	2	these	these	DET
ijassa-493	22	3	viruses	virus	NOUN
ijassa-493	22	4	are	be	AUX
ijassa-493	22	5	able	able	ADJ
ijassa-493	22	6	to	to	PART
ijassa-493	22	7	identify	identify	VERB
ijassa-493	22	8	the	the	DET
ijassa-493	22	9	tumor	tumor	NOUN
ijassa-493	22	10	cells	cell	NOUN
ijassa-493	22	11	based	base	VERB
ijassa-493	22	12	on	on	ADP
ijassa-493	22	13	their	their	PRON
ijassa-493	22	14	high	high	ADJ
ijassa-493	22	15	proliferation	proliferation	NOUN
ijassa-493	22	16	rates	rate	NOUN
ijassa-493	22	17	,	,	PUNCT
ijassa-493	22	18	and	and	CCONJ
ijassa-493	22	19	specifically	specifically	ADV
ijassa-493	22	20	target	target	VERB
ijassa-493	22	21	them	they	PRON
ijassa-493	22	22	without	without	ADP
ijassa-493	22	23	attacking	attack	VERB
ijassa-493	22	24	the	the	DET
ijassa-493	22	25	normal	normal	ADJ
ijassa-493	22	26	tissues	tissue	NOUN
ijassa-493	22	27	[	[	X
ijassa-493	22	28	18	18	NUM
ijassa-493	22	29	-	-	SYM
ijassa-493	22	30	19	19	NUM
ijassa-493	22	31	]	]	PUNCT
ijassa-493	22	32	.	.	PUNCT
ijassa-493	23	1	experimental	experimental	ADJ
ijassa-493	23	2	studies	study	NOUN
ijassa-493	23	3	of	of	ADP
ijassa-493	23	4	rat	rat	NOUN
ijassa-493	23	5	parvovirus	parvovirus	NOUN
ijassa-493	23	6	h-1	h-1	NOUN
ijassa-493	23	7	indicate	indicate	VERB
ijassa-493	23	8	that	that	SCONJ
ijassa-493	23	9	there	there	PRON
ijassa-493	23	10	are	be	VERB
ijassa-493	23	11	two	two	NUM
ijassa-493	23	12	possible	possible	ADJ
ijassa-493	23	13	mechanisms	mechanism	NOUN
ijassa-493	23	14	of	of	ADP
ijassa-493	23	15	the	the	DET
ijassa-493	23	16	tumor	tumor	NOUN
ijassa-493	23	17	cells	cell	NOUN
ijassa-493	23	18	’	’	PART
ijassa-493	23	19	death	death	NOUN
ijassa-493	23	20	as	as	ADP
ijassa-493	23	21	a	a	DET
ijassa-493	23	22	result	result	NOUN
ijassa-493	23	23	of	of	ADP
ijassa-493	23	24	vaccine	vaccine	NOUN
ijassa-493	23	25	introduction	introduction	NOUN
ijassa-493	23	26	.	.	PUNCT
ijassa-493	24	1	firstly	firstly	ADV
ijassa-493	24	2	,	,	PUNCT
ijassa-493	24	3	the	the	DET
ijassa-493	24	4	virus	virus	NOUN
ijassa-493	24	5	blocks	block	VERB
ijassa-493	24	6	the	the	DET
ijassa-493	24	7	cycle	cycle	NOUN
ijassa-493	24	8	of	of	ADP
ijassa-493	24	9	the	the	DET
ijassa-493	24	10	tumor	tumor	NOUN
ijassa-493	24	11	cells	cell	NOUN
ijassa-493	24	12	[	[	X
ijassa-493	24	13	16	16	NUM
ijassa-493	24	14	-	-	SYM
ijassa-493	24	15	18	18	NUM
ijassa-493	24	16	]	]	PUNCT
ijassa-493	24	17	.	.	PUNCT
ijassa-493	25	1	secondly	secondly	ADV
ijassa-493	25	2	,	,	PUNCT
ijassa-493	25	3	it	it	PRON
ijassa-493	25	4	produces	produce	VERB
ijassa-493	25	5	specific	specific	ADJ
ijassa-493	25	6	protein	protein	NOUN
ijassa-493	25	7	formations	formation	NOUN
ijassa-493	25	8	on	on	ADP
ijassa-493	25	9	the	the	DET
ijassa-493	25	10	tumor	tumor	NOUN
ijassa-493	25	11	cell	cell	NOUN
ijassa-493	25	12	surface	surface	NOUN
ijassa-493	25	13	that	that	PRON
ijassa-493	25	14	stimulate	stimulate	VERB
ijassa-493	25	15	the	the	DET
ijassa-493	25	16	immune	immune	ADJ
ijassa-493	25	17	system	system	NOUN
ijassa-493	25	18	to	to	PART
ijassa-493	25	19	develop	develop	VERB
ijassa-493	25	20	antibodies	antibody	NOUN
ijassa-493	25	21	against	against	ADP
ijassa-493	25	22	these	these	DET
ijassa-493	25	23	cells	cell	NOUN
ijassa-493	25	24	,	,	PUNCT
ijassa-493	25	25	resulting	result	VERB
ijassa-493	25	26	in	in	ADP
ijassa-493	25	27	their	their	PRON
ijassa-493	25	28	death	death	NOUN
ijassa-493	25	29	[	[	X
ijassa-493	25	30	13	13	NUM
ijassa-493	25	31	-	-	SYM
ijassa-493	25	32	14	14	NUM
ijassa-493	25	33	,	,	PUNCT
ijassa-493	25	34	19	19	NUM
ijassa-493	25	35	-	-	SYM
ijassa-493	25	36	21	21	NUM
ijassa-493	25	37	]	]	PUNCT
ijassa-493	25	38	.	.	PUNCT
ijassa-493	26	1	this	this	PRON
ijassa-493	26	2	corresponds	correspond	VERB
ijassa-493	26	3	to	to	ADP
ijassa-493	26	4	the	the	DET
ijassa-493	26	5	results	result	NOUN
ijassa-493	26	6	of	of	ADP
ijassa-493	26	7	the	the	DET
ijassa-493	26	8	experimental	experimental	ADJ
ijassa-493	26	9	studies	study	NOUN
ijassa-493	26	10	of	of	ADP
ijassa-493	26	11	the	the	DET
ijassa-493	26	12	impact	impact	NOUN
ijassa-493	26	13	of	of	ADP
ijassa-493	26	14	the	the	DET
ijassa-493	26	15	vee	vee	PROPN
ijassa-493	26	16	virus	virus	PROPN
ijassa-493	26	17	on	on	ADP
ijassa-493	26	18	tumor	tumor	NOUN
ijassa-493	26	19	growth	growth	NOUN
ijassa-493	26	20	[	[	X
ijassa-493	26	21	4	4	NUM
ijassa-493	26	22	-	-	SYM
ijassa-493	26	23	6	6	NUM
ijassa-493	26	24	]	]	PUNCT
ijassa-493	26	25	.	.	PUNCT
ijassa-493	27	1	however	however	ADV
ijassa-493	27	2	,	,	PUNCT
ijassa-493	27	3	since	since	SCONJ
ijassa-493	27	4	such	such	ADJ
ijassa-493	27	5	experiments	experiment	NOUN
ijassa-493	27	6	require	require	VERB
ijassa-493	27	7	mailto:babushkina_na@mail.ru	mailto:babushkina_na@mail.ru	ADJ
ijassa-493	27	8	mailto:kate_k93@mail.ru	mailto:kate_k93@mail.ru	ADV
ijassa-493	27	9	60	60	NUM
ijassa-493	27	10	n.a	n.a	PROPN
ijassa-493	27	11	.	.	PROPN
ijassa-493	27	12	babushkina	babushkina	PROPN
ijassa-493	27	13	,	,	PUNCT
ijassa-493	27	14	e.a	e.a	PROPN
ijassa-493	27	15	.	.	PROPN
ijassa-493	27	16	kuzina	kuzina	PROPN
ijassa-493	27	17	extensive	extensive	PROPN
ijassa-493	27	18	funding	funding	PROPN
ijassa-493	27	19	,	,	PUNCT
ijassa-493	27	20	these	these	DET
ijassa-493	27	21	studies	study	NOUN
ijassa-493	27	22	did	do	AUX
ijassa-493	27	23	not	not	PART
ijassa-493	27	24	determine	determine	VERB
ijassa-493	27	25	the	the	DET
ijassa-493	27	26	maximal	maximal	ADJ
ijassa-493	27	27	and	and	CCONJ
ijassa-493	27	28	minimal	minimal	ADJ
ijassa-493	27	29	effective	effective	ADJ
ijassa-493	27	30	dosages	dosage	NOUN
ijassa-493	27	31	and	and	CCONJ
ijassa-493	27	32	the	the	DET
ijassa-493	27	33	optimal	optimal	ADJ
ijassa-493	27	34	moment	moment	NOUN
ijassa-493	27	35	of	of	ADP
ijassa-493	27	36	vaccine	vaccine	NOUN
ijassa-493	27	37	introduction	introduction	NOUN
ijassa-493	27	38	.	.	PUNCT
ijassa-493	28	1	thus	thus	ADV
ijassa-493	28	2	,	,	PUNCT
ijassa-493	28	3	the	the	DET
ijassa-493	28	4	present	present	ADJ
ijassa-493	28	5	study	study	NOUN
ijassa-493	28	6	presents	present	VERB
ijassa-493	28	7	an	an	DET
ijassa-493	28	8	algorithm	algorithm	NOUN
ijassa-493	28	9	that	that	PRON
ijassa-493	28	10	allows	allow	VERB
ijassa-493	28	11	to	to	PART
ijassa-493	28	12	determine	determine	VERB
ijassa-493	28	13	the	the	DET
ijassa-493	28	14	optimal	optimal	ADJ
ijassa-493	28	15	dosage	dosage	NOUN
ijassa-493	28	16	of	of	ADP
ijassa-493	28	17	the	the	DET
ijassa-493	28	18	vee	vee	PROPN
ijassa-493	28	19	virus	virus	NOUN
ijassa-493	28	20	-	-	PUNCT
ijassa-493	28	21	derived	derive	VERB
ijassa-493	28	22	vaccine	vaccine	NOUN
ijassa-493	28	23	and	and	CCONJ
ijassa-493	28	24	the	the	DET
ijassa-493	28	25	moment	moment	NOUN
ijassa-493	28	26	of	of	ADP
ijassa-493	28	27	its	its	PRON
ijassa-493	28	28	introduction	introduction	NOUN
ijassa-493	28	29	that	that	PRON
ijassa-493	28	30	will	will	AUX
ijassa-493	28	31	ensure	ensure	VERB
ijassa-493	28	32	the	the	DET
ijassa-493	28	33	maximal	maximal	ADJ
ijassa-493	28	34	rate	rate	NOUN
ijassa-493	28	35	of	of	ADP
ijassa-493	28	36	tumor	tumor	NOUN
ijassa-493	28	37	cells	cell	NOUN
ijassa-493	28	38	’	'	PUNCT
ijassa-493	28	39	death	death	NOUN
ijassa-493	28	40	,	,	PUNCT
ijassa-493	28	41	building	build	VERB
ijassa-493	28	42	on	on	ADP
ijassa-493	28	43	the	the	DET
ijassa-493	28	44	mathematical	mathematical	ADJ
ijassa-493	28	45	models	model	NOUN
ijassa-493	28	46	of	of	ADP
ijassa-493	28	47	anti	anti	ADJ
ijassa-493	28	48	-	-	ADJ
ijassa-493	28	49	tumor	tumor	ADJ
ijassa-493	28	50	therapy	therapy	NOUN
ijassa-493	28	51	and	and	CCONJ
ijassa-493	28	52	vaccine	vaccine	NOUN
ijassa-493	28	53	therapy	therapy	NOUN
ijassa-493	28	54	developed	develop	VERB
ijassa-493	28	55	in	in	ADP
ijassa-493	28	56	[	[	PUNCT
ijassa-493	28	57	7	7	NUM
ijassa-493	28	58	-	-	SYM
ijassa-493	28	59	9	9	NUM
ijassa-493	28	60	]	]	PUNCT
ijassa-493	28	61	.	.	PUNCT
ijassa-493	29	1	2	2	X
ijassa-493	29	2	.	.	X
ijassa-493	29	3	the	the	DET
ijassa-493	29	4	mathematical	mathematical	ADJ
ijassa-493	29	5	model	model	NOUN
ijassa-493	29	6	of	of	ADP
ijassa-493	29	7	the	the	DET
ijassa-493	29	8	vee	vee	PROPN
ijassa-493	29	9	virus	virus	PROPN
ijassa-493	29	10	vaccine	vaccine	NOUN
ijassa-493	29	11	therapy	therapy	VERB
ijassa-493	29	12	the	the	DET
ijassa-493	29	13	mathematical	mathematical	ADJ
ijassa-493	29	14	model	model	NOUN
ijassa-493	29	15	of	of	ADP
ijassa-493	29	16	vaccine	vaccine	NOUN
ijassa-493	29	17	therapy	therapy	NOUN
ijassa-493	29	18	describes	describe	VERB
ijassa-493	29	19	the	the	DET
ijassa-493	29	20	mechanism	mechanism	NOUN
ijassa-493	29	21	of	of	ADP
ijassa-493	29	22	two	two	NUM
ijassa-493	29	23	-	-	PUNCT
ijassa-493	29	24	stage	stage	NOUN
ijassa-493	29	25	death	death	NOUN
ijassa-493	29	26	of	of	ADP
ijassa-493	29	27	tumor	tumor	NOUN
ijassa-493	29	28	cells	cell	NOUN
ijassa-493	29	29	caused	cause	VERB
ijassa-493	29	30	by	by	ADP
ijassa-493	29	31	the	the	DET
ijassa-493	29	32	virus	virus	NOUN
ijassa-493	29	33	itself	itself	PRON
ijassa-493	29	34	and	and	CCONJ
ijassa-493	29	35	as	as	ADP
ijassa-493	29	36	a	a	DET
ijassa-493	29	37	result	result	NOUN
ijassa-493	29	38	of	of	ADP
ijassa-493	29	39	the	the	DET
ijassa-493	29	40	immune	immune	ADJ
ijassa-493	29	41	system	system	NOUN
ijassa-493	29	42	stimulation	stimulation	NOUN
ijassa-493	29	43	against	against	ADP
ijassa-493	29	44	the	the	DET
ijassa-493	29	45	infected	infected	ADJ
ijassa-493	29	46	tumor	tumor	NOUN
ijassa-493	29	47	cells	cell	NOUN
ijassa-493	29	48	.	.	PUNCT
ijassa-493	30	1	based	base	VERB
ijassa-493	30	2	on	on	ADP
ijassa-493	30	3	the	the	DET
ijassa-493	30	4	experimental	experimental	ADJ
ijassa-493	30	5	data	datum	NOUN
ijassa-493	30	6	on	on	ADP
ijassa-493	30	7	the	the	DET
ijassa-493	30	8	growth	growth	NOUN
ijassa-493	30	9	of	of	ADP
ijassa-493	30	10	erlich	erlich	NOUN
ijassa-493	30	11	adenocarcinoma	adenocarcinoma	NOUN
ijassa-493	30	12	in	in	ADP
ijassa-493	30	13	mice	mouse	NOUN
ijassa-493	30	14	after	after	ADP
ijassa-493	30	15	a	a	DET
ijassa-493	30	16	single	single	ADJ
ijassa-493	30	17	introduction	introduction	NOUN
ijassa-493	30	18	of	of	ADP
ijassa-493	30	19	the	the	DET
ijassa-493	30	20	vee	vee	PROPN
ijassa-493	30	21	virus	virus	PROPN
ijassa-493	30	22	vaccine	vaccine	NOUN
ijassa-493	30	23	,	,	PUNCT
ijassa-493	30	24	one	one	NUM
ijassa-493	30	25	day	day	NOUN
ijassa-493	30	26	after	after	SCONJ
ijassa-493	30	27	the	the	DET
ijassa-493	30	28	tumor	tumor	NOUN
ijassa-493	30	29	was	be	AUX
ijassa-493	30	30	transplanted	transplant	VERB
ijassa-493	30	31	to	to	ADP
ijassa-493	30	32	animals	animal	NOUN
ijassa-493	30	33	(	(	PUNCT
ijassa-493	30	34	figure	figure	NOUN
ijassa-493	30	35	1	1	NUM
ijassa-493	30	36	)	)	PUNCT
ijassa-493	30	37	,	,	PUNCT
ijassa-493	30	38	the	the	DET
ijassa-493	30	39	parameters	parameter	NOUN
ijassa-493	30	40	of	of	ADP
ijassa-493	30	41	the	the	DET
ijassa-493	30	42	model	model	NOUN
ijassa-493	30	43	were	be	AUX
ijassa-493	30	44	estimated	estimate	VERB
ijassa-493	30	45	and	and	CCONJ
ijassa-493	30	46	its	its	PRON
ijassa-493	30	47	adequacy	adequacy	NOUN
ijassa-493	30	48	was	be	AUX
ijassa-493	30	49	tested	test	VERB
ijassa-493	30	50	using	use	VERB
ijassa-493	30	51	experimental	experimental	ADJ
ijassa-493	30	52	dosages	dosage	NOUN
ijassa-493	30	53	of	of	ADP
ijassa-493	30	54	the	the	DET
ijassa-493	30	55	vee	vee	PROPN
ijassa-493	30	56	virus	virus	PROPN
ijassa-493	30	57	vaccine	vaccine	NOUN
ijassa-493	31	1	[	[	X
ijassa-493	31	2	8	8	NUM
ijassa-493	31	3	-	-	SYM
ijassa-493	31	4	11	11	NUM
ijassa-493	31	5	]	]	PUNCT
ijassa-493	31	6	.	.	PUNCT
ijassa-493	32	1	the	the	DET
ijassa-493	32	2	values	value	NOUN
ijassa-493	32	3	of	of	ADP
ijassa-493	32	4	the	the	DET
ijassa-493	32	5	model	model	NOUN
ijassa-493	32	6	parameters	parameter	NOUN
ijassa-493	32	7	are	be	AUX
ijassa-493	32	8	shown	show	VERB
ijassa-493	32	9	in	in	ADP
ijassa-493	32	10	appendix	appendix	NOUN
ijassa-493	32	11	1	1	NUM
ijassa-493	32	12	.	.	PUNCT
ijassa-493	32	13	fig	fig	NOUN
ijassa-493	32	14	.	.	PUNCT
ijassa-493	33	1	1	1	X
ijassa-493	33	2	.	.	X
ijassa-493	33	3	experimental	experimental	ADJ
ijassa-493	33	4	curves	curve	NOUN
ijassa-493	33	5	of	of	ADP
ijassa-493	33	6	the	the	DET
ijassa-493	33	7	ehrlich	ehrlich	NOUN
ijassa-493	33	8	adenocarcinoma	adenocarcinoma	NOUN
ijassa-493	33	9	growth	growth	NOUN
ijassa-493	33	10	without	without	ADP
ijassa-493	33	11	vaccine	vaccine	NOUN
ijassa-493	33	12	administration	administration	NOUN
ijassa-493	33	13	(	(	PUNCT
ijassa-493	33	14	control	control	PROPN
ijassa-493	33	15	)	)	PUNCT
ijassa-493	33	16	and	and	CCONJ
ijassa-493	33	17	after	after	ADP
ijassa-493	33	18	single	single	ADJ
ijassa-493	33	19	vaccine	vaccine	NOUN
ijassa-493	33	20	administration	administration	NOUN
ijassa-493	33	21	the	the	DET
ijassa-493	33	22	mathematical	mathematical	ADJ
ijassa-493	33	23	model	model	NOUN
ijassa-493	33	24	of	of	ADP
ijassa-493	33	25	the	the	DET
ijassa-493	33	26	two	two	NUM
ijassa-493	33	27	-	-	PUNCT
ijassa-493	33	28	stage	stage	NOUN
ijassa-493	33	29	death	death	NOUN
ijassa-493	33	30	of	of	ADP
ijassa-493	33	31	tumor	tumor	NOUN
ijassa-493	33	32	cells	cell	NOUN
ijassa-493	33	33	after	after	SCONJ
ijassa-493	33	34	the	the	DET
ijassa-493	33	35	viral	viral	ADJ
ijassa-493	33	36	vaccine	vaccine	NOUN
ijassa-493	33	37	introduction	introduction	NOUN
ijassa-493	33	38	is	be	AUX
ijassa-493	33	39	described	describe	VERB
ijassa-493	33	40	by	by	ADP
ijassa-493	33	41	the	the	DET
ijassa-493	33	42	following	follow	VERB
ijassa-493	33	43	system	system	NOUN
ijassa-493	33	44	of	of	ADP
ijassa-493	33	45	differential	differential	ADJ
ijassa-493	33	46	equations	equation	NOUN
ijassa-493	33	47	(	(	PUNCT
ijassa-493	33	48	1	1	NUM
ijassa-493	33	49	-	-	SYM
ijassa-493	33	50	8)	8)	NUM
ijassa-493	33	51	[	[	PUNCT
ijassa-493	33	52	7	7	NUM
ijassa-493	33	53	-	-	SYM
ijassa-493	33	54	10	10	NUM
ijassa-493	33	55	]	]	PUNCT
ijassa-493	33	56	:	:	PUNCT
ijassa-493	33	57	(	(	PUNCT
ijassa-493	33	58	)	)	PUNCT
ijassa-493	33	59	(	(	PUNCT
ijassa-493	33	60	)	)	PUNCT
ijassa-493	33	61	(	(	PUNCT
ijassa-493	33	62	)	)	PUNCT
ijassa-493	33	63	(	(	PUNCT
ijassa-493	33	64	)	)	PUNCT
ijassa-493	33	65	(	(	PUNCT
ijassa-493	33	66	)	)	PUNCT
ijassa-493	33	67	(	(	PUNCT
ijassa-493	33	68	)	)	PUNCT
ijassa-493	33	69	(	(	PUNCT
ijassa-493	33	70	)	)	PUNCT
ijassa-493	33	71	(	(	PUNCT
ijassa-493	33	72	)	)	PUNCT
ijassa-493	33	73	(	(	PUNCT
ijassa-493	33	74	)	)	PUNCT
ijassa-493	33	75	(	(	PUNCT
ijassa-493	33	76	)	)	PUNCT
ijassa-493	33	77	(	(	PUNCT
ijassa-493	33	78	)	)	PUNCT
ijassa-493	33	79	(	(	PUNCT
ijassa-493	33	80	)	)	PUNCT
ijassa-493	33	81	v	v	NOUN
ijassa-493	33	82	v	v	NUM
ijassa-493	33	83	v	v	NUM
ijassa-493	33	84	v	v	NOUN
ijassa-493	33	85	v	v	ADP
ijassa-493	33	86	av	av	PROPN
ijassa-493	33	87	v	v	NUM
ijassa-493	33	88	v	v	NUM
ijassa-493	33	89	v	v	NUM
ijassa-493	33	90	v	v	NOUN
ijassa-493	33	91	n	n	ADP
ijassa-493	33	92	n	n	ADV
ijassa-493	33	93	an	an	DET
ijassa-493	33	94	n	n	CCONJ
ijassa-493	33	95	n	n	CCONJ
ijassa-493	33	96	n	n	NOUN
ijassa-493	33	97	dn	dn	PROPN
ijassa-493	33	98	t	t	PROPN
ijassa-493	33	99	t	t	PROPN
ijassa-493	33	100	n	n	ADP
ijassa-493	33	101	t	t	PROPN
ijassa-493	33	102	t	t	PROPN
ijassa-493	33	103	t	t	PROPN
ijassa-493	33	104	t	t	PROPN
ijassa-493	34	1	t	t	PROPN
ijassa-493	34	2	k	k	PROPN
ijassa-493	34	3	v	v	INTJ
ijassa-493	34	4	t	t	X
ijassa-493	34	5	t	t	PROPN
ijassa-493	34	6	k	k	PROPN
ijassa-493	34	7	a	a	DET
ijassa-493	34	8	t	t	PROPN
ijassa-493	34	9	t	t	PROPN
ijassa-493	34	10	n	n	ADP
ijassa-493	34	11	t	t	PROPN
ijassa-493	34	12	t	t	PROPN
ijassa-493	34	13	t	t	PROPN
ijassa-493	34	14	t	t	PROPN
ijassa-493	34	15	dt	dt	X
ijassa-493	35	1	t	t	PROPN
ijassa-493	35	2	t	t	PROPN
ijassa-493	35	3	k	k	PROPN
ijassa-493	36	1	a	a	DET
ijassa-493	36	2	t	t	PROPN
ijassa-493	36	3	t	t	PROPN
ijassa-493	36	4	n	n	PROPN
ijassa-493	36	5	t	t	PROPN
ijassa-493	36	6	t	t	PROPN
ijassa-493	36	7			X
ijassa-493	36	8			PROPN
ijassa-493	36	9			PROPN
ijassa-493	36	10			PROPN
ijassa-493	36	11			PROPN
ijassa-493	36	12			PROPN
ijassa-493	36	13	=	=	PROPN
ijassa-493	36	14			PROPN
ijassa-493	36	15			PROPN
ijassa-493	36	16	−	−	PROPN
ijassa-493	36	17	+	+	CCONJ
ijassa-493	36	18	−	−	PROPN
ijassa-493	36	19	−	−	NUM
ijassa-493	36	20	−	−	NOUN
ijassa-493	36	21	−	−	NOUN
ijassa-493	36	22	−	−	PROPN
ijassa-493	36	23			NUM
ijassa-493	36	24	−	−	NOUN
ijassa-493	36	25	−	−	PROPN
ijassa-493	37	1	+	+	NOUN
ijassa-493	37	2			PROPN
ijassa-493	37	3			PROPN
ijassa-493	37	4			PROPN
ijassa-493	37	5	+	+	NOUN
ijassa-493	37	6	−	−	PROPN
ijassa-493	37	7	−	−	NOUN
ijassa-493	37	8	−	−	PROPN
ijassa-493	37	9			ADJ
ijassa-493	37	10	−	−	PROPN
ijassa-493	37	11			PROPN
ijassa-493	37	12	(	(	PUNCT
ijassa-493	37	13	1	1	NUM
ijassa-493	37	14	)	)	PUNCT
ijassa-493	37	15	where	where	SCONJ
ijassa-493	37	16	(	(	PUNCT
ijassa-493	37	17	)	)	PUNCT
ijassa-493	37	18	v	v	NOUN
ijassa-493	37	19	t	t	PROPN
ijassa-493	37	20	is	be	AUX
ijassa-493	37	21	the	the	DET
ijassa-493	37	22	number	number	NOUN
ijassa-493	37	23	of	of	ADP
ijassa-493	37	24	viruses	virus	NOUN
ijassa-493	37	25	,	,	PUNCT
ijassa-493	37	26	(	(	PUNCT
ijassa-493	37	27	)	)	PUNCT
ijassa-493	37	28	n	n	PRON
ijassa-493	37	29	t	t	PROPN
ijassa-493	37	30	is	be	AUX
ijassa-493	37	31	the	the	DET
ijassa-493	37	32	number	number	NOUN
ijassa-493	37	33	of	of	ADP
ijassa-493	37	34	tumor	tumor	NOUN
ijassa-493	37	35	cells	cell	NOUN
ijassa-493	37	36	without	without	ADP
ijassa-493	37	37	vaccine	vaccine	NOUN
ijassa-493	37	38	introduction	introduction	NOUN
ijassa-493	37	39	,	,	PUNCT
ijassa-493	37	40	described	describe	VERB
ijassa-493	37	41	by	by	ADP
ijassa-493	37	42	the	the	DET
ijassa-493	37	43	following	follow	VERB
ijassa-493	37	44	differential	differential	ADJ
ijassa-493	37	45	equation	equation	NOUN
ijassa-493	37	46	:	:	PUNCT
ijassa-493	37	47	(	(	PUNCT
ijassa-493	37	48	)	)	PUNCT
ijassa-493	37	49	(	(	PUNCT
ijassa-493	37	50	)	)	PUNCT
ijassa-493	37	51	(	(	PUNCT
ijassa-493	37	52	)	)	PUNCT
ijassa-493	37	53	dn	dn	PROPN
ijassa-493	37	54	t	t	PROPN
ijassa-493	37	55	t	t	PROPN
ijassa-493	37	56	n	n	ADP
ijassa-493	37	57	t	t	NOUN
ijassa-493	37	58	dt	dt	X
ijassa-493	37	59	=	=	SYM
ijassa-493	37	60			PROPN
ijassa-493	37	61	,	,	PUNCT
ijassa-493	37	62	at	at	ADP
ijassa-493	37	63	0	0	NUM
ijassa-493	37	64	0	0	NUM
ijassa-493	37	65	(	(	PUNCT
ijassa-493	37	66	)	)	PUNCT
ijassa-493	37	67	n	n	PRON
ijassa-493	37	68	t	t	PROPN
ijassa-493	37	69	n=	n=	ADJ
ijassa-493	37	70	(	(	PUNCT
ijassa-493	37	71	2	2	X
ijassa-493	37	72	)	)	PUNCT
ijassa-493	37	73	where	where	SCONJ
ijassa-493	37	74			X
ijassa-493	37	75	(	(	PUNCT
ijassa-493	37	76	t	t	NOUN
ijassa-493	37	77	)	)	PUNCT
ijassa-493	37	78	is	be	AUX
ijassa-493	37	79	the	the	DET
ijassa-493	37	80	rate	rate	NOUN
ijassa-493	37	81	of	of	ADP
ijassa-493	37	82	tumor	tumor	NOUN
ijassa-493	37	83	cells	cell	NOUN
ijassa-493	37	84	’	'	PUNCT
ijassa-493	37	85	proliferation	proliferation	NOUN
ijassa-493	37	86	,	,	PUNCT
ijassa-493	37	87	analytical	analytical	ADJ
ijassa-493	37	88	study	study	NOUN
ijassa-493	37	89	of	of	ADP
ijassa-493	37	90	antitumor	antitumor	PROPN
ijassa-493	37	91	viral	viral	ADJ
ijassa-493	37	92	vaccine	vaccine	NOUN
ijassa-493	37	93	61	61	NUM
ijassa-493	37	94	(	(	PUNCT
ijassa-493	37	95	)	)	PUNCT
ijassa-493	37	96	vn	vn	PROPN
ijassa-493	37	97	t	t	PROPN
ijassa-493	37	98	is	be	AUX
ijassa-493	37	99	the	the	DET
ijassa-493	37	100	number	number	NOUN
ijassa-493	37	101	of	of	ADP
ijassa-493	37	102	infected	infected	ADJ
ijassa-493	37	103	tumor	tumor	NOUN
ijassa-493	37	104	cells	cell	NOUN
ijassa-493	37	105	after	after	ADP
ijassa-493	37	106	the	the	DET
ijassa-493	37	107	vaccine	vaccine	NOUN
ijassa-493	37	108	introduction	introduction	NOUN
ijassa-493	37	109	,	,	PUNCT
ijassa-493	37	110	1v	1v	NUM
ijassa-493	37	111	cvt	cvt	PROPN
ijassa-493	37	112	z=	z=	PROPN
ijassa-493	37	113	+	+	CCONJ
ijassa-493	37	114	is	be	AUX
ijassa-493	37	115	the	the	DET
ijassa-493	37	116	moment	moment	NOUN
ijassa-493	37	117	of	of	ADP
ijassa-493	37	118	the	the	DET
ijassa-493	37	119	start	start	NOUN
ijassa-493	37	120	of	of	ADP
ijassa-493	37	121	immune	immune	ADJ
ijassa-493	37	122	response	response	NOUN
ijassa-493	37	123	against	against	ADP
ijassa-493	37	124	viruses	virus	NOUN
ijassa-493	37	125	,	,	PUNCT
ijassa-493	37	126	1n	1n	PROPN
ijassa-493	37	127	cnt	cnt	PROPN
ijassa-493	37	128	z=	z=	PROPN
ijassa-493	37	129	+	+	CCONJ
ijassa-493	37	130	is	be	AUX
ijassa-493	37	131	the	the	DET
ijassa-493	37	132	moment	moment	NOUN
ijassa-493	37	133	of	of	ADP
ijassa-493	37	134	the	the	DET
ijassa-493	37	135	start	start	NOUN
ijassa-493	37	136	of	of	ADP
ijassa-493	37	137	immune	immune	ADJ
ijassa-493	37	138	response	response	NOUN
ijassa-493	37	139	against	against	ADP
ijassa-493	37	140	tumor	tumor	NOUN
ijassa-493	37	141	cells	cell	NOUN
ijassa-493	37	142	,	,	PUNCT
ijassa-493	37	143	1	1	NUM
ijassa-493	37	144	is	be	AUX
ijassa-493	37	145	the	the	DET
ijassa-493	37	146	moment	moment	NOUN
ijassa-493	37	147	of	of	ADP
ijassa-493	37	148	vaccine	vaccine	NOUN
ijassa-493	37	149	introduction	introduction	NOUN
ijassa-493	37	150	,	,	PUNCT
ijassa-493	37	151	cvz	cvz	NOUN
ijassa-493	37	152	and	and	CCONJ
ijassa-493	37	153	cnz	cnz	NOUN
ijassa-493	37	154	are	be	AUX
ijassa-493	37	155	the	the	DET
ijassa-493	37	156	time	time	NOUN
ijassa-493	37	157	lag	lag	NOUN
ijassa-493	37	158	of	of	ADP
ijassa-493	37	159	immune	immune	ADJ
ijassa-493	37	160	response	response	NOUN
ijassa-493	37	161	against	against	ADP
ijassa-493	37	162	the	the	DET
ijassa-493	37	163	virus	virus	NOUN
ijassa-493	37	164	and	and	CCONJ
ijassa-493	37	165	infected	infect	VERB
ijassa-493	37	166	tumor	tumor	NOUN
ijassa-493	37	167	cells	cell	NOUN
ijassa-493	37	168	,	,	PUNCT
ijassa-493	37	169	(	(	PUNCT
ijassa-493	37	170	)	)	PUNCT
ijassa-493	37	171	v	v	NOUN
ijassa-493	37	172	va	va	PROPN
ijassa-493	37	173	t	t	PROPN
ijassa-493	37	174	t−	t−	PROPN
ijassa-493	37	175	is	be	AUX
ijassa-493	37	176	the	the	DET
ijassa-493	37	177	number	number	NOUN
ijassa-493	37	178	of	of	ADP
ijassa-493	37	179	antibodies	antibody	NOUN
ijassa-493	37	180	against	against	ADP
ijassa-493	37	181	the	the	DET
ijassa-493	37	182	virus	virus	NOUN
ijassa-493	37	183	,	,	PUNCT
ijassa-493	37	184	(	(	PUNCT
ijassa-493	37	185	)	)	PUNCT
ijassa-493	37	186	n	n	CCONJ
ijassa-493	37	187	na	na	NOUN
ijassa-493	37	188	t	t	X
ijassa-493	37	189	t−	t−	PROPN
ijassa-493	37	190	is	be	AUX
ijassa-493	37	191	the	the	DET
ijassa-493	37	192	number	number	NOUN
ijassa-493	37	193	of	of	ADP
ijassa-493	37	194	antibodies	antibody	NOUN
ijassa-493	37	195	against	against	ADP
ijassa-493	37	196	infected	infected	ADJ
ijassa-493	37	197	tumor	tumor	NOUN
ijassa-493	37	198	cells	cell	NOUN
ijassa-493	37	199	,	,	PUNCT
ijassa-493	37	200	(	(	PUNCT
ijassa-493	37	201	)	)	PUNCT
ijassa-493	37	202	vt	vt	PROPN
ijassa-493	37	203	t	t	NOUN
ijassa-493	37	204	−	−	PROPN
ijassa-493	37	205	and	and	CCONJ
ijassa-493	37	206	(	(	PUNCT
ijassa-493	37	207	)	)	PUNCT
ijassa-493	37	208	nt	not	PART
ijassa-493	37	209	t	t	ADJ
ijassa-493	37	210	−	−	PROPN
ijassa-493	37	211	are	be	AUX
ijassa-493	37	212	the	the	DET
ijassa-493	37	213	heaviside	heaviside	ADJ
ijassa-493	37	214	step	step	NOUN
ijassa-493	37	215	function	function	NOUN
ijassa-493	37	216	,	,	PUNCT
ijassa-493	37	217	avk	avk	PROPN
ijassa-493	37	218	,	,	PUNCT
ijassa-493	37	219	ank	ank	PROPN
ijassa-493	37	220	,	,	PUNCT
ijassa-493	37	221	and	and	CCONJ
ijassa-493	37	222	vk	vk	PROPN
ijassa-493	37	223	are	be	AUX
ijassa-493	37	224	the	the	DET
ijassa-493	37	225	dimension	dimension	NOUN
ijassa-493	37	226	factors	factor	NOUN
ijassa-493	37	227	.	.	PUNCT
ijassa-493	38	1	the	the	DET
ijassa-493	38	2	first	first	ADJ
ijassa-493	38	3	component	component	NOUN
ijassa-493	38	4	of	of	ADP
ijassa-493	38	5	equation	equation	NOUN
ijassa-493	38	6	(	(	PUNCT
ijassa-493	38	7	1	1	X
ijassa-493	38	8	)	)	PUNCT
ijassa-493	38	9	describes	describe	VERB
ijassa-493	38	10	the	the	DET
ijassa-493	38	11	dynamics	dynamic	NOUN
ijassa-493	38	12	of	of	ADP
ijassa-493	38	13	the	the	DET
ijassa-493	38	14	tumor	tumor	NOUN
ijassa-493	38	15	cells	cell	NOUN
ijassa-493	38	16	’	'	PUNCT
ijassa-493	38	17	growth	growth	NOUN
ijassa-493	38	18	before	before	ADP
ijassa-493	38	19	the	the	DET
ijassa-493	38	20	introduction	introduction	NOUN
ijassa-493	38	21	of	of	ADP
ijassa-493	38	22	the	the	DET
ijassa-493	38	23	viral	viral	ADJ
ijassa-493	38	24	vaccine	vaccine	NOUN
ijassa-493	38	25	.	.	PUNCT
ijassa-493	39	1	the	the	DET
ijassa-493	39	2	second	second	ADJ
ijassa-493	39	3	component	component	NOUN
ijassa-493	39	4	of	of	ADP
ijassa-493	39	5	equation	equation	NOUN
ijassa-493	39	6	(	(	PUNCT
ijassa-493	39	7	1	1	X
ijassa-493	39	8	)	)	PUNCT
ijassa-493	39	9	describes	describe	VERB
ijassa-493	39	10	the	the	DET
ijassa-493	39	11	death	death	NOUN
ijassa-493	39	12	of	of	ADP
ijassa-493	39	13	infected	infected	ADJ
ijassa-493	39	14	tumor	tumor	NOUN
ijassa-493	39	15	cells	cell	NOUN
ijassa-493	39	16	caused	cause	VERB
ijassa-493	39	17	by	by	ADP
ijassa-493	39	18	the	the	DET
ijassa-493	39	19	virus	virus	NOUN
ijassa-493	39	20	.	.	PUNCT
ijassa-493	40	1	the	the	DET
ijassa-493	40	2	first	first	ADJ
ijassa-493	40	3	stage	stage	NOUN
ijassa-493	40	4	of	of	ADP
ijassa-493	40	5	the	the	DET
ijassa-493	40	6	immune	immune	ADJ
ijassa-493	40	7	system	system	NOUN
ijassa-493	40	8	stimulation	stimulation	NOUN
ijassa-493	40	9	is	be	AUX
ijassa-493	40	10	production	production	NOUN
ijassa-493	40	11	of	of	ADP
ijassa-493	40	12	antibodies	antibody	NOUN
ijassa-493	40	13	against	against	ADP
ijassa-493	40	14	the	the	DET
ijassa-493	40	15	virus	virus	NOUN
ijassa-493	40	16	(	(	PUNCT
ijassa-493	40	17	figure	figure	NOUN
ijassa-493	40	18	2	2	NUM
ijassa-493	40	19	–	–	PUNCT
ijassa-493	40	20	(	(	PUNCT
ijassa-493	40	21	)	)	PUNCT
ijassa-493	40	22	vc	vc	PROPN
ijassa-493	40	23	t	t	PROPN
ijassa-493	40	24	,	,	PUNCT
ijassa-493	40	25	(	(	PUNCT
ijassa-493	40	26	)	)	PUNCT
ijassa-493	40	27	va	va	PROPN
ijassa-493	40	28	t	t	PROPN
ijassa-493	40	29	)	)	PUNCT
ijassa-493	40	30	.	.	PUNCT
ijassa-493	41	1	at	at	ADP
ijassa-493	41	2	this	this	DET
ijassa-493	41	3	stage	stage	NOUN
ijassa-493	41	4	the	the	DET
ijassa-493	41	5	death	death	NOUN
ijassa-493	41	6	of	of	ADP
ijassa-493	41	7	tumor	tumor	NOUN
ijassa-493	41	8	cells	cell	NOUN
ijassa-493	41	9	is	be	AUX
ijassa-493	41	10	caused	cause	VERB
ijassa-493	41	11	by	by	ADP
ijassa-493	41	12	the	the	DET
ijassa-493	41	13	penetration	penetration	NOUN
ijassa-493	41	14	of	of	ADP
ijassa-493	41	15	the	the	DET
ijassa-493	41	16	virus	virus	NOUN
ijassa-493	41	17	inside	inside	ADP
ijassa-493	41	18	the	the	DET
ijassa-493	41	19	tumor	tumor	NOUN
ijassa-493	41	20	cells	cell	NOUN
ijassa-493	41	21	(	(	PUNCT
ijassa-493	41	22	figure	figure	NOUN
ijassa-493	41	23	3	3	NUM
ijassa-493	41	24	)	)	PUNCT
ijassa-493	41	25	.	.	PUNCT
ijassa-493	42	1	the	the	DET
ijassa-493	42	2	third	third	ADJ
ijassa-493	42	3	component	component	NOUN
ijassa-493	42	4	of	of	ADP
ijassa-493	42	5	the	the	DET
ijassa-493	42	6	equation	equation	NOUN
ijassa-493	42	7	describes	describe	VERB
ijassa-493	42	8	the	the	DET
ijassa-493	42	9	death	death	NOUN
ijassa-493	42	10	of	of	ADP
ijassa-493	42	11	tumor	tumor	NOUN
ijassa-493	42	12	cells	cell	NOUN
ijassa-493	42	13	caused	cause	VERB
ijassa-493	42	14	by	by	ADP
ijassa-493	42	15	antibodies	antibody	NOUN
ijassa-493	42	16	produced	produce	VERB
ijassa-493	42	17	against	against	ADP
ijassa-493	42	18	the	the	DET
ijassa-493	42	19	infected	infected	ADJ
ijassa-493	42	20	tumor	tumor	NOUN
ijassa-493	42	21	cells	cell	NOUN
ijassa-493	42	22	(	(	PUNCT
ijassa-493	42	23	figure	figure	NOUN
ijassa-493	42	24	2	2	NUM
ijassa-493	42	25	–	–	PUNCT
ijassa-493	42	26	(	(	PUNCT
ijassa-493	42	27	)	)	PUNCT
ijassa-493	42	28	nc	nc	PROPN
ijassa-493	42	29	t	t	PROPN
ijassa-493	42	30	,	,	PUNCT
ijassa-493	42	31	(	(	PUNCT
ijassa-493	42	32	)	)	PUNCT
ijassa-493	42	33	na	na	NOUN
ijassa-493	42	34	t	t	NOUN
ijassa-493	42	35	)	)	PUNCT
ijassa-493	42	36	.	.	PUNCT
ijassa-493	43	1	reproducing	reproduce	VERB
ijassa-493	43	2	in	in	ADP
ijassa-493	43	3	tumor	tumor	NOUN
ijassa-493	43	4	cells	cell	NOUN
ijassa-493	43	5	,	,	PUNCT
ijassa-493	43	6	the	the	DET
ijassa-493	43	7	viruses	virus	NOUN
ijassa-493	43	8	induce	induce	VERB
ijassa-493	43	9	the	the	DET
ijassa-493	43	10	development	development	NOUN
ijassa-493	43	11	of	of	ADP
ijassa-493	43	12	new	new	ADJ
ijassa-493	43	13	protein	protein	NOUN
ijassa-493	43	14	formations	formation	NOUN
ijassa-493	43	15	on	on	ADP
ijassa-493	43	16	the	the	DET
ijassa-493	43	17	surface	surface	NOUN
ijassa-493	43	18	of	of	ADP
ijassa-493	43	19	the	the	DET
ijassa-493	43	20	tumor	tumor	NOUN
ijassa-493	43	21	cell	cell	NOUN
ijassa-493	43	22	membranes	membrane	NOUN
ijassa-493	43	23	.	.	PUNCT
ijassa-493	44	1	such	such	ADJ
ijassa-493	44	2	infected	infected	ADJ
ijassa-493	44	3	tumor	tumor	NOUN
ijassa-493	44	4	cells	cell	NOUN
ijassa-493	44	5	are	be	AUX
ijassa-493	44	6	perceived	perceive	VERB
ijassa-493	44	7	by	by	ADP
ijassa-493	44	8	the	the	DET
ijassa-493	44	9	immune	immune	ADJ
ijassa-493	44	10	system	system	NOUN
ijassa-493	44	11	as	as	ADP
ijassa-493	44	12	foreign	foreign	ADJ
ijassa-493	44	13	to	to	ADP
ijassa-493	44	14	the	the	DET
ijassa-493	44	15	body	body	NOUN
ijassa-493	44	16	.	.	PUNCT
ijassa-493	45	1	as	as	ADP
ijassa-493	45	2	a	a	DET
ijassa-493	45	3	result	result	NOUN
ijassa-493	45	4	,	,	PUNCT
ijassa-493	45	5	immune	immune	ADJ
ijassa-493	45	6	system	system	NOUN
ijassa-493	45	7	produces	produce	VERB
ijassa-493	45	8	antibodies	antibodie	VERB
ijassa-493	45	9	specific	specific	ADJ
ijassa-493	45	10	to	to	ADP
ijassa-493	45	11	the	the	DET
ijassa-493	45	12	tumor	tumor	NOUN
ijassa-493	45	13	cells	cell	NOUN
ijassa-493	45	14	,	,	PUNCT
ijassa-493	45	15	and	and	CCONJ
ijassa-493	45	16	they	they	PRON
ijassa-493	45	17	destroy	destroy	VERB
ijassa-493	45	18	the	the	DET
ijassa-493	45	19	infected	infected	ADJ
ijassa-493	45	20	tumor	tumor	NOUN
ijassa-493	45	21	cells	cell	NOUN
ijassa-493	45	22	(	(	PUNCT
ijassa-493	45	23	figure	figure	NOUN
ijassa-493	45	24	3	3	NUM
ijassa-493	45	25	)	)	PUNCT
ijassa-493	45	26	.	.	PUNCT
ijassa-493	46	1	the	the	DET
ijassa-493	46	2	patterns	pattern	NOUN
ijassa-493	46	3	of	of	ADP
ijassa-493	46	4	immune	immune	ADJ
ijassa-493	46	5	response	response	NOUN
ijassa-493	46	6	to	to	ADP
ijassa-493	46	7	the	the	DET
ijassa-493	46	8	foreign	foreign	ADJ
ijassa-493	46	9	cells	cell	NOUN
ijassa-493	46	10	are	be	AUX
ijassa-493	46	11	based	base	VERB
ijassa-493	46	12	on	on	ADP
ijassa-493	46	13	marchuk	marchuk	PROPN
ijassa-493	46	14	's	's	PART
ijassa-493	46	15	mathematical	mathematical	ADJ
ijassa-493	46	16	model	model	NOUN
ijassa-493	46	17	of	of	ADP
ijassa-493	46	18	infectious	infectious	ADJ
ijassa-493	46	19	diseases	disease	NOUN
ijassa-493	46	20	[	[	X
ijassa-493	46	21	24	24	NUM
ijassa-493	46	22	-	-	SYM
ijassa-493	46	23	27	27	NUM
ijassa-493	46	24	]	]	PUNCT
ijassa-493	46	25	.	.	PUNCT
ijassa-493	47	1	this	this	DET
ijassa-493	47	2	model	model	NOUN
ijassa-493	47	3	treats	treat	VERB
ijassa-493	47	4	the	the	DET
ijassa-493	47	5	immune	immune	ADJ
ijassa-493	47	6	response	response	NOUN
ijassa-493	47	7	(	(	PUNCT
ijassa-493	47	8	production	production	NOUN
ijassa-493	47	9	of	of	ADP
ijassa-493	47	10	t	t	PROPN
ijassa-493	47	11	and	and	CCONJ
ijassa-493	47	12	b	b	PROPN
ijassa-493	47	13	cells	cell	NOUN
ijassa-493	47	14	)	)	PUNCT
ijassa-493	47	15	as	as	ADP
ijassa-493	47	16	a	a	DET
ijassa-493	47	17	combined	combined	ADJ
ijassa-493	47	18	action	action	NOUN
ijassa-493	47	19	.	.	PUNCT
ijassa-493	48	1	therefore	therefore	ADV
ijassa-493	48	2	in	in	ADP
ijassa-493	48	3	the	the	DET
ijassa-493	48	4	present	present	ADJ
ijassa-493	48	5	study	study	NOUN
ijassa-493	48	6	the	the	DET
ijassa-493	48	7	immune	immune	ADJ
ijassa-493	48	8	response	response	NOUN
ijassa-493	48	9	means	mean	VERB
ijassa-493	48	10	the	the	DET
ijassa-493	48	11	formation	formation	NOUN
ijassa-493	48	12	of	of	ADP
ijassa-493	48	13	antibodies	antibody	NOUN
ijassa-493	48	14	and	and	CCONJ
ijassa-493	48	15	plasma	plasma	NOUN
ijassa-493	48	16	cells	cell	NOUN
ijassa-493	48	17	specific	specific	ADJ
ijassa-493	48	18	to	to	ADP
ijassa-493	48	19	the	the	DET
ijassa-493	48	20	vee	vee	PROPN
ijassa-493	48	21	virus	virus	PROPN
ijassa-493	48	22	and	and	CCONJ
ijassa-493	48	23	infected	infect	VERB
ijassa-493	48	24	tumor	tumor	NOUN
ijassa-493	48	25	cells	cell	NOUN
ijassa-493	48	26	.	.	PUNCT
ijassa-493	49	1	using	use	VERB
ijassa-493	49	2	marchuk	marchuk	PROPN
ijassa-493	49	3	’s	’s	PART
ijassa-493	49	4	model	model	NOUN
ijassa-493	49	5	,	,	PUNCT
ijassa-493	49	6	the	the	DET
ijassa-493	49	7	dynamics	dynamic	NOUN
ijassa-493	49	8	of	of	ADP
ijassa-493	49	9	the	the	DET
ijassa-493	49	10	number	number	NOUN
ijassa-493	49	11	of	of	ADP
ijassa-493	49	12	viruses	virus	NOUN
ijassa-493	49	13	is	be	AUX
ijassa-493	49	14	described	describe	VERB
ijassa-493	49	15	by	by	ADP
ijassa-493	49	16	the	the	DET
ijassa-493	49	17	following	follow	VERB
ijassa-493	49	18	equation	equation	NOUN
ijassa-493	49	19	:	:	PUNCT
ijassa-493	49	20	(	(	PUNCT
ijassa-493	49	21	)	)	PUNCT
ijassa-493	49	22	(	(	PUNCT
ijassa-493	49	23	)	)	PUNCT
ijassa-493	49	24	(	(	PUNCT
ijassa-493	49	25	)	)	PUNCT
ijassa-493	49	26	(	(	PUNCT
ijassa-493	49	27	)	)	PUNCT
ijassa-493	49	28	,	,	PUNCT
ijassa-493	49	29	v	v	X
ijassa-493	49	30	v	v	NUM
ijassa-493	49	31	v	v	ADP
ijassa-493	49	32	dv	dv	PROPN
ijassa-493	49	33	t	t	PROPN
ijassa-493	49	34	v	v	PROPN
ijassa-493	49	35	t	t	PROPN
ijassa-493	49	36	a	a	DET
ijassa-493	49	37	t	t	NOUN
ijassa-493	49	38	v	v	ADP
ijassa-493	49	39	t	t	NOUN
ijassa-493	49	40	dt	dt	X
ijassa-493	49	41			X
ijassa-493	49	42	=	=	NOUN
ijassa-493	49	43	−	−	PROPN
ijassa-493	49	44	(	(	PUNCT
ijassa-493	49	45	3	3	NUM
ijassa-493	49	46	)	)	PUNCT
ijassa-493	49	47	where	where	SCONJ
ijassa-493	49	48	0	0	NUM
ijassa-493	49	49	1	1	NUM
ijassa-493	49	50	(	(	PUNCT
ijassa-493	49	51	)	)	PUNCT
ijassa-493	49	52	v	v	NOUN
ijassa-493	49	53	v	v	NOUN
ijassa-493	49	54	=	=	NOUN
ijassa-493	49	55	is	be	AUX
ijassa-493	49	56	the	the	DET
ijassa-493	49	57	initial	initial	ADJ
ijassa-493	49	58	dose	dose	NOUN
ijassa-493	49	59	of	of	ADP
ijassa-493	49	60	the	the	DET
ijassa-493	49	61	viral	viral	ADJ
ijassa-493	49	62	vaccine	vaccine	NOUN
ijassa-493	49	63	,	,	PUNCT
ijassa-493	49	64	1	1	NUM
ijassa-493	49	65	is	be	AUX
ijassa-493	49	66	the	the	DET
ijassa-493	49	67	moment	moment	NOUN
ijassa-493	49	68	of	of	ADP
ijassa-493	49	69	the	the	DET
ijassa-493	49	70	first	first	ADJ
ijassa-493	49	71	administration	administration	NOUN
ijassa-493	49	72	of	of	ADP
ijassa-493	49	73	the	the	DET
ijassa-493	49	74	viral	viral	ADJ
ijassa-493	49	75	vaccine	vaccine	NOUN
ijassa-493	49	76	,	,	PUNCT
ijassa-493	49	77	v	v	PROPN
ijassa-493	49	78	is	be	AUX
ijassa-493	49	79	the	the	DET
ijassa-493	49	80	rate	rate	NOUN
ijassa-493	49	81	of	of	ADP
ijassa-493	49	82	viruses	virus	NOUN
ijassa-493	49	83	’	'	PUNCT
ijassa-493	49	84	reproduction	reproduction	NOUN
ijassa-493	49	85	within	within	ADP
ijassa-493	49	86	the	the	DET
ijassa-493	49	87	cell	cell	NOUN
ijassa-493	49	88	,	,	PUNCT
ijassa-493	49	89	v	v	X
ijassa-493	49	90	is	be	AUX
ijassa-493	49	91	the	the	DET
ijassa-493	49	92	death	death	NOUN
ijassa-493	49	93	rate	rate	NOUN
ijassa-493	49	94	of	of	ADP
ijassa-493	49	95	viruses	virus	NOUN
ijassa-493	49	96	when	when	SCONJ
ijassa-493	49	97	they	they	PRON
ijassa-493	49	98	interact	interact	VERB
ijassa-493	49	99	with	with	ADP
ijassa-493	49	100	antibodies	antibody	NOUN
ijassa-493	49	101	(	(	PUNCT
ijassa-493	49	102	)	)	PUNCT
ijassa-493	49	103	va	va	PROPN
ijassa-493	49	104	t	t	PROPN
ijassa-493	49	105	.	.	PUNCT
ijassa-493	50	1	in	in	ADP
ijassa-493	50	2	the	the	DET
ijassa-493	50	3	vaccine	vaccine	NOUN
ijassa-493	50	4	therapy	therapy	NOUN
ijassa-493	50	5	model	model	NOUN
ijassa-493	50	6	,	,	PUNCT
ijassa-493	50	7	the	the	DET
ijassa-493	50	8	initial	initial	ADJ
ijassa-493	50	9	condition	condition	NOUN
ijassa-493	50	10	0	0	NUM
ijassa-493	50	11	1	1	NUM
ijassa-493	50	12	(	(	PUNCT
ijassa-493	50	13	)	)	PUNCT
ijassa-493	50	14	v	v	NOUN
ijassa-493	50	15	v	v	NOUN
ijassa-493	50	16	=	=	NOUN
ijassa-493	50	17	denotes	denote	VERB
ijassa-493	50	18	the	the	DET
ijassa-493	50	19	dosage	dosage	NOUN
ijassa-493	50	20	of	of	ADP
ijassa-493	50	21	the	the	DET
ijassa-493	50	22	vaccine	vaccine	NOUN
ijassa-493	50	23	.	.	PUNCT
ijassa-493	51	1	the	the	DET
ijassa-493	51	2	immune	immune	ADJ
ijassa-493	51	3	response	response	NOUN
ijassa-493	51	4	of	of	ADP
ijassa-493	51	5	the	the	DET
ijassa-493	51	6	body	body	NOUN
ijassa-493	51	7	to	to	ADP
ijassa-493	51	8	the	the	DET
ijassa-493	51	9	virus	virus	NOUN
ijassa-493	51	10	introduction	introduction	NOUN
ijassa-493	51	11	results	result	VERB
ijassa-493	51	12	in	in	ADP
ijassa-493	51	13	production	production	NOUN
ijassa-493	51	14	of	of	ADP
ijassa-493	51	15	antibodies	antibody	NOUN
ijassa-493	51	16	and	and	CCONJ
ijassa-493	51	17	plasma	plasma	NOUN
ijassa-493	51	18	cells	cell	NOUN
ijassa-493	51	19	.	.	PUNCT
ijassa-493	52	1	their	their	PRON
ijassa-493	52	2	numbers	number	NOUN
ijassa-493	52	3	are	be	AUX
ijassa-493	52	4	calculated	calculate	VERB
ijassa-493	52	5	using	use	VERB
ijassa-493	52	6	the	the	DET
ijassa-493	52	7	following	follow	VERB
ijassa-493	52	8	four	four	NUM
ijassa-493	52	9	differential	differential	ADJ
ijassa-493	52	10	equations	equation	NOUN
ijassa-493	53	1	[	[	X
ijassa-493	53	2	24	24	NUM
ijassa-493	53	3	-	-	SYM
ijassa-493	53	4	25	25	NUM
ijassa-493	53	5	]	]	PUNCT
ijassa-493	53	6	for	for	ADP
ijassa-493	53	7	each	each	PRON
ijassa-493	53	8	of	of	ADP
ijassa-493	53	9	the	the	DET
ijassa-493	53	10	two	two	NUM
ijassa-493	53	11	stages	stage	NOUN
ijassa-493	53	12	of	of	ADP
ijassa-493	53	13	the	the	DET
ijassa-493	53	14	immune	immune	ADJ
ijassa-493	53	15	response	response	NOUN
ijassa-493	53	16	–	–	PUNCT
ijassa-493	53	17	against	against	ADP
ijassa-493	53	18	the	the	DET
ijassa-493	53	19	virus	virus	NOUN
ijassa-493	53	20	and	and	CCONJ
ijassa-493	53	21	against	against	ADP
ijassa-493	53	22	the	the	DET
ijassa-493	53	23	infected	infected	ADJ
ijassa-493	53	24	tumor	tumor	NOUN
ijassa-493	53	25	cells	cell	NOUN
ijassa-493	53	26	.	.	PUNCT
ijassa-493	54	1	the	the	DET
ijassa-493	54	2	dynamics	dynamic	NOUN
ijassa-493	54	3	of	of	ADP
ijassa-493	54	4	the	the	DET
ijassa-493	54	5	number	number	NOUN
ijassa-493	54	6	of	of	ADP
ijassa-493	54	7	antibodies	antibody	NOUN
ijassa-493	54	8	to	to	ADP
ijassa-493	54	9	the	the	DET
ijassa-493	54	10	virus	virus	NOUN
ijassa-493	54	11	(	(	PUNCT
ijassa-493	54	12	)	)	PUNCT
ijassa-493	54	13	va	va	PROPN
ijassa-493	54	14	t	t	PROPN
ijassa-493	54	15	:	:	PUNCT
ijassa-493	54	16	1	1	NUM
ijassa-493	54	17	(	(	PUNCT
ijassa-493	54	18	)	)	PUNCT
ijassa-493	54	19	(	(	PUNCT
ijassa-493	54	20	)	)	PUNCT
ijassa-493	54	21	(	(	PUNCT
ijassa-493	54	22	)	)	PUNCT
ijassa-493	54	23	(	(	PUNCT
ijassa-493	54	24	)	)	PUNCT
ijassa-493	54	25	(	(	PUNCT
ijassa-493	54	26	)	)	PUNCT
ijassa-493	54	27	,	,	PUNCT
ijassa-493	54	28	v	v	ADP
ijassa-493	54	29	a	a	DET
ijassa-493	54	30	v	v	NOUN
ijassa-493	54	31	v	v	ADP
ijassa-493	54	32	av	av	PROPN
ijassa-493	54	33	v	v	NUM
ijassa-493	54	34	v	v	NUM
ijassa-493	54	35	v	v	NUM
ijassa-493	54	36	v	v	NOUN
ijassa-493	54	37	v	v	NOUN
ijassa-493	54	38	da	da	PROPN
ijassa-493	54	39	t	t	PROPN
ijassa-493	54	40	c	c	PROPN
ijassa-493	54	41	t	t	PROPN
ijassa-493	54	42	t	t	PROPN
ijassa-493	54	43	a	a	DET
ijassa-493	54	44	t	t	NOUN
ijassa-493	54	45	t	t	NOUN
ijassa-493	54	46	v	v	NOUN
ijassa-493	54	47	t	t	PROPN
ijassa-493	54	48	t	t	PROPN
ijassa-493	54	49	a	a	DET
ijassa-493	54	50	t	t	NOUN
ijassa-493	54	51	dt	dt	X
ijassa-493	54	52			NOUN
ijassa-493	54	53			PROPN
ijassa-493	54	54			PROPN
ijassa-493	54	55	=	=	NOUN
ijassa-493	54	56	−	−	PROPN
ijassa-493	55	1	−	−	PROPN
ijassa-493	56	1	−	−	PROPN
ijassa-493	57	1	−	−	PROPN
ijassa-493	58	1	−	−	PROPN
ijassa-493	58	2	−	−	PROPN
ijassa-493	58	3	(	(	PUNCT
ijassa-493	58	4	4	4	NUM
ijassa-493	58	5	)	)	PUNCT
ijassa-493	58	6	62	62	NUM
ijassa-493	58	7	n.a	n.a	PROPN
ijassa-493	58	8	.	.	PROPN
ijassa-493	58	9	babushkina	babushkina	PROPN
ijassa-493	58	10	,	,	PUNCT
ijassa-493	58	11	e.a	e.a	PROPN
ijassa-493	58	12	.	.	PROPN
ijassa-493	58	13	kuzina	kuzina	PROPN
ijassa-493	58	14	where	where	SCONJ
ijassa-493	58	15	a	a	ADV
ijassa-493	58	16	is	be	AUX
ijassa-493	58	17	the	the	DET
ijassa-493	58	18	rate	rate	NOUN
ijassa-493	58	19	of	of	ADP
ijassa-493	58	20	formation	formation	NOUN
ijassa-493	58	21	of	of	ADP
ijassa-493	58	22	antibodies	antibody	NOUN
ijassa-493	58	23	from	from	ADP
ijassa-493	58	24	a	a	DET
ijassa-493	58	25	single	single	ADJ
ijassa-493	58	26	plasma	plasma	NOUN
ijassa-493	58	27	cell	cell	NOUN
ijassa-493	58	28	,	,	PUNCT
ijassa-493	58	29	av	av	NOUN
ijassa-493	58	30	is	be	AUX
ijassa-493	58	31	the	the	DET
ijassa-493	58	32	death	death	NOUN
ijassa-493	58	33	rate	rate	NOUN
ijassa-493	58	34	of	of	ADP
ijassa-493	58	35	antibodies	antibody	NOUN
ijassa-493	58	36	due	due	ADP
ijassa-493	58	37	to	to	ADP
ijassa-493	58	38	interaction	interaction	NOUN
ijassa-493	58	39	with	with	ADP
ijassa-493	58	40	viruses	virus	NOUN
ijassa-493	58	41	(	(	PUNCT
ijassa-493	58	42	)	)	PUNCT
ijassa-493	58	43	va	va	PROPN
ijassa-493	58	44	t	t	PROPN
ijassa-493	58	45	,	,	PUNCT
ijassa-493	58	46	v	v	X
ijassa-493	58	47	is	be	AUX
ijassa-493	58	48	the	the	DET
ijassa-493	58	49	rate	rate	NOUN
ijassa-493	58	50	of	of	ADP
ijassa-493	58	51	decrease	decrease	NOUN
ijassa-493	58	52	in	in	ADP
ijassa-493	58	53	the	the	DET
ijassa-493	58	54	number	number	NOUN
ijassa-493	58	55	of	of	ADP
ijassa-493	58	56	antibodies	antibody	NOUN
ijassa-493	58	57	due	due	ADP
ijassa-493	58	58	to	to	ADP
ijassa-493	58	59	natural	natural	ADJ
ijassa-493	58	60	destruction	destruction	NOUN
ijassa-493	58	61	.	.	PUNCT
ijassa-493	59	1	the	the	DET
ijassa-493	59	2	dynamics	dynamic	NOUN
ijassa-493	59	3	of	of	ADP
ijassa-493	59	4	formation	formation	NOUN
ijassa-493	59	5	of	of	ADP
ijassa-493	59	6	plasma	plasma	NOUN
ijassa-493	59	7	cells	cell	NOUN
ijassa-493	59	8	cv(t	cv(t	PUNCT
ijassa-493	59	9	):	):	PUNCT
ijassa-493	59	10	1	1	NUM
ijassa-493	59	11	1	1	NUM
ijassa-493	59	12	(	(	PUNCT
ijassa-493	59	13	)	)	PUNCT
ijassa-493	59	14	(	(	PUNCT
ijassa-493	59	15	)	)	PUNCT
ijassa-493	59	16	(	(	PUNCT
ijassa-493	59	17	)	)	PUNCT
ijassa-493	59	18	(	(	PUNCT
ijassa-493	59	19	)	)	PUNCT
ijassa-493	59	20	v	v	NOUN
ijassa-493	59	21	vc	vc	PROPN
ijassa-493	59	22	v	v	PROPN
ijassa-493	59	23	cv	cv	PROPN
ijassa-493	59	24	v	v	X
ijassa-493	59	25	vn	vn	PROPN
ijassa-493	59	26	dc	dc	PROPN
ijassa-493	59	27	t	t	PROPN
ijassa-493	59	28	v	v	ADP
ijassa-493	59	29	t	t	PROPN
ijassa-493	59	30	a	a	DET
ijassa-493	59	31	t	t	NOUN
ijassa-493	59	32	t	t	NOUN
ijassa-493	59	33	c	c	NOUN
ijassa-493	59	34	t	t	NOUN
ijassa-493	59	35	c	c	NOUN
ijassa-493	59	36	dt	dt	X
ijassa-493	59	37			X
ijassa-493	59	38			PROPN
ijassa-493	59	39			PROPN
ijassa-493	59	40			NOUN
ijassa-493	59	41			X
ijassa-493	59	42			NOUN
ijassa-493	59	43			PROPN
ijassa-493	59	44			PROPN
ijassa-493	59	45	=	=	PUNCT
ijassa-493	59	46	−	−	PROPN
ijassa-493	59	47	−	−	NUM
ijassa-493	59	48	−	−	PROPN
ijassa-493	59	49	−	−	PROPN
ijassa-493	59	50	−	−	PROPN
ijassa-493	59	51	,	,	PUNCT
ijassa-493	59	52	at	at	ADP
ijassa-493	59	53	1	1	NUM
ijassa-493	59	54	,	,	PUNCT
ijassa-493	59	55	(	(	PUNCT
ijassa-493	59	56	)	)	PUNCT
ijassa-493	59	57	v	v	NOUN
ijassa-493	59	58	vnc	vnc	NOUN
ijassa-493	59	59	c	c	PROPN
ijassa-493	59	60	=	=	X
ijassa-493	59	61	(	(	PUNCT
ijassa-493	59	62	5	5	NUM
ijassa-493	59	63	)	)	PUNCT
ijassa-493	59	64	where	where	SCONJ
ijassa-493	59	65	с	с	PROPN
ijassa-493	59	66	is	be	AUX
ijassa-493	59	67	the	the	DET
ijassa-493	59	68	rate	rate	NOUN
ijassa-493	59	69	of	of	ADP
ijassa-493	59	70	formation	formation	NOUN
ijassa-493	59	71	of	of	ADP
ijassa-493	59	72	plasma	plasma	NOUN
ijassa-493	59	73	cells	cell	NOUN
ijassa-493	59	74	,	,	PUNCT
ijassa-493	59	75	cv	cv	ADV
ijassa-493	59	76	is	be	AUX
ijassa-493	59	77	the	the	DET
ijassa-493	59	78	dimension	dimension	NOUN
ijassa-493	59	79	factor	factor	NOUN
ijassa-493	59	80	,	,	PUNCT
ijassa-493	59	81	cvz	cvz	PROPN
ijassa-493	59	82	is	be	AUX
ijassa-493	59	83	the	the	DET
ijassa-493	59	84	time	time	NOUN
ijassa-493	59	85	lag	lag	NOUN
ijassa-493	59	86	of	of	ADP
ijassa-493	59	87	the	the	DET
ijassa-493	59	88	immune	immune	ADJ
ijassa-493	59	89	response	response	NOUN
ijassa-493	59	90	to	to	ADP
ijassa-493	59	91	the	the	DET
ijassa-493	59	92	formation	formation	NOUN
ijassa-493	59	93	of	of	ADP
ijassa-493	59	94	a	a	DET
ijassa-493	59	95	plasma	plasma	NOUN
ijassa-493	59	96	cell	cell	NOUN
ijassa-493	59	97	clone	clone	NOUN
ijassa-493	59	98	.	.	PUNCT
ijassa-493	60	1	the	the	DET
ijassa-493	60	2	second	second	ADJ
ijassa-493	60	3	term	term	NOUN
ijassa-493	60	4	of	of	ADP
ijassa-493	60	5	this	this	DET
ijassa-493	60	6	equation	equation	NOUN
ijassa-493	60	7	defines	define	VERB
ijassa-493	60	8	the	the	DET
ijassa-493	60	9	deviation	deviation	NOUN
ijassa-493	60	10	of	of	ADP
ijassa-493	60	11	the	the	DET
ijassa-493	60	12	actual	actual	ADJ
ijassa-493	60	13	number	number	NOUN
ijassa-493	60	14	of	of	ADP
ijassa-493	60	15	plasma	plasma	NOUN
ijassa-493	60	16	cells	cell	NOUN
ijassa-493	60	17	from	from	ADP
ijassa-493	60	18	the	the	DET
ijassa-493	60	19	norm	norm	NOUN
ijassa-493	60	20	cvn	cvn	PROPN
ijassa-493	60	21	.	.	PUNCT
ijassa-493	61	1	the	the	DET
ijassa-493	61	2	equation	equation	NOUN
ijassa-493	61	3	for	for	ADP
ijassa-493	61	4	the	the	DET
ijassa-493	61	5	dynamics	dynamic	NOUN
ijassa-493	61	6	of	of	ADP
ijassa-493	61	7	the	the	DET
ijassa-493	61	8	number	number	NOUN
ijassa-493	61	9	of	of	ADP
ijassa-493	61	10	antibodies	antibody	NOUN
ijassa-493	61	11	(	(	PUNCT
ijassa-493	61	12	)	)	PUNCT
ijassa-493	61	13	na	na	PART
ijassa-493	61	14	t	t	NOUN
ijassa-493	61	15	acting	act	VERB
ijassa-493	61	16	against	against	ADP
ijassa-493	61	17	infected	infected	ADJ
ijassa-493	61	18	tumor	tumor	NOUN
ijassa-493	61	19	cells	cell	NOUN
ijassa-493	61	20	is	be	AUX
ijassa-493	61	21	as	as	SCONJ
ijassa-493	61	22	follows	follow	VERB
ijassa-493	61	23	:	:	PUNCT
ijassa-493	61	24	(	(	PUNCT
ijassa-493	61	25	)	)	PUNCT
ijassa-493	61	26	(	(	PUNCT
ijassa-493	61	27	)	)	PUNCT
ijassa-493	61	28	(	(	PUNCT
ijassa-493	61	29	)	)	PUNCT
ijassa-493	61	30	(	(	PUNCT
ijassa-493	61	31	)	)	PUNCT
ijassa-493	61	32	(	(	PUNCT
ijassa-493	61	33	)	)	PUNCT
ijassa-493	61	34	,	,	PUNCT
ijassa-493	61	35	n	n	PROPN
ijassa-493	61	36	an	an	DET
ijassa-493	61	37	n	n	CCONJ
ijassa-493	61	38	n	n	ADV
ijassa-493	61	39	an	an	DET
ijassa-493	61	40	n	n	CCONJ
ijassa-493	61	41	n	n	ADV
ijassa-493	61	42	v	v	NOUN
ijassa-493	61	43	n	n	CCONJ
ijassa-493	61	44	nn	nn	PROPN
ijassa-493	61	45	n	n	CCONJ
ijassa-493	61	46	n	n	CCONJ
ijassa-493	61	47	da	da	PROPN
ijassa-493	61	48	t	t	PROPN
ijassa-493	62	1	c	c	PROPN
ijassa-493	62	2	t	t	PROPN
ijassa-493	62	3	t	t	PROPN
ijassa-493	62	4	a	a	DET
ijassa-493	62	5	t	t	NOUN
ijassa-493	62	6	t	t	PROPN
ijassa-493	62	7	n	n	ADP
ijassa-493	62	8	t	t	PROPN
ijassa-493	62	9	t	t	PROPN
ijassa-493	62	10	a	a	DET
ijassa-493	62	11	t	t	NOUN
ijassa-493	62	12	t	t	NOUN
ijassa-493	62	13	dt	dt	NOUN
ijassa-493	62	14			NOUN
ijassa-493	62	15			VERB
ijassa-493	62	16	=	=	NOUN
ijassa-493	62	17	−	−	PROPN
ijassa-493	63	1	−	−	PROPN
ijassa-493	63	2	−	−	PROPN
ijassa-493	64	1	−	−	PROPN
ijassa-493	64	2	−	−	PROPN
ijassa-493	64	3	−	−	PROPN
ijassa-493	64	4	(	(	PUNCT
ijassa-493	64	5	6	6	NUM
ijassa-493	64	6	)	)	PUNCT
ijassa-493	64	7	where	where	SCONJ
ijassa-493	64	8	an	an	NOUN
ijassa-493	64	9	is	be	AUX
ijassa-493	64	10	the	the	DET
ijassa-493	64	11	rate	rate	NOUN
ijassa-493	64	12	of	of	ADP
ijassa-493	64	13	formation	formation	NOUN
ijassa-493	64	14	of	of	ADP
ijassa-493	64	15	antibodies	antibody	NOUN
ijassa-493	64	16	from	from	ADP
ijassa-493	64	17	a	a	DET
ijassa-493	64	18	single	single	ADJ
ijassa-493	64	19	plasma	plasma	NOUN
ijassa-493	64	20	cell	cell	NOUN
ijassa-493	64	21	,	,	PUNCT
ijassa-493	64	22	an	an	PROPN
ijassa-493	64	23	is	be	AUX
ijassa-493	64	24	the	the	DET
ijassa-493	64	25	death	death	NOUN
ijassa-493	64	26	rate	rate	NOUN
ijassa-493	64	27	of	of	ADP
ijassa-493	64	28	antibodies	antibody	NOUN
ijassa-493	64	29	(	(	PUNCT
ijassa-493	64	30	)	)	PUNCT
ijassa-493	64	31	na	na	NOUN
ijassa-493	64	32	t	t	NOUN
ijassa-493	64	33	due	due	ADP
ijassa-493	64	34	to	to	ADP
ijassa-493	64	35	interaction	interaction	NOUN
ijassa-493	64	36	with	with	ADP
ijassa-493	64	37	infected	infected	ADJ
ijassa-493	64	38	tumor	tumor	NOUN
ijassa-493	64	39	cells	cell	NOUN
ijassa-493	64	40	(	(	PUNCT
ijassa-493	64	41	)	)	PUNCT
ijassa-493	64	42	vn	vn	PROPN
ijassa-493	64	43	t	t	PROPN
ijassa-493	64	44	,	,	PUNCT
ijassa-493	64	45	nn	nn	PROPN
ijassa-493	64	46	is	be	AUX
ijassa-493	64	47	rate	rate	NOUN
ijassa-493	64	48	of	of	ADP
ijassa-493	64	49	decrease	decrease	NOUN
ijassa-493	64	50	in	in	ADP
ijassa-493	64	51	the	the	DET
ijassa-493	64	52	number	number	NOUN
ijassa-493	64	53	of	of	ADP
ijassa-493	64	54	antibodies	antibody	NOUN
ijassa-493	64	55	due	due	ADP
ijassa-493	64	56	to	to	ADP
ijassa-493	64	57	natural	natural	ADJ
ijassa-493	64	58	destruction	destruction	NOUN
ijassa-493	64	59	.	.	PUNCT
ijassa-493	65	1	the	the	DET
ijassa-493	65	2	dynamics	dynamic	NOUN
ijassa-493	65	3	of	of	ADP
ijassa-493	65	4	formation	formation	NOUN
ijassa-493	65	5	of	of	ADP
ijassa-493	65	6	plasma	plasma	NOUN
ijassa-493	65	7	cells	cell	NOUN
ijassa-493	65	8	(	(	PUNCT
ijassa-493	65	9	)	)	PUNCT
ijassa-493	65	10	nc	nc	PROPN
ijassa-493	65	11	t	t	PROPN
ijassa-493	65	12	:	:	PUNCT
ijassa-493	65	13	,	,	PUNCT
ijassa-493	65	14	(	(	PUNCT
ijassa-493	65	15	)	)	PUNCT
ijassa-493	65	16	(	(	PUNCT
ijassa-493	65	17	)	)	PUNCT
ijassa-493	65	18	(	(	PUNCT
ijassa-493	65	19	)	)	PUNCT
ijassa-493	65	20	(	(	PUNCT
ijassa-493	65	21	)	)	PUNCT
ijassa-493	65	22	n	n	X
ijassa-493	65	23	cn	cn	PROPN
ijassa-493	65	24	v	v	PROPN
ijassa-493	65	25	n	n	CCONJ
ijassa-493	65	26	n	n	ADV
ijassa-493	65	27	cn	cn	PROPN
ijassa-493	65	28	n	n	CCONJ
ijassa-493	65	29	n	n	CCONJ
ijassa-493	65	30	nn	nn	PROPN
ijassa-493	65	31	dc	dc	PROPN
ijassa-493	65	32	t	t	PROPN
ijassa-493	65	33	n	n	ADP
ijassa-493	65	34	t	t	PROPN
ijassa-493	65	35	a	a	DET
ijassa-493	65	36	t	t	NOUN
ijassa-493	65	37	t	t	X
ijassa-493	65	38	c	c	PROPN
ijassa-493	66	1	t	t	PROPN
ijassa-493	66	2	t	t	NOUN
ijassa-493	66	3	c	c	NOUN
ijassa-493	66	4	dt	dt	X
ijassa-493	66	5			X
ijassa-493	66	6			PROPN
ijassa-493	66	7			PROPN
ijassa-493	66	8			NOUN
ijassa-493	66	9			NOUN
ijassa-493	66	10			PROPN
ijassa-493	66	11			PROPN
ijassa-493	66	12	=	=	PUNCT
ijassa-493	67	1	−	−	PROPN
ijassa-493	67	2	−	−	PROPN
ijassa-493	68	1	−	−	NOUN
ijassa-493	68	2	−	−	PROPN
ijassa-493	68	3	(	(	PUNCT
ijassa-493	68	4	7	7	NUM
ijassa-493	68	5	)	)	PUNCT
ijassa-493	68	6	at	at	ADP
ijassa-493	68	7	1	1	NUM
ijassa-493	68	8	(	(	PUNCT
ijassa-493	68	9	)	)	PUNCT
ijassa-493	68	10	,	,	PUNCT
ijassa-493	68	11	an	an	DET
ijassa-493	68	12	nnc	nnc	PROPN
ijassa-493	68	13	c	c	PROPN
ijassa-493	68	14	=	=	PROPN
ijassa-493	68	15	where	where	SCONJ
ijassa-493	68	16	cn	cn	NOUN
ijassa-493	68	17	is	be	AUX
ijassa-493	68	18	rate	rate	NOUN
ijassa-493	68	19	of	of	ADP
ijassa-493	68	20	formation	formation	NOUN
ijassa-493	68	21	of	of	ADP
ijassa-493	68	22	plasma	plasma	NOUN
ijassa-493	68	23	cells	cell	NOUN
ijassa-493	68	24	,	,	PUNCT
ijassa-493	68	25	cn	cn	PROPN
ijassa-493	68	26	is	be	AUX
ijassa-493	68	27	the	the	DET
ijassa-493	68	28	dimension	dimension	NOUN
ijassa-493	68	29	factor	factor	NOUN
ijassa-493	68	30	,	,	PUNCT
ijassa-493	68	31	zcn	zcn	NOUN
ijassa-493	68	32	is	be	AUX
ijassa-493	68	33	the	the	DET
ijassa-493	68	34	time	time	NOUN
ijassa-493	68	35	lag	lag	NOUN
ijassa-493	68	36	of	of	ADP
ijassa-493	68	37	the	the	DET
ijassa-493	68	38	immune	immune	ADJ
ijassa-493	68	39	response	response	NOUN
ijassa-493	68	40	to	to	ADP
ijassa-493	68	41	the	the	DET
ijassa-493	68	42	formation	formation	NOUN
ijassa-493	68	43	of	of	ADP
ijassa-493	68	44	a	a	DET
ijassa-493	68	45	plasma	plasma	NOUN
ijassa-493	68	46	cell	cell	NOUN
ijassa-493	68	47	clone	clone	NOUN
ijassa-493	68	48	against	against	ADP
ijassa-493	68	49	the	the	DET
ijassa-493	68	50	infected	infected	ADJ
ijassa-493	68	51	tumor	tumor	NOUN
ijassa-493	68	52	cells	cell	NOUN
ijassa-493	68	53	.	.	PUNCT
ijassa-493	69	1	dynamics	dynamic	NOUN
ijassa-493	69	2	of	of	ADP
ijassa-493	69	3	antibodies	antibody	NOUN
ijassa-493	69	4	(	(	PUNCT
ijassa-493	69	5	)	)	PUNCT
ijassa-493	69	6	va	va	PROPN
ijassa-493	69	7	t	t	PROPN
ijassa-493	69	8	against	against	ADP
ijassa-493	69	9	the	the	DET
ijassa-493	69	10	virus	virus	NOUN
ijassa-493	69	11	and	and	CCONJ
ijassa-493	69	12	against	against	ADP
ijassa-493	69	13	infected	infect	VERB
ijassa-493	69	14	tumor	tumor	NOUN
ijassa-493	69	15	cells	cell	NOUN
ijassa-493	69	16	(	(	PUNCT
ijassa-493	69	17	)	)	PUNCT
ijassa-493	69	18	na	na	NOUN
ijassa-493	69	19	t	t	PROPN
ijassa-493	69	20	are	be	AUX
ijassa-493	69	21	shown	show	VERB
ijassa-493	69	22	in	in	ADP
ijassa-493	69	23	figure	figure	NOUN
ijassa-493	69	24	2	2	NUM
ijassa-493	69	25	.	.	PUNCT
ijassa-493	69	26	fig	fig	NOUN
ijassa-493	69	27	.	.	PUNCT
ijassa-493	70	1	2	2	X
ijassa-493	70	2	.	.	X
ijassa-493	70	3	population	population	NOUN
ijassa-493	70	4	dynamics	dynamic	NOUN
ijassa-493	70	5	of	of	ADP
ijassa-493	70	6	antibodies	antibody	NOUN
ijassa-493	70	7	(	(	PUNCT
ijassa-493	70	8	)	)	PUNCT
ijassa-493	70	9	va	va	PROPN
ijassa-493	70	10	t	t	PROPN
ijassa-493	70	11	against	against	ADP
ijassa-493	70	12	the	the	DET
ijassa-493	70	13	virus	virus	NOUN
ijassa-493	70	14	and	and	CCONJ
ijassa-493	70	15	against	against	ADP
ijassa-493	70	16	infected	infect	VERB
ijassa-493	70	17	tumor	tumor	NOUN
ijassa-493	70	18	cells	cell	NOUN
ijassa-493	70	19	an(t	an(t	PUNCT
ijassa-493	70	20	)	)	PUNCT
ijassa-493	70	21	for	for	ADP
ijassa-493	70	22	experimental	experimental	ADJ
ijassa-493	70	23	dosage	dosage	NOUN
ijassa-493	70	24	0	0	NUM
ijassa-493	70	25	0,015v	0,015v	NUM
ijassa-493	70	26	=	=	PUNCT
ijassa-493	70	27	on	on	ADP
ijassa-493	70	28	1	1	NUM
ijassa-493	70	29	=	=	SYM
ijassa-493	70	30	day	day	NOUN
ijassa-493	70	31	1	1	NUM
ijassa-493	70	32	(	(	PUNCT
ijassa-493	70	33	the	the	DET
ijassa-493	70	34	first	first	ADJ
ijassa-493	70	35	and	and	CCONJ
ijassa-493	70	36	second	second	ADJ
ijassa-493	70	37	stages	stage	NOUN
ijassa-493	70	38	of	of	ADP
ijassa-493	70	39	the	the	DET
ijassa-493	70	40	immune	immune	ADJ
ijassa-493	70	41	response	response	NOUN
ijassa-493	70	42	)	)	PUNCT
ijassa-493	70	43	analytical	analytical	ADJ
ijassa-493	70	44	study	study	NOUN
ijassa-493	70	45	of	of	ADP
ijassa-493	70	46	antitumor	antitumor	PROPN
ijassa-493	70	47	viral	viral	ADJ
ijassa-493	70	48	vaccine	vaccine	NOUN
ijassa-493	70	49	63	63	NUM
ijassa-493	70	50	in	in	ADP
ijassa-493	70	51	the	the	DET
ijassa-493	70	52	equations	equation	NOUN
ijassa-493	70	53	that	that	PRON
ijassa-493	70	54	describe	describe	VERB
ijassa-493	70	55	the	the	DET
ijassa-493	70	56	dynamics	dynamic	NOUN
ijassa-493	70	57	of	of	ADP
ijassa-493	70	58	the	the	DET
ijassa-493	70	59	formation	formation	NOUN
ijassa-493	70	60	of	of	ADP
ijassa-493	70	61	antibodies	antibody	NOUN
ijassa-493	70	62	(	(	PUNCT
ijassa-493	70	63	6	6	NUM
ijassa-493	70	64	)	)	PUNCT
ijassa-493	70	65	and	and	CCONJ
ijassa-493	70	66	plasma	plasma	NOUN
ijassa-493	70	67	cells	cell	NOUN
ijassa-493	70	68	(	(	PUNCT
ijassa-493	70	69	7	7	NUM
ijassa-493	70	70	)	)	PUNCT
ijassa-493	70	71	,	,	PUNCT
ijassa-493	70	72	the	the	DET
ijassa-493	70	73	number	number	NOUN
ijassa-493	70	74	of	of	ADP
ijassa-493	70	75	infected	infected	ADJ
ijassa-493	70	76	tumor	tumor	NOUN
ijassa-493	70	77	cells	cell	NOUN
ijassa-493	70	78	was	be	AUX
ijassa-493	70	79	calculated	calculate	VERB
ijassa-493	70	80	as	as	ADP
ijassa-493	70	81	(	(	PUNCT
ijassa-493	70	82	)	)	PUNCT
ijassa-493	70	83	(	(	PUNCT
ijassa-493	70	84	)	)	PUNCT
ijassa-493	70	85	(	(	PUNCT
ijassa-493	70	86	)	)	PUNCT
ijassa-493	70	87	,	,	PUNCT
ijassa-493	70	88	v	v	PART
ijassa-493	70	89	n	n	CCONJ
ijassa-493	70	90	nn	nn	PROPN
ijassa-493	70	91	t	t	PROPN
ijassa-493	71	1	n	n	PROPN
ijassa-493	71	2	t	t	PROPN
ijassa-493	71	3	p	p	X
ijassa-493	71	4	t=	t=	VERB
ijassa-493	71	5			PROPN
ijassa-493	71	6	where	where	SCONJ
ijassa-493	71	7	(	(	PUNCT
ijassa-493	71	8	)	)	PUNCT
ijassa-493	71	9	np	np	ADP
ijassa-493	71	10	t	t	PROPN
ijassa-493	71	11	accounts	account	VERB
ijassa-493	71	12	for	for	ADP
ijassa-493	71	13	the	the	DET
ijassa-493	71	14	proportion	proportion	NOUN
ijassa-493	71	15	of	of	ADP
ijassa-493	71	16	rapidly	rapidly	ADV
ijassa-493	71	17	proliferating	proliferate	VERB
ijassa-493	71	18	cell	cell	NOUN
ijassa-493	71	19	fraction	fraction	NOUN
ijassa-493	71	20	as	as	ADP
ijassa-493	71	21	the	the	DET
ijassa-493	71	22	size	size	NOUN
ijassa-493	71	23	of	of	ADP
ijassa-493	71	24	the	the	DET
ijassa-493	71	25	tumor	tumor	NOUN
ijassa-493	71	26	increases	increase	VERB
ijassa-493	71	27	[	[	X
ijassa-493	71	28	14	14	NUM
ijassa-493	71	29	]	]	SYM
ijassa-493	71	30	:	:	PUNCT
ijassa-493	71	31	2	2	NUM
ijassa-493	71	32	2	2	NUM
ijassa-493	71	33	21	21	NUM
ijassa-493	71	34	(	(	PUNCT
ijassa-493	71	35	)	)	PUNCT
ijassa-493	71	36	1	1	NUM
ijassa-493	71	37	(	(	PUNCT
ijassa-493	71	38	)	)	PUNCT
ijassa-493	71	39	,	,	PUNCT
ijassa-493	71	40	1	1	NUM
ijassa-493	71	41	p	p	NOUN
ijassa-493	71	42	p	p	X
ijassa-493	71	43	p	p	X
ijassa-493	71	44	p	p	PROPN
ijassa-493	71	45	t	t	PROPN
ijassa-493	71	46	p	p	PROPN
ijassa-493	71	47	t	t	PROPN
ijassa-493	71	48	arctg	arctg	VERB
ijassa-493	71	49	k	k	PROPN
ijassa-493	71	50	t	t	PROPN
ijassa-493	71	51			NUM
ijassa-493	71	52			PROPN
ijassa-493	71	53			PROPN
ijassa-493	71	54			PROPN
ijassa-493	71	55			PROPN
ijassa-493	71	56			PROPN
ijassa-493	71	57	=	=	SYM
ijassa-493	71	58	−	−	PROPN
ijassa-493	71	59			NOUN
ijassa-493	71	60			NOUN
ijassa-493	71	61	−	−	PROPN
ijassa-493	71	62			NOUN
ijassa-493	71	63			PROPN
ijassa-493	71	64			PROPN
ijassa-493	71	65	(	(	PUNCT
ijassa-493	71	66	8)	8)	NUM
ijassa-493	71	67	where	where	SCONJ
ijassa-493	71	68	p	p	NOUN
ijassa-493	71	69	and	and	CCONJ
ijassa-493	71	70	kp	kp	PROPN
ijassa-493	71	71	are	be	AUX
ijassa-493	71	72	constant	constant	ADJ
ijassa-493	71	73	parameters	parameter	NOUN
ijassa-493	71	74	,	,	PUNCT
ijassa-493	71	75	t	t	PROPN
ijassa-493	71	76	is	be	AUX
ijassa-493	71	77	the	the	DET
ijassa-493	71	78	current	current	ADJ
ijassa-493	71	79	time	time	NOUN
ijassa-493	71	80	of	of	ADP
ijassa-493	71	81	the	the	DET
ijassa-493	71	82	tumor	tumor	NOUN
ijassa-493	71	83	cell	cell	NOUN
ijassa-493	71	84	population	population	NOUN
ijassa-493	71	85	growth	growth	NOUN
ijassa-493	71	86	,	,	PUNCT
ijassa-493	71	87	*	*	NOUN
ijassa-493	71	88	1	1	NUM
ijassa-493	71	89	,	,	PUNCT
ijassa-493	71	90	p	p	PROPN
ijassa-493	71	91	t	t	PROPN
ijassa-493	71	92			PROPN
ijassa-493	71	93	=	=	PUNCT
ijassa-493	71	94	where	where	SCONJ
ijassa-493	71	95	*	*	PUNCT
ijassa-493	71	96	t	t	PROPN
ijassa-493	71	97	is	be	AUX
ijassa-493	71	98	the	the	DET
ijassa-493	71	99	moment	moment	NOUN
ijassa-493	71	100	when	when	SCONJ
ijassa-493	71	101	the	the	DET
ijassa-493	71	102	numbers	number	NOUN
ijassa-493	71	103	of	of	ADP
ijassa-493	71	104	the	the	DET
ijassa-493	71	105	rapidly	rapidly	ADV
ijassa-493	71	106	and	and	CCONJ
ijassa-493	71	107	slowly	slowly	ADV
ijassa-493	71	108	proliferating	proliferate	VERB
ijassa-493	71	109	cells	cell	NOUN
ijassa-493	71	110	are	be	AUX
ijassa-493	71	111	equal	equal	ADJ
ijassa-493	71	112	.	.	PUNCT
ijassa-493	72	1	the	the	DET
ijassa-493	72	2	fraction	fraction	NOUN
ijassa-493	72	3	of	of	ADP
ijassa-493	72	4	rapidly	rapidly	ADV
ijassa-493	72	5	proliferating	proliferate	VERB
ijassa-493	72	6	tumor	tumor	NOUN
ijassa-493	72	7	cells	cell	NOUN
ijassa-493	72	8	is	be	AUX
ijassa-493	72	9	located	locate	VERB
ijassa-493	72	10	near	near	ADP
ijassa-493	72	11	the	the	DET
ijassa-493	72	12	blood	blood	NOUN
ijassa-493	72	13	vessels	vessel	NOUN
ijassa-493	72	14	(	(	PUNCT
ijassa-493	72	15	oxygenated	oxygenated	ADJ
ijassa-493	72	16	fraction	fraction	NOUN
ijassa-493	72	17	)	)	PUNCT
ijassa-493	72	18	,	,	PUNCT
ijassa-493	72	19	while	while	SCONJ
ijassa-493	72	20	the	the	DET
ijassa-493	72	21	fraction	fraction	NOUN
ijassa-493	72	22	of	of	ADP
ijassa-493	72	23	slowly	slowly	ADV
ijassa-493	72	24	proliferating	proliferate	VERB
ijassa-493	72	25	cells	cell	NOUN
ijassa-493	72	26	is	be	AUX
ijassa-493	72	27	pushed	push	VERB
ijassa-493	72	28	to	to	ADP
ijassa-493	72	29	the	the	DET
ijassa-493	72	30	tumor	tumor	NOUN
ijassa-493	72	31	periphery	periphery	NOUN
ijassa-493	72	32	(	(	PUNCT
ijassa-493	72	33	hypoxic	hypoxic	ADJ
ijassa-493	72	34	fraction	fraction	NOUN
ijassa-493	72	35	)	)	PUNCT
ijassa-493	72	36	.	.	PUNCT
ijassa-493	73	1	the	the	DET
ijassa-493	73	2	process	process	NOUN
ijassa-493	73	3	of	of	ADP
ijassa-493	73	4	the	the	DET
ijassa-493	73	5	change	change	NOUN
ijassa-493	73	6	in	in	ADP
ijassa-493	73	7	the	the	DET
ijassa-493	73	8	proportion	proportion	NOUN
ijassa-493	73	9	of	of	ADP
ijassa-493	73	10	the	the	DET
ijassa-493	73	11	rapidly	rapidly	ADV
ijassa-493	73	12	and	and	CCONJ
ijassa-493	73	13	slowly	slowly	ADV
ijassa-493	73	14	proliferating	proliferate	VERB
ijassa-493	73	15	cells	cell	NOUN
ijassa-493	73	16	with	with	ADP
ijassa-493	73	17	the	the	DET
ijassa-493	73	18	increase	increase	NOUN
ijassa-493	73	19	in	in	ADP
ijassa-493	73	20	the	the	DET
ijassa-493	73	21	tumor	tumor	NOUN
ijassa-493	73	22	size	size	NOUN
ijassa-493	73	23	is	be	AUX
ijassa-493	73	24	described	describe	VERB
ijassa-493	73	25	in	in	ADP
ijassa-493	73	26	the	the	DET
ijassa-493	73	27	skipper	skipper	NOUN
ijassa-493	73	28	model	model	NOUN
ijassa-493	73	29	[	[	X
ijassa-493	73	30	31	31	NUM
ijassa-493	73	31	]	]	PUNCT
ijassa-493	73	32	.	.	PUNCT
ijassa-493	74	1	as	as	SCONJ
ijassa-493	74	2	the	the	DET
ijassa-493	74	3	number	number	NOUN
ijassa-493	74	4	of	of	ADP
ijassa-493	74	5	the	the	DET
ijassa-493	74	6	fast	fast	ADV
ijassa-493	74	7	-	-	PUNCT
ijassa-493	74	8	proliferating	proliferate	VERB
ijassa-493	74	9	tumor	tumor	NOUN
ijassa-493	74	10	cells	cell	NOUN
ijassa-493	74	11	decreases	decrease	VERB
ijassa-493	74	12	,	,	PUNCT
ijassa-493	74	13	the	the	DET
ijassa-493	74	14	virus	virus	NOUN
ijassa-493	74	15	ceases	cease	VERB
ijassa-493	74	16	to	to	PART
ijassa-493	74	17	affect	affect	VERB
ijassa-493	74	18	them	they	PRON
ijassa-493	74	19	.	.	PUNCT
ijassa-493	75	1	this	this	PRON
ijassa-493	75	2	causes	cause	VERB
ijassa-493	75	3	the	the	DET
ijassa-493	75	4	decrease	decrease	NOUN
ijassa-493	75	5	of	of	ADP
ijassa-493	75	6	the	the	DET
ijassa-493	75	7	tumor	tumor	NOUN
ijassa-493	75	8	sensitivity	sensitivity	NOUN
ijassa-493	75	9	to	to	ADP
ijassa-493	75	10	the	the	DET
ijassa-493	75	11	viral	viral	ADJ
ijassa-493	75	12	vaccines	vaccine	NOUN
ijassa-493	75	13	and	and	CCONJ
ijassa-493	75	14	of	of	ADP
ijassa-493	75	15	the	the	DET
ijassa-493	75	16	number	number	NOUN
ijassa-493	75	17	of	of	ADP
ijassa-493	75	18	infected	infected	ADJ
ijassa-493	75	19	tumor	tumor	NOUN
ijassa-493	75	20	cells	cell	NOUN
ijassa-493	75	21	(	(	PUNCT
ijassa-493	75	22	)	)	PUNCT
ijassa-493	75	23	vn	vn	PROPN
ijassa-493	75	24	t	t	PROPN
ijassa-493	75	25	that	that	PRON
ijassa-493	75	26	can	can	AUX
ijassa-493	75	27	induce	induce	VERB
ijassa-493	75	28	the	the	DET
ijassa-493	75	29	immune	immune	ADJ
ijassa-493	75	30	response	response	NOUN
ijassa-493	75	31	.	.	PUNCT
ijassa-493	76	1	as	as	ADP
ijassa-493	76	2	a	a	DET
ijassa-493	76	3	result	result	NOUN
ijassa-493	76	4	,	,	PUNCT
ijassa-493	76	5	the	the	DET
ijassa-493	76	6	number	number	NOUN
ijassa-493	76	7	of	of	ADP
ijassa-493	76	8	the	the	DET
ijassa-493	76	9	antibodies	antibody	NOUN
ijassa-493	76	10	developed	develop	VERB
ijassa-493	76	11	against	against	ADP
ijassa-493	76	12	tumor	tumor	NOUN
ijassa-493	76	13	cells	cell	NOUN
ijassa-493	76	14	is	be	AUX
ijassa-493	76	15	reduced	reduce	VERB
ijassa-493	76	16	,	,	PUNCT
ijassa-493	76	17	and	and	CCONJ
ijassa-493	76	18	the	the	DET
ijassa-493	76	19	effectiveness	effectiveness	NOUN
ijassa-493	76	20	of	of	ADP
ijassa-493	76	21	the	the	DET
ijassa-493	76	22	viral	viral	ADJ
ijassa-493	76	23	vaccines	vaccine	NOUN
ijassa-493	76	24	declines	decline	VERB
ijassa-493	76	25	.	.	PUNCT
ijassa-493	77	1	thus	thus	ADV
ijassa-493	77	2	,	,	PUNCT
ijassa-493	77	3	the	the	DET
ijassa-493	77	4	mathematical	mathematical	ADJ
ijassa-493	77	5	model	model	NOUN
ijassa-493	77	6	of	of	ADP
ijassa-493	77	7	vaccine	vaccine	NOUN
ijassa-493	77	8	therapy	therapy	NOUN
ijassa-493	77	9	describes	describe	VERB
ijassa-493	77	10	the	the	DET
ijassa-493	77	11	mechanism	mechanism	NOUN
ijassa-493	77	12	of	of	ADP
ijassa-493	77	13	two	two	NUM
ijassa-493	77	14	-	-	PUNCT
ijassa-493	77	15	stage	stage	NOUN
ijassa-493	77	16	death	death	NOUN
ijassa-493	77	17	of	of	ADP
ijassa-493	77	18	tumor	tumor	NOUN
ijassa-493	77	19	cells	cell	NOUN
ijassa-493	77	20	caused	cause	VERB
ijassa-493	77	21	by	by	ADP
ijassa-493	77	22	the	the	DET
ijassa-493	77	23	virus	virus	NOUN
ijassa-493	77	24	itself	itself	PRON
ijassa-493	77	25	and	and	CCONJ
ijassa-493	77	26	as	as	ADP
ijassa-493	77	27	a	a	DET
ijassa-493	77	28	result	result	NOUN
ijassa-493	77	29	of	of	ADP
ijassa-493	77	30	the	the	DET
ijassa-493	77	31	immune	immune	ADJ
ijassa-493	77	32	system	system	NOUN
ijassa-493	77	33	stimulation	stimulation	NOUN
ijassa-493	77	34	against	against	ADP
ijassa-493	77	35	the	the	DET
ijassa-493	77	36	infected	infected	ADJ
ijassa-493	77	37	tumor	tumor	NOUN
ijassa-493	77	38	cells	cell	NOUN
ijassa-493	77	39	.	.	PUNCT
ijassa-493	78	1	the	the	DET
ijassa-493	78	2	calculated	calculate	VERB
ijassa-493	78	3	curves	curve	NOUN
ijassa-493	78	4	that	that	PRON
ijassa-493	78	5	describe	describe	VERB
ijassa-493	78	6	the	the	DET
ijassa-493	78	7	dynamics	dynamic	NOUN
ijassa-493	78	8	of	of	ADP
ijassa-493	78	9	the	the	DET
ijassa-493	78	10	two	two	NUM
ijassa-493	78	11	-	-	PUNCT
ijassa-493	78	12	stage	stage	NOUN
ijassa-493	78	13	death	death	NOUN
ijassa-493	78	14	of	of	ADP
ijassa-493	78	15	infected	infected	ADJ
ijassa-493	78	16	tumor	tumor	NOUN
ijassa-493	78	17	cells	cell	NOUN
ijassa-493	78	18	(	(	PUNCT
ijassa-493	78	19	)	)	PUNCT
ijassa-493	78	20	vn	vn	PROPN
ijassa-493	78	21	t	t	PROPN
ijassa-493	78	22	and	and	CCONJ
ijassa-493	78	23	the	the	DET
ijassa-493	78	24	production	production	NOUN
ijassa-493	78	25	of	of	ADP
ijassa-493	78	26	antibodies	antibody	NOUN
ijassa-493	78	27	and	and	CCONJ
ijassa-493	78	28	plasma	plasma	NOUN
ijassa-493	78	29	cells	cell	NOUN
ijassa-493	78	30	at	at	ADP
ijassa-493	78	31	the	the	DET
ijassa-493	78	32	each	each	PRON
ijassa-493	78	33	of	of	ADP
ijassa-493	78	34	the	the	DET
ijassa-493	78	35	two	two	NUM
ijassa-493	78	36	stages	stage	NOUN
ijassa-493	78	37	of	of	ADP
ijassa-493	78	38	the	the	DET
ijassa-493	78	39	immune	immune	ADJ
ijassa-493	78	40	system	system	NOUN
ijassa-493	78	41	stimulation	stimulation	NOUN
ijassa-493	78	42	are	be	AUX
ijassa-493	78	43	shown	show	VERB
ijassa-493	78	44	in	in	ADP
ijassa-493	78	45	figure	figure	NOUN
ijassa-493	78	46	3	3	NUM
ijassa-493	78	47	[	[	X
ijassa-493	78	48	8	8	NUM
ijassa-493	78	49	-	-	SYM
ijassa-493	78	50	10	10	NUM
ijassa-493	78	51	]	]	PUNCT
ijassa-493	78	52	.	.	PUNCT
ijassa-493	79	1	fig	fig	NOUN
ijassa-493	79	2	.	.	PUNCT
ijassa-493	80	1	3	3	X
ijassa-493	80	2	.	.	NUM
ijassa-493	80	3	calculated	calculate	VERB
ijassa-493	80	4	growth	growth	NOUN
ijassa-493	80	5	curve	curve	NOUN
ijassa-493	80	6	of	of	ADP
ijassa-493	80	7	the	the	DET
ijassa-493	80	8	total	total	ADJ
ijassa-493	80	9	number	number	NOUN
ijassa-493	80	10	of	of	ADP
ijassa-493	80	11	tumor	tumor	NOUN
ijassa-493	80	12	cells	cell	NOUN
ijassa-493	80	13	n(t	n(t	PROPN
ijassa-493	80	14	)	)	PUNCT
ijassa-493	80	15	(	(	PUNCT
ijassa-493	80	16	full	full	ADJ
ijassa-493	80	17	line	line	NOUN
ijassa-493	80	18	)	)	PUNCT
ijassa-493	80	19	that	that	PRON
ijassa-493	80	20	approximates	approximate	VERB
ijassa-493	80	21	experimental	experimental	ADJ
ijassa-493	80	22	data	datum	NOUN
ijassa-493	80	23	(	(	PUNCT
ijassa-493	80	24	+	+	NOUN
ijassa-493	80	25	)	)	PUNCT
ijassa-493	80	26	based	base	VERB
ijassa-493	80	27	on	on	ADP
ijassa-493	80	28	the	the	DET
ijassa-493	80	29	mathematical	mathematical	ADJ
ijassa-493	80	30	model	model	NOUN
ijassa-493	80	31	of	of	ADP
ijassa-493	80	32	antitumor	antitumor	PROPN
ijassa-493	80	33	therapy	therapy	NOUN
ijassa-493	80	34	(	(	PUNCT
ijassa-493	80	35	dosage	dosage	NOUN
ijassa-493	80	36	0	0	NUM
ijassa-493	80	37	0,015v	0,015v	NUM
ijassa-493	80	38	=	=	PUNCT
ijassa-493	80	39	on	on	ADP
ijassa-493	80	40	1	1	NUM
ijassa-493	80	41	=	=	SYM
ijassa-493	80	42	day	day	NOUN
ijassa-493	80	43	1	1	NUM
ijassa-493	80	44	)	)	PUNCT
ijassa-493	81	1	;	;	PUNCT
ijassa-493	81	2	the	the	DET
ijassa-493	81	3	dotted	dotted	ADJ
ijassa-493	81	4	line	line	NOUN
ijassa-493	81	5	indicates	indicate	VERB
ijassa-493	81	6	the	the	DET
ijassa-493	81	7	dynamics	dynamic	NOUN
ijassa-493	81	8	of	of	ADP
ijassa-493	81	9	the	the	DET
ijassa-493	81	10	number	number	NOUN
ijassa-493	81	11	of	of	ADP
ijassa-493	81	12	infected	infected	ADJ
ijassa-493	81	13	tumor	tumor	NOUN
ijassa-493	81	14	cells	cell	NOUN
ijassa-493	81	15	(	(	PUNCT
ijassa-493	81	16	)	)	PUNCT
ijassa-493	81	17	vn	vn	PROPN
ijassa-493	81	18	t	t	PROPN
ijassa-493	81	19	.	.	PUNCT
ijassa-493	82	1	64	64	NUM
ijassa-493	82	2	n.a	n.a	PROPN
ijassa-493	82	3	.	.	PROPN
ijassa-493	82	4	babushkina	babushkina	PROPN
ijassa-493	82	5	,	,	PUNCT
ijassa-493	82	6	e.a	e.a	PROPN
ijassa-493	82	7	.	.	PROPN
ijassa-493	82	8	kuzina	kuzina	PROPN
ijassa-493	82	9	calculations	calculations	PROPN
ijassa-493	82	10	show	show	VERB
ijassa-493	82	11	that	that	SCONJ
ijassa-493	82	12	the	the	DET
ijassa-493	82	13	curve	curve	NOUN
ijassa-493	82	14	that	that	PRON
ijassa-493	82	15	describes	describe	VERB
ijassa-493	82	16	the	the	DET
ijassa-493	82	17	dynamics	dynamic	NOUN
ijassa-493	82	18	of	of	ADP
ijassa-493	82	19	the	the	DET
ijassa-493	82	20	number	number	NOUN
ijassa-493	82	21	of	of	ADP
ijassa-493	82	22	infected	infected	ADJ
ijassa-493	82	23	tumor	tumor	NOUN
ijassa-493	82	24	cells	cell	NOUN
ijassa-493	82	25	is	be	AUX
ijassa-493	82	26	located	locate	VERB
ijassa-493	82	27	below	below	ADP
ijassa-493	82	28	the	the	DET
ijassa-493	82	29	experimental	experimental	ADJ
ijassa-493	82	30	curve	curve	NOUN
ijassa-493	82	31	of	of	ADP
ijassa-493	82	32	the	the	DET
ijassa-493	82	33	tumor	tumor	NOUN
ijassa-493	82	34	growth	growth	NOUN
ijassa-493	82	35	.	.	PUNCT
ijassa-493	83	1	this	this	PRON
ijassa-493	83	2	indicates	indicate	VERB
ijassa-493	83	3	that	that	SCONJ
ijassa-493	83	4	when	when	SCONJ
ijassa-493	83	5	the	the	DET
ijassa-493	83	6	viral	viral	ADJ
ijassa-493	83	7	vaccine	vaccine	NOUN
ijassa-493	83	8	is	be	AUX
ijassa-493	83	9	administered	administer	VERB
ijassa-493	83	10	,	,	PUNCT
ijassa-493	83	11	it	it	PRON
ijassa-493	83	12	does	do	AUX
ijassa-493	83	13	not	not	PART
ijassa-493	83	14	infect	infect	VERB
ijassa-493	83	15	the	the	DET
ijassa-493	83	16	entire	entire	ADJ
ijassa-493	83	17	tumor	tumor	NOUN
ijassa-493	83	18	cell	cell	NOUN
ijassa-493	83	19	population	population	NOUN
ijassa-493	83	20	(	(	PUNCT
ijassa-493	83	21	)	)	PUNCT
ijassa-493	83	22	.n	.n	PROPN
ijassa-493	83	23	t	t	VERB
ijassa-493	83	24	some	some	DET
ijassa-493	83	25	cells	cell	NOUN
ijassa-493	83	26	remain	remain	VERB
ijassa-493	83	27	uninfected	uninfected	ADJ
ijassa-493	83	28	(	(	PUNCT
ijassa-493	83	29	)	)	PUNCT
ijassa-493	83	30	rn	rn	PROPN
ijassa-493	83	31	t	t	PROPN
ijassa-493	83	32	and	and	CCONJ
ijassa-493	83	33	continue	continue	VERB
ijassa-493	83	34	to	to	PART
ijassa-493	83	35	multiply	multiply	VERB
ijassa-493	83	36	,	,	PUNCT
ijassa-493	83	37	causing	cause	VERB
ijassa-493	83	38	a	a	DET
ijassa-493	83	39	repeated	repeat	VERB
ijassa-493	83	40	growth	growth	NOUN
ijassa-493	83	41	of	of	ADP
ijassa-493	83	42	the	the	DET
ijassa-493	83	43	tumor	tumor	NOUN
ijassa-493	83	44	,	,	PUNCT
ijassa-493	83	45	as	as	SCONJ
ijassa-493	83	46	observed	observe	VERB
ijassa-493	83	47	in	in	ADP
ijassa-493	83	48	the	the	DET
ijassa-493	83	49	experiment	experiment	NOUN
ijassa-493	83	50	(	(	PUNCT
ijassa-493	83	51	figure	figure	NOUN
ijassa-493	83	52	1	1	NUM
ijassa-493	83	53	)	)	PUNCT
ijassa-493	83	54	.	.	PUNCT
ijassa-493	84	1	some	some	DET
ijassa-493	84	2	cells	cell	NOUN
ijassa-493	84	3	survive	survive	VERB
ijassa-493	84	4	(	(	PUNCT
ijassa-493	84	5	0	0	NUM
ijassa-493	84	6	vrn	vrn	NOUN
ijassa-493	84	7	–	–	PUNCT
ijassa-493	84	8	after	after	ADP
ijassa-493	84	9	the	the	DET
ijassa-493	84	10	1st	1st	ADJ
ijassa-493	84	11	stage	stage	NOUN
ijassa-493	84	12	of	of	ADP
ijassa-493	84	13	immune	immune	ADJ
ijassa-493	84	14	response	response	NOUN
ijassa-493	84	15	,	,	PUNCT
ijassa-493	84	16	0	0	NUM
ijassa-493	84	17	nrn	nrn	NOUN
ijassa-493	84	18	–	–	PUNCT
ijassa-493	84	19	after	after	ADP
ijassa-493	84	20	the	the	DET
ijassa-493	84	21	2nd	2nd	ADJ
ijassa-493	84	22	stage	stage	NOUN
ijassa-493	84	23	)	)	PUNCT
ijassa-493	84	24	,	,	PUNCT
ijassa-493	84	25	causing	cause	VERB
ijassa-493	84	26	a	a	DET
ijassa-493	84	27	repeated	repeat	VERB
ijassa-493	84	28	growth	growth	NOUN
ijassa-493	84	29	of	of	ADP
ijassa-493	84	30	the	the	DET
ijassa-493	84	31	tumor	tumor	NOUN
ijassa-493	84	32	as	as	SCONJ
ijassa-493	84	33	observed	observe	VERB
ijassa-493	84	34	in	in	ADP
ijassa-493	84	35	the	the	DET
ijassa-493	84	36	experiment	experiment	NOUN
ijassa-493	84	37	(	(	PUNCT
ijassa-493	84	38	figure	figure	NOUN
ijassa-493	84	39	1	1	NUM
ijassa-493	84	40	)	)	PUNCT
ijassa-493	84	41	.	.	PUNCT
ijassa-493	85	1	3	3	X
ijassa-493	85	2	.	.	X
ijassa-493	85	3	the	the	DET
ijassa-493	85	4	mathematical	mathematical	ADJ
ijassa-493	85	5	model	model	NOUN
ijassa-493	85	6	of	of	ADP
ijassa-493	85	7	antitumor	antitumor	PROPN
ijassa-493	85	8	therapy	therapy	NOUN
ijassa-493	85	9	with	with	ADP
ijassa-493	85	10	discontinous	discontinous	ADJ
ijassa-493	85	11	trajectories	trajectory	NOUN
ijassa-493	85	12	for	for	ADP
ijassa-493	85	13	assessing	assess	VERB
ijassa-493	85	14	the	the	DET
ijassa-493	85	15	tumor	tumor	NOUN
ijassa-493	85	16	growth	growth	NOUN
ijassa-493	85	17	delay	delay	NOUN
ijassa-493	85	18	after	after	ADP
ijassa-493	85	19	the	the	DET
ijassa-493	85	20	two	two	NUM
ijassa-493	85	21	-	-	PUNCT
ijassa-493	85	22	stage	stage	NOUN
ijassa-493	85	23	death	death	NOUN
ijassa-493	85	24	of	of	ADP
ijassa-493	85	25	tumor	tumor	NOUN
ijassa-493	85	26	cells	cell	NOUN
ijassa-493	85	27	the	the	DET
ijassa-493	85	28	mathematical	mathematical	ADJ
ijassa-493	85	29	model	model	NOUN
ijassa-493	85	30	of	of	ADP
ijassa-493	85	31	antitumor	antitumor	PROPN
ijassa-493	85	32	therapy	therapy	NOUN
ijassa-493	85	33	with	with	ADP
ijassa-493	85	34	discontinuous	discontinuous	ADJ
ijassa-493	85	35	trajectories	trajectory	NOUN
ijassa-493	85	36	was	be	AUX
ijassa-493	85	37	developed	develop	VERB
ijassa-493	85	38	to	to	PART
ijassa-493	85	39	control	control	VERB
ijassa-493	85	40	and	and	CCONJ
ijassa-493	85	41	optimize	optimize	VERB
ijassa-493	85	42	the	the	DET
ijassa-493	85	43	regimes	regime	NOUN
ijassa-493	85	44	of	of	ADP
ijassa-493	85	45	applying	apply	VERB
ijassa-493	85	46	different	different	ADJ
ijassa-493	85	47	antitumor	antitumor	PROPN
ijassa-493	85	48	therapy	therapy	NOUN
ijassa-493	85	49	methods	method	NOUN
ijassa-493	85	50	based	base	VERB
ijassa-493	85	51	on	on	ADP
ijassa-493	85	52	kinetic	kinetic	ADJ
ijassa-493	85	53	curves	curve	NOUN
ijassa-493	85	54	of	of	ADP
ijassa-493	85	55	tumor	tumor	NOUN
ijassa-493	85	56	growth	growth	NOUN
ijassa-493	86	1	[	[	X
ijassa-493	86	2	8	8	NUM
ijassa-493	86	3	-	-	SYM
ijassa-493	86	4	10	10	NUM
ijassa-493	86	5	]	]	PUNCT
ijassa-493	86	6	.	.	PUNCT
ijassa-493	87	1	figure	figure	NOUN
ijassa-493	87	2	3	3	NUM
ijassa-493	87	3	shows	show	VERB
ijassa-493	87	4	the	the	DET
ijassa-493	87	5	calculated	calculate	VERB
ijassa-493	87	6	growth	growth	NOUN
ijassa-493	87	7	curve	curve	NOUN
ijassa-493	87	8	of	of	ADP
ijassa-493	87	9	the	the	DET
ijassa-493	87	10	total	total	ADJ
ijassa-493	87	11	number	number	NOUN
ijassa-493	87	12	of	of	ADP
ijassa-493	87	13	tumor	tumor	NOUN
ijassa-493	87	14	cells	cell	NOUN
ijassa-493	87	15	n(t	n(t	PROPN
ijassa-493	87	16	)	)	PUNCT
ijassa-493	87	17	(	(	PUNCT
ijassa-493	87	18	full	full	ADJ
ijassa-493	87	19	line	line	NOUN
ijassa-493	87	20	)	)	PUNCT
ijassa-493	87	21	,	,	PUNCT
ijassa-493	87	22	which	which	PRON
ijassa-493	87	23	was	be	AUX
ijassa-493	87	24	obtained	obtain	VERB
ijassa-493	87	25	based	base	VERB
ijassa-493	87	26	on	on	ADP
ijassa-493	87	27	the	the	DET
ijassa-493	87	28	mathematical	mathematical	ADJ
ijassa-493	87	29	model	model	NOUN
ijassa-493	87	30	of	of	ADP
ijassa-493	87	31	antitumor	antitumor	PROPN
ijassa-493	87	32	therapy	therapy	NOUN
ijassa-493	87	33	by	by	ADP
ijassa-493	87	34	approximating	approximate	VERB
ijassa-493	87	35	the	the	DET
ijassa-493	87	36	experimental	experimental	ADJ
ijassa-493	87	37	data	datum	NOUN
ijassa-493	87	38	.	.	PUNCT
ijassa-493	88	1	the	the	DET
ijassa-493	88	2	duration	duration	NOUN
ijassa-493	88	3	of	of	ADP
ijassa-493	88	4	tumor	tumor	NOUN
ijassa-493	88	5	growth	growth	NOUN
ijassa-493	88	6	delay	delay	NOUN
ijassa-493	88	7	was	be	AUX
ijassa-493	88	8	estimated	estimate	VERB
ijassa-493	88	9	based	base	VERB
ijassa-493	88	10	on	on	ADP
ijassa-493	88	11	the	the	DET
ijassa-493	88	12	following	follow	VERB
ijassa-493	88	13	assumptions	assumption	NOUN
ijassa-493	88	14	adopted	adopt	VERB
ijassa-493	88	15	in	in	ADP
ijassa-493	88	16	the	the	DET
ijassa-493	88	17	mathematical	mathematical	ADJ
ijassa-493	88	18	model	model	NOUN
ijassa-493	88	19	of	of	ADP
ijassa-493	88	20	antitumor	antitumor	PROPN
ijassa-493	88	21	therapy	therapy	NOUN
ijassa-493	89	1	[	[	X
ijassa-493	89	2	8	8	NUM
ijassa-493	89	3	-	-	SYM
ijassa-493	89	4	10	10	NUM
ijassa-493	89	5	]	]	SYM
ijassa-493	89	6	:	:	PUNCT
ijassa-493	89	7	1	1	X
ijassa-493	89	8	.	.	PUNCT
ijassa-493	89	9	the	the	DET
ijassa-493	89	10	cell	cell	NOUN
ijassa-493	89	11	death	death	NOUN
ijassa-493	89	12	occurs	occur	VERB
ijassa-493	89	13	instantly	instantly	ADV
ijassa-493	89	14	at	at	ADP
ijassa-493	89	15	each	each	PRON
ijassa-493	89	16	of	of	ADP
ijassa-493	89	17	the	the	DET
ijassa-493	89	18	two	two	NUM
ijassa-493	89	19	stages	stage	NOUN
ijassa-493	89	20	of	of	ADP
ijassa-493	89	21	the	the	DET
ijassa-493	89	22	immune	immune	ADJ
ijassa-493	89	23	system	system	NOUN
ijassa-493	89	24	stimulation	stimulation	NOUN
ijassa-493	89	25	.	.	PUNCT
ijassa-493	90	1	the	the	DET
ijassa-493	90	2	abrupt	abrupt	ADJ
ijassa-493	90	3	decrease	decrease	NOUN
ijassa-493	90	4	in	in	ADP
ijassa-493	90	5	the	the	DET
ijassa-493	90	6	tumor	tumor	NOUN
ijassa-493	90	7	size	size	NOUN
ijassa-493	90	8	occurs	occur	VERB
ijassa-493	90	9	at	at	ADP
ijassa-493	90	10	the	the	DET
ijassa-493	90	11	moment	moment	NOUN
ijassa-493	90	12	when	when	SCONJ
ijassa-493	90	13	the	the	DET
ijassa-493	90	14	maximal	maximal	ADJ
ijassa-493	90	15	number	number	NOUN
ijassa-493	90	16	of	of	ADP
ijassa-493	90	17	antibodies	antibody	NOUN
ijassa-493	90	18	to	to	ADP
ijassa-493	90	19	the	the	DET
ijassa-493	90	20	virus	virus	NOUN
ijassa-493	90	21	and	and	CCONJ
ijassa-493	90	22	infected	infect	VERB
ijassa-493	90	23	tumor	tumor	NOUN
ijassa-493	90	24	cells	cell	NOUN
ijassa-493	90	25	is	be	AUX
ijassa-493	90	26	produced	produce	VERB
ijassa-493	90	27	.	.	PUNCT
ijassa-493	91	1	2	2	X
ijassa-493	91	2	.	.	X
ijassa-493	91	3	reduction	reduction	NOUN
ijassa-493	91	4	in	in	ADP
ijassa-493	91	5	the	the	DET
ijassa-493	91	6	tumor	tumor	NOUN
ijassa-493	91	7	size	size	NOUN
ijassa-493	91	8	occurs	occur	VERB
ijassa-493	91	9	only	only	ADV
ijassa-493	91	10	due	due	ADP
ijassa-493	91	11	to	to	ADP
ijassa-493	91	12	the	the	DET
ijassa-493	91	13	death	death	NOUN
ijassa-493	91	14	of	of	ADP
ijassa-493	91	15	the	the	DET
ijassa-493	91	16	virus	virus	NOUN
ijassa-493	91	17	-	-	PUNCT
ijassa-493	91	18	infected	infect	VERB
ijassa-493	91	19	tumor	tumor	NOUN
ijassa-493	91	20	cells	cell	NOUN
ijassa-493	91	21	.	.	PUNCT
ijassa-493	92	1	3	3	X
ijassa-493	92	2	.	.	X
ijassa-493	92	3	the	the	DET
ijassa-493	92	4	surviving	survive	VERB
ijassa-493	92	5	tumor	tumor	NOUN
ijassa-493	92	6	cells	cell	NOUN
ijassa-493	92	7	continue	continue	VERB
ijassa-493	92	8	to	to	PART
ijassa-493	92	9	grow	grow	VERB
ijassa-493	92	10	at	at	ADP
ijassa-493	92	11	the	the	DET
ijassa-493	92	12	same	same	ADJ
ijassa-493	92	13	reproduction	reproduction	NOUN
ijassa-493	92	14	rate	rate	NOUN
ijassa-493	92	15	.	.	PUNCT
ijassa-493	93	1	the	the	DET
ijassa-493	93	2	kinetic	kinetic	ADJ
ijassa-493	93	3	curves	curve	NOUN
ijassa-493	93	4	of	of	ADP
ijassa-493	93	5	their	their	PRON
ijassa-493	93	6	growth	growth	NOUN
ijassa-493	93	7	are	be	AUX
ijassa-493	93	8	described	describe	VERB
ijassa-493	93	9	by	by	ADP
ijassa-493	93	10	the	the	DET
ijassa-493	93	11	gompertz	gompertz	NOUN
ijassa-493	93	12	function	function	NOUN
ijassa-493	93	13	,	,	PUNCT
ijassa-493	93	14	keeping	keep	VERB
ijassa-493	93	15	the	the	DET
ijassa-493	93	16	parameters	parameter	NOUN
ijassa-493	93	17	of	of	ADP
ijassa-493	93	18	the	the	DET
ijassa-493	93	19	tumor	tumor	NOUN
ijassa-493	93	20	growth	growth	NOUN
ijassa-493	93	21	without	without	ADP
ijassa-493	93	22	treatment	treatment	NOUN
ijassa-493	93	23	(	(	PUNCT
ijassa-493	93	24	control	control	NOUN
ijassa-493	93	25	)	)	PUNCT
ijassa-493	93	26	,	,	PUNCT
ijassa-493	93	27	but	but	CCONJ
ijassa-493	93	28	accounting	account	VERB
ijassa-493	93	29	for	for	ADP
ijassa-493	93	30	the	the	DET
ijassa-493	93	31	time	time	NOUN
ijassa-493	93	32	shift	shift	NOUN
ijassa-493	93	33	caused	cause	VERB
ijassa-493	93	34	by	by	ADP
ijassa-493	93	35	tumor	tumor	NOUN
ijassa-493	93	36	growth	growth	NOUN
ijassa-493	93	37	delay	delay	NOUN
ijassa-493	93	38	0	0	NUM
ijassa-493	93	39	(	(	PUNCT
ijassa-493	93	40	)	)	PUNCT
ijassa-493	93	41	v	v	NOUN
ijassa-493	93	42	v	v	PROPN
ijassa-493	93	43	and	and	CCONJ
ijassa-493	93	44	0	0	NUM
ijassa-493	93	45	(	(	PUNCT
ijassa-493	93	46	)	)	PUNCT
ijassa-493	93	47	n	n	X
ijassa-493	93	48	v	v	VERB
ijassa-493	93	49	after	after	ADP
ijassa-493	93	50	each	each	DET
ijassa-493	93	51	stage	stage	NOUN
ijassa-493	93	52	of	of	ADP
ijassa-493	93	53	their	their	PRON
ijassa-493	93	54	death	death	NOUN
ijassa-493	93	55	(	(	PUNCT
ijassa-493	93	56	figure	figure	NOUN
ijassa-493	93	57	4	4	NUM
ijassa-493	93	58	)	)	PUNCT
ijassa-493	93	59	.	.	PUNCT
ijassa-493	94	1	according	accord	VERB
ijassa-493	94	2	to	to	ADP
ijassa-493	94	3	the	the	DET
ijassa-493	94	4	basic	basic	ADJ
ijassa-493	94	5	antitumor	antitumor	PROPN
ijassa-493	94	6	therapy	therapy	NOUN
ijassa-493	94	7	model	model	NOUN
ijassa-493	94	8	[	[	X
ijassa-493	94	9	8	8	NUM
ijassa-493	94	10	-	-	SYM
ijassa-493	94	11	10	10	NUM
ijassa-493	94	12	]	]	PUNCT
ijassa-493	94	13	,	,	PUNCT
ijassa-493	94	14	the	the	DET
ijassa-493	94	15	kinetic	kinetic	ADJ
ijassa-493	94	16	curves	curve	NOUN
ijassa-493	94	17	of	of	ADP
ijassa-493	94	18	tumor	tumor	NOUN
ijassa-493	94	19	growth	growth	NOUN
ijassa-493	94	20	without	without	ADP
ijassa-493	94	21	treatment	treatment	NOUN
ijassa-493	94	22	are	be	AUX
ijassa-493	94	23	described	describe	VERB
ijassa-493	94	24	by	by	ADP
ijassa-493	94	25	a	a	DET
ijassa-493	94	26	simple	simple	ADJ
ijassa-493	94	27	differential	differential	NOUN
ijassa-493	94	28	equation	equation	NOUN
ijassa-493	94	29	(	(	PUNCT
ijassa-493	94	30	)	)	PUNCT
ijassa-493	94	31	exp	exp	NOUN
ijassa-493	94	32	(	(	PUNCT
ijassa-493	94	33	)	)	PUNCT
ijassa-493	94	34	(	(	PUNCT
ijassa-493	94	35	)	)	PUNCT
ijassa-493	94	36	n	n	CCONJ
ijassa-493	94	37	n	n	CCONJ
ijassa-493	94	38	n	n	CCONJ
ijassa-493	94	39	dn	dn	PROPN
ijassa-493	94	40	t	t	PROPN
ijassa-493	94	41	t	t	PROPN
ijassa-493	94	42	n	n	ADP
ijassa-493	94	43	t	t	NOUN
ijassa-493	94	44	dt	dt	X
ijassa-493	94	45			X
ijassa-493	94	46			PROPN
ijassa-493	94	47	=	=	PROPN
ijassa-493	94	48	−	−	PROPN
ijassa-493	94	49	,	,	PUNCT
ijassa-493	94	50	at	at	ADP
ijassa-493	94	51	0(0)n	0(0)n	PROPN
ijassa-493	94	52	n=	n=	ADV
ijassa-493	94	53	,	,	PUNCT
ijassa-493	94	54	(	(	PUNCT
ijassa-493	94	55	9	9	X
ijassa-493	94	56	)	)	PUNCT
ijassa-493	94	57	where	where	SCONJ
ijassa-493	94	58	0n	0n	NOUN
ijassa-493	94	59	is	be	AUX
ijassa-493	94	60	the	the	DET
ijassa-493	94	61	initial	initial	ADJ
ijassa-493	94	62	number	number	NOUN
ijassa-493	94	63	of	of	ADP
ijassa-493	94	64	tumor	tumor	NOUN
ijassa-493	94	65	cells	cell	NOUN
ijassa-493	94	66	at	at	ADP
ijassa-493	94	67	the	the	DET
ijassa-493	94	68	time	time	NOUN
ijassa-493	94	69	of	of	ADP
ijassa-493	94	70	tumor	tumor	NOUN
ijassa-493	94	71	transplantation	transplantation	NOUN
ijassa-493	94	72	to	to	ADP
ijassa-493	94	73	animals	animal	NOUN
ijassa-493	94	74	at	at	ADP
ijassa-493	94	75	t	t	PROPN
ijassa-493	94	76	=	=	SYM
ijassa-493	94	77	0	0	PROPN
ijassa-493	94	78	,	,	PUNCT
ijassa-493	94	79	n(t	n(t	PROPN
ijassa-493	94	80	)	)	PUNCT
ijassa-493	94	81	is	be	AUX
ijassa-493	94	82	the	the	DET
ijassa-493	94	83	number	number	NOUN
ijassa-493	94	84	of	of	ADP
ijassa-493	94	85	cells	cell	NOUN
ijassa-493	94	86	in	in	ADP
ijassa-493	94	87	the	the	DET
ijassa-493	94	88	tumor	tumor	NOUN
ijassa-493	94	89	at	at	ADP
ijassa-493	94	90	time	time	NOUN
ijassa-493	94	91	t	t	PROPN
ijassa-493	94	92	,	,	PUNCT
ijassa-493	94	93	n	n	ADJ
ijassa-493	94	94	and	and	CCONJ
ijassa-493	94	95	n	n	NOUN
ijassa-493	94	96	are	be	AUX
ijassa-493	94	97	the	the	DET
ijassa-493	94	98	parameters	parameter	NOUN
ijassa-493	94	99	of	of	ADP
ijassa-493	94	100	the	the	DET
ijassa-493	94	101	gompertz	gompertz	NOUN
ijassa-493	94	102	function	function	NOUN
ijassa-493	94	103	,	,	PUNCT
ijassa-493	94	104	which	which	PRON
ijassa-493	94	105	approximates	approximate	VERB
ijassa-493	94	106	the	the	DET
ijassa-493	94	107	experimental	experimental	ADJ
ijassa-493	94	108	kinetic	kinetic	ADJ
ijassa-493	94	109	curve	curve	NOUN
ijassa-493	94	110	of	of	ADP
ijassa-493	94	111	ehrlich	ehrlich	NOUN
ijassa-493	94	112	adenocarcinoma	adenocarcinoma	NOUN
ijassa-493	94	113	growth	growth	NOUN
ijassa-493	94	114	without	without	ADP
ijassa-493	94	115	treatment	treatment	NOUN
ijassa-493	94	116	(	(	PUNCT
ijassa-493	94	117	figure	figure	NOUN
ijassa-493	94	118	1	1	NUM
ijassa-493	94	119	)	)	PUNCT
ijassa-493	95	1	[	[	X
ijassa-493	95	2	5	5	NUM
ijassa-493	95	3	-	-	SYM
ijassa-493	95	4	7	7	NUM
ijassa-493	95	5	,	,	PUNCT
ijassa-493	95	6	10	10	NUM
ijassa-493	95	7	-	-	SYM
ijassa-493	95	8	14	14	NUM
ijassa-493	95	9	]	]	PUNCT
ijassa-493	95	10	.	.	PUNCT
ijassa-493	96	1	based	base	VERB
ijassa-493	96	2	on	on	ADP
ijassa-493	96	3	the	the	DET
ijassa-493	96	4	assumptions	assumption	NOUN
ijassa-493	96	5	listed	list	VERB
ijassa-493	96	6	above	above	ADV
ijassa-493	96	7	,	,	PUNCT
ijassa-493	96	8	tumor	tumor	NOUN
ijassa-493	96	9	growth	growth	NOUN
ijassa-493	96	10	after	after	ADP
ijassa-493	96	11	the	the	DET
ijassa-493	96	12	introduction	introduction	NOUN
ijassa-493	96	13	of	of	ADP
ijassa-493	96	14	viral	viral	ADJ
ijassa-493	96	15	vaccines	vaccine	NOUN
ijassa-493	96	16	follows	follow	VERB
ijassa-493	96	17	a	a	DET
ijassa-493	96	18	differential	differential	ADJ
ijassa-493	96	19	equation	equation	NOUN
ijassa-493	96	20	describing	describe	VERB
ijassa-493	96	21	the	the	DET
ijassa-493	96	22	two	two	NUM
ijassa-493	96	23	-	-	PUNCT
ijassa-493	96	24	stage	stage	NOUN
ijassa-493	96	25	death	death	NOUN
ijassa-493	96	26	of	of	ADP
ijassa-493	96	27	tumor	tumor	NOUN
ijassa-493	96	28	cells	cell	NOUN
ijassa-493	96	29	:	:	PUNCT
ijassa-493	96	30	,	,	PUNCT
ijassa-493	96	31	0	0	NUM
ijassa-493	96	32	1	1	NUM
ijassa-493	96	33	0	0	NUM
ijassa-493	96	34	,	,	PUNCT
ijassa-493	96	35	1	1	NUM
ijassa-493	96	36	0	0	NUM
ijassa-493	96	37	(	(	PUNCT
ijassa-493	96	38	)	)	PUNCT
ijassa-493	96	39	(	(	PUNCT
ijassa-493	96	40	)	)	PUNCT
ijassa-493	96	41	(	(	PUNCT
ijassa-493	96	42	)	)	PUNCT
ijassa-493	96	43	(	(	PUNCT
ijassa-493	96	44	)	)	PUNCT
ijassa-493	96	45	(	(	PUNCT
ijassa-493	96	46	)	)	PUNCT
ijassa-493	96	47	(	(	PUNCT
ijassa-493	96	48	)	)	PUNCT
ijassa-493	96	49	(	(	PUNCT
ijassa-493	96	50	)	)	PUNCT
ijassa-493	96	51	(	(	PUNCT
ijassa-493	96	52	)	)	PUNCT
ijassa-493	96	53	(	(	PUNCT
ijassa-493	96	54	(	(	PUNCT
ijassa-493	96	55	)	)	PUNCT
ijassa-493	96	56	)	)	PUNCT
ijassa-493	96	57	(	(	PUNCT
ijassa-493	96	58	)	)	PUNCT
ijassa-493	96	59	(	(	PUNCT
ijassa-493	96	60	)	)	PUNCT
ijassa-493	96	61	(	(	PUNCT
ijassa-493	96	62	)	)	PUNCT
ijassa-493	96	63	(	(	PUNCT
ijassa-493	96	64	)	)	PUNCT
ijassa-493	96	65	(	(	PUNCT
ijassa-493	96	66	)	)	PUNCT
ijassa-493	96	67	(	(	PUNCT
ijassa-493	96	68	(	(	PUNCT
ijassa-493	96	69	)	)	PUNCT
ijassa-493	96	70	)	)	PUNCT
ijassa-493	96	71	,	,	PUNCT
ijassa-493	96	72	v	v	X
ijassa-493	96	73	v	v	NUM
ijassa-493	96	74	v	v	NUM
ijassa-493	96	75	v	v	NUM
ijassa-493	96	76	v	v	NOUN
ijassa-493	96	77	v	v	NOUN
ijassa-493	96	78	n	n	ADP
ijassa-493	96	79	n	n	ADV
ijassa-493	96	80	v	v	NOUN
ijassa-493	96	81	n	n	CCONJ
ijassa-493	96	82	n	n	CCONJ
ijassa-493	96	83	n	n	CCONJ
ijassa-493	96	84	n	n	CCONJ
ijassa-493	96	85	dn	dn	PROPN
ijassa-493	96	86	t	t	PROPN
ijassa-493	96	87	t	t	PROPN
ijassa-493	96	88	n	n	ADP
ijassa-493	96	89	t	t	PROPN
ijassa-493	96	90	t	t	PROPN
ijassa-493	96	91	t	t	PROPN
ijassa-493	96	92	s	s	PROPN
ijassa-493	96	93	v	v	PROPN
ijassa-493	96	94	n	n	ADP
ijassa-493	96	95	t	t	NOUN
ijassa-493	96	96	t	t	PROPN
ijassa-493	96	97	t	t	PROPN
ijassa-493	96	98	t	t	PROPN
ijassa-493	96	99	t	t	PROPN
ijassa-493	96	100	n	n	ADP
ijassa-493	96	101	t	t	PROPN
ijassa-493	96	102	v	v	X
ijassa-493	96	103	t	t	PROPN
ijassa-493	96	104	t	t	PROPN
ijassa-493	96	105	dt	dt	X
ijassa-493	96	106	s	s	PART
ijassa-493	96	107	n	n	CCONJ
ijassa-493	96	108	n	n	PROPN
ijassa-493	96	109	t	t	NOUN
ijassa-493	96	110	t	t	PROPN
ijassa-493	96	111	t	t	PROPN
ijassa-493	96	112	t	t	PROPN
ijassa-493	96	113	t	t	PROPN
ijassa-493	96	114	n	n	PROPN
ijassa-493	96	115	t	t	PROPN
ijassa-493	96	116	v	v	NUM
ijassa-493	96	117			ADJ
ijassa-493	96	118			PROPN
ijassa-493	96	119			PROPN
ijassa-493	96	120			NUM
ijassa-493	96	121			ADJ
ijassa-493	96	122			PROPN
ijassa-493	96	123			PROPN
ijassa-493	96	124			PROPN
ijassa-493	96	125			NUM
ijassa-493	96	126			ADJ
ijassa-493	96	127			NOUN
ijassa-493	96	128	=	=	PUNCT
ijassa-493	97	1	−	−	PROPN
ijassa-493	97	2	−	−	PROPN
ijassa-493	98	1	−	−	PROPN
ijassa-493	99	1	+	+	CCONJ
ijassa-493	99	2	−	−	PROPN
ijassa-493	99	3	−	−	NUM
ijassa-493	99	4	−	−	PROPN
ijassa-493	99	5	−	−	PROPN
ijassa-493	99	6	−	−	PROPN
ijassa-493	99	7	−	−	PROPN
ijassa-493	100	1	+	+	CCONJ
ijassa-493	100	2	−	−	PROPN
ijassa-493	101	1	−	−	PROPN
ijassa-493	101	2	(	(	PUNCT
ijassa-493	101	3	10	10	NUM
ijassa-493	101	4	)	)	PUNCT
ijassa-493	101	5	where	where	SCONJ
ijassa-493	101	6	(	(	PUNCT
ijassa-493	101	7	)	)	PUNCT
ijassa-493	101	8	n	n	PRON
ijassa-493	101	9	t	t	PROPN
ijassa-493	101	10	is	be	AUX
ijassa-493	101	11	the	the	DET
ijassa-493	101	12	total	total	ADJ
ijassa-493	101	13	number	number	NOUN
ijassa-493	101	14	of	of	ADP
ijassa-493	101	15	tumor	tumor	NOUN
ijassa-493	101	16	cells	cell	NOUN
ijassa-493	101	17	at	at	ADP
ijassa-493	101	18	time	time	NOUN
ijassa-493	101	19	t	t	PROPN
ijassa-493	101	20	,	,	PUNCT
ijassa-493	101	21	(	(	PUNCT
ijassa-493	101	22	)	)	PUNCT
ijassa-493	101	23	t	t	PROPN
ijassa-493	101	24	is	be	AUX
ijassa-493	101	25	the	the	DET
ijassa-493	101	26	growth	growth	NOUN
ijassa-493	101	27	rate	rate	NOUN
ijassa-493	101	28	of	of	ADP
ijassa-493	101	29	a	a	DET
ijassa-493	101	30	given	give	VERB
ijassa-493	101	31	type	type	NOUN
ijassa-493	101	32	of	of	ADP
ijassa-493	101	33	a	a	DET
ijassa-493	101	34	tumor	tumor	NOUN
ijassa-493	101	35	,	,	PUNCT
ijassa-493	101	36	(	(	PUNCT
ijassa-493	101	37	)	)	PUNCT
ijassa-493	101	38	vt	vt	PROPN
ijassa-493	101	39	t	t	NOUN
ijassa-493	101	40	−	−	PROPN
ijassa-493	101	41	and	and	CCONJ
ijassa-493	101	42	(	(	PUNCT
ijassa-493	101	43	)	)	PUNCT
ijassa-493	101	44	nt	not	PART
ijassa-493	101	45	t	t	ADJ
ijassa-493	101	46	−	−	PROPN
ijassa-493	101	47	is	be	AUX
ijassa-493	101	48	the	the	DET
ijassa-493	101	49	heaviside	heaviside	ADJ
ijassa-493	101	50	step	step	NOUN
ijassa-493	101	51	function	function	NOUN
ijassa-493	101	52	,	,	PUNCT
ijassa-493	101	53	1v	1v	NUM
ijassa-493	101	54	cvt	cvt	PROPN
ijassa-493	101	55	z=	z=	PROPN
ijassa-493	101	56	+	+	PROPN
ijassa-493	101	57	and	and	CCONJ
ijassa-493	101	58	1n	1n	NUM
ijassa-493	101	59	cnt	cnt	PROPN
ijassa-493	101	60	z=	z=	PROPN
ijassa-493	101	61	+	+	CCONJ
ijassa-493	101	62	are	be	AUX
ijassa-493	101	63	the	the	DET
ijassa-493	101	64	moments	moment	NOUN
ijassa-493	101	65	of	of	ADP
ijassa-493	101	66	the	the	DET
ijassa-493	101	67	tumor	tumor	NOUN
ijassa-493	101	68	cells	cell	NOUN
ijassa-493	101	69	'	'	PART
ijassa-493	101	70	death	death	NOUN
ijassa-493	101	71	at	at	ADP
ijassa-493	101	72	each	each	PRON
ijassa-493	101	73	of	of	ADP
ijassa-493	101	74	the	the	DET
ijassa-493	101	75	two	two	NUM
ijassa-493	101	76	stages	stage	NOUN
ijassa-493	101	77	of	of	ADP
ijassa-493	101	78	the	the	DET
ijassa-493	101	79	immune	immune	ADJ
ijassa-493	101	80	system	system	NOUN
ijassa-493	101	81	stimulation	stimulation	NOUN
ijassa-493	101	82	,	,	PUNCT
ijassa-493	101	83	1	1	NUM
ijassa-493	101	84	is	be	AUX
ijassa-493	101	85	the	the	DET
ijassa-493	101	86	moment	moment	NOUN
ijassa-493	101	87	of	of	ADP
ijassa-493	101	88	the	the	DET
ijassa-493	101	89	viral	viral	ADJ
ijassa-493	101	90	vaccine	vaccine	NOUN
ijassa-493	101	91	introduction	introduction	NOUN
ijassa-493	101	92	,	,	PUNCT
ijassa-493	101	93	analytical	analytical	ADJ
ijassa-493	101	94	study	study	NOUN
ijassa-493	101	95	of	of	ADP
ijassa-493	101	96	antitumor	antitumor	PROPN
ijassa-493	101	97	viral	viral	ADJ
ijassa-493	101	98	vaccine	vaccine	NOUN
ijassa-493	101	99	65	65	NUM
ijassa-493	101	100	cvz	cvz	NOUN
ijassa-493	101	101	and	and	CCONJ
ijassa-493	101	102	cnz	cnz	NOUN
ijassa-493	101	103	denote	denote	VERB
ijassa-493	101	104	the	the	DET
ijassa-493	101	105	time	time	NOUN
ijassa-493	101	106	lag	lag	NOUN
ijassa-493	101	107	of	of	ADP
ijassa-493	101	108	the	the	DET
ijassa-493	101	109	immune	immune	ADJ
ijassa-493	101	110	response	response	NOUN
ijassa-493	101	111	against	against	ADP
ijassa-493	101	112	the	the	DET
ijassa-493	101	113	virus	virus	NOUN
ijassa-493	101	114	and	and	CCONJ
ijassa-493	101	115	infected	infect	VERB
ijassa-493	101	116	tumor	tumor	NOUN
ijassa-493	101	117	cells	cell	NOUN
ijassa-493	101	118	,	,	PUNCT
ijassa-493	101	119	(	(	PUNCT
ijassa-493	101	120	)	)	PUNCT
ijassa-493	101	121	vt	vt	NOUN
ijassa-493	101	122	t	t	PROPN
ijassa-493	101	123	−	−	PROPN
ijassa-493	102	1	and	and	CCONJ
ijassa-493	102	2	(	(	PUNCT
ijassa-493	102	3	)	)	PUNCT
ijassa-493	102	4	nt	not	PART
ijassa-493	102	5	t	t	PROPN
ijassa-493	102	6	−	−	NOUN
ijassa-493	102	7	are	be	AUX
ijassa-493	102	8	the	the	DET
ijassa-493	102	9	dirac	dirac	PROPN
ijassa-493	102	10	delta	delta	NOUN
ijassa-493	102	11	function	function	NOUN
ijassa-493	102	12	describing	describe	VERB
ijassa-493	102	13	instant	instant	ADJ
ijassa-493	102	14	death	death	NOUN
ijassa-493	102	15	of	of	ADP
ijassa-493	102	16	tumor	tumor	NOUN
ijassa-493	102	17	cells	cell	NOUN
ijassa-493	102	18	at	at	ADP
ijassa-493	102	19	each	each	PRON
ijassa-493	102	20	of	of	ADP
ijassa-493	102	21	two	two	NUM
ijassa-493	102	22	stages	stage	NOUN
ijassa-493	102	23	of	of	ADP
ijassa-493	102	24	the	the	DET
ijassa-493	102	25	immune	immune	ADJ
ijassa-493	102	26	system	system	NOUN
ijassa-493	102	27	stimulation	stimulation	NOUN
ijassa-493	102	28	,	,	PUNCT
ijassa-493	102	29	,	,	PUNCT
ijassa-493	102	30	0	0	NUM
ijassa-493	102	31	(	(	PUNCT
ijassa-493	102	32	)	)	PUNCT
ijassa-493	102	33	v	v	NOUN
ijassa-493	102	34	vs	vs	ADP
ijassa-493	102	35	v	v	NOUN
ijassa-493	102	36	t	t	NOUN
ijassa-493	102	37	and	and	CCONJ
ijassa-493	102	38	,	,	PUNCT
ijassa-493	102	39	0	0	NUM
ijassa-493	102	40	(	(	PUNCT
ijassa-493	102	41	)	)	PUNCT
ijassa-493	102	42	v	v	NOUN
ijassa-493	102	43	ns	ns	NUM
ijassa-493	102	44	v	v	ADP
ijassa-493	102	45	t	t	NOUN
ijassa-493	102	46	are	be	AUX
ijassa-493	102	47	the	the	DET
ijassa-493	102	48	relative	relative	ADJ
ijassa-493	102	49	decrease	decrease	NOUN
ijassa-493	102	50	in	in	ADP
ijassa-493	102	51	the	the	DET
ijassa-493	102	52	tumor	tumor	NOUN
ijassa-493	102	53	size	size	NOUN
ijassa-493	102	54	at	at	ADP
ijassa-493	102	55	the	the	DET
ijassa-493	102	56	time	time	NOUN
ijassa-493	102	57	the	the	DET
ijassa-493	102	58	tumor	tumor	NOUN
ijassa-493	102	59	cells	cell	NOUN
ijassa-493	102	60	’	’	PART
ijassa-493	102	61	death	death	NOUN
ijassa-493	102	62	at	at	ADP
ijassa-493	102	63	each	each	PRON
ijassa-493	102	64	of	of	ADP
ijassa-493	102	65	the	the	DET
ijassa-493	102	66	two	two	NUM
ijassa-493	102	67	stages	stage	NOUN
ijassa-493	102	68	,	,	PUNCT
ijassa-493	102	69	,	,	PUNCT
ijassa-493	102	70	0	0	NUM
ijassa-493	102	71	(	(	PUNCT
ijassa-493	102	72	)	)	PUNCT
ijassa-493	102	73	v	v	NOUN
ijassa-493	102	74	vv	vv	NOUN
ijassa-493	102	75	t	t	PROPN
ijassa-493	102	76	and	and	CCONJ
ijassa-493	102	77	,	,	PUNCT
ijassa-493	102	78	0	0	NUM
ijassa-493	102	79	(	(	PUNCT
ijassa-493	102	80	)	)	PUNCT
ijassa-493	102	81	n	n	CCONJ
ijassa-493	102	82	nv	nv	PROPN
ijassa-493	102	83	t	t	PROPN
ijassa-493	102	84	are	be	AUX
ijassa-493	102	85	the	the	DET
ijassa-493	102	86	tumor	tumor	NOUN
ijassa-493	102	87	growth	growth	NOUN
ijassa-493	102	88	delay	delay	NOUN
ijassa-493	102	89	after	after	ADP
ijassa-493	102	90	cells	cell	NOUN
ijassa-493	102	91	’	’	PART
ijassa-493	102	92	death	death	NOUN
ijassa-493	102	93	at	at	ADP
ijassa-493	102	94	each	each	PRON
ijassa-493	102	95	of	of	ADP
ijassa-493	102	96	the	the	DET
ijassa-493	102	97	two	two	NUM
ijassa-493	102	98	stages	stage	NOUN
ijassa-493	102	99	of	of	ADP
ijassa-493	102	100	the	the	DET
ijassa-493	102	101	immune	immune	ADJ
ijassa-493	102	102	system	system	NOUN
ijassa-493	102	103	stimulation	stimulation	NOUN
ijassa-493	102	104	(	(	PUNCT
ijassa-493	102	105	figure	figure	NOUN
ijassa-493	102	106	3	3	NUM
ijassa-493	102	107	)	)	PUNCT
ijassa-493	102	108	.	.	PUNCT
ijassa-493	103	1	in	in	ADP
ijassa-493	103	2	the	the	DET
ijassa-493	103	3	vaccine	vaccine	NOUN
ijassa-493	103	4	therapy	therapy	NOUN
ijassa-493	103	5	model	model	NOUN
ijassa-493	103	6	,	,	PUNCT
ijassa-493	103	7	it	it	PRON
ijassa-493	103	8	was	be	AUX
ijassa-493	103	9	assumed	assume	VERB
ijassa-493	103	10	that	that	SCONJ
ijassa-493	103	11	the	the	DET
ijassa-493	103	12	relative	relative	ADJ
ijassa-493	103	13	decrease	decrease	NOUN
ijassa-493	103	14	in	in	ADP
ijassa-493	103	15	tumor	tumor	NOUN
ijassa-493	103	16	volume	volume	NOUN
ijassa-493	103	17	occurs	occur	VERB
ijassa-493	103	18	only	only	ADV
ijassa-493	103	19	due	due	ADP
ijassa-493	103	20	to	to	ADP
ijassa-493	103	21	the	the	DET
ijassa-493	103	22	death	death	NOUN
ijassa-493	103	23	of	of	ADP
ijassa-493	103	24	the	the	DET
ijassa-493	103	25	virus	virus	NOUN
ijassa-493	103	26	-	-	PUNCT
ijassa-493	103	27	infected	infect	VERB
ijassa-493	103	28	tumor	tumor	NOUN
ijassa-493	103	29	cells	cell	NOUN
ijassa-493	103	30	nv(t	nv(t	NUM
ijassa-493	103	31	)	)	PUNCT
ijassa-493	103	32	.	.	PUNCT
ijassa-493	104	1	thus	thus	ADV
ijassa-493	104	2	in	in	ADP
ijassa-493	104	3	this	this	DET
ijassa-493	104	4	model	model	NOUN
ijassa-493	104	5	the	the	DET
ijassa-493	104	6	number	number	NOUN
ijassa-493	104	7	of	of	ADP
ijassa-493	104	8	dying	die	VERB
ijassa-493	104	9	cells	cell	NOUN
ijassa-493	104	10	was	be	AUX
ijassa-493	104	11	calculated	calculate	VERB
ijassa-493	104	12	as	as	ADP
ijassa-493	104	13	the	the	DET
ijassa-493	104	14	difference	difference	NOUN
ijassa-493	104	15	between	between	ADP
ijassa-493	104	16	the	the	DET
ijassa-493	104	17	maximum	maximum	ADJ
ijassa-493	104	18	and	and	CCONJ
ijassa-493	104	19	minimum	minimum	ADJ
ijassa-493	104	20	number	number	NOUN
ijassa-493	104	21	of	of	ADP
ijassa-493	104	22	infected	infected	ADJ
ijassa-493	104	23	cells	cell	NOUN
ijassa-493	104	24	:	:	PUNCT
ijassa-493	104	25	1	1	NUM
ijassa-493	104	26	2	2	NUM
ijassa-493	104	27	(	(	PUNCT
ijassa-493	104	28	)	)	PUNCT
ijassa-493	104	29	(	(	PUNCT
ijassa-493	104	30	)	)	PUNCT
ijassa-493	104	31	(	(	PUNCT
ijassa-493	104	32	)	)	PUNCT
ijassa-493	104	33	v	v	NOUN
ijassa-493	104	34	v	v	NUM
ijassa-493	104	35	v	v	NOUN
ijassa-493	104	36	vv	vv	INTJ
ijassa-493	104	37	vn	vn	PROPN
ijassa-493	104	38	t	t	PROPN
ijassa-493	104	39	n	n	PROPN
ijassa-493	104	40	t	t	PROPN
ijassa-493	104	41	n	n	CCONJ
ijassa-493	104	42	t	t	NOUN
ijassa-493	104	43	=	=	SYM
ijassa-493	104	44	−	−	PROPN
ijassa-493	104	45	and	and	CCONJ
ijassa-493	104	46	1	1	NUM
ijassa-493	104	47	2	2	NUM
ijassa-493	104	48	(	(	PUNCT
ijassa-493	104	49	)	)	PUNCT
ijassa-493	104	50	(	(	PUNCT
ijassa-493	104	51	)	)	PUNCT
ijassa-493	104	52	(	(	PUNCT
ijassa-493	104	53	)	)	PUNCT
ijassa-493	104	54	n	n	CCONJ
ijassa-493	104	55	n	n	PRON
ijassa-493	104	56	v	v	NOUN
ijassa-493	104	57	vv	vv	INTJ
ijassa-493	104	58	nn	nn	PROPN
ijassa-493	104	59	t	t	PROPN
ijassa-493	104	60	n	n	PROPN
ijassa-493	104	61	t	t	PROPN
ijassa-493	104	62	n	n	CCONJ
ijassa-493	104	63	t	t	NOUN
ijassa-493	104	64	=	=	SYM
ijassa-493	104	65	−	−	PROPN
ijassa-493	104	66	,	,	PUNCT
ijassa-493	104	67	(	(	PUNCT
ijassa-493	104	68	11	11	NUM
ijassa-493	104	69	)	)	PUNCT
ijassa-493	104	70	where	where	SCONJ
ijassa-493	104	71	1	1	NUM
ijassa-493	104	72	vt	vt	NOUN
ijassa-493	104	73	and	and	CCONJ
ijassa-493	104	74	1	1	NUM
ijassa-493	104	75	nt	not	PART
ijassa-493	104	76	are	be	AUX
ijassa-493	104	77	the	the	DET
ijassa-493	104	78	starting	start	VERB
ijassa-493	104	79	moments	moment	NOUN
ijassa-493	104	80	for	for	ADP
ijassa-493	104	81	the	the	DET
ijassa-493	104	82	immune	immune	ADJ
ijassa-493	104	83	response	response	NOUN
ijassa-493	104	84	against	against	ADP
ijassa-493	104	85	the	the	DET
ijassa-493	104	86	virus	virus	NOUN
ijassa-493	104	87	and	and	CCONJ
ijassa-493	104	88	against	against	ADP
ijassa-493	104	89	the	the	DET
ijassa-493	104	90	infected	infected	ADJ
ijassa-493	104	91	tumor	tumor	NOUN
ijassa-493	104	92	cells	cell	NOUN
ijassa-493	104	93	,	,	PUNCT
ijassa-493	104	94	2	2	NUM
ijassa-493	104	95	vt	vt	NOUN
ijassa-493	104	96	and	and	CCONJ
ijassa-493	104	97	2	2	NUM
ijassa-493	104	98	nt	not	PART
ijassa-493	104	99	are	be	AUX
ijassa-493	104	100	the	the	DET
ijassa-493	104	101	ending	end	VERB
ijassa-493	104	102	moments	moment	NOUN
ijassa-493	104	103	of	of	ADP
ijassa-493	104	104	the	the	DET
ijassa-493	104	105	immune	immune	ADJ
ijassa-493	104	106	response	response	NOUN
ijassa-493	104	107	.	.	PUNCT
ijassa-493	105	1	according	accord	VERB
ijassa-493	105	2	to	to	ADP
ijassa-493	105	3	the	the	DET
ijassa-493	105	4	model	model	NOUN
ijassa-493	105	5	of	of	ADP
ijassa-493	105	6	antitumor	antitumor	PROPN
ijassa-493	105	7	therapy	therapy	NOUN
ijassa-493	105	8	,	,	PUNCT
ijassa-493	105	9	the	the	DET
ijassa-493	105	10	relative	relative	ADJ
ijassa-493	105	11	decrease	decrease	NOUN
ijassa-493	105	12	in	in	ADP
ijassa-493	105	13	tumor	tumor	NOUN
ijassa-493	105	14	size	size	NOUN
ijassa-493	105	15	at	at	ADP
ijassa-493	105	16	the	the	DET
ijassa-493	105	17	time	time	NOUN
ijassa-493	105	18	of	of	ADP
ijassa-493	105	19	the	the	DET
ijassa-493	105	20	tumor	tumor	NOUN
ijassa-493	105	21	cells	cell	NOUN
ijassa-493	105	22	’	’	PART
ijassa-493	105	23	death	death	NOUN
ijassa-493	105	24	at	at	ADP
ijassa-493	105	25	each	each	PRON
ijassa-493	105	26	of	of	ADP
ijassa-493	105	27	the	the	DET
ijassa-493	105	28	two	two	NUM
ijassa-493	105	29	stages	stage	NOUN
ijassa-493	105	30	was	be	AUX
ijassa-493	105	31	determined	determine	VERB
ijassa-493	105	32	from	from	ADP
ijassa-493	105	33	the	the	DET
ijassa-493	105	34	following	following	ADJ
ijassa-493	105	35	equations	equation	NOUN
ijassa-493	105	36	:	:	PUNCT
ijassa-493	105	37	0	0	PUNCT
ijassa-493	105	38	(	(	PUNCT
ijassa-493	105	39	)	)	PUNCT
ijassa-493	105	40	(	(	PUNCT
ijassa-493	105	41	,	,	PUNCT
ijassa-493	105	42	)	)	PUNCT
ijassa-493	105	43	(	(	PUNCT
ijassa-493	105	44	)	)	PUNCT
ijassa-493	105	45	v	v	NOUN
ijassa-493	105	46	v	v	NUM
ijassa-493	105	47	v	v	NUM
ijassa-493	105	48	v	v	NOUN
ijassa-493	105	49	v	v	NOUN
ijassa-493	105	50	n	n	ADP
ijassa-493	105	51	t	t	NOUN
ijassa-493	105	52	s	s	PROPN
ijassa-493	105	53	v	v	ADP
ijassa-493	105	54	t	t	PROPN
ijassa-493	105	55	n	n	PRON
ijassa-493	105	56	t	t	NOUN
ijassa-493	105	57			PUNCT
ijassa-493	106	1	=	=	X
ijassa-493	106	2	и	и	X
ijassa-493	106	3	0	0	NUM
ijassa-493	106	4	(	(	PUNCT
ijassa-493	106	5	)	)	PUNCT
ijassa-493	106	6	(	(	PUNCT
ijassa-493	106	7	,	,	PUNCT
ijassa-493	106	8	)	)	PUNCT
ijassa-493	106	9	,	,	PUNCT
ijassa-493	106	10	(	(	PUNCT
ijassa-493	106	11	)	)	PUNCT
ijassa-493	106	12	v	v	NOUN
ijassa-493	106	13	n	n	CCONJ
ijassa-493	106	14	n	n	CCONJ
ijassa-493	106	15	n	n	CCONJ
ijassa-493	106	16	n	n	CCONJ
ijassa-493	106	17	n	n	NOUN
ijassa-493	106	18	t	t	NOUN
ijassa-493	106	19	s	s	PROPN
ijassa-493	106	20	v	v	ADP
ijassa-493	106	21	t	t	PROPN
ijassa-493	106	22	n	n	PRON
ijassa-493	106	23	t	t	NOUN
ijassa-493	106	24			PUNCT
ijassa-493	107	1	=	=	PUNCT
ijassa-493	107	2	(	(	PUNCT
ijassa-493	107	3	12	12	NUM
ijassa-493	107	4	)	)	PUNCT
ijassa-493	107	5	where	where	SCONJ
ijassa-493	107	6	(	(	PUNCT
ijassa-493	107	7	)	)	PUNCT
ijassa-493	107	8	vn	vn	PROPN
ijassa-493	107	9	t	t	PROPN
ijassa-493	107	10	and	and	CCONJ
ijassa-493	107	11	(	(	PUNCT
ijassa-493	107	12	)	)	PUNCT
ijassa-493	107	13	nn	nn	PROPN
ijassa-493	107	14	t	t	PROPN
ijassa-493	107	15	denote	denote	VERB
ijassa-493	107	16	the	the	DET
ijassa-493	107	17	total	total	ADJ
ijassa-493	107	18	number	number	NOUN
ijassa-493	107	19	of	of	ADP
ijassa-493	107	20	cells	cell	NOUN
ijassa-493	107	21	in	in	ADP
ijassa-493	107	22	the	the	DET
ijassa-493	107	23	tumor	tumor	NOUN
ijassa-493	107	24	at	at	ADP
ijassa-493	107	25	the	the	DET
ijassa-493	107	26	time	time	NOUN
ijassa-493	107	27	points	point	NOUN
ijassa-493	107	28	vt	vt	PROPN
ijassa-493	107	29	and	and	CCONJ
ijassa-493	107	30	nt	not	PART
ijassa-493	107	31	.	.	PUNCT
ijassa-493	108	1	the	the	DET
ijassa-493	108	2	death	death	NOUN
ijassa-493	108	3	of	of	ADP
ijassa-493	108	4	tumor	tumor	NOUN
ijassa-493	108	5	cells	cell	NOUN
ijassa-493	108	6	causes	cause	VERB
ijassa-493	108	7	tumor	tumor	NOUN
ijassa-493	108	8	growth	growth	NOUN
ijassa-493	108	9	delay	delay	NOUN
ijassa-493	108	10	,	,	PUNCT
ijassa-493	108	11	and	and	CCONJ
ijassa-493	108	12	its	its	PRON
ijassa-493	108	13	duration	duration	NOUN
ijassa-493	108	14	serves	serve	VERB
ijassa-493	108	15	as	as	ADP
ijassa-493	108	16	a	a	DET
ijassa-493	108	17	quantitative	quantitative	ADJ
ijassa-493	108	18	measure	measure	NOUN
ijassa-493	108	19	of	of	ADP
ijassa-493	108	20	the	the	DET
ijassa-493	108	21	cells	cell	NOUN
ijassa-493	108	22	’	’	PART
ijassa-493	108	23	death	death	NOUN
ijassa-493	108	24	depending	depend	VERB
ijassa-493	108	25	on	on	ADP
ijassa-493	108	26	the	the	DET
ijassa-493	108	27	dosage	dosage	NOUN
ijassa-493	108	28	of	of	ADP
ijassa-493	108	29	the	the	DET
ijassa-493	108	30	viral	viral	ADJ
ijassa-493	108	31	vaccine	vaccine	NOUN
ijassa-493	108	32	.	.	PUNCT
ijassa-493	109	1	the	the	DET
ijassa-493	109	2	tumor	tumor	NOUN
ijassa-493	109	3	growth	growth	NOUN
ijassa-493	109	4	delay	delay	NOUN
ijassa-493	109	5	,	,	PUNCT
ijassa-493	109	6	0	0	NUM
ijassa-493	109	7	(	(	PUNCT
ijassa-493	109	8	)	)	PUNCT
ijassa-493	109	9	v	v	NOUN
ijassa-493	109	10	vv	vv	NOUN
ijassa-493	109	11	t	t	PROPN
ijassa-493	109	12	and	and	CCONJ
ijassa-493	109	13	,	,	PUNCT
ijassa-493	109	14	0	0	NUM
ijassa-493	109	15	(	(	PUNCT
ijassa-493	109	16	)	)	PUNCT
ijassa-493	109	17	n	n	CCONJ
ijassa-493	109	18	nv	nv	PROPN
ijassa-493	109	19	t	t	PROPN
ijassa-493	109	20	equals	equal	VERB
ijassa-493	109	21	the	the	DET
ijassa-493	109	22	time	time	NOUN
ijassa-493	109	23	interval	interval	NOUN
ijassa-493	109	24	between	between	ADP
ijassa-493	109	25	the	the	DET
ijassa-493	109	26	cells	cell	NOUN
ijassa-493	109	27	’	’	PART
ijassa-493	109	28	death	death	NOUN
ijassa-493	109	29	and	and	CCONJ
ijassa-493	109	30	their	their	PRON
ijassa-493	109	31	subsequent	subsequent	ADJ
ijassa-493	109	32	recovery	recovery	NOUN
ijassa-493	109	33	to	to	ADP
ijassa-493	109	34	the	the	DET
ijassa-493	109	35	original	original	ADJ
ijassa-493	109	36	size	size	NOUN
ijassa-493	109	37	at	at	ADP
ijassa-493	109	38	the	the	DET
ijassa-493	109	39	moment	moment	NOUN
ijassa-493	109	40	of	of	ADP
ijassa-493	109	41	vaccine	vaccine	NOUN
ijassa-493	109	42	introduction	introduction	NOUN
ijassa-493	109	43	(	(	PUNCT
ijassa-493	109	44	figure	figure	NOUN
ijassa-493	109	45	3	3	NUM
ijassa-493	109	46	):	):	PUNCT
ijassa-493	109	47	0	0	NUM
ijassa-493	109	48	(	(	PUNCT
ijassa-493	109	49	)	)	PUNCT
ijassa-493	109	50	(	(	PUNCT
ijassa-493	109	51	(	(	PUNCT
ijassa-493	109	52	,	,	PUNCT
ijassa-493	109	53	)	)	PUNCT
ijassa-493	109	54	)	)	PUNCT
ijassa-493	110	1	v	v	X
ijassa-493	110	2	v	v	NUM
ijassa-493	110	3	v	v	ADP
ijassa-493	110	4	vn	vn	PROPN
ijassa-493	110	5	t	t	PROPN
ijassa-493	110	6	n	n	PROPN
ijassa-493	110	7	t	t	PROPN
ijassa-493	110	8	v	v	NUM
ijassa-493	110	9	t=	t=	NOUN
ijassa-493	110	10	+	+	X
ijassa-493	110	11	и	и	PROPN
ijassa-493	110	12	0	0	NUM
ijassa-493	110	13	(	(	PUNCT
ijassa-493	110	14	)	)	PUNCT
ijassa-493	110	15	(	(	PUNCT
ijassa-493	110	16	(	(	PUNCT
ijassa-493	110	17	,	,	PUNCT
ijassa-493	110	18	)	)	PUNCT
ijassa-493	110	19	)	)	PUNCT
ijassa-493	111	1	.n	.n	PROPN
ijassa-493	111	2	n	n	CCONJ
ijassa-493	111	3	n	n	CCONJ
ijassa-493	111	4	nn	nn	PROPN
ijassa-493	111	5	t	t	PROPN
ijassa-493	111	6	n	n	PROPN
ijassa-493	111	7	t	t	PROPN
ijassa-493	111	8	v	v	NUM
ijassa-493	111	9	t=	t=	NOUN
ijassa-493	111	10	+	+	X
ijassa-493	111	11	(	(	PUNCT
ijassa-493	111	12	13	13	NUM
ijassa-493	111	13	)	)	PUNCT
ijassa-493	111	14	then	then	ADV
ijassa-493	111	15	the	the	DET
ijassa-493	111	16	tumor	tumor	NOUN
ijassa-493	111	17	growth	growth	NOUN
ijassa-493	111	18	after	after	ADP
ijassa-493	111	19	each	each	DET
ijassa-493	111	20	stage	stage	NOUN
ijassa-493	111	21	of	of	ADP
ijassa-493	111	22	the	the	DET
ijassa-493	111	23	infected	infected	ADJ
ijassa-493	111	24	cells	cell	NOUN
ijassa-493	111	25	'	'	PART
ijassa-493	111	26	death	death	NOUN
ijassa-493	111	27	is	be	AUX
ijassa-493	111	28	described	describe	VERB
ijassa-493	111	29	by	by	ADP
ijassa-493	111	30	gompertz	gompertz	NOUN
ijassa-493	111	31	equations	equation	NOUN
ijassa-493	111	32	with	with	ADP
ijassa-493	111	33	a	a	DET
ijassa-493	111	34	time	time	NOUN
ijassa-493	111	35	shift	shift	NOUN
ijassa-493	111	36	that	that	PRON
ijassa-493	111	37	accounts	account	VERB
ijassa-493	111	38	for	for	ADP
ijassa-493	111	39	the	the	DET
ijassa-493	111	40	duration	duration	NOUN
ijassa-493	111	41	of	of	ADP
ijassa-493	111	42	the	the	DET
ijassa-493	111	43	tumor	tumor	NOUN
ijassa-493	111	44	growth	growth	NOUN
ijassa-493	111	45	delay	delay	NOUN
ijassa-493	111	46	as	as	SCONJ
ijassa-493	111	47	follows	follow	VERB
ijassa-493	111	48	:	:	PUNCT
ijassa-493	111	49	0	0	NUM
ijassa-493	111	50	0	0	NUM
ijassa-493	111	51	(	(	PUNCT
ijassa-493	111	52	)	)	PUNCT
ijassa-493	111	53	exp	exp	NOUN
ijassa-493	111	54	(	(	PUNCT
ijassa-493	111	55	(	(	PUNCT
ijassa-493	111	56	1	1	NUM
ijassa-493	111	57	exp	exp	NOUN
ijassa-493	111	58	(	(	PUNCT
ijassa-493	111	59	(	(	PUNCT
ijassa-493	111	60	(	(	PUNCT
ijassa-493	111	61	)	)	PUNCT
ijassa-493	111	62	)	)	PUNCT
ijassa-493	111	63	)	)	PUNCT
ijassa-493	111	64	)	)	PUNCT
ijassa-493	111	65	)	)	PUNCT
ijassa-493	111	66	,	,	PUNCT
ijassa-493	111	67	v	v	X
ijassa-493	111	68	v	v	VERB
ijassa-493	111	69	n	n	ADP
ijassa-493	111	70	n	n	ADV
ijassa-493	111	71	v	v	NOUN
ijassa-493	111	72	vn	vn	PROPN
ijassa-493	111	73	t	t	PROPN
ijassa-493	111	74	t	t	PROPN
ijassa-493	111	75	rn	rn	PROPN
ijassa-493	111	76	t	t	PROPN
ijassa-493	111	77	v	v	ADP
ijassa-493	111	78			PROPN
ijassa-493	111	79	−	−	NOUN
ijassa-493	111	80	=	=	PUNCT
ijassa-493	111	81	−	−	PROPN
ijassa-493	111	82	−	−	NOUN
ijassa-493	111	83	−	−	PROPN
ijassa-493	111	84	(	(	PUNCT
ijassa-493	111	85	14	14	NUM
ijassa-493	111	86	)	)	PUNCT
ijassa-493	111	87	0	0	NUM
ijassa-493	111	88	0	0	NUM
ijassa-493	111	89	(	(	PUNCT
ijassa-493	111	90	)	)	PUNCT
ijassa-493	111	91	exp	exp	NOUN
ijassa-493	111	92	(	(	PUNCT
ijassa-493	111	93	(	(	PUNCT
ijassa-493	111	94	1	1	NUM
ijassa-493	111	95	exp	exp	NOUN
ijassa-493	111	96	(	(	PUNCT
ijassa-493	111	97	(	(	PUNCT
ijassa-493	111	98	(	(	PUNCT
ijassa-493	111	99	)	)	PUNCT
ijassa-493	111	100	)	)	PUNCT
ijassa-493	111	101	)	)	PUNCT
ijassa-493	111	102	)	)	PUNCT
ijassa-493	111	103	)	)	PUNCT
ijassa-493	111	104	n	n	CCONJ
ijassa-493	111	105	n	n	CCONJ
ijassa-493	111	106	n	n	CCONJ
ijassa-493	111	107	n	n	CCONJ
ijassa-493	111	108	n	n	CCONJ
ijassa-493	111	109	nn	nn	PROPN
ijassa-493	111	110	t	t	PROPN
ijassa-493	111	111	t	t	PROPN
ijassa-493	111	112	rn	rn	PROPN
ijassa-493	111	113	t	t	PROPN
ijassa-493	111	114	v	v	ADP
ijassa-493	111	115			PROPN
ijassa-493	111	116	−	−	NOUN
ijassa-493	111	117	=	=	PUNCT
ijassa-493	111	118	−	−	PROPN
ijassa-493	111	119	−	−	NOUN
ijassa-493	111	120	−	−	PROPN
ijassa-493	111	121	(	(	PUNCT
ijassa-493	111	122	15	15	NUM
ijassa-493	111	123	)	)	PUNCT
ijassa-493	111	124	where	where	SCONJ
ijassa-493	111	125	0	0	NUM
ijassa-493	111	126	vrn	vrn	NOUN
ijassa-493	111	127	and	and	CCONJ
ijassa-493	111	128	0	0	NUM
ijassa-493	111	129	nrn	nrn	NOUN
ijassa-493	111	130	is	be	AUX
ijassa-493	111	131	the	the	DET
ijassa-493	111	132	number	number	NOUN
ijassa-493	111	133	of	of	ADP
ijassa-493	111	134	surviving	survive	VERB
ijassa-493	111	135	cells	cell	NOUN
ijassa-493	111	136	after	after	ADP
ijassa-493	111	137	the	the	DET
ijassa-493	111	138	1st	1st	NOUN
ijassa-493	111	139	and	and	CCONJ
ijassa-493	111	140	the	the	DET
ijassa-493	111	141	2nd	2nd	ADJ
ijassa-493	111	142	stages	stage	NOUN
ijassa-493	111	143	of	of	ADP
ijassa-493	111	144	immune	immune	ADJ
ijassa-493	111	145	response	response	NOUN
ijassa-493	111	146	.	.	PUNCT
ijassa-493	112	1	figure	figure	NOUN
ijassa-493	112	2	3	3	NUM
ijassa-493	112	3	shows	show	VERB
ijassa-493	112	4	the	the	DET
ijassa-493	112	5	calculated	calculated	ADJ
ijassa-493	112	6	curve	curve	NOUN
ijassa-493	112	7	that	that	PRON
ijassa-493	112	8	describes	describe	VERB
ijassa-493	112	9	the	the	DET
ijassa-493	112	10	total	total	ADJ
ijassa-493	112	11	number	number	NOUN
ijassa-493	112	12	of	of	ADP
ijassa-493	112	13	tumor	tumor	NOUN
ijassa-493	112	14	cells	cell	NOUN
ijassa-493	112	15	n(t	n(t	PROPN
ijassa-493	112	16	)	)	PUNCT
ijassa-493	112	17	(	(	PUNCT
ijassa-493	112	18	upper	upper	ADJ
ijassa-493	112	19	curve	curve	NOUN
ijassa-493	112	20	)	)	PUNCT
ijassa-493	112	21	derived	derive	VERB
ijassa-493	112	22	from	from	ADP
ijassa-493	112	23	the	the	DET
ijassa-493	112	24	mathematical	mathematical	ADJ
ijassa-493	112	25	model	model	NOUN
ijassa-493	112	26	of	of	ADP
ijassa-493	112	27	antitumor	antitumor	PROPN
ijassa-493	112	28	therapy	therapy	NOUN
ijassa-493	112	29	with	with	ADP
ijassa-493	112	30	discontinuous	discontinuous	ADJ
ijassa-493	112	31	trajectories	trajectory	NOUN
ijassa-493	112	32	of	of	ADP
ijassa-493	112	33	tumor	tumor	NOUN
ijassa-493	112	34	growth	growth	NOUN
ijassa-493	112	35	by	by	ADP
ijassa-493	112	36	approximating	approximate	VERB
ijassa-493	112	37	the	the	DET
ijassa-493	112	38	experimental	experimental	ADJ
ijassa-493	112	39	data	datum	NOUN
ijassa-493	112	40	.	.	PUNCT
ijassa-493	113	1	this	this	DET
ijassa-493	113	2	curve	curve	NOUN
ijassa-493	113	3	describes	describe	VERB
ijassa-493	113	4	the	the	DET
ijassa-493	113	5	tumor	tumor	NOUN
ijassa-493	113	6	growth	growth	NOUN
ijassa-493	113	7	n(t	n(t	NOUN
ijassa-493	113	8	)	)	PUNCT
ijassa-493	113	9	following	follow	VERB
ijassa-493	113	10	three	three	NUM
ijassa-493	113	11	gompertz	gompertz	NOUN
ijassa-493	113	12	equations	equation	NOUN
ijassa-493	113	13	(	(	PUNCT
ijassa-493	113	14	one	one	NUM
ijassa-493	113	15	for	for	ADP
ijassa-493	113	16	a	a	DET
ijassa-493	113	17	control	control	NOUN
ijassa-493	113	18	group	group	NOUN
ijassa-493	113	19	)	)	PUNCT
ijassa-493	113	20	with	with	ADP
ijassa-493	113	21	a	a	DET
ijassa-493	113	22	time	time	NOUN
ijassa-493	113	23	shift	shift	NOUN
ijassa-493	113	24	that	that	PRON
ijassa-493	113	25	accounts	account	VERB
ijassa-493	113	26	for	for	ADP
ijassa-493	113	27	the	the	DET
ijassa-493	113	28	tumor	tumor	NOUN
ijassa-493	113	29	growth	growth	NOUN
ijassa-493	113	30	delay	delay	NOUN
ijassa-493	113	31	after	after	ADP
ijassa-493	113	32	each	each	DET
ijassa-493	113	33	stage	stage	NOUN
ijassa-493	113	34	of	of	ADP
ijassa-493	113	35	the	the	DET
ijassa-493	113	36	cells	cell	NOUN
ijassa-493	113	37	’	’	PART
ijassa-493	113	38	death	death	NOUN
ijassa-493	114	1	[	[	X
ijassa-493	114	2	8	8	NUM
ijassa-493	114	3	-	-	SYM
ijassa-493	114	4	10	10	NUM
ijassa-493	114	5	]	]	PUNCT
ijassa-493	114	6	.	.	PUNCT
ijassa-493	115	1	appendix	appendix	NOUN
ijassa-493	115	2	1	1	NUM
ijassa-493	115	3	shows	show	VERB
ijassa-493	115	4	the	the	DET
ijassa-493	115	5	values	value	NOUN
ijassa-493	115	6	of	of	ADP
ijassa-493	115	7	the	the	DET
ijassa-493	115	8	parameters	parameter	NOUN
ijassa-493	115	9	for	for	ADP
ijassa-493	115	10	the	the	DET
ijassa-493	115	11	vaccine	vaccine	NOUN
ijassa-493	115	12	therapy	therapy	NOUN
ijassa-493	115	13	model	model	NOUN
ijassa-493	115	14	and	and	CCONJ
ijassa-493	115	15	the	the	DET
ijassa-493	115	16	antitumor	antitumor	PROPN
ijassa-493	115	17	therapy	therapy	NOUN
ijassa-493	115	18	model	model	NOUN
ijassa-493	115	19	,	,	PUNCT
ijassa-493	115	20	estimated	estimate	VERB
ijassa-493	115	21	based	base	VERB
ijassa-493	115	22	on	on	ADP
ijassa-493	115	23	the	the	DET
ijassa-493	115	24	experimental	experimental	ADJ
ijassa-493	115	25	data	datum	NOUN
ijassa-493	115	26	provided	provide	VERB
ijassa-493	115	27	in	in	ADP
ijassa-493	115	28	[	[	PUNCT
ijassa-493	115	29	10	10	NUM
ijassa-493	115	30	-	-	SYM
ijassa-493	115	31	14	14	NUM
ijassa-493	115	32	]	]	PUNCT
ijassa-493	115	33	.	.	PUNCT
ijassa-493	116	1	66	66	NUM
ijassa-493	116	2	n.a	n.a	PROPN
ijassa-493	116	3	.	.	PROPN
ijassa-493	116	4	babushkina	babushkina	PROPN
ijassa-493	116	5	,	,	PUNCT
ijassa-493	116	6	e.a	e.a	PROPN
ijassa-493	116	7	.	.	PROPN
ijassa-493	116	8	kuzina	kuzina	PROPN
ijassa-493	116	9	4	4	PROPN
ijassa-493	116	10	.	.	PUNCT
ijassa-493	116	11	algorithm	algorithm	NOUN
ijassa-493	116	12	for	for	ADP
ijassa-493	116	13	calculating	calculate	VERB
ijassa-493	116	14	effective	effective	ADJ
ijassa-493	116	15	administration	administration	NOUN
ijassa-493	116	16	regimens	regimen	NOUN
ijassa-493	116	17	for	for	ADP
ijassa-493	116	18	viral	viral	ADJ
ijassa-493	116	19	vaccines	vaccine	NOUN
ijassa-493	116	20	mathematical	mathematical	ADJ
ijassa-493	116	21	model	model	NOUN
ijassa-493	116	22	of	of	ADP
ijassa-493	116	23	vaccine	vaccine	NOUN
ijassa-493	116	24	therapy	therapy	NOUN
ijassa-493	116	25	and	and	CCONJ
ijassa-493	116	26	mathematical	mathematical	ADJ
ijassa-493	116	27	model	model	NOUN
ijassa-493	116	28	of	of	ADP
ijassa-493	116	29	antitumor	antitumor	PROPN
ijassa-493	116	30	therapy	therapy	NOUN
ijassa-493	116	31	with	with	ADP
ijassa-493	116	32	discontinuous	discontinuous	ADJ
ijassa-493	116	33	trajectories	trajectory	NOUN
ijassa-493	116	34	of	of	ADP
ijassa-493	116	35	tumor	tumor	NOUN
ijassa-493	116	36	growth	growth	NOUN
ijassa-493	116	37	were	be	AUX
ijassa-493	116	38	developed	develop	VERB
ijassa-493	116	39	in	in	ADP
ijassa-493	116	40	matlab	matlab	PROPN
ijassa-493	116	41	-	-	PUNCT
ijassa-493	116	42	simulink	simulink	NOUN
ijassa-493	116	43	to	to	PART
ijassa-493	116	44	conduct	conduct	VERB
ijassa-493	116	45	a	a	DET
ijassa-493	116	46	computing	compute	VERB
ijassa-493	116	47	experiment	experiment	NOUN
ijassa-493	116	48	(	(	PUNCT
ijassa-493	116	49	in	in	ADP
ijassa-493	116	50	silico	silico	NOUN
ijassa-493	116	51	)	)	PUNCT
ijassa-493	116	52	.	.	PUNCT
ijassa-493	117	1	the	the	DET
ijassa-493	117	2	experiment	experiment	NOUN
ijassa-493	117	3	aimed	aim	VERB
ijassa-493	117	4	to	to	PART
ijassa-493	117	5	identify	identify	VERB
ijassa-493	117	6	the	the	DET
ijassa-493	117	7	efficient	efficient	ADJ
ijassa-493	117	8	vaccine	vaccine	NOUN
ijassa-493	117	9	therapy	therapy	NOUN
ijassa-493	117	10	regimes	regime	VERB
ijassa-493	117	11	for	for	ADP
ijassa-493	117	12	a	a	DET
ijassa-493	117	13	wide	wide	ADJ
ijassa-493	117	14	range	range	NOUN
ijassa-493	117	15	of	of	ADP
ijassa-493	117	16	vee	vee	PROPN
ijassa-493	117	17	virus	virus	NOUN
ijassa-493	117	18	dosages	dosage	NOUN
ijassa-493	117	19	and	and	CCONJ
ijassa-493	117	20	for	for	ADP
ijassa-493	117	21	different	different	ADJ
ijassa-493	117	22	moments	moment	NOUN
ijassa-493	117	23	of	of	ADP
ijassa-493	117	24	vaccine	vaccine	NOUN
ijassa-493	117	25	introduction	introduction	NOUN
ijassa-493	117	26	.	.	PUNCT
ijassa-493	118	1	the	the	DET
ijassa-493	118	2	efficiency	efficiency	NOUN
ijassa-493	118	3	of	of	ADP
ijassa-493	118	4	the	the	DET
ijassa-493	118	5	vaccine	vaccine	NOUN
ijassa-493	118	6	therapy	therapy	NOUN
ijassa-493	118	7	was	be	AUX
ijassa-493	118	8	assessed	assess	VERB
ijassa-493	118	9	after	after	ADP
ijassa-493	118	10	each	each	PRON
ijassa-493	118	11	of	of	ADP
ijassa-493	118	12	the	the	DET
ijassa-493	118	13	two	two	NUM
ijassa-493	118	14	stages	stage	NOUN
ijassa-493	118	15	of	of	ADP
ijassa-493	118	16	immune	immune	ADJ
ijassa-493	118	17	response	response	NOUN
ijassa-493	118	18	based	base	VERB
ijassa-493	118	19	on	on	ADP
ijassa-493	118	20	two	two	NUM
ijassa-493	118	21	parameters	parameter	NOUN
ijassa-493	118	22	:	:	PUNCT
ijassa-493	118	23	1	1	NUM
ijassa-493	118	24	–	–	PUNCT
ijassa-493	118	25	number	number	NOUN
ijassa-493	118	26	of	of	ADP
ijassa-493	118	27	produced	produce	VERB
ijassa-493	118	28	antibodies	antibody	NOUN
ijassa-493	118	29	(	(	PUNCT
ijassa-493	118	30	)	)	PUNCT
ijassa-493	118	31	va	va	PROPN
ijassa-493	118	32	t	t	PROPN
ijassa-493	118	33	and	and	CCONJ
ijassa-493	118	34	(	(	PUNCT
ijassa-493	118	35	)	)	PUNCT
ijassa-493	118	36	na	na	ADP
ijassa-493	118	37	t	t	NOUN
ijassa-493	118	38	,	,	PUNCT
ijassa-493	118	39	2	2	NUM
ijassa-493	118	40	–	–	PUNCT
ijassa-493	118	41	number	number	NOUN
ijassa-493	118	42	of	of	ADP
ijassa-493	118	43	dying	die	VERB
ijassa-493	118	44	tumor	tumor	NOUN
ijassa-493	118	45	cells	cell	NOUN
ijassa-493	118	46	(	(	PUNCT
ijassa-493	118	47	)	)	PUNCT
ijassa-493	118	48	v	v	NOUN
ijassa-493	118	49	vn	vn	PROPN
ijassa-493	118	50	t	t	NOUN
ijassa-493	118	51	and	and	CCONJ
ijassa-493	118	52	(	(	PUNCT
ijassa-493	118	53	)	)	PUNCT
ijassa-493	118	54	v	v	NOUN
ijassa-493	118	55	nn	nn	PROPN
ijassa-493	118	56	t	t	NOUN
ijassa-493	118	57	.	.	PUNCT
ijassa-493	119	1	the	the	DET
ijassa-493	119	2	efficiency	efficiency	NOUN
ijassa-493	119	3	of	of	ADP
ijassa-493	119	4	vaccine	vaccine	NOUN
ijassa-493	119	5	therapy	therapy	NOUN
ijassa-493	119	6	method	method	NOUN
ijassa-493	119	7	was	be	AUX
ijassa-493	119	8	estimated	estimate	VERB
ijassa-493	119	9	by	by	ADP
ijassa-493	119	10	two	two	NUM
ijassa-493	119	11	criteria	criterion	NOUN
ijassa-493	119	12	.	.	PUNCT
ijassa-493	120	1	the	the	DET
ijassa-493	120	2	first	first	ADJ
ijassa-493	120	3	was	be	AUX
ijassa-493	120	4	the	the	DET
ijassa-493	120	5	number	number	NOUN
ijassa-493	120	6	of	of	ADP
ijassa-493	120	7	antibodies	antibody	NOUN
ijassa-493	120	8	formed	form	VERB
ijassa-493	120	9	by	by	ADP
ijassa-493	120	10	the	the	DET
ijassa-493	120	11	immune	immune	ADJ
ijassa-493	120	12	system	system	NOUN
ijassa-493	120	13	at	at	ADP
ijassa-493	120	14	each	each	PRON
ijassa-493	120	15	of	of	ADP
ijassa-493	120	16	the	the	DET
ijassa-493	120	17	two	two	NUM
ijassa-493	120	18	stages	stage	NOUN
ijassa-493	120	19	of	of	ADP
ijassa-493	120	20	its	its	PRON
ijassa-493	120	21	stimulation	stimulation	NOUN
ijassa-493	120	22	.	.	PUNCT
ijassa-493	121	1	we	we	PRON
ijassa-493	121	2	needed	need	VERB
ijassa-493	121	3	to	to	PART
ijassa-493	121	4	determine	determine	VERB
ijassa-493	121	5	the	the	DET
ijassa-493	121	6	dosage	dosage	NOUN
ijassa-493	121	7	that	that	PRON
ijassa-493	121	8	results	result	VERB
ijassa-493	121	9	in	in	ADP
ijassa-493	121	10	the	the	DET
ijassa-493	121	11	maximum	maximum	ADJ
ijassa-493	121	12	number	number	NOUN
ijassa-493	121	13	of	of	ADP
ijassa-493	121	14	antibodies	antibody	NOUN
ijassa-493	121	15	against	against	ADP
ijassa-493	121	16	infected	infected	ADJ
ijassa-493	121	17	tumor	tumor	NOUN
ijassa-493	121	18	cells	cell	NOUN
ijassa-493	121	19	[	[	X
ijassa-493	121	20	10	10	NUM
ijassa-493	121	21	-	-	SYM
ijassa-493	121	22	13	13	NUM
ijassa-493	121	23	]	]	PUNCT
ijassa-493	121	24	.	.	PUNCT
ijassa-493	122	1	when	when	SCONJ
ijassa-493	122	2	this	this	DET
ijassa-493	122	3	condition	condition	NOUN
ijassa-493	122	4	is	be	AUX
ijassa-493	122	5	met	meet	VERB
ijassa-493	122	6	,	,	PUNCT
ijassa-493	122	7	the	the	DET
ijassa-493	122	8	tumor	tumor	NOUN
ijassa-493	122	9	-	-	PUNCT
ijassa-493	122	10	bearing	bear	VERB
ijassa-493	122	11	organism	organism	NOUN
ijassa-493	122	12	is	be	AUX
ijassa-493	122	13	able	able	ADJ
ijassa-493	122	14	to	to	PART
ijassa-493	122	15	restrain	restrain	VERB
ijassa-493	122	16	the	the	DET
ijassa-493	122	17	growth	growth	NOUN
ijassa-493	122	18	of	of	ADP
ijassa-493	122	19	the	the	DET
ijassa-493	122	20	surviving	survive	VERB
ijassa-493	122	21	tumor	tumor	NOUN
ijassa-493	122	22	cells	cell	NOUN
ijassa-493	122	23	.	.	PUNCT
ijassa-493	123	1	the	the	DET
ijassa-493	123	2	second	second	ADJ
ijassa-493	123	3	criterion	criterion	NOUN
ijassa-493	123	4	was	be	AUX
ijassa-493	123	5	the	the	DET
ijassa-493	123	6	tumor	tumor	NOUN
ijassa-493	123	7	growth	growth	NOUN
ijassa-493	123	8	delay	delay	NOUN
ijassa-493	123	9	.	.	PUNCT
ijassa-493	124	1	it	it	PRON
ijassa-493	124	2	depends	depend	VERB
ijassa-493	124	3	on	on	ADP
ijassa-493	124	4	the	the	DET
ijassa-493	124	5	number	number	NOUN
ijassa-493	124	6	of	of	ADP
ijassa-493	124	7	dying	die	VERB
ijassa-493	124	8	cells	cell	NOUN
ijassa-493	124	9	on	on	ADP
ijassa-493	124	10	each	each	PRON
ijassa-493	124	11	of	of	ADP
ijassa-493	124	12	the	the	DET
ijassa-493	124	13	two	two	NUM
ijassa-493	124	14	stages	stage	NOUN
ijassa-493	124	15	of	of	ADP
ijassa-493	124	16	immune	immune	ADJ
ijassa-493	124	17	response	response	NOUN
ijassa-493	124	18	.	.	PUNCT
ijassa-493	125	1	therefore	therefore	ADV
ijassa-493	125	2	,	,	PUNCT
ijassa-493	125	3	the	the	DET
ijassa-493	125	4	algorithm	algorithm	NOUN
ijassa-493	125	5	for	for	ADP
ijassa-493	125	6	calculating	calculate	VERB
ijassa-493	125	7	optimal	optimal	ADJ
ijassa-493	125	8	regimen	regiman	NOUN
ijassa-493	125	9	of	of	ADP
ijassa-493	125	10	the	the	DET
ijassa-493	125	11	viral	viral	ADJ
ijassa-493	125	12	vaccine	vaccine	NOUN
ijassa-493	125	13	is	be	AUX
ijassa-493	125	14	based	base	VERB
ijassa-493	125	15	on	on	ADP
ijassa-493	125	16	defining	define	VERB
ijassa-493	125	17	a	a	DET
ijassa-493	125	18	maximal	maximal	ADJ
ijassa-493	125	19	effective	effective	ADJ
ijassa-493	125	20	dosage	dosage	NOUN
ijassa-493	125	21	when	when	SCONJ
ijassa-493	125	22	the	the	DET
ijassa-493	125	23	immune	immune	ADJ
ijassa-493	125	24	system	system	NOUN
ijassa-493	125	25	produces	produce	VERB
ijassa-493	125	26	the	the	DET
ijassa-493	125	27	biggest	big	ADJ
ijassa-493	125	28	number	number	NOUN
ijassa-493	125	29	of	of	ADP
ijassa-493	125	30	antibodies	antibody	NOUN
ijassa-493	125	31	.	.	PUNCT
ijassa-493	126	1	4.1	4.1	NUM
ijassa-493	126	2	.	.	PUNCT
ijassa-493	126	3	calculating	calculate	VERB
ijassa-493	126	4	the	the	DET
ijassa-493	126	5	viral	viral	ADJ
ijassa-493	126	6	vaccine	vaccine	NOUN
ijassa-493	126	7	dosage	dosage	NOUN
ijassa-493	126	8	using	use	VERB
ijassa-493	126	9	the	the	DET
ijassa-493	126	10	criterion	criterion	NOUN
ijassa-493	126	11	of	of	ADP
ijassa-493	126	12	the	the	DET
ijassa-493	126	13	production	production	NOUN
ijassa-493	126	14	of	of	ADP
ijassa-493	126	15	antibodies	antibody	NOUN
ijassa-493	126	16	against	against	ADP
ijassa-493	126	17	infected	infected	ADJ
ijassa-493	126	18	tumor	tumor	NOUN
ijassa-493	126	19	cells	cell	NOUN
ijassa-493	126	20	based	base	VERB
ijassa-493	126	21	on	on	ADP
ijassa-493	126	22	the	the	DET
ijassa-493	126	23	model	model	NOUN
ijassa-493	126	24	of	of	ADP
ijassa-493	126	25	vaccine	vaccine	NOUN
ijassa-493	126	26	therapy	therapy	NOUN
ijassa-493	126	27	with	with	ADP
ijassa-493	126	28	a	a	DET
ijassa-493	126	29	single	single	ADJ
ijassa-493	126	30	introduction	introduction	NOUN
ijassa-493	126	31	of	of	ADP
ijassa-493	126	32	the	the	DET
ijassa-493	126	33	varying	vary	VERB
ijassa-493	126	34	dosages	dosage	NOUN
ijassa-493	126	35	of	of	ADP
ijassa-493	126	36	the	the	DET
ijassa-493	126	37	viral	viral	ADJ
ijassa-493	126	38	vaccines	vaccine	NOUN
ijassa-493	126	39	at	at	ADP
ijassa-493	126	40	the	the	DET
ijassa-493	126	41	varying	vary	VERB
ijassa-493	126	42	moments	moment	NOUN
ijassa-493	126	43	(	(	PUNCT
ijassa-493	126	44	from	from	ADP
ijassa-493	126	45	the	the	DET
ijassa-493	126	46	1st	1st	NOUN
ijassa-493	126	47	to	to	ADP
ijassa-493	126	48	35th	35th	ADJ
ijassa-493	126	49	day	day	NOUN
ijassa-493	126	50	)	)	PUNCT
ijassa-493	126	51	,	,	PUNCT
ijassa-493	126	52	the	the	DET
ijassa-493	126	53	graphs	graph	NOUN
ijassa-493	126	54	that	that	PRON
ijassa-493	126	55	show	show	VERB
ijassa-493	126	56	the	the	DET
ijassa-493	126	57	changes	change	NOUN
ijassa-493	126	58	in	in	ADP
ijassa-493	126	59	the	the	DET
ijassa-493	126	60	number	number	NOUN
ijassa-493	126	61	of	of	ADP
ijassa-493	126	62	antibodies	antibody	NOUN
ijassa-493	126	63	against	against	ADP
ijassa-493	126	64	the	the	DET
ijassa-493	126	65	virus	virus	NOUN
ijassa-493	126	66	(	(	PUNCT
ijassa-493	126	67	)	)	PUNCT
ijassa-493	126	68	va	va	PROPN
ijassa-493	126	69	t	t	PROPN
ijassa-493	126	70	(	(	PUNCT
ijassa-493	126	71	figure	figure	NOUN
ijassa-493	126	72	4	4	NUM
ijassa-493	126	73	)	)	PUNCT
ijassa-493	126	74	and	and	CCONJ
ijassa-493	126	75	antibodies	antibodie	VERB
ijassa-493	126	76	against	against	ADP
ijassa-493	126	77	infected	infected	ADJ
ijassa-493	126	78	tumor	tumor	NOUN
ijassa-493	126	79	cells	cell	NOUN
ijassa-493	126	80	(	(	PUNCT
ijassa-493	126	81	)	)	PUNCT
ijassa-493	126	82	na	na	PART
ijassa-493	126	83	t	t	PROPN
ijassa-493	126	84	(	(	PUNCT
ijassa-493	126	85	figure	figure	NOUN
ijassa-493	126	86	5	5	NUM
ijassa-493	126	87	)	)	PUNCT
ijassa-493	126	88	were	be	AUX
ijassa-493	126	89	developed	develop	VERB
ijassa-493	126	90	[	[	X
ijassa-493	126	91	14	14	NUM
ijassa-493	126	92	]	]	PUNCT
ijassa-493	126	93	.	.	PUNCT
ijassa-493	127	1	these	these	DET
ijassa-493	127	2	graphs	graph	NOUN
ijassa-493	127	3	reflect	reflect	VERB
ijassa-493	127	4	two	two	NUM
ijassa-493	127	5	fundamentally	fundamentally	ADV
ijassa-493	127	6	different	different	ADJ
ijassa-493	127	7	types	type	NOUN
ijassa-493	127	8	of	of	ADP
ijassa-493	127	9	the	the	DET
ijassa-493	127	10	production	production	NOUN
ijassa-493	127	11	of	of	ADP
ijassa-493	127	12	antibodies	antibody	NOUN
ijassa-493	127	13	against	against	ADP
ijassa-493	127	14	the	the	DET
ijassa-493	127	15	virus	virus	NOUN
ijassa-493	127	16	and	and	CCONJ
ijassa-493	127	17	against	against	ADP
ijassa-493	127	18	the	the	DET
ijassa-493	127	19	tumor	tumor	NOUN
ijassa-493	127	20	cells	cell	NOUN
ijassa-493	127	21	,	,	PUNCT
ijassa-493	127	22	depending	depend	VERB
ijassa-493	127	23	on	on	ADP
ijassa-493	127	24	the	the	DET
ijassa-493	127	25	vaccine	vaccine	NOUN
ijassa-493	127	26	dosage	dosage	NOUN
ijassa-493	127	27	.	.	PUNCT
ijassa-493	128	1	the	the	DET
ijassa-493	128	2	number	number	NOUN
ijassa-493	128	3	of	of	ADP
ijassa-493	128	4	antibodies	antibody	NOUN
ijassa-493	128	5	against	against	ADP
ijassa-493	128	6	the	the	DET
ijassa-493	128	7	virus	virus	NOUN
ijassa-493	128	8	increases	increase	VERB
ijassa-493	128	9	in	in	ADP
ijassa-493	128	10	proportion	proportion	NOUN
ijassa-493	128	11	to	to	ADP
ijassa-493	128	12	the	the	DET
ijassa-493	128	13	dosage	dosage	NOUN
ijassa-493	128	14	increase	increase	NOUN
ijassa-493	128	15	,	,	PUNCT
ijassa-493	128	16	i.e.	i.e.	X
ijassa-493	128	17	there	there	PRON
ijassa-493	128	18	is	be	VERB
ijassa-493	128	19	a	a	DET
ijassa-493	128	20	linear	linear	ADJ
ijassa-493	128	21	dependence	dependence	NOUN
ijassa-493	128	22	between	between	ADP
ijassa-493	128	23	these	these	DET
ijassa-493	128	24	variables	variable	NOUN
ijassa-493	128	25	(	(	PUNCT
ijassa-493	128	26	figure	figure	NOUN
ijassa-493	128	27	4	4	NUM
ijassa-493	128	28	)	)	PUNCT
ijassa-493	128	29	.	.	PUNCT
ijassa-493	129	1	however	however	ADV
ijassa-493	129	2	,	,	PUNCT
ijassa-493	129	3	the	the	DET
ijassa-493	129	4	increase	increase	NOUN
ijassa-493	129	5	in	in	ADP
ijassa-493	129	6	the	the	DET
ijassa-493	129	7	number	number	NOUN
ijassa-493	129	8	of	of	ADP
ijassa-493	129	9	antibodies	antibody	NOUN
ijassa-493	129	10	against	against	ADP
ijassa-493	129	11	infected	infected	ADJ
ijassa-493	129	12	tumor	tumor	NOUN
ijassa-493	129	13	cells	cell	NOUN
ijassa-493	129	14	0	0	NUM
ijassa-493	129	15	1	1	NUM
ijassa-493	129	16	(	(	PUNCT
ijassa-493	129	17	,	,	PUNCT
ijassa-493	129	18	)	)	PUNCT
ijassa-493	129	19	na	na	PART
ijassa-493	129	20	v	v	ADP
ijassa-493	129	21			NOUN
ijassa-493	129	22	is	be	AUX
ijassa-493	129	23	non	non	ADJ
ijassa-493	129	24	-	-	ADJ
ijassa-493	129	25	linear	linear	ADJ
ijassa-493	129	26	,	,	PUNCT
ijassa-493	129	27	and	and	CCONJ
ijassa-493	129	28	depends	depend	VERB
ijassa-493	129	29	on	on	ADP
ijassa-493	129	30	the	the	DET
ijassa-493	129	31	tumor	tumor	NOUN
ijassa-493	129	32	size	size	NOUN
ijassa-493	129	33	at	at	ADP
ijassa-493	129	34	the	the	DET
ijassa-493	129	35	moment	moment	NOUN
ijassa-493	129	36	of	of	ADP
ijassa-493	129	37	vaccine	vaccine	NOUN
ijassa-493	129	38	introduction	introduction	NOUN
ijassa-493	129	39	(	(	PUNCT
ijassa-493	129	40	figure	figure	NOUN
ijassa-493	129	41	5	5	NUM
ijassa-493	129	42	)	)	PUNCT
ijassa-493	129	43	.	.	PUNCT
ijassa-493	130	1	this	this	DET
ijassa-493	130	2	non	non	ADJ
ijassa-493	130	3	-	-	ADJ
ijassa-493	130	4	linear	linear	ADJ
ijassa-493	130	5	dependence	dependence	NOUN
ijassa-493	130	6	allows	allow	VERB
ijassa-493	130	7	determining	determine	VERB
ijassa-493	130	8	the	the	DET
ijassa-493	130	9	virus	virus	NOUN
ijassa-493	130	10	dose	dose	VERB
ijassa-493	130	11	max	max	PROPN
ijassa-493	130	12	0v	0v	X
ijassa-493	130	13	=	=	SYM
ijassa-493	130	14	0,024	0,024	NUM
ijassa-493	130	15	that	that	PRON
ijassa-493	130	16	results	result	VERB
ijassa-493	130	17	in	in	ADP
ijassa-493	130	18	the	the	DET
ijassa-493	130	19	maximal	maximal	ADJ
ijassa-493	130	20	production	production	NOUN
ijassa-493	130	21	of	of	ADP
ijassa-493	130	22	antibodies	antibody	NOUN
ijassa-493	130	23	against	against	ADP
ijassa-493	130	24	the	the	DET
ijassa-493	130	25	infected	infected	ADJ
ijassa-493	130	26	tumor	tumor	NOUN
ijassa-493	130	27	cells	cell	NOUN
ijassa-493	130	28	.	.	PUNCT
ijassa-493	131	1	analytical	analytical	ADJ
ijassa-493	131	2	study	study	NOUN
ijassa-493	131	3	of	of	ADP
ijassa-493	131	4	antitumor	antitumor	PROPN
ijassa-493	131	5	viral	viral	ADJ
ijassa-493	131	6	vaccine	vaccine	NOUN
ijassa-493	131	7	67	67	NUM
ijassa-493	131	8	fig	fig	NOUN
ijassa-493	131	9	.	.	PUNCT
ijassa-493	132	1	4	4	X
ijassa-493	132	2	.	.	X
ijassa-493	132	3	maximum	maximum	ADJ
ijassa-493	132	4	number	number	NOUN
ijassa-493	132	5	of	of	ADP
ijassa-493	132	6	antibodies	antibody	NOUN
ijassa-493	132	7	against	against	ADP
ijassa-493	132	8	the	the	DET
ijassa-493	132	9	virus	virus	NOUN
ijassa-493	132	10	max	max	PROPN
ijassa-493	132	11	0	0	PROPN
ijassa-493	132	12	(	(	PUNCT
ijassa-493	132	13	)	)	PUNCT
ijassa-493	132	14	va	va	PROPN
ijassa-493	132	15	v	v	NOUN
ijassa-493	132	16	depending	depend	VERB
ijassa-493	132	17	on	on	ADP
ijassa-493	132	18	the	the	DET
ijassa-493	132	19	dose	dose	NOUN
ijassa-493	132	20	0v	0v	NOUN
ijassa-493	132	21	administered	administer	VERB
ijassa-493	132	22	on	on	ADP
ijassa-493	132	23	day	day	NOUN
ijassa-493	132	24	1	1	NUM
ijassa-493	132	25	(	(	PUNCT
ijassa-493	132	26	the	the	DET
ijassa-493	132	27	first	first	ADJ
ijassa-493	132	28	stage	stage	NOUN
ijassa-493	132	29	of	of	ADP
ijassa-493	132	30	the	the	DET
ijassa-493	132	31	immune	immune	ADJ
ijassa-493	132	32	system	system	NOUN
ijassa-493	132	33	stimulation	stimulation	NOUN
ijassa-493	132	34	)	)	PUNCT
ijassa-493	132	35	fig	fig	NOUN
ijassa-493	132	36	.	.	PUNCT
ijassa-493	133	1	5	5	X
ijassa-493	133	2	.	.	PUNCT
ijassa-493	133	3	maximum	maximum	ADJ
ijassa-493	133	4	number	number	NOUN
ijassa-493	133	5	of	of	ADP
ijassa-493	133	6	antibodies	antibody	NOUN
ijassa-493	133	7	against	against	ADP
ijassa-493	133	8	infected	infected	ADJ
ijassa-493	133	9	tumor	tumor	NOUN
ijassa-493	133	10	cells	cell	NOUN
ijassa-493	133	11	max	max	PROPN
ijassa-493	133	12	0	0	NUM
ijassa-493	133	13	(	(	PUNCT
ijassa-493	133	14	)	)	PUNCT
ijassa-493	133	15	na	na	AUX
ijassa-493	133	16	v	v	ADP
ijassa-493	133	17	depending	depend	VERB
ijassa-493	133	18	on	on	ADP
ijassa-493	133	19	the	the	DET
ijassa-493	133	20	dose	dose	NOUN
ijassa-493	133	21	of	of	ADP
ijassa-493	133	22	0v	0v	NOUN
ijassa-493	133	23	administered	administer	VERB
ijassa-493	133	24	at	at	ADP
ijassa-493	133	25	different	different	ADJ
ijassa-493	133	26	moments	moment	NOUN
ijassa-493	133	27	(	(	PUNCT
ijassa-493	133	28	the	the	DET
ijassa-493	133	29	second	second	ADJ
ijassa-493	133	30	stage	stage	NOUN
ijassa-493	133	31	of	of	ADP
ijassa-493	133	32	the	the	DET
ijassa-493	133	33	immune	immune	ADJ
ijassa-493	133	34	system	system	NOUN
ijassa-493	133	35	stimulation	stimulation	NOUN
ijassa-493	133	36	)	)	PUNCT
ijassa-493	133	37	;	;	PUNCT
ijassa-493	133	38	1	1	NUM
ijassa-493	133	39	=	=	SYM
ijassa-493	133	40	1	1	NUM
ijassa-493	133	41	,	,	PUNCT
ijassa-493	133	42	5	5	NUM
ijassa-493	133	43	,	,	PUNCT
ijassa-493	133	44	15	15	NUM
ijassa-493	133	45	,	,	PUNCT
ijassa-493	133	46	25	25	NUM
ijassa-493	133	47	,	,	PUNCT
ijassa-493	133	48	35	35	NUM
ijassa-493	133	49	days	day	NOUN
ijassa-493	133	50	the	the	DET
ijassa-493	133	51	non	non	ADJ
ijassa-493	133	52	-	-	ADJ
ijassa-493	133	53	linear	linear	ADJ
ijassa-493	133	54	dependence	dependence	NOUN
ijassa-493	133	55	of	of	ADP
ijassa-493	133	56	production	production	NOUN
ijassa-493	133	57	of	of	ADP
ijassa-493	133	58	antibodies	antibody	NOUN
ijassa-493	133	59	on	on	ADP
ijassa-493	133	60	the	the	DET
ijassa-493	133	61	dosage	dosage	NOUN
ijassa-493	133	62	increase	increase	NOUN
ijassa-493	133	63	0	0	NUM
ijassa-493	133	64	1	1	NUM
ijassa-493	133	65	(	(	PUNCT
ijassa-493	133	66	,	,	PUNCT
ijassa-493	133	67	)	)	PUNCT
ijassa-493	133	68	na	na	PART
ijassa-493	133	69	v	v	ADP
ijassa-493	133	70			NOUN
ijassa-493	133	71	may	may	AUX
ijassa-493	133	72	be	be	AUX
ijassa-493	133	73	due	due	ADJ
ijassa-493	133	74	to	to	ADP
ijassa-493	133	75	the	the	DET
ijassa-493	133	76	changes	change	NOUN
ijassa-493	133	77	in	in	ADP
ijassa-493	133	78	the	the	DET
ijassa-493	133	79	number	number	NOUN
ijassa-493	133	80	of	of	ADP
ijassa-493	133	81	infected	infected	ADJ
ijassa-493	133	82	tumor	tumor	NOUN
ijassa-493	133	83	cells	cell	NOUN
ijassa-493	133	84	on	on	ADP
ijassa-493	133	85	the	the	DET
ijassa-493	133	86	1st	1st	ADJ
ijassa-493	133	87	and	and	CCONJ
ijassa-493	133	88	2nd	2nd	ADJ
ijassa-493	133	89	stages	stage	NOUN
ijassa-493	133	90	of	of	ADP
ijassa-493	133	91	immune	immune	ADJ
ijassa-493	133	92	response	response	NOUN
ijassa-493	133	93	.	.	PUNCT
ijassa-493	134	1	when	when	SCONJ
ijassa-493	134	2	the	the	DET
ijassa-493	134	3	dosage	dosage	NOUN
ijassa-493	134	4	is	be	AUX
ijassa-493	134	5	small	small	ADJ
ijassa-493	134	6	,	,	PUNCT
ijassa-493	134	7	the	the	DET
ijassa-493	134	8	number	number	NOUN
ijassa-493	134	9	of	of	ADP
ijassa-493	134	10	the	the	DET
ijassa-493	134	11	dying	die	VERB
ijassa-493	134	12	cells	cell	NOUN
ijassa-493	134	13	is	be	AUX
ijassa-493	134	14	low	low	ADJ
ijassa-493	134	15	,	,	PUNCT
ijassa-493	134	16	but	but	CCONJ
ijassa-493	134	17	many	many	ADJ
ijassa-493	134	18	cells	cell	NOUN
ijassa-493	134	19	get	get	AUX
ijassa-493	134	20	infected	infect	VERB
ijassa-493	134	21	by	by	ADP
ijassa-493	134	22	the	the	DET
ijassa-493	134	23	virus	virus	NOUN
ijassa-493	134	24	.	.	PUNCT
ijassa-493	135	1	with	with	ADP
ijassa-493	135	2	the	the	DET
ijassa-493	135	3	further	further	ADJ
ijassa-493	135	4	increase	increase	NOUN
ijassa-493	135	5	of	of	ADP
ijassa-493	135	6	the	the	DET
ijassa-493	135	7	dosage	dosage	NOUN
ijassa-493	135	8	exceeding	exceed	VERB
ijassa-493	135	9	max	max	PROPN
ijassa-493	135	10	0v	0v	X
ijassa-493	135	11	=	=	SYM
ijassa-493	135	12	0,024	0,024	PROPN
ijassa-493	135	13	,	,	PUNCT
ijassa-493	135	14	the	the	DET
ijassa-493	135	15	number	number	NOUN
ijassa-493	135	16	of	of	ADP
ijassa-493	135	17	cells	cell	NOUN
ijassa-493	135	18	dying	die	VERB
ijassa-493	135	19	at	at	ADP
ijassa-493	135	20	the	the	DET
ijassa-493	135	21	1st	1st	ADJ
ijassa-493	135	22	stage	stage	NOUN
ijassa-493	135	23	of	of	ADP
ijassa-493	135	24	immune	immune	ADJ
ijassa-493	135	25	response	response	NOUN
ijassa-493	135	26	increases	increase	NOUN
ijassa-493	135	27	.	.	PUNCT
ijassa-493	136	1	this	this	PRON
ijassa-493	136	2	leads	lead	VERB
ijassa-493	136	3	to	to	ADP
ijassa-493	136	4	reduction	reduction	NOUN
ijassa-493	136	5	of	of	ADP
ijassa-493	136	6	the	the	DET
ijassa-493	136	7	number	number	NOUN
ijassa-493	136	8	of	of	ADP
ijassa-493	136	9	infected	infected	ADJ
ijassa-493	136	10	cells	cell	NOUN
ijassa-493	136	11	,	,	PUNCT
ijassa-493	136	12	and	and	CCONJ
ijassa-493	136	13	the	the	DET
ijassa-493	136	14	consequent	consequent	ADJ
ijassa-493	136	15	decrease	decrease	NOUN
ijassa-493	136	16	in	in	ADP
ijassa-493	136	17	the	the	DET
ijassa-493	136	18	number	number	NOUN
ijassa-493	136	19	of	of	ADP
ijassa-493	136	20	antibodies	antibody	NOUN
ijassa-493	136	21	against	against	ADP
ijassa-493	136	22	these	these	DET
ijassa-493	136	23	cells	cell	NOUN
ijassa-493	136	24	on	on	ADP
ijassa-493	136	25	the	the	DET
ijassa-493	136	26	2nd	2nd	ADJ
ijassa-493	136	27	stage	stage	NOUN
ijassa-493	136	28	of	of	ADP
ijassa-493	136	29	immune	immune	ADJ
ijassa-493	136	30	response	response	NOUN
ijassa-493	136	31	.	.	PUNCT
ijassa-493	137	1	thus	thus	ADV
ijassa-493	137	2	,	,	PUNCT
ijassa-493	137	3	with	with	ADP
ijassa-493	137	4	the	the	DET
ijassa-493	137	5	administration	administration	NOUN
ijassa-493	137	6	of	of	ADP
ijassa-493	137	7	significant	significant	ADJ
ijassa-493	137	8	doses	dose	NOUN
ijassa-493	137	9	of	of	ADP
ijassa-493	137	10	the	the	DET
ijassa-493	137	11	virus	virus	NOUN
ijassa-493	137	12	,	,	PUNCT
ijassa-493	137	13	almost	almost	ADV
ijassa-493	137	14	the	the	DET
ijassa-493	137	15	entire	entire	ADJ
ijassa-493	137	16	population	population	NOUN
ijassa-493	137	17	of	of	ADP
ijassa-493	137	18	tumor	tumor	NOUN
ijassa-493	137	19	cells	cell	NOUN
ijassa-493	137	20	is	be	AUX
ijassa-493	137	21	killed	kill	VERB
ijassa-493	137	22	already	already	ADV
ijassa-493	137	23	at	at	ADP
ijassa-493	137	24	the	the	DET
ijassa-493	137	25	1st	1st	ADJ
ijassa-493	137	26	stage	stage	NOUN
ijassa-493	137	27	of	of	ADP
ijassa-493	137	28	immune	immune	ADJ
ijassa-493	137	29	response	response	NOUN
ijassa-493	137	30	.	.	PUNCT
ijassa-493	138	1	this	this	PRON
ijassa-493	138	2	leads	lead	VERB
ijassa-493	138	3	to	to	ADP
ijassa-493	138	4	a	a	DET
ijassa-493	138	5	rapid	rapid	ADJ
ijassa-493	138	6	and	and	CCONJ
ijassa-493	138	7	effective	effective	ADJ
ijassa-493	138	8	destruction	destruction	NOUN
ijassa-493	138	9	of	of	ADP
ijassa-493	138	10	the	the	DET
ijassa-493	138	11	tumor	tumor	NOUN
ijassa-493	138	12	,	,	PUNCT
ijassa-493	138	13	but	but	CCONJ
ijassa-493	138	14	does	do	AUX
ijassa-493	138	15	n’t	not	PART
ijassa-493	138	16	stimulate	stimulate	VERB
ijassa-493	138	17	the	the	DET
ijassa-493	138	18	2nd	2nd	ADJ
ijassa-493	138	19	stage	stage	NOUN
ijassa-493	138	20	of	of	ADP
ijassa-493	138	21	immune	immune	ADJ
ijassa-493	138	22	response	response	NOUN
ijassa-493	138	23	;	;	PUNCT
ijassa-493	138	24	therefore	therefore	ADV
ijassa-493	138	25	the	the	DET
ijassa-493	138	26	antibodies	antibody	NOUN
ijassa-493	138	27	against	against	ADP
ijassa-493	138	28	the	the	DET
ijassa-493	138	29	infected	infected	ADJ
ijassa-493	138	30	tumor	tumor	NOUN
ijassa-493	138	31	cells	cell	NOUN
ijassa-493	138	32	are	be	AUX
ijassa-493	138	33	not	not	PART
ijassa-493	138	34	produced	produce	VERB
ijassa-493	138	35	.	.	PUNCT
ijassa-493	139	1	68	68	NUM
ijassa-493	139	2	n.a	n.a	PROPN
ijassa-493	139	3	.	.	PROPN
ijassa-493	139	4	babushkina	babushkina	PROPN
ijassa-493	139	5	,	,	PUNCT
ijassa-493	139	6	e.a	e.a	PROPN
ijassa-493	139	7	.	.	PROPN
ijassa-493	139	8	kuzina	kuzina	PROPN
ijassa-493	139	9	the	the	DET
ijassa-493	139	10	effectiveness	effectiveness	NOUN
ijassa-493	139	11	of	of	ADP
ijassa-493	139	12	production	production	NOUN
ijassa-493	139	13	of	of	ADP
ijassa-493	139	14	the	the	DET
ijassa-493	139	15	antibodies	antibody	NOUN
ijassa-493	139	16	against	against	ADP
ijassa-493	139	17	the	the	DET
ijassa-493	139	18	infected	infected	ADJ
ijassa-493	139	19	tumor	tumor	NOUN
ijassa-493	139	20	cells	cell	NOUN
ijassa-493	139	21	depends	depend	VERB
ijassa-493	139	22	on	on	ADP
ijassa-493	139	23	the	the	DET
ijassa-493	139	24	tumor	tumor	NOUN
ijassa-493	139	25	size	size	NOUN
ijassa-493	139	26	.	.	PUNCT
ijassa-493	140	1	as	as	SCONJ
ijassa-493	140	2	indicated	indicate	VERB
ijassa-493	140	3	by	by	ADP
ijassa-493	140	4	the	the	DET
ijassa-493	140	5	calculations	calculation	NOUN
ijassa-493	140	6	[	[	X
ijassa-493	140	7	14	14	NUM
ijassa-493	140	8	]	]	X
ijassa-493	140	9	,	,	PUNCT
ijassa-493	140	10	after	after	ADP
ijassa-493	140	11	35	35	NUM
ijassa-493	140	12	days	day	NOUN
ijassa-493	140	13	the	the	DET
ijassa-493	140	14	number	number	NOUN
ijassa-493	140	15	of	of	ADP
ijassa-493	140	16	fastproliferating	fastproliferate	VERB
ijassa-493	140	17	tumor	tumor	NOUN
ijassa-493	140	18	cells	cell	NOUN
ijassa-493	140	19	starts	start	VERB
ijassa-493	140	20	to	to	PART
ijassa-493	140	21	decrease	decrease	VERB
ijassa-493	140	22	,	,	PUNCT
ijassa-493	140	23	and	and	CCONJ
ijassa-493	140	24	this	this	PRON
ijassa-493	140	25	leads	lead	VERB
ijassa-493	140	26	to	to	ADP
ijassa-493	140	27	the	the	DET
ijassa-493	140	28	decline	decline	NOUN
ijassa-493	140	29	in	in	ADP
ijassa-493	140	30	the	the	DET
ijassa-493	140	31	number	number	NOUN
ijassa-493	140	32	of	of	ADP
ijassa-493	140	33	infected	infected	ADJ
ijassa-493	140	34	tumor	tumor	NOUN
ijassa-493	140	35	cells	cell	NOUN
ijassa-493	140	36	and	and	CCONJ
ijassa-493	140	37	antibodies	antibodie	VERB
ijassa-493	140	38	against	against	ADP
ijassa-493	140	39	them	they	PRON
ijassa-493	140	40	at	at	ADP
ijassa-493	140	41	the	the	DET
ijassa-493	140	42	later	later	ADJ
ijassa-493	140	43	stages	stage	NOUN
ijassa-493	140	44	of	of	ADP
ijassa-493	140	45	vaccine	vaccine	NOUN
ijassa-493	140	46	therapy	therapy	NOUN
ijassa-493	140	47	.	.	PUNCT
ijassa-493	141	1	thus	thus	ADV
ijassa-493	141	2	,	,	PUNCT
ijassa-493	141	3	the	the	DET
ijassa-493	141	4	calculations	calculation	NOUN
ijassa-493	141	5	using	use	VERB
ijassa-493	141	6	the	the	DET
ijassa-493	141	7	mathematical	mathematical	ADJ
ijassa-493	141	8	model	model	NOUN
ijassa-493	141	9	of	of	ADP
ijassa-493	141	10	vaccine	vaccine	NOUN
ijassa-493	141	11	therapy	therapy	NOUN
ijassa-493	141	12	allowed	allow	VERB
ijassa-493	141	13	to	to	PART
ijassa-493	141	14	define	define	VERB
ijassa-493	141	15	the	the	DET
ijassa-493	141	16	maximal	maximal	ADJ
ijassa-493	141	17	effective	effective	ADJ
ijassa-493	141	18	dosage	dosage	NOUN
ijassa-493	141	19	of	of	ADP
ijassa-493	141	20	the	the	DET
ijassa-493	141	21	vee	vee	PROPN
ijassa-493	141	22	virus	virus	NOUN
ijassa-493	141	23	-	-	PUNCT
ijassa-493	141	24	derived	derive	VERB
ijassa-493	141	25	vaccine	vaccine	NOUN
ijassa-493	141	26	and	and	CCONJ
ijassa-493	141	27	to	to	PART
ijassa-493	141	28	identify	identify	VERB
ijassa-493	141	29	the	the	DET
ijassa-493	141	30	moment	moment	NOUN
ijassa-493	141	31	of	of	ADP
ijassa-493	141	32	its	its	PRON
ijassa-493	141	33	administration	administration	NOUN
ijassa-493	141	34	that	that	PRON
ijassa-493	141	35	results	result	VERB
ijassa-493	141	36	in	in	ADP
ijassa-493	141	37	the	the	DET
ijassa-493	141	38	maximal	maximal	ADJ
ijassa-493	141	39	number	number	NOUN
ijassa-493	141	40	of	of	ADP
ijassa-493	141	41	infected	infected	ADJ
ijassa-493	141	42	tumor	tumor	NOUN
ijassa-493	141	43	cells	cell	NOUN
ijassa-493	141	44	maxt	maxt	NOUN
ijassa-493	142	1	[	[	X
ijassa-493	142	2	14	14	NUM
ijassa-493	142	3	]	]	PUNCT
ijassa-493	142	4	.	.	PUNCT
ijassa-493	143	1	based	base	VERB
ijassa-493	143	2	on	on	ADP
ijassa-493	143	3	the	the	DET
ijassa-493	143	4	model	model	NOUN
ijassa-493	143	5	of	of	ADP
ijassa-493	143	6	vaccine	vaccine	NOUN
ijassa-493	143	7	therapy	therapy	VERB
ijassa-493	143	8	the	the	DET
ijassa-493	143	9	graphs	graph	NOUN
ijassa-493	143	10	that	that	PRON
ijassa-493	143	11	show	show	VERB
ijassa-493	143	12	the	the	DET
ijassa-493	143	13	number	number	NOUN
ijassa-493	143	14	of	of	ADP
ijassa-493	143	15	infected	infected	ADJ
ijassa-493	143	16	tumor	tumor	NOUN
ijassa-493	143	17	cells	cell	NOUN
ijassa-493	143	18	that	that	PRON
ijassa-493	143	19	die	die	VERB
ijassa-493	143	20	at	at	ADP
ijassa-493	143	21	the	the	DET
ijassa-493	143	22	1st	1st	ADJ
ijassa-493	143	23	and	and	CCONJ
ijassa-493	143	24	2nd	2nd	ADJ
ijassa-493	143	25	stages	stage	NOUN
ijassa-493	143	26	of	of	ADP
ijassa-493	143	27	immune	immune	ADJ
ijassa-493	143	28	response	response	NOUN
ijassa-493	143	29	were	be	AUX
ijassa-493	143	30	developed	develop	VERB
ijassa-493	143	31	based	base	VERB
ijassa-493	143	32	on	on	ADP
ijassa-493	143	33	equation	equation	NOUN
ijassa-493	143	34	(	(	PUNCT
ijassa-493	143	35	11	11	NUM
ijassa-493	143	36	)	)	PUNCT
ijassa-493	143	37	(	(	PUNCT
ijassa-493	143	38	figures	figure	NOUN
ijassa-493	143	39	6	6	NUM
ijassa-493	143	40	and	and	CCONJ
ijassa-493	143	41	7	7	NUM
ijassa-493	143	42	)	)	PUNCT
ijassa-493	143	43	.	.	PUNCT
ijassa-493	144	1	fig	fig	NOUN
ijassa-493	144	2	.	.	PUNCT
ijassa-493	145	1	6	6	NUM
ijassa-493	145	2	.	.	NUM
ijassa-493	145	3	calculated	calculate	VERB
ijassa-493	145	4	curves	curve	NOUN
ijassa-493	145	5	describing	describe	VERB
ijassa-493	145	6	the	the	DET
ijassa-493	145	7	dynamics	dynamic	NOUN
ijassa-493	145	8	of	of	ADP
ijassa-493	145	9	the	the	DET
ijassa-493	145	10	tumor	tumor	NOUN
ijassa-493	145	11	cells	cell	NOUN
ijassa-493	145	12	’	’	PART
ijassa-493	145	13	death	death	NOUN
ijassa-493	145	14	0	0	NUM
ijassa-493	145	15	(	(	PUNCT
ijassa-493	145	16	)	)	PUNCT
ijassa-493	145	17	v	v	NOUN
ijassa-493	145	18	vn	vn	INTJ
ijassa-493	145	19	v	v	NOUN
ijassa-493	145	20	depending	depend	VERB
ijassa-493	145	21	on	on	ADP
ijassa-493	145	22	the	the	DET
ijassa-493	145	23	dosage	dosage	NOUN
ijassa-493	145	24	on	on	ADP
ijassa-493	145	25	1	1	NUM
ijassa-493	145	26	=	=	SYM
ijassa-493	145	27	day	day	NOUN
ijassa-493	145	28	1	1	NUM
ijassa-493	145	29	,	,	PUNCT
ijassa-493	145	30	15	15	NUM
ijassa-493	145	31	,	,	PUNCT
ijassa-493	145	32	25	25	NUM
ijassa-493	145	33	(	(	PUNCT
ijassa-493	145	34	1st	1st	ADJ
ijassa-493	145	35	stage	stage	NOUN
ijassa-493	145	36	of	of	ADP
ijassa-493	145	37	immune	immune	ADJ
ijassa-493	145	38	response	response	NOUN
ijassa-493	145	39	)	)	PUNCT
ijassa-493	145	40	fig	fig	NOUN
ijassa-493	145	41	.	.	PUNCT
ijassa-493	146	1	7	7	X
ijassa-493	146	2	.	.	NUM
ijassa-493	146	3	calculated	calculate	VERB
ijassa-493	146	4	curves	curve	NOUN
ijassa-493	146	5	describing	describe	VERB
ijassa-493	146	6	the	the	DET
ijassa-493	146	7	dynamics	dynamic	NOUN
ijassa-493	146	8	of	of	ADP
ijassa-493	146	9	the	the	DET
ijassa-493	146	10	infected	infected	ADJ
ijassa-493	146	11	cells	cell	NOUN
ijassa-493	146	12	’	’	PART
ijassa-493	146	13	death	death	NOUN
ijassa-493	146	14	0	0	NUM
ijassa-493	146	15	(	(	PUNCT
ijassa-493	146	16	)	)	PUNCT
ijassa-493	146	17	n	n	CCONJ
ijassa-493	146	18	vn	vn	X
ijassa-493	146	19	v	v	NOUN
ijassa-493	146	20	depending	depend	VERB
ijassa-493	146	21	on	on	ADP
ijassa-493	146	22	the	the	DET
ijassa-493	146	23	dosage	dosage	NOUN
ijassa-493	146	24	on	on	ADP
ijassa-493	146	25	1	1	NUM
ijassa-493	146	26	=	=	SYM
ijassa-493	146	27	day	day	NOUN
ijassa-493	146	28	1	1	NUM
ijassa-493	146	29	,	,	PUNCT
ijassa-493	146	30	15	15	NUM
ijassa-493	146	31	,	,	PUNCT
ijassa-493	146	32	25	25	NUM
ijassa-493	146	33	(	(	PUNCT
ijassa-493	146	34	2nd	2nd	ADJ
ijassa-493	146	35	stage	stage	NOUN
ijassa-493	146	36	of	of	ADP
ijassa-493	146	37	immune	immune	ADJ
ijassa-493	146	38	response	response	NOUN
ijassa-493	146	39	)	)	PUNCT
ijassa-493	146	40	analytical	analytical	ADJ
ijassa-493	146	41	study	study	NOUN
ijassa-493	146	42	of	of	ADP
ijassa-493	146	43	antitumor	antitumor	PROPN
ijassa-493	146	44	viral	viral	ADJ
ijassa-493	146	45	vaccine	vaccine	NOUN
ijassa-493	146	46	69	69	NUM
ijassa-493	146	47	there	there	PRON
ijassa-493	146	48	are	be	VERB
ijassa-493	146	49	fundamental	fundamental	ADJ
ijassa-493	146	50	differences	difference	NOUN
ijassa-493	146	51	in	in	ADP
ijassa-493	146	52	the	the	DET
ijassa-493	146	53	dynamics	dynamic	NOUN
ijassa-493	146	54	of	of	ADP
ijassa-493	146	55	the	the	DET
ijassa-493	146	56	tumor	tumor	NOUN
ijassa-493	146	57	cells	cell	NOUN
ijassa-493	146	58	’	’	PART
ijassa-493	146	59	death	death	NOUN
ijassa-493	146	60	on	on	ADP
ijassa-493	146	61	each	each	DET
ijassa-493	146	62	stage	stage	NOUN
ijassa-493	146	63	of	of	ADP
ijassa-493	146	64	the	the	DET
ijassa-493	146	65	immune	immune	ADJ
ijassa-493	146	66	response	response	NOUN
ijassa-493	146	67	.	.	PUNCT
ijassa-493	147	1	on	on	ADP
ijassa-493	147	2	the	the	DET
ijassa-493	147	3	1st	1st	ADJ
ijassa-493	147	4	stage	stage	NOUN
ijassa-493	147	5	the	the	DET
ijassa-493	147	6	number	number	NOUN
ijassa-493	147	7	of	of	ADP
ijassa-493	147	8	dying	die	VERB
ijassa-493	147	9	cells	cell	NOUN
ijassa-493	147	10	increases	increase	VERB
ijassa-493	147	11	with	with	ADP
ijassa-493	147	12	the	the	DET
ijassa-493	147	13	increase	increase	NOUN
ijassa-493	147	14	in	in	ADP
ijassa-493	147	15	the	the	DET
ijassa-493	147	16	dosage	dosage	NOUN
ijassa-493	147	17	,	,	PUNCT
ijassa-493	147	18	and	and	CCONJ
ijassa-493	147	19	depends	depend	VERB
ijassa-493	147	20	on	on	ADP
ijassa-493	147	21	the	the	DET
ijassa-493	147	22	tumor	tumor	NOUN
ijassa-493	147	23	size	size	NOUN
ijassa-493	147	24	at	at	ADP
ijassa-493	147	25	the	the	DET
ijassa-493	147	26	moment	moment	NOUN
ijassa-493	147	27	of	of	ADP
ijassa-493	147	28	vaccine	vaccine	NOUN
ijassa-493	147	29	introduction	introduction	NOUN
ijassa-493	147	30	(	(	PUNCT
ijassa-493	147	31	figure	figure	NOUN
ijassa-493	147	32	6	6	NUM
ijassa-493	147	33	)	)	PUNCT
ijassa-493	147	34	.	.	PUNCT
ijassa-493	148	1	on	on	ADP
ijassa-493	148	2	the	the	DET
ijassa-493	148	3	2nd	2nd	ADJ
ijassa-493	148	4	stage	stage	NOUN
ijassa-493	148	5	the	the	DET
ijassa-493	148	6	number	number	NOUN
ijassa-493	148	7	of	of	ADP
ijassa-493	148	8	dying	die	VERB
ijassa-493	148	9	cells	cell	NOUN
ijassa-493	148	10	declines	decline	NOUN
ijassa-493	148	11	due	due	ADP
ijassa-493	148	12	to	to	ADP
ijassa-493	148	13	the	the	DET
ijassa-493	148	14	decreasing	decrease	VERB
ijassa-493	148	15	number	number	NOUN
ijassa-493	148	16	of	of	ADP
ijassa-493	148	17	produced	produce	VERB
ijassa-493	148	18	antibodies	antibody	NOUN
ijassa-493	148	19	,	,	PUNCT
ijassa-493	148	20	as	as	SCONJ
ijassa-493	148	21	shown	show	VERB
ijassa-493	148	22	by	by	ADP
ijassa-493	148	23	the	the	DET
ijassa-493	148	24	0	0	NUM
ijassa-493	148	25	1	1	NUM
ijassa-493	148	26	(	(	PUNCT
ijassa-493	148	27	,	,	PUNCT
ijassa-493	148	28	)	)	PUNCT
ijassa-493	148	29	na	na	PART
ijassa-493	148	30	v	v	ADP
ijassa-493	148	31			NOUN
ijassa-493	148	32	graphs	graph	NOUN
ijassa-493	148	33	(	(	PUNCT
ijassa-493	148	34	figures	figure	NOUN
ijassa-493	148	35	5	5	NUM
ijassa-493	148	36	and	and	CCONJ
ijassa-493	148	37	7	7	NUM
ijassa-493	148	38	)	)	PUNCT
ijassa-493	148	39	.	.	PUNCT
ijassa-493	149	1	4.2	4.2	NUM
ijassa-493	149	2	.	.	PUNCT
ijassa-493	150	1	kinetic	kinetic	ADJ
ijassa-493	150	2	curves	curve	NOUN
ijassa-493	150	3	of	of	ADP
ijassa-493	150	4	tumor	tumor	NOUN
ijassa-493	150	5	cells	cell	NOUN
ijassa-493	150	6	’	'	PUNCT
ijassa-493	150	7	growth	growth	NOUN
ijassa-493	150	8	after	after	ADP
ijassa-493	150	9	1st	1st	ADJ
ijassa-493	150	10	and	and	CCONJ
ijassa-493	150	11	2nd	2nd	ADJ
ijassa-493	150	12	stages	stage	NOUN
ijassa-493	150	13	of	of	ADP
ijassa-493	150	14	immune	immune	ADJ
ijassa-493	150	15	response	response	NOUN
ijassa-493	150	16	a	a	DET
ijassa-493	150	17	model	model	NOUN
ijassa-493	150	18	of	of	ADP
ijassa-493	150	19	antitumor	antitumor	PROPN
ijassa-493	150	20	therapy	therapy	NOUN
ijassa-493	150	21	with	with	ADP
ijassa-493	150	22	discontinuous	discontinuous	ADJ
ijassa-493	150	23	trajectories	trajectory	NOUN
ijassa-493	150	24	(	(	PUNCT
ijassa-493	150	25	equations	equation	NOUN
ijassa-493	150	26	(	(	PUNCT
ijassa-493	150	27	9)-(16	9)-(16	NUM
ijassa-493	150	28	)	)	PUNCT
ijassa-493	150	29	)	)	PUNCT
ijassa-493	150	30	was	be	AUX
ijassa-493	150	31	used	use	VERB
ijassa-493	150	32	to	to	PART
ijassa-493	150	33	forecast	forecast	VERB
ijassa-493	150	34	the	the	DET
ijassa-493	150	35	dynamics	dynamic	NOUN
ijassa-493	150	36	of	of	ADP
ijassa-493	150	37	the	the	DET
ijassa-493	150	38	tumor	tumor	NOUN
ijassa-493	150	39	growth	growth	NOUN
ijassa-493	150	40	after	after	ADP
ijassa-493	150	41	the	the	DET
ijassa-493	150	42	introduction	introduction	NOUN
ijassa-493	150	43	of	of	ADP
ijassa-493	150	44	the	the	DET
ijassa-493	150	45	viral	viral	ADJ
ijassa-493	150	46	vaccines	vaccine	NOUN
ijassa-493	150	47	in	in	ADP
ijassa-493	150	48	different	different	ADJ
ijassa-493	150	49	regimes	regime	NOUN
ijassa-493	150	50	.	.	PUNCT
ijassa-493	151	1	calculated	calculate	VERB
ijassa-493	151	2	curves	curve	NOUN
ijassa-493	151	3	of	of	ADP
ijassa-493	151	4	tumor	tumor	NOUN
ijassa-493	151	5	growth	growth	NOUN
ijassa-493	151	6	are	be	AUX
ijassa-493	151	7	shown	show	VERB
ijassa-493	151	8	in	in	ADP
ijassa-493	151	9	appendix	appendix	NOUN
ijassa-493	151	10	2	2	NUM
ijassa-493	151	11	.	.	PUNCT
ijassa-493	152	1	the	the	DET
ijassa-493	152	2	model	model	NOUN
ijassa-493	152	3	includes	include	VERB
ijassa-493	152	4	a	a	DET
ijassa-493	152	5	threshold	threshold	NOUN
ijassa-493	152	6	value	value	NOUN
ijassa-493	152	7	0	0	NUM
ijassa-493	152	8	cut	cut	VERB
ijassa-493	152	9	offn	offn	NOUN
ijassa-493	152	10	−	−	PROPN
ijassa-493	152	11	that	that	PRON
ijassa-493	152	12	indicates	indicate	VERB
ijassa-493	152	13	the	the	DET
ijassa-493	152	14	minimal	minimal	ADJ
ijassa-493	152	15	number	number	NOUN
ijassa-493	152	16	of	of	ADP
ijassa-493	152	17	the	the	DET
ijassa-493	152	18	tumor	tumor	NOUN
ijassa-493	152	19	cells	cell	NOUN
ijassa-493	152	20	that	that	PRON
ijassa-493	152	21	can	can	AUX
ijassa-493	152	22	trigger	trigger	VERB
ijassa-493	152	23	the	the	DET
ijassa-493	152	24	renewed	renew	VERB
ijassa-493	152	25	experimental	experimental	ADJ
ijassa-493	152	26	tumor	tumor	NOUN
ijassa-493	152	27	growth	growth	NOUN
ijassa-493	152	28	.	.	PUNCT
ijassa-493	153	1	after	after	ADP
ijassa-493	153	2	each	each	PRON
ijassa-493	153	3	of	of	ADP
ijassa-493	153	4	the	the	DET
ijassa-493	153	5	two	two	NUM
ijassa-493	153	6	stages	stage	NOUN
ijassa-493	153	7	of	of	ADP
ijassa-493	153	8	tumor	tumor	NOUN
ijassa-493	153	9	cells	cell	NOUN
ijassa-493	153	10	’	'	PUNCT
ijassa-493	153	11	death	death	NOUN
ijassa-493	153	12	the	the	DET
ijassa-493	153	13	tumor	tumor	NOUN
ijassa-493	153	14	can	can	AUX
ijassa-493	153	15	resume	resume	VERB
ijassa-493	153	16	its	its	PRON
ijassa-493	153	17	growth	growth	NOUN
ijassa-493	153	18	if	if	SCONJ
ijassa-493	153	19	the	the	DET
ijassa-493	153	20	number	number	NOUN
ijassa-493	153	21	of	of	ADP
ijassa-493	153	22	surviving	survive	VERB
ijassa-493	153	23	cells	cell	NOUN
ijassa-493	153	24	0	0	NUM
ijassa-493	153	25	vrn	vrn	ADJ
ijassa-493	153	26	and	and	CCONJ
ijassa-493	153	27	0	0	NUM
ijassa-493	153	28	nrn	nrn	NOUN
ijassa-493	153	29	exceeds	exceed	VERB
ijassa-493	153	30	the	the	DET
ijassa-493	153	31	threshold	threshold	NOUN
ijassa-493	153	32	0	0	PUNCT
ijassa-493	153	33	cut	cut	VERB
ijassa-493	153	34	offn	offn	NOUN
ijassa-493	153	35	−	−	PROPN
ijassa-493	153	36	.	.	PUNCT
ijassa-493	154	1	threshold	threshold	NOUN
ijassa-493	154	2	value	value	NOUN
ijassa-493	154	3	depends	depend	VERB
ijassa-493	154	4	on	on	ADP
ijassa-493	154	5	the	the	DET
ijassa-493	154	6	normal	normal	ADJ
ijassa-493	154	7	level	level	NOUN
ijassa-493	154	8	of	of	ADP
ijassa-493	154	9	plasma	plasma	NOUN
ijassa-493	154	10	cells	cell	NOUN
ijassa-493	154	11	vnc	vnc	VERB
ijassa-493	154	12	and	and	CCONJ
ijassa-493	154	13	nnc	nnc	PROPN
ijassa-493	154	14	(	(	PUNCT
ijassa-493	154	15	equations	equation	NOUN
ijassa-493	154	16	(	(	PUNCT
ijassa-493	154	17	5	5	NUM
ijassa-493	154	18	)	)	PUNCT
ijassa-493	154	19	and	and	CCONJ
ijassa-493	154	20	(	(	PUNCT
ijassa-493	154	21	7	7	NUM
ijassa-493	154	22	)	)	PUNCT
ijassa-493	154	23	)	)	PUNCT
ijassa-493	154	24	.	.	PUNCT
ijassa-493	155	1	threshold	threshold	NOUN
ijassa-493	155	2	value	value	NOUN
ijassa-493	155	3	was	be	AUX
ijassa-493	155	4	defined	define	VERB
ijassa-493	155	5	based	base	VERB
ijassa-493	155	6	on	on	ADP
ijassa-493	155	7	proportion	proportion	NOUN
ijassa-493	155	8	0	0	NUM
ijassa-493	155	9	0	0	NUM
ijassa-493	155	10	0,76	0,76	NUM
ijassa-493	155	11	0,4	0,4	NOUN
ijassa-493	155	12	2	2	NUM
ijassa-493	155	13	2	2	NUM
ijassa-493	155	14	cut	cut	VERB
ijassa-493	155	15	off	off	ADP
ijassa-493	155	16	n	n	CCONJ
ijassa-493	155	17	n	n	NOUN
ijassa-493	155	18	−	−	NOUN
ijassa-493	156	1	=	=	PUNCT
ijassa-493	157	1	=	=	PUNCT
ijassa-493	158	1	=	=	NOUN
ijassa-493	158	2	,	,	PUNCT
ijassa-493	158	3	where	where	SCONJ
ijassa-493	158	4	0n	0n	NOUN
ijassa-493	158	5	is	be	AUX
ijassa-493	158	6	the	the	DET
ijassa-493	158	7	initial	initial	ADJ
ijassa-493	158	8	number	number	NOUN
ijassa-493	158	9	of	of	ADP
ijassa-493	158	10	tumor	tumor	NOUN
ijassa-493	158	11	cells	cell	NOUN
ijassa-493	158	12	(	(	PUNCT
ijassa-493	158	13	equation	equation	NOUN
ijassa-493	158	14	(	(	PUNCT
ijassa-493	158	15	2	2	NUM
ijassa-493	158	16	)	)	PUNCT
ijassa-493	158	17	)	)	PUNCT
ijassa-493	158	18	.	.	PUNCT
ijassa-493	159	1	if	if	SCONJ
ijassa-493	159	2	the	the	DET
ijassa-493	159	3	number	number	NOUN
ijassa-493	159	4	of	of	ADP
ijassa-493	159	5	surviving	survive	VERB
ijassa-493	159	6	cells	cell	NOUN
ijassa-493	159	7	is	be	AUX
ijassa-493	159	8	below	below	ADP
ijassa-493	159	9	the	the	DET
ijassa-493	159	10	threshold	threshold	NOUN
ijassa-493	159	11	,	,	PUNCT
ijassa-493	159	12	then	then	ADV
ijassa-493	159	13	the	the	DET
ijassa-493	159	14	tumor	tumor	NOUN
ijassa-493	159	15	will	will	AUX
ijassa-493	159	16	not	not	PART
ijassa-493	159	17	be	be	AUX
ijassa-493	159	18	able	able	ADJ
ijassa-493	159	19	to	to	PART
ijassa-493	159	20	resume	resume	VERB
ijassa-493	159	21	its	its	PRON
ijassa-493	159	22	growth	growth	NOUN
ijassa-493	159	23	.	.	PUNCT
ijassa-493	160	1	in	in	ADP
ijassa-493	160	2	the	the	DET
ijassa-493	160	3	model	model	NOUN
ijassa-493	160	4	this	this	PRON
ijassa-493	160	5	is	be	AUX
ijassa-493	160	6	taken	take	VERB
ijassa-493	160	7	as	as	ADP
ijassa-493	160	8	complete	complete	ADJ
ijassa-493	160	9	elimination	elimination	NOUN
ijassa-493	160	10	of	of	ADP
ijassa-493	160	11	tumor	tumor	NOUN
ijassa-493	160	12	cells	cell	NOUN
ijassa-493	160	13	.	.	PUNCT
ijassa-493	161	1	in	in	ADP
ijassa-493	161	2	this	this	DET
ijassa-493	161	3	case	case	NOUN
ijassa-493	161	4	the	the	DET
ijassa-493	161	5	lifetime	lifetime	NOUN
ijassa-493	161	6	of	of	ADP
ijassa-493	161	7	the	the	DET
ijassa-493	161	8	vaccine	vaccine	NOUN
ijassa-493	161	9	-	-	PUNCT
ijassa-493	161	10	treated	treat	VERB
ijassa-493	161	11	animals	animal	NOUN
ijassa-493	161	12	will	will	AUX
ijassa-493	161	13	be	be	AUX
ijassa-493	161	14	equal	equal	ADJ
ijassa-493	161	15	to	to	ADP
ijassa-493	161	16	the	the	DET
ijassa-493	161	17	average	average	ADJ
ijassa-493	161	18	lifetime	lifetime	NOUN
ijassa-493	161	19	of	of	ADP
ijassa-493	161	20	the	the	DET
ijassa-493	161	21	experimental	experimental	ADJ
ijassa-493	161	22	animals	animal	NOUN
ijassa-493	161	23	without	without	ADP
ijassa-493	161	24	treatment	treatment	NOUN
ijassa-493	161	25	.	.	PUNCT
ijassa-493	162	1	the	the	DET
ijassa-493	162	2	resulting	result	VERB
ijassa-493	162	3	kinetic	kinetic	ADJ
ijassa-493	162	4	curves	curve	NOUN
ijassa-493	162	5	that	that	PRON
ijassa-493	162	6	describe	describe	VERB
ijassa-493	162	7	tumor	tumor	NOUN
ijassa-493	162	8	growth	growth	NOUN
ijassa-493	162	9	after	after	ADP
ijassa-493	162	10	vaccine	vaccine	NOUN
ijassa-493	162	11	introduction	introduction	NOUN
ijassa-493	162	12	on	on	ADP
ijassa-493	162	13	1	1	NUM
ijassa-493	162	14	=	=	SYM
ijassa-493	162	15	1	1	NUM
ijassa-493	162	16	day	day	NOUN
ijassa-493	162	17	(	(	PUNCT
ijassa-493	162	18	figures	figure	NOUN
ijassa-493	162	19	8	8	NUM
ijassa-493	162	20	-	-	SYM
ijassa-493	162	21	15	15	NUM
ijassa-493	162	22	)	)	PUNCT
ijassa-493	162	23	allow	allow	VERB
ijassa-493	162	24	to	to	PART
ijassa-493	162	25	identify	identify	VERB
ijassa-493	162	26	two	two	NUM
ijassa-493	162	27	dosage	dosage	NOUN
ijassa-493	162	28	ranges	range	NOUN
ijassa-493	162	29	that	that	PRON
ijassa-493	162	30	determine	determine	VERB
ijassa-493	162	31	two	two	NUM
ijassa-493	162	32	possible	possible	ADJ
ijassa-493	162	33	regimens	regimen	NOUN
ijassa-493	162	34	for	for	ADP
ijassa-493	162	35	administering	administer	VERB
ijassa-493	162	36	antitumor	antitumor	PROPN
ijassa-493	162	37	vaccines	vaccine	NOUN
ijassa-493	162	38	.	.	PUNCT
ijassa-493	163	1	the	the	DET
ijassa-493	163	2	first	first	ADJ
ijassa-493	163	3	regimen	regimen	NOUN
ijassa-493	163	4	(	(	PUNCT
ijassa-493	163	5	with	with	ADP
ijassa-493	163	6	dosages	dosage	NOUN
ijassa-493	163	7	exceeding	exceed	VERB
ijassa-493	163	8	exp	exp	NOUN
ijassa-493	163	9	0	0	NUM
ijassa-493	163	10	03	03	NUM
ijassa-493	163	11	0,045v	0,045v	PRON
ijassa-493	163	12	v=	v=	VERB
ijassa-493	163	13			NUM
ijassa-493	163	14	=	=	PUNCT
ijassa-493	163	15	)	)	PUNCT
ijassa-493	163	16	makes	make	VERB
ijassa-493	163	17	it	it	PRON
ijassa-493	163	18	possible	possible	ADJ
ijassa-493	163	19	to	to	PART
ijassa-493	163	20	ensure	ensure	VERB
ijassa-493	163	21	that	that	SCONJ
ijassa-493	163	22	at	at	ADP
ijassa-493	163	23	the	the	DET
ijassa-493	163	24	1st	1st	ADJ
ijassa-493	163	25	stage	stage	NOUN
ijassa-493	163	26	of	of	ADP
ijassa-493	163	27	immune	immune	ADJ
ijassa-493	163	28	response	response	NOUN
ijassa-493	163	29	the	the	DET
ijassa-493	163	30	number	number	NOUN
ijassa-493	163	31	of	of	ADP
ijassa-493	163	32	tumor	tumor	NOUN
ijassa-493	163	33	cells	cell	NOUN
ijassa-493	163	34	drops	drop	VERB
ijassa-493	163	35	below	below	ADP
ijassa-493	163	36	the	the	DET
ijassa-493	163	37	threshold	threshold	NOUN
ijassa-493	163	38	0	0	PUNCT
ijassa-493	163	39	cut	cut	VERB
ijassa-493	163	40	offn	offn	NOUN
ijassa-493	163	41	−	−	PROPN
ijassa-493	163	42	(	(	PUNCT
ijassa-493	163	43	figures	figure	NOUN
ijassa-493	163	44	8	8	NUM
ijassa-493	163	45	-	-	SYM
ijassa-493	163	46	15	15	NUM
ijassa-493	163	47	)	)	PUNCT
ijassa-493	163	48	,	,	PUNCT
ijassa-493	163	49	which	which	PRON
ijassa-493	163	50	is	be	AUX
ijassa-493	163	51	equivalent	equivalent	ADJ
ijassa-493	163	52	to	to	ADP
ijassa-493	163	53	elimination	elimination	NOUN
ijassa-493	163	54	of	of	ADP
ijassa-493	163	55	tumor	tumor	NOUN
ijassa-493	163	56	cells	cell	NOUN
ijassa-493	163	57	.	.	PUNCT
ijassa-493	164	1	the	the	DET
ijassa-493	164	2	second	second	ADJ
ijassa-493	164	3	regime	regime	NOUN
ijassa-493	164	4	(	(	PUNCT
ijassa-493	164	5	with	with	ADP
ijassa-493	164	6	dosages	dosage	NOUN
ijassa-493	164	7	between	between	ADP
ijassa-493	164	8	exp	exp	NOUN
ijassa-493	164	9	0	0	NUM
ijassa-493	164	10	0,015v	0,015v	NUM
ijassa-493	164	11	=	=	PUNCT
ijassa-493	164	12	and	and	CCONJ
ijassa-493	164	13	exp	exp	NOUN
ijassa-493	164	14	03	03	NUM
ijassa-493	164	15	0,045v	0,045v	PROPN
ijassa-493	164	16	=	=	PUNCT
ijassa-493	164	17	)	)	PUNCT
ijassa-493	164	18	does	do	AUX
ijassa-493	164	19	not	not	PART
ijassa-493	164	20	produce	produce	VERB
ijassa-493	164	21	the	the	DET
ijassa-493	164	22	decline	decline	NOUN
ijassa-493	164	23	in	in	ADP
ijassa-493	164	24	the	the	DET
ijassa-493	164	25	number	number	NOUN
ijassa-493	164	26	of	of	ADP
ijassa-493	164	27	tumor	tumor	NOUN
ijassa-493	164	28	cells	cell	NOUN
ijassa-493	164	29	below	below	ADP
ijassa-493	164	30	the	the	DET
ijassa-493	164	31	threshold	threshold	NOUN
ijassa-493	164	32	level	level	NOUN
ijassa-493	164	33	0	0	NUM
ijassa-493	164	34	cut	cut	VERB
ijassa-493	164	35	offn	offn	NOUN
ijassa-493	164	36	−	−	PROPN
ijassa-493	164	37	.	.	PUNCT
ijassa-493	165	1	however	however	ADV
ijassa-493	165	2	,	,	PUNCT
ijassa-493	165	3	these	these	DET
ijassa-493	165	4	dosages	dosage	NOUN
ijassa-493	165	5	cause	cause	VERB
ijassa-493	165	6	the	the	DET
ijassa-493	165	7	death	death	NOUN
ijassa-493	165	8	of	of	ADP
ijassa-493	165	9	the	the	DET
ijassa-493	165	10	tumor	tumor	NOUN
ijassa-493	165	11	cells	cell	NOUN
ijassa-493	165	12	at	at	ADP
ijassa-493	165	13	both	both	DET
ijassa-493	165	14	stages	stage	NOUN
ijassa-493	165	15	of	of	ADP
ijassa-493	165	16	immune	immune	ADJ
ijassa-493	165	17	response	response	NOUN
ijassa-493	165	18	,	,	PUNCT
ijassa-493	165	19	and	and	CCONJ
ijassa-493	165	20	this	this	PRON
ijassa-493	165	21	initiates	initiate	VERB
ijassa-493	165	22	the	the	DET
ijassa-493	165	23	production	production	NOUN
ijassa-493	165	24	of	of	ADP
ijassa-493	165	25	antibodies	antibody	NOUN
ijassa-493	165	26	against	against	ADP
ijassa-493	165	27	infected	infected	ADJ
ijassa-493	165	28	cells	cell	NOUN
ijassa-493	165	29	.	.	PUNCT
ijassa-493	166	1	when	when	SCONJ
ijassa-493	166	2	these	these	DET
ijassa-493	166	3	antibodies	antibody	NOUN
ijassa-493	166	4	exist	exist	VERB
ijassa-493	166	5	,	,	PUNCT
ijassa-493	166	6	the	the	DET
ijassa-493	166	7	process	process	NOUN
ijassa-493	166	8	of	of	ADP
ijassa-493	166	9	tumor	tumor	NOUN
ijassa-493	166	10	growth	growth	NOUN
ijassa-493	166	11	can	can	AUX
ijassa-493	166	12	be	be	AUX
ijassa-493	166	13	controlled	control	VERB
ijassa-493	166	14	through	through	ADP
ijassa-493	166	15	recurrent	recurrent	ADJ
ijassa-493	166	16	introductions	introduction	NOUN
ijassa-493	166	17	of	of	ADP
ijassa-493	166	18	the	the	DET
ijassa-493	166	19	viral	viral	ADJ
ijassa-493	166	20	vaccine	vaccine	NOUN
ijassa-493	166	21	.	.	PUNCT
ijassa-493	167	1	this	this	DET
ijassa-493	167	2	regimen	regimen	NOUN
ijassa-493	167	3	will	will	AUX
ijassa-493	167	4	stabilize	stabilize	VERB
ijassa-493	167	5	the	the	DET
ijassa-493	167	6	initial	initial	ADJ
ijassa-493	167	7	tumor	tumor	NOUN
ijassa-493	167	8	size	size	NOUN
ijassa-493	167	9	.	.	PUNCT
ijassa-493	168	1	if	if	SCONJ
ijassa-493	168	2	the	the	DET
ijassa-493	168	3	initial	initial	ADJ
ijassa-493	168	4	tumor	tumor	NOUN
ijassa-493	168	5	size	size	NOUN
ijassa-493	168	6	is	be	AUX
ijassa-493	168	7	small	small	ADJ
ijassa-493	168	8	,	,	PUNCT
ijassa-493	168	9	this	this	DET
ijassa-493	168	10	regimen	regimen	NOUN
ijassa-493	168	11	makes	make	VERB
ijassa-493	168	12	it	it	PRON
ijassa-493	168	13	possible	possible	ADJ
ijassa-493	168	14	to	to	PART
ijassa-493	168	15	avoid	avoid	VERB
ijassa-493	168	16	the	the	DET
ijassa-493	168	17	surgical	surgical	ADJ
ijassa-493	168	18	intervention	intervention	NOUN
ijassa-493	168	19	,	,	PUNCT
ijassa-493	168	20	with	with	ADP
ijassa-493	168	21	vaccine	vaccine	NOUN
ijassa-493	168	22	therapy	therapy	NOUN
ijassa-493	168	23	acting	act	VERB
ijassa-493	168	24	as	as	ADP
ijassa-493	168	25	a	a	DET
ijassa-493	168	26	regular	regular	ADJ
ijassa-493	168	27	vaccination	vaccination	NOUN
ijassa-493	168	28	against	against	ADP
ijassa-493	168	29	autologous	autologous	ADJ
ijassa-493	168	30	tumor	tumor	NOUN
ijassa-493	168	31	cells	cell	NOUN
ijassa-493	168	32	.	.	PUNCT
ijassa-493	169	1	the	the	DET
ijassa-493	169	2	calculations	calculation	NOUN
ijassa-493	169	3	show	show	VERB
ijassa-493	169	4	that	that	SCONJ
ijassa-493	169	5	if	if	SCONJ
ijassa-493	169	6	the	the	DET
ijassa-493	169	7	vaccine	vaccine	NOUN
ijassa-493	169	8	is	be	AUX
ijassa-493	169	9	introduced	introduce	VERB
ijassa-493	169	10	on	on	ADP
ijassa-493	169	11	1	1	NUM
ijassa-493	169	12	=	=	SYM
ijassa-493	169	13	25	25	NUM
ijassa-493	169	14	day	day	NOUN
ijassa-493	169	15	(	(	PUNCT
ijassa-493	169	16	appendix	appendix	NOUN
ijassa-493	169	17	2	2	NUM
ijassa-493	169	18	)	)	PUNCT
ijassa-493	169	19	with	with	ADP
ijassa-493	169	20	dosages	dosage	NOUN
ijassa-493	169	21	between	between	ADP
ijassa-493	169	22	exp	exp	NOUN
ijassa-493	169	23	0	0	NOUN
ijassa-493	169	24	0,015v	0,015v	NOUN
ijassa-493	169	25	=	=	PUNCT
ijassa-493	169	26	to	to	ADP
ijassa-493	169	27	0	0	NUM
ijassa-493	169	28	0,1v	0,1v	NUM
ijassa-493	169	29	=	=	PRON
ijassa-493	169	30	,	,	PUNCT
ijassa-493	169	31	the	the	DET
ijassa-493	169	32	decrease	decrease	NOUN
ijassa-493	169	33	of	of	ADP
ijassa-493	169	34	the	the	DET
ijassa-493	169	35	number	number	NOUN
ijassa-493	169	36	of	of	ADP
ijassa-493	169	37	tumor	tumor	NOUN
ijassa-493	169	38	cells	cell	NOUN
ijassa-493	169	39	below	below	ADP
ijassa-493	169	40	the	the	DET
ijassa-493	169	41	threshold	threshold	NOUN
ijassa-493	169	42	level	level	NOUN
ijassa-493	169	43	is	be	AUX
ijassa-493	169	44	not	not	PART
ijassa-493	169	45	possible	possible	ADJ
ijassa-493	169	46	.	.	PUNCT
ijassa-493	170	1	therefore	therefore	ADV
ijassa-493	170	2	if	if	SCONJ
ijassa-493	170	3	the	the	DET
ijassa-493	170	4	tumor	tumor	NOUN
ijassa-493	170	5	size	size	NOUN
ijassa-493	170	6	is	be	AUX
ijassa-493	170	7	big	big	ADJ
ijassa-493	170	8	,	,	PUNCT
ijassa-493	170	9	it	it	PRON
ijassa-493	170	10	needs	need	VERB
ijassa-493	170	11	to	to	PART
ijassa-493	170	12	be	be	AUX
ijassa-493	170	13	surgically	surgically	ADV
ijassa-493	170	14	removed	remove	VERB
ijassa-493	170	15	.	.	PUNCT
ijassa-493	171	1	however	however	ADV
ijassa-493	171	2	,	,	PUNCT
ijassa-493	171	3	if	if	SCONJ
ijassa-493	171	4	the	the	DET
ijassa-493	171	5	surgical	surgical	ADJ
ijassa-493	171	6	intervention	intervention	NOUN
ijassa-493	171	7	is	be	AUX
ijassa-493	171	8	contraindicated	contraindicate	VERB
ijassa-493	171	9	,	,	PUNCT
ijassa-493	171	10	the	the	DET
ijassa-493	171	11	tumor	tumor	NOUN
ijassa-493	171	12	size	size	NOUN
ijassa-493	171	13	can	can	AUX
ijassa-493	171	14	be	be	AUX
ijassa-493	171	15	stabilized	stabilize	VERB
ijassa-493	171	16	through	through	ADP
ijassa-493	171	17	recurrent	recurrent	ADJ
ijassa-493	171	18	vaccinations	vaccination	NOUN
ijassa-493	171	19	.	.	PUNCT
ijassa-493	172	1	in	in	ADP
ijassa-493	172	2	any	any	DET
ijassa-493	172	3	case	case	NOUN
ijassa-493	172	4	,	,	PUNCT
ijassa-493	172	5	this	this	DET
ijassa-493	172	6	decision	decision	NOUN
ijassa-493	172	7	rests	rest	VERB
ijassa-493	172	8	with	with	ADP
ijassa-493	172	9	the	the	DET
ijassa-493	172	10	physician	physician	NOUN
ijassa-493	172	11	.	.	PUNCT
ijassa-493	173	1	5	5	NUM
ijassa-493	173	2	.	.	NOUN
ijassa-493	173	3	time	time	NOUN
ijassa-493	173	4	frame	frame	NOUN
ijassa-493	173	5	for	for	ADP
ijassa-493	173	6	recurrent	recurrent	ADJ
ijassa-493	173	7	introduction	introduction	NOUN
ijassa-493	173	8	of	of	ADP
ijassa-493	173	9	the	the	DET
ijassa-493	173	10	viral	viral	ADJ
ijassa-493	173	11	vaccines	vaccine	NOUN
ijassa-493	173	12	a	a	DET
ijassa-493	173	13	model	model	NOUN
ijassa-493	173	14	of	of	ADP
ijassa-493	173	15	antitumor	antitumor	PROPN
ijassa-493	173	16	therapy	therapy	NOUN
ijassa-493	173	17	with	with	ADP
ijassa-493	173	18	discontinuous	discontinuous	ADJ
ijassa-493	173	19	trajectories	trajectory	NOUN
ijassa-493	173	20	of	of	ADP
ijassa-493	173	21	tumor	tumor	NOUN
ijassa-493	173	22	growth	growth	NOUN
ijassa-493	173	23	(	(	PUNCT
ijassa-493	173	24	equations	equation	NOUN
ijassa-493	173	25	(	(	PUNCT
ijassa-493	173	26	9)(16	9)(16	NUM
ijassa-493	173	27	)	)	PUNCT
ijassa-493	173	28	)	)	PUNCT
ijassa-493	173	29	was	be	AUX
ijassa-493	173	30	used	use	VERB
ijassa-493	173	31	to	to	PART
ijassa-493	173	32	identify	identify	VERB
ijassa-493	173	33	the	the	DET
ijassa-493	173	34	time	time	NOUN
ijassa-493	173	35	frame	frame	NOUN
ijassa-493	173	36	for	for	ADP
ijassa-493	173	37	recurrent	recurrent	ADJ
ijassa-493	173	38	viral	viral	ADJ
ijassa-493	173	39	vaccine	vaccine	NOUN
ijassa-493	173	40	introductions	introduction	NOUN
ijassa-493	173	41	.	.	PUNCT
ijassa-493	174	1	the	the	DET
ijassa-493	174	2	time	time	NOUN
ijassa-493	174	3	length	length	NOUN
ijassa-493	174	4	between	between	ADP
ijassa-493	174	5	the	the	DET
ijassa-493	174	6	recurrent	recurrent	ADJ
ijassa-493	174	7	vaccine	vaccine	NOUN
ijassa-493	174	8	introductions	introduction	NOUN
ijassa-493	174	9	t	t	NOUN
ijassa-493	174	10	is	be	AUX
ijassa-493	174	11	equal	equal	ADJ
ijassa-493	174	12	to	to	ADP
ijassa-493	174	13	the	the	DET
ijassa-493	174	14	interval	interval	NOUN
ijassa-493	174	15	between	between	ADP
ijassa-493	174	16	the	the	DET
ijassa-493	174	17	moment	moment	NOUN
ijassa-493	174	18	of	of	ADP
ijassa-493	174	19	initial	initial	ADJ
ijassa-493	174	20	introduction	introduction	NOUN
ijassa-493	174	21	1	1	NUM
ijassa-493	174	22	and	and	CCONJ
ijassa-493	174	23	2	2	NUM
ijassa-493	174	24	–	–	PUNCT
ijassa-493	174	25	the	the	DET
ijassa-493	174	26	moment	moment	NOUN
ijassa-493	174	27	when	when	SCONJ
ijassa-493	174	28	the	the	DET
ijassa-493	174	29	tumor	tumor	NOUN
ijassa-493	174	30	size	size	NOUN
ijassa-493	174	31	n	n	CCONJ
ijassa-493	174	32	(	(	PUNCT
ijassa-493	174	33	1	1	NUM
ijassa-493	174	34	)	)	PUNCT
ijassa-493	174	35	=	=	SYM
ijassa-493	174	36	n	n	CCONJ
ijassa-493	174	37	(	(	PUNCT
ijassa-493	174	38	2	2	NUM
ijassa-493	174	39	)	)	PUNCT
ijassa-493	174	40	.	.	PUNCT
ijassa-493	175	1	70	70	NUM
ijassa-493	175	2	n.a	n.a	PROPN
ijassa-493	175	3	.	.	PROPN
ijassa-493	175	4	babushkina	babushkina	PROPN
ijassa-493	175	5	,	,	PUNCT
ijassa-493	175	6	e.a	e.a	PROPN
ijassa-493	175	7	.	.	PROPN
ijassa-493	175	8	kuzina	kuzina	PROPN
ijassa-493	175	9	kinetic	kinetic	PROPN
ijassa-493	175	10	curves	curve	NOUN
ijassa-493	175	11	of	of	ADP
ijassa-493	175	12	tumor	tumor	NOUN
ijassa-493	175	13	growth	growth	NOUN
ijassa-493	175	14	after	after	SCONJ
ijassa-493	175	15	the	the	DET
ijassa-493	175	16	viral	viral	ADJ
ijassa-493	175	17	vaccine	vaccine	NOUN
ijassa-493	175	18	is	be	AUX
ijassa-493	175	19	introduced	introduce	VERB
ijassa-493	175	20	on	on	ADP
ijassa-493	175	21	1	1	NUM
ijassa-493	175	22	=	=	SYM
ijassa-493	175	23	1	1	NUM
ijassa-493	175	24	day	day	NOUN
ijassa-493	175	25	,	,	PUNCT
ijassa-493	175	26	with	with	ADP
ijassa-493	175	27	dosages	dosage	NOUN
ijassa-493	175	28	between	between	ADP
ijassa-493	175	29	exp	exp	NOUN
ijassa-493	175	30	0	0	NUM
ijassa-493	175	31	0,015v	0,015v	NUM
ijassa-493	175	32	=	=	PUNCT
ijassa-493	175	33	to	to	PART
ijassa-493	175	34	exp	exp	NOUN
ijassa-493	175	35	0	0	NUM
ijassa-493	175	36	02,67	02,67	PROPN
ijassa-493	175	37	0,04v	0,04v	NUM
ijassa-493	175	38	v=	v=	NOUN
ijassa-493	175	39			PROPN
ijassa-493	175	40	=	=	PUNCT
ijassa-493	175	41	,	,	PUNCT
ijassa-493	175	42	indicate	indicate	VERB
ijassa-493	175	43	that	that	SCONJ
ijassa-493	175	44	the	the	DET
ijassa-493	175	45	time	time	NOUN
ijassa-493	175	46	frame	frame	NOUN
ijassa-493	175	47	for	for	ADP
ijassa-493	175	48	subsequent	subsequent	ADJ
ijassa-493	175	49	introduction	introduction	NOUN
ijassa-493	175	50	lies	lie	VERB
ijassa-493	175	51	in	in	ADP
ijassa-493	175	52	the	the	DET
ijassa-493	175	53	range	range	NOUN
ijassa-493	175	54	of	of	ADP
ijassa-493	175	55	t	t	NOUN
ijassa-493	175	56	=	=	SYM
ijassa-493	175	57	14,5	14,5	NUM
ijassa-493	175	58	days	day	NOUN
ijassa-493	175	59	to	to	ADP
ijassa-493	175	60	t	t	NOUN
ijassa-493	175	61	=	=	SYM
ijassa-493	175	62	18,9	18,9	NUM
ijassa-493	175	63	days	day	NOUN
ijassa-493	175	64	depending	depend	VERB
ijassa-493	175	65	on	on	ADP
ijassa-493	175	66	the	the	DET
ijassa-493	175	67	dosage	dosage	NOUN
ijassa-493	175	68	.	.	PUNCT
ijassa-493	176	1	therefore	therefore	ADV
ijassa-493	176	2	,	,	PUNCT
ijassa-493	176	3	if	if	SCONJ
ijassa-493	176	4	the	the	DET
ijassa-493	176	5	tumor	tumor	NOUN
ijassa-493	176	6	size	size	NOUN
ijassa-493	176	7	is	be	AUX
ijassa-493	176	8	small	small	ADJ
ijassa-493	176	9	,	,	PUNCT
ijassa-493	176	10	it	it	PRON
ijassa-493	176	11	can	can	AUX
ijassa-493	176	12	be	be	AUX
ijassa-493	176	13	stabilized	stabilize	VERB
ijassa-493	176	14	through	through	ADP
ijassa-493	176	15	recurrent	recurrent	ADJ
ijassa-493	176	16	introduction	introduction	NOUN
ijassa-493	176	17	of	of	ADP
ijassa-493	176	18	these	these	DET
ijassa-493	176	19	dosages	dosage	NOUN
ijassa-493	176	20	within	within	ADP
ijassa-493	176	21	14,5	14,5	NUM
ijassa-493	176	22	–	–	PUNCT
ijassa-493	176	23	18,9	18,9	NUM
ijassa-493	176	24	days	day	NOUN
ijassa-493	176	25	.	.	PUNCT
ijassa-493	177	1	when	when	SCONJ
ijassa-493	177	2	the	the	DET
ijassa-493	177	3	tumor	tumor	NOUN
ijassa-493	177	4	is	be	AUX
ijassa-493	177	5	already	already	ADV
ijassa-493	177	6	big	big	ADJ
ijassa-493	177	7	,	,	PUNCT
ijassa-493	177	8	its	its	PRON
ijassa-493	177	9	size	size	NOUN
ijassa-493	177	10	can	can	AUX
ijassa-493	177	11	be	be	AUX
ijassa-493	177	12	stabilized	stabilize	VERB
ijassa-493	177	13	while	while	SCONJ
ijassa-493	177	14	it	it	PRON
ijassa-493	177	15	is	be	AUX
ijassa-493	177	16	dominated	dominate	VERB
ijassa-493	177	17	by	by	ADP
ijassa-493	177	18	the	the	DET
ijassa-493	177	19	fraction	fraction	NOUN
ijassa-493	177	20	of	of	ADP
ijassa-493	177	21	the	the	DET
ijassa-493	177	22	fast	fast	ADV
ijassa-493	177	23	-	-	PUNCT
ijassa-493	177	24	proliferating	proliferate	VERB
ijassa-493	177	25	cells	cell	NOUN
ijassa-493	177	26	(	(	PUNCT
ijassa-493	177	27	*	*	NOUN
ijassa-493	177	28	35	35	NUM
ijassa-493	177	29	t	t	NOUN
ijassa-493	177	30	=	=	PUNCT
ijassa-493	177	31	days	day	NOUN
ijassa-493	177	32	)	)	PUNCT
ijassa-493	177	33	.	.	PUNCT
ijassa-493	178	1	if	if	SCONJ
ijassa-493	178	2	the	the	DET
ijassa-493	178	3	vaccine	vaccine	NOUN
ijassa-493	178	4	is	be	AUX
ijassa-493	178	5	initially	initially	ADV
ijassa-493	178	6	introduced	introduce	VERB
ijassa-493	178	7	on	on	ADP
ijassa-493	178	8	1	1	NUM
ijassa-493	178	9	=	=	SYM
ijassa-493	178	10	25	25	NUM
ijassa-493	178	11	day	day	NOUN
ijassa-493	178	12	,	,	PUNCT
ijassa-493	178	13	stabilizing	stabilize	VERB
ijassa-493	178	14	regimen	regiman	NOUN
ijassa-493	178	15	can	can	AUX
ijassa-493	178	16	be	be	AUX
ijassa-493	178	17	implemented	implement	VERB
ijassa-493	178	18	through	through	ADP
ijassa-493	178	19	subsequent	subsequent	ADJ
ijassa-493	178	20	administration	administration	NOUN
ijassa-493	178	21	of	of	ADP
ijassa-493	178	22	dosages	dosage	NOUN
ijassa-493	178	23	that	that	PRON
ijassa-493	178	24	produce	produce	VERB
ijassa-493	178	25	two	two	NUM
ijassa-493	178	26	-	-	PUNCT
ijassa-493	178	27	stage	stage	NOUN
ijassa-493	178	28	immune	immune	ADJ
ijassa-493	178	29	response	response	NOUN
ijassa-493	178	30	.	.	PUNCT
ijassa-493	179	1	introduction	introduction	NOUN
ijassa-493	179	2	of	of	ADP
ijassa-493	179	3	dosages	dosage	NOUN
ijassa-493	179	4	in	in	ADP
ijassa-493	179	5	the	the	DET
ijassa-493	179	6	range	range	NOUN
ijassa-493	179	7	of	of	ADP
ijassa-493	179	8	exp	exp	NOUN
ijassa-493	179	9	0	0	NOUN
ijassa-493	179	10	0,015v	0,015v	NUM
ijassa-493	179	11	=	=	PUNCT
ijassa-493	179	12	to	to	PART
ijassa-493	179	13	exp	exp	NOUN
ijassa-493	179	14	0	0	NUM
ijassa-493	179	15	03	03	NUM
ijassa-493	179	16	0,045v	0,045v	PRON
ijassa-493	179	17	v=	v=	VERB
ijassa-493	179	18			PROPN
ijassa-493	179	19	=	=	PUNCT
ijassa-493	179	20	within	within	ADP
ijassa-493	179	21	the	the	DET
ijassa-493	179	22	time	time	NOUN
ijassa-493	179	23	frame	frame	NOUN
ijassa-493	179	24	of	of	ADP
ijassa-493	179	25	t	t	NOUN
ijassa-493	179	26	=	=	SYM
ijassa-493	179	27	30,5	30,5	PROPN
ijassa-493	179	28	can	can	AUX
ijassa-493	179	29	stabilize	stabilize	VERB
ijassa-493	179	30	the	the	DET
ijassa-493	179	31	tumor	tumor	NOUN
ijassa-493	179	32	size	size	NOUN
ijassa-493	179	33	on	on	ADP
ijassa-493	179	34	its	its	PRON
ijassa-493	179	35	pretreatment	pretreatment	NOUN
ijassa-493	179	36	level	level	NOUN
ijassa-493	179	37	as	as	ADP
ijassa-493	179	38	of	of	ADP
ijassa-493	179	39	day	day	NOUN
ijassa-493	179	40	25	25	NUM
ijassa-493	179	41	.	.	PUNCT
ijassa-493	180	1	this	this	PRON
ijassa-493	180	2	allows	allow	VERB
ijassa-493	180	3	to	to	PART
ijassa-493	180	4	avoid	avoid	VERB
ijassa-493	180	5	surgical	surgical	ADJ
ijassa-493	180	6	removal	removal	NOUN
ijassa-493	180	7	of	of	ADP
ijassa-493	180	8	the	the	DET
ijassa-493	180	9	tumor	tumor	NOUN
ijassa-493	180	10	.	.	PUNCT
ijassa-493	181	1	6	6	NUM
ijassa-493	181	2	.	.	X
ijassa-493	181	3	prediction	prediction	NOUN
ijassa-493	181	4	of	of	ADP
ijassa-493	181	5	the	the	DET
ijassa-493	181	6	frequency	frequency	NOUN
ijassa-493	181	7	of	of	ADP
ijassa-493	181	8	repeated	repeat	VERB
ijassa-493	181	9	viral	viral	ADJ
ijassa-493	181	10	vaccine	vaccine	NOUN
ijassa-493	181	11	administration	administration	NOUN
ijassa-493	181	12	for	for	ADP
ijassa-493	181	13	the	the	DET
ijassa-493	181	14	clinical	clinical	ADJ
ijassa-493	181	15	setting	set	VERB
ijassa-493	181	16	the	the	DET
ijassa-493	181	17	model	model	NOUN
ijassa-493	181	18	used	use	VERB
ijassa-493	181	19	in	in	ADP
ijassa-493	181	20	this	this	DET
ijassa-493	181	21	study	study	NOUN
ijassa-493	181	22	allows	allow	VERB
ijassa-493	181	23	to	to	PART
ijassa-493	181	24	calculate	calculate	VERB
ijassa-493	181	25	the	the	DET
ijassa-493	181	26	time	time	NOUN
ijassa-493	181	27	frame	frame	NOUN
ijassa-493	181	28	for	for	ADP
ijassa-493	181	29	recurrent	recurrent	ADJ
ijassa-493	181	30	viral	viral	ADJ
ijassa-493	181	31	vaccine	vaccine	NOUN
ijassa-493	181	32	introductions	introduction	NOUN
ijassa-493	181	33	for	for	ADP
ijassa-493	181	34	experimental	experimental	ADJ
ijassa-493	181	35	animals	animal	NOUN
ijassa-493	181	36	.	.	PUNCT
ijassa-493	182	1	in	in	ADP
ijassa-493	182	2	humans	human	NOUN
ijassa-493	182	3	,	,	PUNCT
ijassa-493	182	4	these	these	DET
ijassa-493	182	5	time	time	NOUN
ijassa-493	182	6	intervals	interval	NOUN
ijassa-493	182	7	will	will	AUX
ijassa-493	182	8	be	be	AUX
ijassa-493	182	9	different	different	ADJ
ijassa-493	182	10	.	.	PUNCT
ijassa-493	183	1	however	however	ADV
ijassa-493	183	2	,	,	PUNCT
ijassa-493	183	3	it	it	PRON
ijassa-493	183	4	is	be	AUX
ijassa-493	183	5	possible	possible	ADJ
ijassa-493	183	6	to	to	PART
ijassa-493	183	7	calculate	calculate	VERB
ijassa-493	183	8	their	their	PRON
ijassa-493	183	9	approximate	approximate	ADJ
ijassa-493	183	10	duration	duration	NOUN
ijassa-493	183	11	by	by	ADP
ijassa-493	183	12	applying	apply	VERB
ijassa-493	183	13	allometric	allometric	ADJ
ijassa-493	183	14	relationship	relationship	NOUN
ijassa-493	183	15	(	(	PUNCT
ijassa-493	183	16	16	16	NUM
ijassa-493	183	17	)	)	PUNCT
ijassa-493	183	18	that	that	PRON
ijassa-493	183	19	describes	describe	VERB
ijassa-493	183	20	the	the	DET
ijassa-493	183	21	dependence	dependence	NOUN
ijassa-493	183	22	of	of	ADP
ijassa-493	183	23	the	the	DET
ijassa-493	183	24	metabolic	metabolic	NOUN
ijassa-493	183	25	processes	process	NOUN
ijassa-493	183	26	in	in	ADP
ijassa-493	183	27	mammals	mammal	NOUN
ijassa-493	183	28	on	on	ADP
ijassa-493	183	29	their	their	PRON
ijassa-493	183	30	body	body	NOUN
ijassa-493	183	31	weight	weight	NOUN
ijassa-493	183	32	[	[	X
ijassa-493	183	33	32	32	NUM
ijassa-493	183	34	,	,	PUNCT
ijassa-493	183	35	33	33	NUM
ijassa-493	183	36	]	]	PUNCT
ijassa-493	183	37	:	:	PUNCT
ijassa-493	183	38	bm	bm	PROPN
ijassa-493	183	39	a	a	DET
ijassa-493	183	40	=	=	NOUN
ijassa-493	183	41			PROPN
ijassa-493	183	42	(	(	PUNCT
ijassa-493	183	43	16	16	NUM
ijassa-493	183	44	)	)	PUNCT
ijassa-493	183	45	where	where	SCONJ
ijassa-493	183	46	m	m	NOUN
ijassa-493	183	47	is	be	AUX
ijassa-493	183	48	the	the	DET
ijassa-493	183	49	mammal	mammal	NOUN
ijassa-493	183	50	's	's	PART
ijassa-493	183	51	body	body	NOUN
ijassa-493	183	52	weight	weight	NOUN
ijassa-493	183	53	,	,	PUNCT
ijassa-493	183	54			ADJ
ijassa-493	183	55	is	be	AUX
ijassa-493	183	56	the	the	DET
ijassa-493	183	57	speed	speed	NOUN
ijassa-493	183	58	of	of	ADP
ijassa-493	183	59	the	the	DET
ijassa-493	183	60	mammal	mammal	NOUN
ijassa-493	183	61	's	's	PART
ijassa-493	183	62	metabolic	metabolic	NOUN
ijassa-493	183	63	processes	process	NOUN
ijassa-493	183	64	,	,	PUNCT
ijassa-493	183	65	a	a	PRON
ijassa-493	183	66	and	and	CCONJ
ijassa-493	183	67	b	b	NOUN
ijassa-493	183	68	are	be	AUX
ijassa-493	183	69	constant	constant	ADJ
ijassa-493	183	70	parameters	parameter	NOUN
ijassa-493	183	71	.	.	PUNCT
ijassa-493	184	1	research	research	NOUN
ijassa-493	184	2	indicates	indicate	VERB
ijassa-493	184	3	that	that	SCONJ
ijassa-493	184	4	body	body	NOUN
ijassa-493	184	5	weight	weight	NOUN
ijassa-493	184	6	and	and	CCONJ
ijassa-493	184	7	lifespan	lifespan	NOUN
ijassa-493	184	8	also	also	ADV
ijassa-493	184	9	follow	follow	VERB
ijassa-493	184	10	an	an	DET
ijassa-493	184	11	allometric	allometric	ADJ
ijassa-493	184	12	relationship	relationship	NOUN
ijassa-493	184	13	for	for	ADP
ijassa-493	184	14	both	both	DET
ijassa-493	184	15	humans	human	NOUN
ijassa-493	184	16	and	and	CCONJ
ijassa-493	184	17	laboratory	laboratory	NOUN
ijassa-493	184	18	mice	mouse	NOUN
ijassa-493	185	1	[	[	X
ijassa-493	185	2	32	32	NUM
ijassa-493	185	3	-	-	SYM
ijassa-493	185	4	34	34	NUM
ijassa-493	185	5	]	]	PUNCT
ijassa-493	185	6	.	.	PUNCT
ijassa-493	186	1	if	if	SCONJ
ijassa-493	186	2	we	we	PRON
ijassa-493	186	3	find	find	VERB
ijassa-493	186	4	the	the	DET
ijassa-493	186	5	logarithm	logarithm	NOUN
ijassa-493	186	6	of	of	ADP
ijassa-493	186	7	equation	equation	NOUN
ijassa-493	186	8	(	(	PUNCT
ijassa-493	186	9	16	16	NUM
ijassa-493	186	10	)	)	PUNCT
ijassa-493	186	11	,	,	PUNCT
ijassa-493	186	12	we	we	PRON
ijassa-493	186	13	obtain	obtain	VERB
ijassa-493	186	14	a	a	DET
ijassa-493	186	15	linear	linear	ADJ
ijassa-493	186	16	equation	equation	NOUN
ijassa-493	186	17	that	that	PRON
ijassa-493	186	18	connects	connect	VERB
ijassa-493	186	19	the	the	DET
ijassa-493	186	20	average	average	ADJ
ijassa-493	186	21	body	body	NOUN
ijassa-493	186	22	weight	weight	NOUN
ijassa-493	186	23	of	of	ADP
ijassa-493	186	24	various	various	ADJ
ijassa-493	186	25	mammals	mammal	NOUN
ijassa-493	186	26	and	and	CCONJ
ijassa-493	186	27	humans	human	NOUN
ijassa-493	186	28	with	with	ADP
ijassa-493	186	29	their	their	PRON
ijassa-493	186	30	average	average	ADJ
ijassa-493	186	31	life	life	NOUN
ijassa-493	186	32	span	span	NOUN
ijassa-493	186	33	tl	tl	PROPN
ijassa-493	186	34	(	(	PUNCT
ijassa-493	186	35	figure	figure	VERB
ijassa-493	186	36	8)	8)	NUM
ijassa-493	186	37	:	:	PUNCT
ijassa-493	186	38	ln	ln	PROPN
ijassa-493	186	39	ln	ln	PROPN
ijassa-493	187	1	ln	ln	ADJ
ijassa-493	187	2	lnm	lnm	PROPN
ijassa-493	187	3	b	b	PROPN
ijassa-493	187	4	tl	tl	PROPN
ijassa-493	187	5	a	a	DET
ijassa-493	187	6	b	b	X
ijassa-493	187	7	tl	tl	PROPN
ijassa-493	187	8	c=	c=	VERB
ijassa-493	187	9			VERB
ijassa-493	187	10	+	+	CCONJ
ijassa-493	187	11	=	=	PUNCT
ijassa-493	187	12			VERB
ijassa-493	187	13	+	+	CCONJ
ijassa-493	187	14	(	(	PUNCT
ijassa-493	187	15	17	17	NUM
ijassa-493	187	16	)	)	PUNCT
ijassa-493	187	17	regression	regression	NOUN
ijassa-493	187	18	analysis	analysis	NOUN
ijassa-493	187	19	allowed	allow	VERB
ijassa-493	187	20	to	to	PART
ijassa-493	187	21	define	define	VERB
ijassa-493	187	22	the	the	DET
ijassa-493	187	23	value	value	NOUN
ijassa-493	187	24	of	of	ADP
ijassa-493	187	25	regression	regression	NOUN
ijassa-493	187	26	coefficient	coefficient	NOUN
ijassa-493	188	1	b	b	PROPN
ijassa-493	189	1	=	=	SYM
ijassa-493	189	2	2,4981	2,4981	PROPN
ijassa-493	189	3	,	,	PUNCT
ijassa-493	189	4	which	which	PRON
ijassa-493	189	5	characterizes	characterize	VERB
ijassa-493	189	6	the	the	DET
ijassa-493	189	7	slope	slope	NOUN
ijassa-493	189	8	of	of	ADP
ijassa-493	189	9	the	the	DET
ijassa-493	189	10	regression	regression	NOUN
ijassa-493	189	11	line	line	NOUN
ijassa-493	189	12	.	.	PUNCT
ijassa-493	190	1	figure	figure	NOUN
ijassa-493	190	2	8	8	NUM
ijassa-493	190	3	.	.	PUNCT
ijassa-493	191	1	dependence	dependence	NOUN
ijassa-493	191	2	of	of	ADP
ijassa-493	191	3	the	the	DET
ijassa-493	191	4	life	life	NOUN
ijassa-493	191	5	span	span	NOUN
ijassa-493	191	6	on	on	ADP
ijassa-493	191	7	body	body	NOUN
ijassa-493	191	8	weight	weight	NOUN
ijassa-493	191	9	for	for	ADP
ijassa-493	191	10	○	○	ADJ
ijassa-493	191	11	mice	mouse	NOUN
ijassa-493	191	12	,	,	PUNCT
ijassa-493	191	13	□	□	PUNCT
ijassa-493	191	14	rats	rat	NOUN
ijassa-493	191	15	,	,	PUNCT
ijassa-493	191	16	+	+	CCONJ
ijassa-493	191	17	guinea	guinea	NOUN
ijassa-493	191	18	pigs	pig	NOUN
ijassa-493	191	19	,	,	PUNCT
ijassa-493	191	20	х	х	PROPN
ijassa-493	191	21	rabbits	rabbit	NOUN
ijassa-493	191	22	,	,	PUNCT
ijassa-493	191	23	◊	◊	ADJ
ijassa-493	191	24	dogs	dog	NOUN
ijassa-493	191	25	,	,	PUNCT
ijassa-493	191	26	and	and	CCONJ
ijassa-493	191	27	*	*	PUNCT
ijassa-493	191	28	humans	human	NOUN
ijassa-493	191	29	analytical	analytical	ADJ
ijassa-493	191	30	study	study	NOUN
ijassa-493	191	31	of	of	ADP
ijassa-493	191	32	antitumor	antitumor	PROPN
ijassa-493	191	33	viral	viral	ADJ
ijassa-493	191	34	vaccine	vaccine	NOUN
ijassa-493	191	35	71	71	NUM
ijassa-493	191	36	allometric	allometric	ADJ
ijassa-493	191	37	relationships	relationship	NOUN
ijassa-493	191	38	that	that	PRON
ijassa-493	191	39	define	define	VERB
ijassa-493	191	40	the	the	DET
ijassa-493	191	41	tumor	tumor	NOUN
ijassa-493	191	42	growth	growth	NOUN
ijassa-493	191	43	delay	delay	NOUN
ijassa-493	191	44	for	for	ADP
ijassa-493	191	45	mice	mouse	NOUN
ijassa-493	191	46	and	and	CCONJ
ijassa-493	191	47	humans	human	NOUN
ijassa-493	191	48	are	be	AUX
ijassa-493	191	49	as	as	SCONJ
ijassa-493	191	50	follows	follow	VERB
ijassa-493	191	51	:	:	PUNCT
ijassa-493	191	52	0	0	NUM
ijassa-493	191	53	(	(	PUNCT
ijassa-493	191	54	)	)	PUNCT
ijassa-493	191	55	human	human	PROPN
ijassa-493	191	56	human	human	PROPN
ijassa-493	191	57	bm	bm	PROPN
ijassa-493	191	58	a	a	DET
ijassa-493	191	59	t	t	PROPN
ijassa-493	191	60	v=	v=	NOUN
ijassa-493	191	61			ADV
ijassa-493	191	62	and	and	CCONJ
ijassa-493	191	63	0	0	NUM
ijassa-493	191	64	(	(	PUNCT
ijassa-493	191	65	)	)	PUNCT
ijassa-493	191	66	mouse	mouse	NOUN
ijassa-493	191	67	mouse	mouse	NOUN
ijassa-493	191	68	bm	bm	PROPN
ijassa-493	191	69	a	a	DET
ijassa-493	191	70	t	t	PROPN
ijassa-493	191	71	v=	v=	NOUN
ijassa-493	191	72			X
ijassa-493	191	73	(	(	PUNCT
ijassa-493	191	74	18	18	NUM
ijassa-493	191	75	)	)	PUNCT
ijassa-493	191	76	where	where	SCONJ
ijassa-493	191	77	0	0	NUM
ijassa-493	191	78	(	(	PUNCT
ijassa-493	191	79	)	)	PUNCT
ijassa-493	191	80	humant	humant	NOUN
ijassa-493	191	81	v	v	NOUN
ijassa-493	191	82	is	be	AUX
ijassa-493	191	83	the	the	DET
ijassa-493	191	84	duration	duration	NOUN
ijassa-493	191	85	of	of	ADP
ijassa-493	191	86	the	the	DET
ijassa-493	191	87	tumor	tumor	NOUN
ijassa-493	191	88	growth	growth	NOUN
ijassa-493	191	89	remission	remission	NOUN
ijassa-493	191	90	in	in	ADP
ijassa-493	191	91	a	a	DET
ijassa-493	191	92	human	human	NOUN
ijassa-493	191	93	after	after	ADP
ijassa-493	191	94	the	the	DET
ijassa-493	191	95	viral	viral	ADJ
ijassa-493	191	96	vaccine	vaccine	NOUN
ijassa-493	191	97	administration	administration	NOUN
ijassa-493	191	98	in	in	ADP
ijassa-493	191	99	clinical	clinical	ADJ
ijassa-493	191	100	oncology	oncology	NOUN
ijassa-493	191	101	,	,	PUNCT
ijassa-493	191	102	0	0	NUM
ijassa-493	191	103	(	(	PUNCT
ijassa-493	191	104	)	)	PUNCT
ijassa-493	191	105	mouset	mouset	NOUN
ijassa-493	191	106	v	v	NOUN
ijassa-493	191	107	is	be	AUX
ijassa-493	191	108	duration	duration	NOUN
ijassa-493	191	109	of	of	ADP
ijassa-493	191	110	tumor	tumor	NOUN
ijassa-493	191	111	growth	growth	NOUN
ijassa-493	191	112	delay	delay	NOUN
ijassa-493	191	113	in	in	ADP
ijassa-493	191	114	a	a	DET
ijassa-493	191	115	mouse	mouse	NOUN
ijassa-493	191	116	in	in	ADP
ijassa-493	191	117	the	the	DET
ijassa-493	191	118	experiment	experiment	NOUN
ijassa-493	191	119	.	.	PUNCT
ijassa-493	192	1	the	the	DET
ijassa-493	192	2	duration	duration	NOUN
ijassa-493	192	3	of	of	ADP
ijassa-493	192	4	tumor	tumor	NOUN
ijassa-493	192	5	growth	growth	NOUN
ijassa-493	192	6	delay	delay	NOUN
ijassa-493	192	7	for	for	ADP
ijassa-493	192	8	a	a	DET
ijassa-493	192	9	mouse	mouse	NOUN
ijassa-493	192	10	and	and	CCONJ
ijassa-493	192	11	a	a	DET
ijassa-493	192	12	human	human	NOUN
ijassa-493	192	13	can	can	AUX
ijassa-493	192	14	be	be	AUX
ijassa-493	192	15	calculated	calculate	VERB
ijassa-493	192	16	using	use	VERB
ijassa-493	192	17	the	the	DET
ijassa-493	192	18	following	follow	VERB
ijassa-493	192	19	proportion	proportion	NOUN
ijassa-493	192	20	1	1	NUM
ijassa-493	192	21	0	0	NUM
ijassa-493	192	22	0	0	NUM
ijassa-493	192	23	(	(	PUNCT
ijassa-493	192	24	)	)	PUNCT
ijassa-493	192	25	(	(	PUNCT
ijassa-493	192	26	)	)	PUNCT
ijassa-493	192	27	human	human	PROPN
ijassa-493	192	28	human	human	PROPN
ijassa-493	192	29	b	b	PROPN
ijassa-493	192	30	mouse	mouse	PROPN
ijassa-493	192	31	mouse	mouse	PROPN
ijassa-493	192	32	t	t	PROPN
ijassa-493	192	33	v	v	NOUN
ijassa-493	192	34	m	m	PROPN
ijassa-493	192	35	t	t	NOUN
ijassa-493	192	36	v	v	NUM
ijassa-493	192	37	m	m	PROPN
ijassa-493	192	38			NOUN
ijassa-493	192	39			PROPN
ijassa-493	193	1	=	=	SYM
ijassa-493	193	2			PROPN
ijassa-493	193	3			PRON
ijassa-493	193	4			PUNCT
ijassa-493	194	1			ADJ
ijassa-493	194	2			NOUN
ijassa-493	194	3	this	this	DET
ijassa-493	194	4	proportion	proportion	NOUN
ijassa-493	194	5	makes	make	VERB
ijassa-493	194	6	it	it	PRON
ijassa-493	194	7	possible	possible	ADJ
ijassa-493	194	8	to	to	PART
ijassa-493	194	9	calculate	calculate	VERB
ijassa-493	194	10	the	the	DET
ijassa-493	194	11	duration	duration	NOUN
ijassa-493	194	12	of	of	ADP
ijassa-493	194	13	tumor	tumor	NOUN
ijassa-493	194	14	remission	remission	NOUN
ijassa-493	194	15	in	in	ADP
ijassa-493	194	16	humans	human	NOUN
ijassa-493	194	17	based	base	VERB
ijassa-493	194	18	on	on	ADP
ijassa-493	194	19	the	the	DET
ijassa-493	194	20	estimated	estimate	VERB
ijassa-493	194	21	tumor	tumor	NOUN
ijassa-493	194	22	growth	growth	NOUN
ijassa-493	194	23	delay	delay	NOUN
ijassa-493	194	24	in	in	ADP
ijassa-493	194	25	mice	mouse	NOUN
ijassa-493	194	26	(	(	PUNCT
ijassa-493	194	27	experimental	experimental	ADJ
ijassa-493	194	28	group	group	NOUN
ijassa-493	194	29	)	)	PUNCT
ijassa-493	194	30	,	,	PUNCT
ijassa-493	194	31	average	average	ADJ
ijassa-493	194	32	body	body	NOUN
ijassa-493	194	33	weight	weight	NOUN
ijassa-493	194	34	of	of	ADP
ijassa-493	194	35	mice	mouse	NOUN
ijassa-493	194	36	(	(	PUNCT
ijassa-493	194	37	experimental	experimental	ADJ
ijassa-493	194	38	group	group	NOUN
ijassa-493	194	39	)	)	PUNCT
ijassa-493	194	40	,	,	PUNCT
ijassa-493	194	41	and	and	CCONJ
ijassa-493	194	42	human	human	ADJ
ijassa-493	194	43	body	body	NOUN
ijassa-493	194	44	weight	weight	NOUN
ijassa-493	194	45	:	:	PUNCT
ijassa-493	194	46	1	1	NUM
ijassa-493	194	47	0	0	NUM
ijassa-493	194	48	0	0	NUM
ijassa-493	194	49	(	(	PUNCT
ijassa-493	194	50	)	)	PUNCT
ijassa-493	194	51	(	(	PUNCT
ijassa-493	194	52	)	)	PUNCT
ijassa-493	194	53	human	human	PROPN
ijassa-493	194	54	b	b	PROPN
ijassa-493	194	55	human	human	PROPN
ijassa-493	194	56	mouse	mouse	PROPN
ijassa-493	194	57	mouse	mouse	PROPN
ijassa-493	194	58	m	m	PROPN
ijassa-493	194	59	t	t	PROPN
ijassa-493	194	60	v	v	NUM
ijassa-493	194	61	t	t	PROPN
ijassa-493	194	62	v	v	NOUN
ijassa-493	194	63	m	m	PROPN
ijassa-493	194	64			NOUN
ijassa-493	194	65			NOUN
ijassa-493	194	66			PUNCT
ijassa-493	194	67	=	=	X
ijassa-493	194	68			PUNCT
ijassa-493	194	69			NUM
ijassa-493	194	70			CCONJ
ijassa-493	194	71			PROPN
ijassa-493	194	72			NOUN
ijassa-493	194	73	(	(	PUNCT
ijassa-493	194	74	19	19	NUM
ijassa-493	194	75	)	)	PUNCT
ijassa-493	194	76	for	for	ADP
ijassa-493	194	77	the	the	DET
ijassa-493	194	78	vaccine	vaccine	NOUN
ijassa-493	194	79	dosage	dosage	VERB
ijassa-493	194	80	max	max	PROPN
ijassa-493	194	81	0	0	NUM
ijassa-493	194	82	0	0	NUM
ijassa-493	194	83	0,024v	0,024v	NUM
ijassa-493	194	84	v=	v=	NOUN
ijassa-493	194	85	=	=	NOUN
ijassa-493	194	86	that	that	PRON
ijassa-493	194	87	produces	produce	VERB
ijassa-493	194	88	the	the	DET
ijassa-493	194	89	maximal	maximal	ADJ
ijassa-493	194	90	number	number	NOUN
ijassa-493	194	91	of	of	ADP
ijassa-493	194	92	antibodies	antibody	NOUN
ijassa-493	194	93	against	against	ADP
ijassa-493	194	94	infected	infected	ADJ
ijassa-493	194	95	tumor	tumor	NOUN
ijassa-493	194	96	cells	cell	NOUN
ijassa-493	194	97	,	,	PUNCT
ijassa-493	194	98	the	the	DET
ijassa-493	194	99	periods	period	NOUN
ijassa-493	194	100	between	between	ADP
ijassa-493	194	101	recurrent	recurrent	ADJ
ijassa-493	194	102	introductions	introduction	NOUN
ijassa-493	194	103	for	for	ADP
ijassa-493	194	104	a	a	DET
ijassa-493	194	105	mouse	mouse	NOUN
ijassa-493	194	106	and	and	CCONJ
ijassa-493	194	107	a	a	DET
ijassa-493	194	108	human	human	NOUN
ijassa-493	194	109	will	will	AUX
ijassa-493	194	110	be	be	AUX
ijassa-493	194	111	as	as	SCONJ
ijassa-493	194	112	follows	follow	VERB
ijassa-493	194	113	:	:	PUNCT
ijassa-493	194	114	for	for	ADP
ijassa-493	194	115	small	small	ADJ
ijassa-493	194	116	tumors	tumor	NOUN
ijassa-493	194	117	,	,	PUNCT
ijassa-493	194	118	when	when	SCONJ
ijassa-493	194	119	the	the	DET
ijassa-493	194	120	vaccine	vaccine	NOUN
ijassa-493	194	121	is	be	AUX
ijassa-493	194	122	initially	initially	ADV
ijassa-493	194	123	administered	administer	VERB
ijassa-493	194	124	on	on	ADP
ijassa-493	194	125	1	1	NUM
ijassa-493	194	126	=	=	SYM
ijassa-493	194	127	1	1	NUM
ijassa-493	194	128	day	day	NOUN
ijassa-493	194	129	:	:	PUNCT
ijassa-493	194	130	0	0	NUM
ijassa-493	194	131	(	(	PUNCT
ijassa-493	194	132	)	)	PUNCT
ijassa-493	194	133	mouset	mouset	NOUN
ijassa-493	194	134	v	v	NOUN
ijassa-493	195	1	=	=	PUNCT
ijassa-493	195	2	16,7	16,7	NUM
ijassa-493	195	3	days	day	NOUN
ijassa-493	195	4	,	,	PUNCT
ijassa-493	195	5	0	0	NUM
ijassa-493	195	6	(	(	PUNCT
ijassa-493	195	7	)	)	PUNCT
ijassa-493	195	8	humant	humant	NOUN
ijassa-493	195	9	v	v	NOUN
ijassa-493	196	1	=	=	NOUN
ijassa-493	196	2	1,3	1,3	NUM
ijassa-493	196	3	years	year	NOUN
ijassa-493	196	4	;	;	PUNCT
ijassa-493	196	5	for	for	ADP
ijassa-493	196	6	bigger	big	ADJ
ijassa-493	196	7	tumors	tumor	NOUN
ijassa-493	196	8	,	,	PUNCT
ijassa-493	196	9	when	when	SCONJ
ijassa-493	196	10	the	the	DET
ijassa-493	196	11	vaccine	vaccine	NOUN
ijassa-493	196	12	is	be	AUX
ijassa-493	196	13	initially	initially	ADV
ijassa-493	196	14	administered	administer	VERB
ijassa-493	196	15	on	on	ADP
ijassa-493	196	16	1	1	NUM
ijassa-493	196	17	=	=	SYM
ijassa-493	196	18	25	25	NUM
ijassa-493	196	19	day	day	NOUN
ijassa-493	196	20	:	:	PUNCT
ijassa-493	196	21	0	0	NUM
ijassa-493	196	22	(	(	PUNCT
ijassa-493	196	23	)	)	PUNCT
ijassa-493	196	24	mouset	mouset	NOUN
ijassa-493	196	25	v	v	NOUN
ijassa-493	196	26	=	=	SYM
ijassa-493	196	27	30,5	30,5	NUM
ijassa-493	196	28	days	day	NOUN
ijassa-493	196	29	,	,	PUNCT
ijassa-493	196	30	0	0	NUM
ijassa-493	196	31	(	(	PUNCT
ijassa-493	196	32	)	)	PUNCT
ijassa-493	196	33	humant	humant	NOUN
ijassa-493	196	34	v	v	NOUN
ijassa-493	197	1	=	=	NOUN
ijassa-493	197	2	2,1	2,1	NUM
ijassa-493	197	3	years	year	NOUN
ijassa-493	197	4	.	.	PUNCT
ijassa-493	198	1	the	the	DET
ijassa-493	198	2	period	period	NOUN
ijassa-493	198	3	for	for	ADP
ijassa-493	198	4	the	the	DET
ijassa-493	198	5	repeated	repeat	VERB
ijassa-493	198	6	vaccine	vaccine	NOUN
ijassa-493	198	7	introduction	introduction	NOUN
ijassa-493	198	8	can	can	AUX
ijassa-493	198	9	be	be	AUX
ijassa-493	198	10	treated	treat	VERB
ijassa-493	198	11	as	as	ADP
ijassa-493	198	12	a	a	DET
ijassa-493	198	13	time	time	NOUN
ijassa-493	198	14	when	when	SCONJ
ijassa-493	198	15	a	a	DET
ijassa-493	198	16	patient	patient	NOUN
ijassa-493	198	17	needs	need	VERB
ijassa-493	198	18	to	to	PART
ijassa-493	198	19	make	make	VERB
ijassa-493	198	20	a	a	DET
ijassa-493	198	21	return	return	NOUN
ijassa-493	198	22	visit	visit	NOUN
ijassa-493	198	23	to	to	ADP
ijassa-493	198	24	the	the	DET
ijassa-493	198	25	therapist	therapist	NOUN
ijassa-493	198	26	for	for	ADP
ijassa-493	198	27	examination	examination	NOUN
ijassa-493	198	28	.	.	PUNCT
ijassa-493	199	1	examination	examination	NOUN
ijassa-493	199	2	will	will	AUX
ijassa-493	199	3	indicate	indicate	VERB
ijassa-493	199	4	whether	whether	SCONJ
ijassa-493	199	5	the	the	DET
ijassa-493	199	6	repeated	repeat	VERB
ijassa-493	199	7	administration	administration	NOUN
ijassa-493	199	8	of	of	ADP
ijassa-493	199	9	the	the	DET
ijassa-493	199	10	vaccine	vaccine	NOUN
ijassa-493	199	11	is	be	AUX
ijassa-493	199	12	needed	need	VERB
ijassa-493	199	13	.	.	PUNCT
ijassa-493	200	1	7	7	X
ijassa-493	200	2	.	.	X
ijassa-493	200	3	conclusion	conclusion	NOUN
ijassa-493	200	4	the	the	DET
ijassa-493	200	5	software	software	NOUN
ijassa-493	200	6	developed	develop	VERB
ijassa-493	200	7	in	in	ADP
ijassa-493	200	8	matlab	matlab	PROPN
ijassa-493	200	9	-	-	PUNCT
ijassa-493	200	10	simulink	simulink	PROPN
ijassa-493	200	11	based	base	VERB
ijassa-493	200	12	on	on	ADP
ijassa-493	200	13	two	two	NUM
ijassa-493	200	14	mathematical	mathematical	ADJ
ijassa-493	200	15	models	model	NOUN
ijassa-493	200	16	describing	describe	VERB
ijassa-493	200	17	tumor	tumor	NOUN
ijassa-493	200	18	growth	growth	NOUN
ijassa-493	200	19	after	after	ADP
ijassa-493	200	20	the	the	DET
ijassa-493	200	21	introduction	introduction	NOUN
ijassa-493	200	22	of	of	ADP
ijassa-493	200	23	antitumoral	antitumoral	ADJ
ijassa-493	200	24	viral	viral	ADJ
ijassa-493	200	25	vaccines	vaccine	NOUN
ijassa-493	200	26	makes	make	VERB
ijassa-493	200	27	it	it	PRON
ijassa-493	200	28	possible	possible	ADJ
ijassa-493	200	29	to	to	PART
ijassa-493	200	30	study	study	VERB
ijassa-493	200	31	the	the	DET
ijassa-493	200	32	effectiveness	effectiveness	NOUN
ijassa-493	200	33	of	of	ADP
ijassa-493	200	34	vaccine	vaccine	NOUN
ijassa-493	200	35	therapy	therapy	NOUN
ijassa-493	200	36	for	for	ADP
ijassa-493	200	37	a	a	DET
ijassa-493	200	38	wide	wide	ADJ
ijassa-493	200	39	range	range	NOUN
ijassa-493	200	40	of	of	ADP
ijassa-493	200	41	dosages	dosage	NOUN
ijassa-493	200	42	and	and	CCONJ
ijassa-493	200	43	times	time	NOUN
ijassa-493	200	44	of	of	ADP
ijassa-493	200	45	introduction	introduction	NOUN
ijassa-493	200	46	.	.	PUNCT
ijassa-493	201	1	the	the	DET
ijassa-493	201	2	proposed	propose	VERB
ijassa-493	201	3	algorithm	algorithm	NOUN
ijassa-493	201	4	for	for	ADP
ijassa-493	201	5	defining	define	VERB
ijassa-493	201	6	the	the	DET
ijassa-493	201	7	optimal	optimal	ADJ
ijassa-493	201	8	regimens	regimen	NOUN
ijassa-493	201	9	of	of	ADP
ijassa-493	201	10	viral	viral	ADJ
ijassa-493	201	11	vaccine	vaccine	NOUN
ijassa-493	201	12	administration	administration	NOUN
ijassa-493	201	13	can	can	AUX
ijassa-493	201	14	be	be	AUX
ijassa-493	201	15	used	use	VERB
ijassa-493	201	16	for	for	ADP
ijassa-493	201	17	various	various	ADJ
ijassa-493	201	18	types	type	NOUN
ijassa-493	201	19	of	of	ADP
ijassa-493	201	20	experimental	experimental	ADJ
ijassa-493	201	21	tumors	tumor	NOUN
ijassa-493	201	22	and	and	CCONJ
ijassa-493	201	23	types	type	NOUN
ijassa-493	201	24	of	of	ADP
ijassa-493	201	25	antitumor	antitumor	PROPN
ijassa-493	201	26	viral	viral	ADJ
ijassa-493	201	27	vaccines	vaccine	NOUN
ijassa-493	201	28	.	.	PUNCT
ijassa-493	202	1	the	the	DET
ijassa-493	202	2	results	result	NOUN
ijassa-493	202	3	of	of	ADP
ijassa-493	202	4	the	the	DET
ijassa-493	202	5	computing	compute	VERB
ijassa-493	202	6	experiment	experiment	NOUN
ijassa-493	202	7	presented	present	VERB
ijassa-493	202	8	in	in	ADP
ijassa-493	202	9	this	this	DET
ijassa-493	202	10	paper	paper	NOUN
ijassa-493	202	11	make	make	VERB
ijassa-493	202	12	it	it	PRON
ijassa-493	202	13	possible	possible	ADJ
ijassa-493	202	14	to	to	PART
ijassa-493	202	15	assess	assess	VERB
ijassa-493	202	16	the	the	DET
ijassa-493	202	17	effectiveness	effectiveness	NOUN
ijassa-493	202	18	of	of	ADP
ijassa-493	202	19	different	different	ADJ
ijassa-493	202	20	regimes	regime	NOUN
ijassa-493	202	21	of	of	ADP
ijassa-493	202	22	vaccine	vaccine	NOUN
ijassa-493	202	23	therapy	therapy	NOUN
ijassa-493	202	24	.	.	PUNCT
ijassa-493	203	1	they	they	PRON
ijassa-493	203	2	suggest	suggest	VERB
ijassa-493	203	3	two	two	NUM
ijassa-493	203	4	strategies	strategy	NOUN
ijassa-493	203	5	for	for	ADP
ijassa-493	203	6	the	the	DET
ijassa-493	203	7	viral	viral	ADJ
ijassa-493	203	8	vaccine	vaccine	NOUN
ijassa-493	203	9	treatment	treatment	NOUN
ijassa-493	203	10	.	.	PUNCT
ijassa-493	204	1	the	the	DET
ijassa-493	204	2	first	first	ADJ
ijassa-493	204	3	strategy	strategy	NOUN
ijassa-493	204	4	allows	allow	VERB
ijassa-493	204	5	a	a	DET
ijassa-493	204	6	complete	complete	ADJ
ijassa-493	204	7	elimination	elimination	NOUN
ijassa-493	204	8	of	of	ADP
ijassa-493	204	9	the	the	DET
ijassa-493	204	10	tumor	tumor	NOUN
ijassa-493	204	11	cells	cell	NOUN
ijassa-493	204	12	.	.	PUNCT
ijassa-493	205	1	this	this	DET
ijassa-493	205	2	strategy	strategy	NOUN
ijassa-493	205	3	implies	imply	VERB
ijassa-493	205	4	a	a	DET
ijassa-493	205	5	single	single	ADJ
ijassa-493	205	6	-	-	PUNCT
ijassa-493	205	7	shot	shot	NOUN
ijassa-493	205	8	administration	administration	NOUN
ijassa-493	205	9	of	of	ADP
ijassa-493	205	10	a	a	DET
ijassa-493	205	11	high	high	ADJ
ijassa-493	205	12	dosage	dosage	NOUN
ijassa-493	205	13	that	that	PRON
ijassa-493	205	14	produces	produce	VERB
ijassa-493	205	15	the	the	DET
ijassa-493	205	16	death	death	NOUN
ijassa-493	205	17	of	of	ADP
ijassa-493	205	18	tumor	tumor	NOUN
ijassa-493	205	19	cells	cell	NOUN
ijassa-493	205	20	at	at	ADP
ijassa-493	205	21	the	the	DET
ijassa-493	205	22	1st	1st	ADJ
ijassa-493	205	23	stage	stage	NOUN
ijassa-493	205	24	of	of	ADP
ijassa-493	205	25	immune	immune	ADJ
ijassa-493	205	26	response	response	NOUN
ijassa-493	205	27	.	.	PUNCT
ijassa-493	206	1	the	the	DET
ijassa-493	206	2	second	second	ADJ
ijassa-493	206	3	strategy	strategy	NOUN
ijassa-493	206	4	does	do	AUX
ijassa-493	206	5	not	not	PART
ijassa-493	206	6	lead	lead	VERB
ijassa-493	206	7	to	to	ADP
ijassa-493	206	8	the	the	DET
ijassa-493	206	9	complete	complete	ADJ
ijassa-493	206	10	elimination	elimination	NOUN
ijassa-493	206	11	of	of	ADP
ijassa-493	206	12	the	the	DET
ijassa-493	206	13	tumor	tumor	NOUN
ijassa-493	206	14	,	,	PUNCT
ijassa-493	206	15	but	but	CCONJ
ijassa-493	206	16	makes	make	VERB
ijassa-493	206	17	it	it	PRON
ijassa-493	206	18	possible	possible	ADJ
ijassa-493	206	19	to	to	PART
ijassa-493	206	20	stabilize	stabilize	VERB
ijassa-493	206	21	its	its	PRON
ijassa-493	206	22	size	size	NOUN
ijassa-493	206	23	through	through	ADP
ijassa-493	206	24	recurrent	recurrent	ADJ
ijassa-493	206	25	introduction	introduction	NOUN
ijassa-493	206	26	of	of	ADP
ijassa-493	206	27	the	the	DET
ijassa-493	206	28	viral	viral	ADJ
ijassa-493	206	29	vaccine	vaccine	NOUN
ijassa-493	206	30	.	.	PUNCT
ijassa-493	207	1	if	if	SCONJ
ijassa-493	207	2	the	the	DET
ijassa-493	207	3	initial	initial	ADJ
ijassa-493	207	4	tumor	tumor	NOUN
ijassa-493	207	5	size	size	NOUN
ijassa-493	207	6	is	be	AUX
ijassa-493	207	7	small	small	ADJ
ijassa-493	207	8	,	,	PUNCT
ijassa-493	207	9	this	this	DET
ijassa-493	207	10	stabilization	stabilization	NOUN
ijassa-493	207	11	gives	give	VERB
ijassa-493	207	12	the	the	DET
ijassa-493	207	13	possibility	possibility	NOUN
ijassa-493	207	14	to	to	PART
ijassa-493	207	15	avoid	avoid	VERB
ijassa-493	207	16	the	the	DET
ijassa-493	207	17	surgical	surgical	ADJ
ijassa-493	207	18	intervention	intervention	NOUN
ijassa-493	207	19	,	,	PUNCT
ijassa-493	207	20	with	with	ADP
ijassa-493	207	21	vaccine	vaccine	NOUN
ijassa-493	207	22	therapy	therapy	NOUN
ijassa-493	207	23	acting	act	VERB
ijassa-493	207	24	as	as	ADP
ijassa-493	207	25	a	a	DET
ijassa-493	207	26	regular	regular	ADJ
ijassa-493	207	27	vaccination	vaccination	NOUN
ijassa-493	207	28	against	against	ADP
ijassa-493	207	29	autologous	autologous	ADJ
ijassa-493	207	30	tumor	tumor	NOUN
ijassa-493	207	31	cells	cell	NOUN
ijassa-493	207	32	.	.	PUNCT
ijassa-493	208	1	the	the	DET
ijassa-493	208	2	present	present	ADJ
ijassa-493	208	3	study	study	NOUN
ijassa-493	208	4	also	also	ADV
ijassa-493	208	5	proposes	propose	VERB
ijassa-493	208	6	the	the	DET
ijassa-493	208	7	method	method	NOUN
ijassa-493	208	8	of	of	ADP
ijassa-493	208	9	using	use	VERB
ijassa-493	208	10	experimental	experimental	ADJ
ijassa-493	208	11	results	result	NOUN
ijassa-493	208	12	to	to	PART
ijassa-493	208	13	predict	predict	VERB
ijassa-493	208	14	the	the	DET
ijassa-493	208	15	duration	duration	NOUN
ijassa-493	208	16	of	of	ADP
ijassa-493	208	17	remission	remission	NOUN
ijassa-493	208	18	for	for	ADP
ijassa-493	208	19	the	the	DET
ijassa-493	208	20	humans	human	NOUN
ijassa-493	208	21	,	,	PUNCT
ijassa-493	208	22	based	base	VERB
ijassa-493	208	23	on	on	ADP
ijassa-493	208	24	allometric	allometric	ADJ
ijassa-493	208	25	relationships	relationship	NOUN
ijassa-493	208	26	.	.	PUNCT
ijassa-493	209	1	this	this	DET
ijassa-493	209	2	method	method	NOUN
ijassa-493	209	3	makes	make	VERB
ijassa-493	209	4	it	it	PRON
ijassa-493	209	5	72	72	NUM
ijassa-493	209	6	n.a	n.a	PROPN
ijassa-493	209	7	.	.	PROPN
ijassa-493	209	8	babushkina	babushkina	PROPN
ijassa-493	209	9	,	,	PUNCT
ijassa-493	209	10	e.a	e.a	PROPN
ijassa-493	209	11	.	.	PROPN
ijassa-493	209	12	kuzina	kuzina	PROPN
ijassa-493	209	13	possible	possible	ADJ
ijassa-493	209	14	to	to	PART
ijassa-493	209	15	define	define	VERB
ijassa-493	209	16	the	the	DET
ijassa-493	209	17	time	time	NOUN
ijassa-493	209	18	when	when	SCONJ
ijassa-493	209	19	a	a	DET
ijassa-493	209	20	patient	patient	NOUN
ijassa-493	209	21	needs	need	VERB
ijassa-493	209	22	to	to	PART
ijassa-493	209	23	make	make	VERB
ijassa-493	209	24	a	a	DET
ijassa-493	209	25	return	return	NOUN
ijassa-493	209	26	visit	visit	NOUN
ijassa-493	209	27	to	to	ADP
ijassa-493	209	28	the	the	DET
ijassa-493	209	29	therapist	therapist	NOUN
ijassa-493	209	30	for	for	ADP
ijassa-493	209	31	repeated	repeat	VERB
ijassa-493	209	32	examination	examination	NOUN
ijassa-493	209	33	and	and	CCONJ
ijassa-493	209	34	decision	decision	NOUN
ijassa-493	209	35	on	on	ADP
ijassa-493	209	36	whether	whether	SCONJ
ijassa-493	209	37	further	further	ADJ
ijassa-493	209	38	antitumor	antitumor	PROPN
ijassa-493	209	39	vaccine	vaccine	NOUN
ijassa-493	209	40	administration	administration	NOUN
ijassa-493	209	41	is	be	AUX
ijassa-493	209	42	required	require	VERB
ijassa-493	209	43	.	.	PUNCT
ijassa-493	210	1	the	the	DET
ijassa-493	210	2	development	development	NOUN
ijassa-493	210	3	of	of	ADP
ijassa-493	210	4	high	high	ADJ
ijassa-493	210	5	-	-	PUNCT
ijassa-493	210	6	tech	tech	NOUN
ijassa-493	210	7	methods	method	NOUN
ijassa-493	210	8	for	for	ADP
ijassa-493	210	9	the	the	DET
ijassa-493	210	10	treatment	treatment	NOUN
ijassa-493	210	11	of	of	ADP
ijassa-493	210	12	oncological	oncological	ADJ
ijassa-493	210	13	diseases	disease	NOUN
ijassa-493	210	14	is	be	AUX
ijassa-493	210	15	directly	directly	ADV
ijassa-493	210	16	related	relate	VERB
ijassa-493	210	17	to	to	ADP
ijassa-493	210	18	the	the	DET
ijassa-493	210	19	cost	cost	NOUN
ijassa-493	210	20	of	of	ADP
ijassa-493	210	21	experimental	experimental	ADJ
ijassa-493	210	22	research	research	NOUN
ijassa-493	210	23	.	.	PUNCT
ijassa-493	211	1	utilization	utilization	NOUN
ijassa-493	211	2	of	of	ADP
ijassa-493	211	3	mathematical	mathematical	ADJ
ijassa-493	211	4	modeling	modeling	NOUN
ijassa-493	211	5	at	at	ADP
ijassa-493	211	6	the	the	DET
ijassa-493	211	7	different	different	ADJ
ijassa-493	211	8	stages	stage	NOUN
ijassa-493	211	9	of	of	ADP
ijassa-493	211	10	experimental	experimental	ADJ
ijassa-493	211	11	studies	study	NOUN
ijassa-493	211	12	and	and	CCONJ
ijassa-493	211	13	on	on	ADP
ijassa-493	211	14	the	the	DET
ijassa-493	211	15	stage	stage	NOUN
ijassa-493	211	16	of	of	ADP
ijassa-493	211	17	transferring	transfer	VERB
ijassa-493	211	18	the	the	DET
ijassa-493	211	19	results	result	NOUN
ijassa-493	211	20	to	to	ADP
ijassa-493	211	21	the	the	DET
ijassa-493	211	22	clinical	clinical	ADJ
ijassa-493	211	23	setting	setting	NOUN
ijassa-493	211	24	can	can	AUX
ijassa-493	211	25	reduce	reduce	VERB
ijassa-493	211	26	the	the	DET
ijassa-493	211	27	cost	cost	NOUN
ijassa-493	211	28	of	of	ADP
ijassa-493	211	29	experiments	experiment	NOUN
ijassa-493	211	30	and	and	CCONJ
ijassa-493	211	31	the	the	DET
ijassa-493	211	32	length	length	NOUN
ijassa-493	211	33	of	of	ADP
ijassa-493	211	34	research	research	NOUN
ijassa-493	211	35	.	.	PUNCT
ijassa-493	212	1	references	reference	NOUN
ijassa-493	212	2	[	[	X
ijassa-493	212	3	1	1	NUM
ijassa-493	212	4	]	]	PUNCT
ijassa-493	212	5	dermime	dermime	NOUN
ijassa-493	212	6	,	,	PUNCT
ijassa-493	212	7	s.	s.	PROPN
ijassa-493	212	8	,	,	PUNCT
ijassa-493	212	9	armstrong	armstrong	PROPN
ijassa-493	212	10	,	,	PUNCT
ijassa-493	212	11	a.	a.	PROPN
ijassa-493	212	12	,	,	PUNCT
ijassa-493	212	13	hawkins	hawkins	PROPN
ijassa-493	212	14	,	,	PUNCT
ijassa-493	212	15	r.e	r.e	PROPN
ijassa-493	212	16	.	.	PROPN
ijassa-493	212	17	&	&	CCONJ
ijassa-493	212	18	stern	stern	PROPN
ijassa-493	212	19	,	,	PUNCT
ijassa-493	212	20	p.l	p.l	PROPN
ijassa-493	212	21	.	.	PROPN
ijassa-493	212	22	(	(	PUNCT
ijassa-493	212	23	2002	2002	NUM
ijassa-493	212	24	)	)	PUNCT
ijassa-493	212	25	cancer	cancer	NOUN
ijassa-493	212	26	vaccines	vaccine	NOUN
ijassa-493	212	27	and	and	CCONJ
ijassa-493	212	28	immunotherapy	immunotherapy	NOUN
ijassa-493	212	29	.	.	PUNCT
ijassa-493	213	1	british	british	ADJ
ijassa-493	213	2	medical	medical	ADJ
ijassa-493	213	3	bulletin	bulletin	NOUN
ijassa-493	213	4	,	,	PUNCT
ijassa-493	213	5	62(1	62(1	NOUN
ijassa-493	213	6	)	)	PUNCT
ijassa-493	213	7	,	,	PUNCT
ijassa-493	213	8	149	149	NUM
ijassa-493	213	9	-	-	SYM
ijassa-493	213	10	162	162	NUM
ijassa-493	213	11	.	.	PUNCT
ijassa-493	214	1	[	[	X
ijassa-493	214	2	2	2	NUM
ijassa-493	214	3	]	]	PUNCT
ijassa-493	214	4	mutsenietse	mutsenietse	PROPN
ijassa-493	214	5	,	,	PUNCT
ijassa-493	214	6	a.	a.	NOUN
ijassa-493	214	7	ya	ya	PROPN
ijassa-493	214	8	.	.	PUNCT
ijassa-493	215	1	(	(	PUNCT
ijassa-493	215	2	1972	1972	NUM
ijassa-493	215	3	)	)	PUNCT
ijassa-493	215	4	onkotropizm	onkotropizm	PROPN
ijassa-493	215	5	virusov	virusov	NOUN
ijassa-493	215	6	i	i	PRON
ijassa-493	215	7	problema	problema	VERB
ijassa-493	215	8	viroterapii	viroterapii	NOUN
ijassa-493	215	9	zlokachestvennyh	zlokachestvennyh	NOUN
ijassa-493	215	10	opuholej	opuholej	NOUN
ijassa-493	215	11	[	[	PUNCT
ijassa-493	215	12	oncotropism	oncotropism	NOUN
ijassa-493	215	13	of	of	ADP
ijassa-493	215	14	viruses	virus	NOUN
ijassa-493	215	15	and	and	CCONJ
ijassa-493	215	16	the	the	DET
ijassa-493	215	17	problem	problem	NOUN
ijassa-493	215	18	of	of	ADP
ijassa-493	215	19	viral	viral	ADJ
ijassa-493	215	20	therapy	therapy	NOUN
ijassa-493	215	21	of	of	ADP
ijassa-493	215	22	malignant	malignant	ADJ
ijassa-493	215	23	tumors	tumor	NOUN
ijassa-493	215	24	]	]	PUNCT
ijassa-493	215	25	.	.	PUNCT
ijassa-493	216	1	riga	riga	ADJ
ijassa-493	216	2	,	,	PUNCT
ijassa-493	216	3	ussr	ussr	ADJ
ijassa-493	216	4	:	:	PUNCT
ijassa-493	216	5	zinatne	zinatne	NOUN
ijassa-493	216	6	,	,	PUNCT
ijassa-493	216	7	[	[	X
ijassa-493	216	8	in	in	ADP
ijassa-493	216	9	russian	russian	NOUN
ijassa-493	216	10	]	]	PUNCT
ijassa-493	216	11	.	.	PUNCT
ijassa-493	217	1	[	[	X
ijassa-493	217	2	3	3	NUM
ijassa-493	217	3	]	]	X
ijassa-493	217	4	mutsenietse	mutsenietse	PROPN
ijassa-493	217	5	,	,	PUNCT
ijassa-493	217	6	a.	a.	NOUN
ijassa-493	217	7	ya	ya	PROPN
ijassa-493	217	8	.	.	PROPN
ijassa-493	217	9	,	,	PUNCT
ijassa-493	217	10	bumbieris	bumbieris	PROPN
ijassa-493	217	11	,	,	PUNCT
ijassa-493	217	12	ya	ya	PROPN
ijassa-493	217	13	.	.	PUNCT
ijassa-493	218	1	v.	v.	PROPN
ijassa-493	218	2	,	,	PUNCT
ijassa-493	218	3	bruvere	bruvere	INTJ
ijassa-493	218	4	,	,	PUNCT
ijassa-493	218	5	r.	r.	PROPN
ijassa-493	218	6	zh	zh	PROPN
ijassa-493	218	7	.	.	PUNCT
ijassa-493	219	1	(	(	PUNCT
ijassa-493	219	2	1982	1982	NUM
ijassa-493	219	3	)	)	PUNCT
ijassa-493	219	4	immunologija	immunologija	NOUN
ijassa-493	219	5	opuholej	opuholej	NOUN
ijassa-493	220	1	[	[	X
ijassa-493	220	2	immunology	immunology	NOUN
ijassa-493	220	3	of	of	ADP
ijassa-493	220	4	tumors	tumor	NOUN
ijassa-493	220	5	]	]	PUNCT
ijassa-493	220	6	.	.	PUNCT
ijassa-493	221	1	riga	riga	ADJ
ijassa-493	221	2	,	,	PUNCT
ijassa-493	221	3	ussr	ussr	ADJ
ijassa-493	221	4	:	:	PUNCT
ijassa-493	221	5	zinatne	zinatne	NOUN
ijassa-493	221	6	,	,	PUNCT
ijassa-493	221	7	[	[	X
ijassa-493	221	8	in	in	ADP
ijassa-493	221	9	russian	russian	NOUN
ijassa-493	221	10	]	]	PUNCT
ijassa-493	221	11	.	.	PUNCT
ijassa-493	222	1	[	[	X
ijassa-493	222	2	4	4	NUM
ijassa-493	222	3	]	]	X
ijassa-493	222	4	moiseenko	moiseenko	ADJ
ijassa-493	222	5	,	,	PUNCT
ijassa-493	222	6	v.	v.	ADP
ijassa-493	222	7	m.	m.	NOUN
ijassa-493	222	8	(	(	PUNCT
ijassa-493	222	9	1999	1999	NUM
ijassa-493	222	10	)	)	PUNCT
ijassa-493	222	11	primenenie	primenenie	NOUN
ijassa-493	222	12	monoklonal'nyh	monoklonal'nyh	PROPN
ijassa-493	222	13	antitel	antitel	PROPN
ijassa-493	222	14	dlja	dlja	ADJ
ijassa-493	222	15	lechenija	lechenija	PROPN
ijassa-493	222	16	zlokachestvennyh	zlokachestvennyh	PROPN
ijassa-493	222	17	solidnyh	solidnyh	NOUN
ijassa-493	222	18	opuholej	opuholej	NOUN
ijassa-493	222	19	[	[	X
ijassa-493	222	20	the	the	DET
ijassa-493	222	21	use	use	NOUN
ijassa-493	222	22	of	of	ADP
ijassa-493	222	23	monoclonal	monoclonal	NOUN
ijassa-493	222	24	antibodies	antibody	NOUN
ijassa-493	222	25	for	for	ADP
ijassa-493	222	26	the	the	DET
ijassa-493	222	27	treatment	treatment	NOUN
ijassa-493	222	28	of	of	ADP
ijassa-493	222	29	malignant	malignant	ADJ
ijassa-493	222	30	solid	solid	ADJ
ijassa-493	222	31	tumors	tumor	NOUN
ijassa-493	222	32	]	]	PUNCT
ijassa-493	222	33	.	.	PUNCT
ijassa-493	223	1	voprosy	voprosy	PROPN
ijassa-493	223	2	onkologii	onkologii	PROPN
ijassa-493	223	3	,	,	PUNCT
ijassa-493	223	4	45(4	45(4	PROPN
ijassa-493	223	5	)	)	PUNCT
ijassa-493	223	6	,	,	PUNCT
ijassa-493	223	7	458	458	NUM
ijassa-493	223	8	-	-	SYM
ijassa-493	223	9	462	462	NUM
ijassa-493	223	10	,	,	PUNCT
ijassa-493	224	1	[	[	X
ijassa-493	224	2	in	in	ADP
ijassa-493	224	3	russian	russian	NOUN
ijassa-493	224	4	]	]	PUNCT
ijassa-493	224	5	.	.	PUNCT
ijassa-493	225	1	[	[	X
ijassa-493	225	2	5	5	NUM
ijassa-493	225	3	]	]	PUNCT
ijassa-493	225	4	gromova	gromova	PROPN
ijassa-493	225	5	a.	a.	PROPN
ijassa-493	225	6	yu	yu	PROPN
ijassa-493	225	7	.	.	PUNCT
ijassa-493	226	1	(	(	PUNCT
ijassa-493	226	2	1999	1999	NUM
ijassa-493	226	3	)	)	PUNCT
ijassa-493	226	4	protivoopuholevye	protivoopuholevye	PROPN
ijassa-493	226	5	svojstva	svojstva	VERB
ijassa-493	226	6	vakcinnogo	vakcinnogo	ADJ
ijassa-493	226	7	shtamma	shtamma	PROPN
ijassa-493	226	8	virusa	virusa	NOUN
ijassa-493	226	9	venesujel'skogo	venesujel'skogo	ADJ
ijassa-493	226	10	jencefalomielita	jencefalomielita	NOUN
ijassa-493	227	1	i	i	PRON
ijassa-493	227	2	ego	ego	ADJ
ijassa-493	227	3	onkolizata	onkolizata	NOUN
ijassa-493	227	4	[	[	X
ijassa-493	227	5	antitumor	antitumor	NOUN
ijassa-493	227	6	properties	property	NOUN
ijassa-493	227	7	of	of	ADP
ijassa-493	227	8	the	the	DET
ijassa-493	227	9	vaccine	vaccine	NOUN
ijassa-493	227	10	strain	strain	VERB
ijassa-493	227	11	of	of	ADP
ijassa-493	227	12	the	the	DET
ijassa-493	227	13	venezuelan	venezuelan	ADJ
ijassa-493	227	14	encephalomyelitis	encephalomyelitis	NOUN
ijassa-493	227	15	virus	virus	NOUN
ijassa-493	227	16	and	and	CCONJ
ijassa-493	227	17	its	its	PRON
ijassa-493	227	18	oncolyte	oncolyte	NOUN
ijassa-493	227	19	]	]	PUNCT
ijassa-493	227	20	.	.	PUNCT
ijassa-493	228	1	phd	phd	NOUN
ijassa-493	228	2	thesis	thesis	NOUN
ijassa-493	228	3	(	(	PUNCT
ijassa-493	228	4	biology	biology	NOUN
ijassa-493	228	5	)	)	PUNCT
ijassa-493	228	6	,	,	PUNCT
ijassa-493	228	7	st	st	PROPN
ijassa-493	228	8	.	.	PROPN
ijassa-493	228	9	petersburg	petersburg	PROPN
ijassa-493	228	10	,	,	PUNCT
ijassa-493	229	1	[	[	X
ijassa-493	229	2	in	in	ADP
ijassa-493	229	3	russian	russian	NOUN
ijassa-493	229	4	]	]	PUNCT
ijassa-493	229	5	.	.	PUNCT
ijassa-493	230	1	[	[	X
ijassa-493	230	2	6	6	NUM
ijassa-493	230	3	]	]	PUNCT
ijassa-493	230	4	urazova	urazova	X
ijassa-493	230	5	,	,	PUNCT
ijassa-493	230	6	l.	l.	PROPN
ijassa-493	230	7	n.	n.	PROPN
ijassa-493	230	8	(	(	PUNCT
ijassa-493	230	9	2003	2003	NUM
ijassa-493	230	10	)	)	PUNCT
ijassa-493	230	11	jeffektivnost	jeffektivnost	NOUN
ijassa-493	230	12	'	'	PUNCT
ijassa-493	231	1	i	i	PRON
ijassa-493	231	2	mehanizmy	mehanizmy	VERB
ijassa-493	231	3	protivoopuholevogo	protivoopuholevogo	PROPN
ijassa-493	231	4	dejstvija	dejstvija	PROPN
ijassa-493	231	5	virusnyh	virusnyh	PROPN
ijassa-493	231	6	vakcin	vakcin	VERB
ijassa-493	231	7	pri	pri	PROPN
ijassa-493	231	8	jeksperimental'nom	jeksperimental'nom	PROPN
ijassa-493	231	9	onkogeneze	onkogeneze	VERB
ijassa-493	231	10	[	[	X
ijassa-493	231	11	efficiency	efficiency	NOUN
ijassa-493	231	12	and	and	CCONJ
ijassa-493	231	13	mechanisms	mechanism	NOUN
ijassa-493	231	14	of	of	ADP
ijassa-493	231	15	the	the	DET
ijassa-493	231	16	antitumor	antitumor	PROPN
ijassa-493	231	17	action	action	NOUN
ijassa-493	231	18	of	of	ADP
ijassa-493	231	19	viral	viral	ADJ
ijassa-493	231	20	vaccines	vaccine	NOUN
ijassa-493	231	21	in	in	ADP
ijassa-493	231	22	experimental	experimental	ADJ
ijassa-493	231	23	oncogenesis	oncogenesis	NOUN
ijassa-493	231	24	]	]	PUNCT
ijassa-493	231	25	.	.	PUNCT
ijassa-493	232	1	phd	phd	NOUN
ijassa-493	232	2	thesis	thesis	NOUN
ijassa-493	232	3	(	(	PUNCT
ijassa-493	232	4	biology	biology	NOUN
ijassa-493	232	5	)	)	PUNCT
ijassa-493	232	6	,	,	PUNCT
ijassa-493	232	7	st	st	PROPN
ijassa-493	232	8	.	.	PROPN
ijassa-493	232	9	petersburg	petersburg	PROPN
ijassa-493	232	10	,	,	PUNCT
ijassa-493	233	1	[	[	X
ijassa-493	233	2	in	in	ADP
ijassa-493	233	3	russian	russian	NOUN
ijassa-493	233	4	]	]	PUNCT
ijassa-493	233	5	.	.	PUNCT
ijassa-493	234	1	[	[	X
ijassa-493	234	2	7	7	X
ijassa-493	234	3	]	]	X
ijassa-493	234	4	vidyaeva	vidyaeva	PROPN
ijassa-493	234	5	i.	i.	PROPN
ijassa-493	234	6	g.	g.	PROPN
ijassa-493	234	7	(	(	PUNCT
ijassa-493	234	8	2005	2005	NUM
ijassa-493	234	9	)	)	PUNCT
ijassa-493	234	10	virusnye	virusnye	NOUN
ijassa-493	234	11	vakciny	vakciny	VERB
ijassa-493	234	12	i	i	PRON
ijassa-493	234	13	ih	ih	VERB
ijassa-493	234	14	onkolizaty	onkolizaty	NOUN
ijassa-493	234	15	v	v	ADP
ijassa-493	234	16	terapii	terapii	NOUN
ijassa-493	234	17	jeksperimental'nyh	jeksperimental'nyh	NOUN
ijassa-493	234	18	opuholej	opuholej	NOUN
ijassa-493	234	19	[	[	PUNCT
ijassa-493	234	20	viral	viral	ADJ
ijassa-493	234	21	vaccines	vaccine	NOUN
ijassa-493	234	22	and	and	CCONJ
ijassa-493	234	23	their	their	PRON
ijassa-493	234	24	oncolytes	oncolyte	NOUN
ijassa-493	234	25	in	in	ADP
ijassa-493	234	26	the	the	DET
ijassa-493	234	27	therapy	therapy	NOUN
ijassa-493	234	28	of	of	ADP
ijassa-493	234	29	experimental	experimental	ADJ
ijassa-493	234	30	tumors	tumor	NOUN
ijassa-493	234	31	]	]	PUNCT
ijassa-493	234	32	.	.	PUNCT
ijassa-493	235	1	phd	phd	NOUN
ijassa-493	235	2	thesis	thesis	NOUN
ijassa-493	235	3	(	(	PUNCT
ijassa-493	235	4	medicine	medicine	NOUN
ijassa-493	235	5	)	)	PUNCT
ijassa-493	235	6	,	,	PUNCT
ijassa-493	235	7	tomsk	tomsk	PROPN
ijassa-493	235	8	,	,	PUNCT
ijassa-493	235	9	[	[	X
ijassa-493	235	10	in	in	ADP
ijassa-493	235	11	russian	russian	NOUN
ijassa-493	235	12	]	]	PUNCT
ijassa-493	235	13	.	.	PUNCT
ijassa-493	236	1	[	[	X
ijassa-493	236	2	8	8	NUM
ijassa-493	236	3	]	]	X
ijassa-493	236	4	babushkina	babushkina	PROPN
ijassa-493	236	5	,	,	PUNCT
ijassa-493	236	6	n.	n.	PROPN
ijassa-493	236	7	a.	a.	PROPN
ijassa-493	236	8	(	(	PUNCT
ijassa-493	236	9	2005	2005	NUM
ijassa-493	236	10	)	)	PUNCT
ijassa-493	236	11	ispol'zovanie	ispol'zovanie	PROPN
ijassa-493	236	12	matematicheskogo	matematicheskogo	PROPN
ijassa-493	236	13	modelirovanija	modelirovanija	ADJ
ijassa-493	236	14	dlja	dlja	ADJ
ijassa-493	236	15	optimizacii	optimizacii	PROPN
ijassa-493	236	16	rezhimov	rezhimov	NOUN
ijassa-493	236	17	himioterapii	himioterapii	NOUN
ijassa-493	236	18	na	na	PART
ijassa-493	236	19	jeksperimental'nyh	jeksperimental'nyh	PROPN
ijassa-493	236	20	opuholjah	opuholjah	PROPN
ijassa-493	236	21	[	[	X
ijassa-493	236	22	the	the	DET
ijassa-493	236	23	use	use	NOUN
ijassa-493	236	24	of	of	ADP
ijassa-493	236	25	mathematical	mathematical	ADJ
ijassa-493	236	26	modeling	modeling	NOUN
ijassa-493	236	27	for	for	ADP
ijassa-493	236	28	the	the	DET
ijassa-493	236	29	optimization	optimization	NOUN
ijassa-493	236	30	of	of	ADP
ijassa-493	236	31	chemotherapy	chemotherapy	NOUN
ijassa-493	236	32	schedules	schedule	NOUN
ijassa-493	236	33	on	on	ADP
ijassa-493	236	34	experimental	experimental	ADJ
ijassa-493	236	35	tumors	tumor	NOUN
ijassa-493	236	36	]	]	PUNCT
ijassa-493	236	37	.	.	PUNCT
ijassa-493	237	1	proceedings	proceeding	NOUN
ijassa-493	237	2	of	of	ADP
ijassa-493	237	3	the	the	DET
ijassa-493	237	4	iv	iv	NUM
ijassa-493	237	5	int	int	NOUN
ijassa-493	237	6	.	.	PUNCT
ijassa-493	238	1	conf	conf	NOUN
ijassa-493	238	2	.	.	PUNCT
ijassa-493	239	1	sicpro-05	sicpro-05	PROPN
ijassa-493	239	2	"	"	PUNCT
ijassa-493	239	3	identification	identification	NOUN
ijassa-493	239	4	of	of	ADP
ijassa-493	239	5	systems	system	NOUN
ijassa-493	239	6	and	and	CCONJ
ijassa-493	239	7	control	control	NOUN
ijassa-493	239	8	tasks	task	NOUN
ijassa-493	239	9	"	"	PUNCT
ijassa-493	239	10	,	,	PUNCT
ijassa-493	239	11	мoscow	мoscow	PRON
ijassa-493	239	12	,	,	PUNCT
ijassa-493	239	13	[	[	X
ijassa-493	239	14	in	in	ADP
ijassa-493	239	15	russian	russian	NOUN
ijassa-493	239	16	]	]	PUNCT
ijassa-493	239	17	.	.	PUNCT
ijassa-493	240	1	[	[	X
ijassa-493	240	2	9	9	NUM
ijassa-493	240	3	]	]	SYM
ijassa-493	240	4	babushkina	babushkina	NOUN
ijassa-493	240	5	,	,	PUNCT
ijassa-493	240	6	n.	n.	PROPN
ijassa-493	240	7	a.	a.	PROPN
ijassa-493	240	8	(	(	PUNCT
ijassa-493	240	9	2011	2011	NUM
ijassa-493	240	10	)	)	PUNCT
ijassa-493	240	11	upravlenie	upravlenie	PROPN
ijassa-493	240	12	processom	processom	NOUN
ijassa-493	240	13	himioterapii	himioterapii	NOUN
ijassa-493	240	14	s	s	PART
ijassa-493	240	15	ispol'zovaniem	ispol'zovaniem	NOUN
ijassa-493	240	16	ferromagnitnyh	ferromagnitnyh	ADJ
ijassa-493	240	17	nanochastic	nanochastic	NOUN
ijassa-493	241	1	[	[	X
ijassa-493	241	2	control	control	NOUN
ijassa-493	241	3	of	of	ADP
ijassa-493	241	4	chemotherapy	chemotherapy	NOUN
ijassa-493	241	5	process	process	NOUN
ijassa-493	241	6	with	with	ADP
ijassa-493	241	7	the	the	DET
ijassa-493	241	8	use	use	NOUN
ijassa-493	241	9	of	of	ADP
ijassa-493	241	10	ferromagnetic	ferromagnetic	ADJ
ijassa-493	241	11	particles	particle	NOUN
ijassa-493	241	12	]	]	PUNCT
ijassa-493	241	13	.	.	PUNCT
ijassa-493	242	1	problemy	problemy	PROPN
ijassa-493	242	2	upravlenija	upravlenija	ADJ
ijassa-493	242	3	[	[	X
ijassa-493	242	4	control	control	NOUN
ijassa-493	242	5	sciences	science	NOUN
ijassa-493	242	6	]	]	PUNCT
ijassa-493	242	7	,	,	PUNCT
ijassa-493	242	8	3	3	NUM
ijassa-493	242	9	,	,	PUNCT
ijassa-493	242	10	56	56	NUM
ijassa-493	242	11	-	-	SYM
ijassa-493	242	12	63	63	NUM
ijassa-493	242	13	,	,	PUNCT
ijassa-493	242	14	[	[	X
ijassa-493	242	15	in	in	ADP
ijassa-493	242	16	russian	russian	NOUN
ijassa-493	242	17	]	]	PUNCT
ijassa-493	242	18	.	.	PUNCT
ijassa-493	243	1	[	[	X
ijassa-493	243	2	10	10	NUM
ijassa-493	243	3	]	]	X
ijassa-493	243	4	babushkina	babushkina	PROPN
ijassa-493	243	5	,	,	PUNCT
ijassa-493	243	6	n.	n.	PROPN
ijassa-493	243	7	a.	a.	PROPN
ijassa-493	244	1	(	(	PUNCT
ijassa-493	244	2	2013	2013	NUM
ijassa-493	244	3	)	)	PUNCT
ijassa-493	244	4	ocenka	ocenka	PROPN
ijassa-493	244	5	upravljajushhih	upravljajushhih	PROPN
ijassa-493	244	6	dozovyh	dozovyh	PROPN
ijassa-493	244	7	vozdejstvij	vozdejstvij	PROPN
ijassa-493	244	8	protivoopuholevoj	protivoopuholevoj	PROPN
ijassa-493	244	9	vakcinoterapii	vakcinoterapii	NOUN
ijassa-493	244	10	s	s	PART
ijassa-493	244	11	pomoshh'ju	pomoshh'ju	NOUN
ijassa-493	244	12	matematicheskogo	matematicheskogo	X
ijassa-493	244	13	modelirovanija	modelirovanija	ADJ
ijassa-493	244	14	[	[	X
ijassa-493	244	15	evaluation	evaluation	NOUN
ijassa-493	244	16	of	of	ADP
ijassa-493	244	17	controlling	control	VERB
ijassa-493	244	18	dosage	dosage	NOUN
ijassa-493	244	19	of	of	ADP
ijassa-493	244	20	vaccine	vaccine	NOUN
ijassa-493	244	21	therapy	therapy	NOUN
ijassa-493	244	22	with	with	ADP
ijassa-493	244	23	the	the	DET
ijassa-493	244	24	use	use	NOUN
ijassa-493	244	25	of	of	ADP
ijassa-493	244	26	mathematical	mathematical	ADJ
ijassa-493	244	27	modeling	modeling	NOUN
ijassa-493	244	28	]	]	PUNCT
ijassa-493	244	29	.	.	PUNCT
ijassa-493	245	1	problemy	problemy	PROPN
ijassa-493	245	2	upravlenija	upravlenija	ADJ
ijassa-493	245	3	[	[	X
ijassa-493	245	4	control	control	NOUN
ijassa-493	245	5	sciences	science	NOUN
ijassa-493	245	6	]	]	PUNCT
ijassa-493	245	7	,	,	PUNCT
ijassa-493	245	8	5	5	NUM
ijassa-493	245	9	,	,	PUNCT
ijassa-493	245	10	60	60	NUM
ijassa-493	245	11	-	-	SYM
ijassa-493	245	12	65	65	NUM
ijassa-493	245	13	.	.	PUNCT
ijassa-493	246	1	[	[	X
ijassa-493	246	2	in	in	ADP
ijassa-493	246	3	russian	russian	PROPN
ijassa-493	246	4	]	]	PUNCT
ijassa-493	246	5	.	.	PUNCT
ijassa-493	247	1	[	[	X
ijassa-493	247	2	11	11	NUM
ijassa-493	247	3	]	]	X
ijassa-493	247	4	babushkina	babushkina	PROPN
ijassa-493	247	5	,	,	PUNCT
ijassa-493	247	6	n.	n.	PROPN
ijassa-493	247	7	a.	a.	PROPN
ijassa-493	247	8	&	&	CCONJ
ijassa-493	247	9	glumov	glumov	PROPN
ijassa-493	247	10	,	,	PUNCT
ijassa-493	247	11	v.	v.	ADP
ijassa-493	247	12	m.	m.	NOUN
ijassa-493	247	13	(	(	PUNCT
ijassa-493	247	14	2014	2014	NUM
ijassa-493	247	15	)	)	PUNCT
ijassa-493	247	16	matematicheskoe	matematicheskoe	PROPN
ijassa-493	247	17	modelirovanie	modelirovanie	PROPN
ijassa-493	247	18	mehanizmov	mehanizmov	PROPN
ijassa-493	247	19	protivoopuholevogo	protivoopuholevogo	PROPN
ijassa-493	247	20	dejstvija	dejstvija	NOUN
ijassa-493	247	21	virusnyh	virusnyh	PROPN
ijassa-493	247	22	vakcin	vakcin	PROPN
ijassa-493	248	1	[	[	X
ijassa-493	248	2	mathematical	mathematical	ADJ
ijassa-493	248	3	modeling	modeling	NOUN
ijassa-493	248	4	of	of	ADP
ijassa-493	248	5	mechanisms	mechanism	NOUN
ijassa-493	248	6	of	of	ADP
ijassa-493	248	7	the	the	DET
ijassa-493	248	8	antitumor	antitumor	PROPN
ijassa-493	248	9	action	action	NOUN
ijassa-493	248	10	of	of	ADP
ijassa-493	248	11	viral	viral	ADJ
ijassa-493	248	12	vaccines	vaccine	NOUN
ijassa-493	248	13	]	]	PUNCT
ijassa-493	248	14	.	.	PUNCT
ijassa-493	249	1	proceedings	proceeding	NOUN
ijassa-493	249	2	of	of	ADP
ijassa-493	249	3	the	the	DET
ijassa-493	249	4	ix	ix	PROPN
ijassa-493	249	5	int	int	PROPN
ijassa-493	249	6	.	.	PUNCT
ijassa-493	250	1	conf	conf	PROPN
ijassa-493	250	2	.	.	PUNCT
ijassa-493	251	1	“	"	PUNCT
ijassa-493	251	2	physics	physics	NOUN
ijassa-493	251	3	analytical	analytical	ADJ
ijassa-493	251	4	study	study	NOUN
ijassa-493	251	5	of	of	ADP
ijassa-493	251	6	antitumor	antitumor	PROPN
ijassa-493	251	7	viral	viral	ADJ
ijassa-493	251	8	vaccine	vaccine	NOUN
ijassa-493	251	9	73	73	NUM
ijassa-493	251	10	and	and	CCONJ
ijassa-493	251	11	radioelectronics	radioelectronic	NOUN
ijassa-493	251	12	in	in	ADP
ijassa-493	251	13	medicine	medicine	NOUN
ijassa-493	251	14	and	and	CCONJ
ijassa-493	251	15	ecology	ecology	NOUN
ijassa-493	251	16	”	"	PUNCT
ijassa-493	251	17	phreme-2014	phreme-2014	NOUN
ijassa-493	251	18	.	.	PUNCT
ijassa-493	252	1	vladimir	vladimir	PROPN
ijassa-493	252	2	,	,	PUNCT
ijassa-493	252	3	russia	russia	PROPN
ijassa-493	252	4	,	,	PUNCT
ijassa-493	252	5	1	1	NUM
ijassa-493	252	6	,	,	PUNCT
ijassa-493	252	7	153	153	NUM
ijassa-493	252	8	-	-	SYM
ijassa-493	252	9	158	158	NUM
ijassa-493	252	10	,	,	PUNCT
ijassa-493	252	11	[	[	X
ijassa-493	252	12	in	in	ADP
ijassa-493	252	13	russian	russian	NOUN
ijassa-493	252	14	]	]	PUNCT
ijassa-493	253	1	[	[	X
ijassa-493	253	2	12	12	NUM
ijassa-493	253	3	]	]	X
ijassa-493	253	4	babushkina	babushkina	PROPN
ijassa-493	253	5	,	,	PUNCT
ijassa-493	253	6	n.	n.	PROPN
ijassa-493	253	7	a.	a.	PROPN
ijassa-493	253	8	&	&	CCONJ
ijassa-493	253	9	kuzina	kuzina	PROPN
ijassa-493	253	10	,	,	PUNCT
ijassa-493	253	11	e.	e.	PROPN
ijassa-493	253	12	a.	a.	PROPN
ijassa-493	253	13	(	(	PUNCT
ijassa-493	253	14	2015	2015	NUM
ijassa-493	253	15	)	)	PUNCT
ijassa-493	253	16	komp'juternye	komp'juternye	PROPN
ijassa-493	253	17	tehnologii	tehnologii	NOUN
ijassa-493	253	18	na	na	PROPN
ijassa-493	253	19	osnove	osnove	NOUN
ijassa-493	253	20	matematicheskogo	matematicheskogo	NOUN
ijassa-493	253	21	modelirovanija	modelirovanija	PROPN
ijassa-493	253	22	v	v	PROPN
ijassa-493	253	23	sistemnoj	sistemnoj	VERB
ijassa-493	253	24	jeksperimental'noj	jeksperimental'noj	PROPN
ijassa-493	253	25	onkologii	onkologii	NOUN
ijassa-493	254	1	[	[	X
ijassa-493	254	2	computer	computer	NOUN
ijassa-493	254	3	technologies	technology	NOUN
ijassa-493	254	4	based	base	VERB
ijassa-493	254	5	on	on	ADP
ijassa-493	254	6	mathematical	mathematical	ADJ
ijassa-493	254	7	modeling	modeling	NOUN
ijassa-493	254	8	in	in	ADP
ijassa-493	254	9	the	the	DET
ijassa-493	254	10	system	system	NOUN
ijassa-493	254	11	of	of	ADP
ijassa-493	254	12	experimental	experimental	ADJ
ijassa-493	254	13	oncology	oncology	NOUN
ijassa-493	254	14	]	]	PUNCT
ijassa-493	254	15	.	.	PUNCT
ijassa-493	255	1	proceedings	proceeding	NOUN
ijassa-493	255	2	of	of	ADP
ijassa-493	255	3	the	the	DET
ijassa-493	255	4	viii	viii	ADJ
ijassa-493	255	5	int	int	NOUN
ijassa-493	255	6	.	.	PUNCT
ijassa-493	256	1	conf	conf	NOUN
ijassa-493	256	2	.	.	PUNCT
ijassa-493	257	1	“	"	PUNCT
ijassa-493	257	2	management	management	NOUN
ijassa-493	257	3	of	of	ADP
ijassa-493	257	4	large	large	ADJ
ijassa-493	257	5	-	-	PUNCT
ijassa-493	257	6	scale	scale	NOUN
ijassa-493	257	7	system	system	NOUN
ijassa-493	257	8	development	development	NOUN
ijassa-493	257	9	”	"	PUNCT
ijassa-493	257	10	(	(	PUNCT
ijassa-493	257	11	mlsd2015	mlsd2015	PROPN
ijassa-493	257	12	)	)	PUNCT
ijassa-493	257	13	.	.	PUNCT
ijassa-493	258	1	moscow	moscow	PROPN
ijassa-493	258	2	,	,	PUNCT
ijassa-493	258	3	272	272	NUM
ijassa-493	258	4	-	-	SYM
ijassa-493	258	5	284	284	NUM
ijassa-493	258	6	.	.	PUNCT
ijassa-493	259	1	[	[	X
ijassa-493	259	2	in	in	ADP
ijassa-493	259	3	russian	russian	PROPN
ijassa-493	259	4	]	]	PUNCT
ijassa-493	260	1	[	[	X
ijassa-493	260	2	13	13	NUM
ijassa-493	260	3	]	]	SYM
ijassa-493	260	4	babushkina	babushkina	PROPN
ijassa-493	260	5	,	,	PUNCT
ijassa-493	260	6	n.	n.	PROPN
ijassa-493	260	7	a.	a.	PROPN
ijassa-493	260	8	,	,	PUNCT
ijassa-493	260	9	glumov	glumov	NOUN
ijassa-493	260	10	,	,	PUNCT
ijassa-493	260	11	v.	v.	ADP
ijassa-493	260	12	m.	m.	PROPN
ijassa-493	260	13	&	&	CCONJ
ijassa-493	260	14	kuzina	kuzina	PROPN
ijassa-493	260	15	,	,	PUNCT
ijassa-493	260	16	e.a	e.a	PROPN
ijassa-493	260	17	.	.	PROPN
ijassa-493	260	18	(	(	PUNCT
ijassa-493	260	19	2016	2016	NUM
ijassa-493	260	20	)	)	PUNCT
ijassa-493	260	21	primenenie	primenenie	NOUN
ijassa-493	260	22	komp'juternyh	komp'juternyh	PROPN
ijassa-493	260	23	tehnologij	tehnologij	NOUN
ijassa-493	260	24	pri	pri	PROPN
ijassa-493	260	25	jeksperimental'nom	jeksperimental'nom	PROPN
ijassa-493	260	26	izuchenii	izuchenii	VERB
ijassa-493	260	27	jeffektivnosti	jeffektivnosti	PROPN
ijassa-493	260	28	protivoopuholevyh	protivoopuholevyh	PROPN
ijassa-493	260	29	virusnyh	virusnyh	PROPN
ijassa-493	260	30	vakcin	vakcin	PROPN
ijassa-493	260	31	[	[	X
ijassa-493	260	32	the	the	DET
ijassa-493	260	33	use	use	NOUN
ijassa-493	260	34	of	of	ADP
ijassa-493	260	35	computer	computer	NOUN
ijassa-493	260	36	technology	technology	NOUN
ijassa-493	260	37	in	in	ADP
ijassa-493	260	38	the	the	DET
ijassa-493	260	39	experimental	experimental	ADJ
ijassa-493	260	40	study	study	NOUN
ijassa-493	260	41	of	of	ADP
ijassa-493	260	42	the	the	DET
ijassa-493	260	43	efficacy	efficacy	NOUN
ijassa-493	260	44	of	of	ADP
ijassa-493	260	45	antitumoral	antitumoral	ADJ
ijassa-493	260	46	viral	viral	ADJ
ijassa-493	260	47	vaccines	vaccine	NOUN
ijassa-493	260	48	]	]	PUNCT
ijassa-493	260	49	.	.	PUNCT
ijassa-493	261	1	proceedings	proceeding	NOUN
ijassa-493	261	2	of	of	ADP
ijassa-493	261	3	the	the	DET
ijassa-493	261	4	xii	xii	PROPN
ijassa-493	261	5	int	int	NOUN
ijassa-493	261	6	.	.	PUNCT
ijassa-493	262	1	conf	conf	NOUN
ijassa-493	262	2	.	.	PUNCT
ijassa-493	263	1	“	"	PUNCT
ijassa-493	263	2	physics	physics	NOUN
ijassa-493	263	3	and	and	CCONJ
ijassa-493	263	4	radioelectronics	radioelectronic	NOUN
ijassa-493	263	5	in	in	ADP
ijassa-493	263	6	medicine	medicine	NOUN
ijassa-493	263	7	and	and	CCONJ
ijassa-493	263	8	ecology	ecology	NOUN
ijassa-493	263	9	”	"	PUNCT
ijassa-493	263	10	phreme-2016	phreme-2016	NOUN
ijassa-493	263	11	.	.	PUNCT
ijassa-493	263	12	vladimir	vladimir	PROPN
ijassa-493	263	13	,	,	PUNCT
ijassa-493	263	14	russia	russia	PROPN
ijassa-493	263	15	,	,	PUNCT
ijassa-493	263	16	1	1	NUM
ijassa-493	263	17	,	,	PUNCT
ijassa-493	263	18	116	116	NUM
ijassa-493	263	19	-	-	SYM
ijassa-493	263	20	121	121	NUM
ijassa-493	263	21	.	.	PUNCT
ijassa-493	264	1	[	[	X
ijassa-493	264	2	in	in	ADP
ijassa-493	264	3	russian	russian	NOUN
ijassa-493	264	4	]	]	PUNCT
ijassa-493	265	1	[	[	X
ijassa-493	265	2	14	14	NUM
ijassa-493	265	3	]	]	X
ijassa-493	265	4	babushkina	babushkina	PROPN
ijassa-493	265	5	,	,	PUNCT
ijassa-493	265	6	n.	n.	PROPN
ijassa-493	265	7	a.	a.	PROPN
ijassa-493	265	8	,	,	PUNCT
ijassa-493	265	9	glumov	glumov	NOUN
ijassa-493	265	10	,	,	PUNCT
ijassa-493	265	11	v.	v.	ADP
ijassa-493	265	12	m.	m.	PROPN
ijassa-493	265	13	&	&	CCONJ
ijassa-493	265	14	kuzina	kuzina	PROPN
ijassa-493	265	15	,	,	PUNCT
ijassa-493	265	16	e.	e.	PROPN
ijassa-493	265	17	a.	a.	PROPN
ijassa-493	265	18	(	(	PUNCT
ijassa-493	265	19	2017	2017	NUM
ijassa-493	265	20	)	)	PUNCT
ijassa-493	265	21	primenenie	primenenie	NOUN
ijassa-493	265	22	matematicheskogo	matematicheskogo	VERB
ijassa-493	265	23	modelirovanija	modelirovanija	ADJ
ijassa-493	265	24	dlja	dlja	PROPN
ijassa-493	265	25	ocenki	ocenki	PROPN
ijassa-493	265	26	jeffektivnosti	jeffektivnosti	PROPN
ijassa-493	265	27	metoda	metoda	PROPN
ijassa-493	265	28	protivoopuholevoj	protivoopuholevoj	PROPN
ijassa-493	265	29	terapii	terapii	PROPN
ijassa-493	266	1	[	[	X
ijassa-493	266	2	application	application	NOUN
ijassa-493	266	3	of	of	ADP
ijassa-493	266	4	mathematical	mathematical	ADJ
ijassa-493	266	5	modeling	modeling	NOUN
ijassa-493	266	6	for	for	ADP
ijassa-493	266	7	the	the	DET
ijassa-493	266	8	evaluation	evaluation	NOUN
ijassa-493	266	9	of	of	ADP
ijassa-493	266	10	the	the	DET
ijassa-493	266	11	effectiveness	effectiveness	NOUN
ijassa-493	266	12	of	of	ADP
ijassa-493	266	13	the	the	DET
ijassa-493	266	14	antitumor	antitumor	PROPN
ijassa-493	266	15	therapy	therapy	NOUN
ijassa-493	266	16	method	method	NOUN
ijassa-493	266	17	]	]	PUNCT
ijassa-493	266	18	.	.	PUNCT
ijassa-493	267	1	problemy	problemy	PROPN
ijassa-493	267	2	upravlenija	upravlenija	ADJ
ijassa-493	267	3	[	[	X
ijassa-493	267	4	control	control	NOUN
ijassa-493	267	5	sciences	science	NOUN
ijassa-493	267	6	]	]	PUNCT
ijassa-493	267	7	,	,	PUNCT
ijassa-493	267	8	3	3	NUM
ijassa-493	267	9	,	,	PUNCT
ijassa-493	267	10	49	49	NUM
ijassa-493	267	11	-	-	SYM
ijassa-493	267	12	56	56	NUM
ijassa-493	267	13	.	.	PUNCT
ijassa-493	268	1	[	[	X
ijassa-493	268	2	in	in	ADP
ijassa-493	268	3	russian	russian	PROPN
ijassa-493	268	4	]	]	PUNCT
ijassa-493	269	1	[	[	X
ijassa-493	269	2	15	15	NUM
ijassa-493	269	3	]	]	X
ijassa-493	269	4	loktev	loktev	NOUN
ijassa-493	269	5	,	,	PUNCT
ijassa-493	269	6	v.b	v.b	PROPN
ijassa-493	269	7	.	.	PROPN
ijassa-493	269	8	,	,	PUNCT
ijassa-493	269	9	ivankina	ivankina	PROPN
ijassa-493	270	1	t.yu	t.yu	PROPN
ijassa-493	270	2	.	.	PROPN
ijassa-493	270	3	,	,	PUNCT
ijassa-493	270	4	netesov	netesov	PROPN
ijassa-493	270	5	s.v	s.v	PROPN
ijassa-493	270	6	.	.	PROPN
ijassa-493	270	7	&	&	CCONJ
ijassa-493	270	8	chumakov	chumakov	PROPN
ijassa-493	270	9	p.m.	p.m.	PROPN
ijassa-493	270	10	(	(	PUNCT
ijassa-493	270	11	2012	2012	NUM
ijassa-493	270	12	)	)	PUNCT
ijassa-493	270	13	onkoliticheskie	onkoliticheskie	NOUN
ijassa-493	270	14	parvovirusy	parvovirusy	NOUN
ijassa-493	270	15	.	.	PUNCT
ijassa-493	271	1	novye	novye	PROPN
ijassa-493	271	2	podhody	podhody	NOUN
ijassa-493	271	3	k	k	PROPN
ijassa-493	271	4	lecheniju	lecheniju	PROPN
ijassa-493	271	5	rakovyh	rakovyh	PROPN
ijassa-493	271	6	zabolevanij	zabolevanij	NOUN
ijassa-493	272	1	[	[	X
ijassa-493	272	2	oncolytic	oncolytic	ADJ
ijassa-493	272	3	parvoviruses	parvovirus	NOUN
ijassa-493	272	4	.	.	PUNCT
ijassa-493	273	1	new	new	ADJ
ijassa-493	273	2	approaches	approach	NOUN
ijassa-493	273	3	to	to	ADP
ijassa-493	273	4	the	the	DET
ijassa-493	273	5	treatment	treatment	NOUN
ijassa-493	273	6	of	of	ADP
ijassa-493	273	7	cancer	cancer	NOUN
ijassa-493	273	8	diseases	disease	NOUN
ijassa-493	273	9	]	]	PUNCT
ijassa-493	273	10	.	.	PUNCT
ijassa-493	274	1	vestnik	vestnik	PROPN
ijassa-493	274	2	rossijskoj	rossijskoj	PROPN
ijassa-493	274	3	akademii	akademii	PROPN
ijassa-493	274	4	medicinskih	medicinskih	NOUN
ijassa-493	274	5	nauk	nauk	NOUN
ijassa-493	275	1	[	[	X
ijassa-493	275	2	bulletin	bulletin	NOUN
ijassa-493	275	3	of	of	ADP
ijassa-493	275	4	the	the	DET
ijassa-493	275	5	russian	russian	ADJ
ijassa-493	275	6	academy	academy	PROPN
ijassa-493	275	7	of	of	ADP
ijassa-493	275	8	medical	medical	ADJ
ijassa-493	275	9	sciences	science	NOUN
ijassa-493	275	10	]	]	PUNCT
ijassa-493	275	11	,	,	PUNCT
ijassa-493	275	12	2	2	NUM
ijassa-493	275	13	,	,	PUNCT
ijassa-493	275	14	42–47	42–47	NUM
ijassa-493	275	15	.	.	PUNCT
ijassa-493	276	1	[	[	X
ijassa-493	276	2	in	in	ADP
ijassa-493	276	3	russian	russian	PROPN
ijassa-493	276	4	]	]	PUNCT
ijassa-493	276	5	.	.	PUNCT
ijassa-493	277	1	[	[	X
ijassa-493	277	2	16	16	NUM
ijassa-493	277	3	]	]	X
ijassa-493	277	4	lezhnin	lezhnin	PROPN
ijassa-493	277	5	yu.n	yu.n	X
ijassa-493	277	6	.	.	PROPN
ijassa-493	277	7	,	,	PUNCT
ijassa-493	277	8	kravchenko	kravchenko	PROPN
ijassa-493	277	9	yu.e	yu.e	NOUN
ijassa-493	277	10	.	.	PROPN
ijassa-493	277	11	,	,	PUNCT
ijassa-493	277	12	frolova	frolova	PROPN
ijassa-493	277	13	e.i	e.i	PROPN
ijassa-493	277	14	.	.	PROPN
ijassa-493	277	15	,	,	PUNCT
ijassa-493	277	16	chumakov	chumakov	PROPN
ijassa-493	277	17	p.m.	p.m.	PROPN
ijassa-493	277	18	,	,	PUNCT
ijassa-493	277	19	chumakov	chumakov	PROPN
ijassa-493	277	20	s.p	s.p	PROPN
ijassa-493	277	21	.	.	PROPN
ijassa-493	278	1	(	(	PUNCT
ijassa-493	278	2	2015	2015	NUM
ijassa-493	278	3	)	)	PUNCT
ijassa-493	278	4	onkotoksicheskie	onkotoksicheskie	NOUN
ijassa-493	278	5	belki	belki	VERB
ijassa-493	278	6	v	v	PRON
ijassa-493	278	7	protivorakovoj	protivorakovoj	PROPN
ijassa-493	278	8	terapii	terapii	NOUN
ijassa-493	278	9	:	:	PUNCT
ijassa-493	278	10	mehanizmy	mehanizmy	PROPN
ijassa-493	278	11	dejstvija	dejstvija	NOUN
ijassa-493	279	1	[	[	X
ijassa-493	279	2	oncotoxic	oncotoxic	ADJ
ijassa-493	279	3	proteins	protein	NOUN
ijassa-493	279	4	in	in	ADP
ijassa-493	279	5	anticancer	anticancer	NOUN
ijassa-493	279	6	therapy	therapy	NOUN
ijassa-493	279	7	:	:	PUNCT
ijassa-493	279	8	mechanisms	mechanism	NOUN
ijassa-493	279	9	of	of	ADP
ijassa-493	279	10	action	action	NOUN
ijassa-493	279	11	]	]	PUNCT
ijassa-493	279	12	.	.	PUNCT
ijassa-493	280	1	molekuljarnaja	molekuljarnaja	PROPN
ijassa-493	280	2	biologija	biologija	NOUN
ijassa-493	280	3	[	[	X
ijassa-493	280	4	molecular	molecular	ADJ
ijassa-493	280	5	biology	biology	NOUN
ijassa-493	280	6	]	]	X
ijassa-493	280	7	,	,	PUNCT
ijassa-493	280	8	49(2	49(2	NUM
ijassa-493	280	9	)	)	PUNCT
ijassa-493	280	10	,	,	PUNCT
ijassa-493	280	11	264	264	NUM
ijassa-493	280	12	-	-	SYM
ijassa-493	280	13	278	278	NUM
ijassa-493	280	14	.	.	PUNCT
ijassa-493	281	1	[	[	X
ijassa-493	281	2	in	in	ADP
ijassa-493	281	3	russian	russian	PROPN
ijassa-493	281	4	]	]	PUNCT
ijassa-493	281	5	.	.	PUNCT
ijassa-493	282	1	[	[	X
ijassa-493	282	2	17	17	NUM
ijassa-493	282	3	]	]	X
ijassa-493	282	4	hristov	hristov	PROPN
ijassa-493	282	5	g.	g.	PROPN
ijassa-493	282	6	,	,	PUNCT
ijassa-493	282	7	krämer	krämer	NOUN
ijassa-493	282	8	,	,	PUNCT
ijassa-493	282	9	m.	m.	NOUN
ijassa-493	282	10	,	,	PUNCT
ijassa-493	282	11	li	li	PROPN
ijassa-493	282	12	,	,	PUNCT
ijassa-493	282	13	j.	j.	PROPN
ijassa-493	282	14	,	,	PUNCT
ijassa-493	282	15	el	el	PROPN
ijassa-493	282	16	-	-	PROPN
ijassa-493	282	17	andaloussi	andaloussi	PROPN
ijassa-493	282	18	,	,	PUNCT
ijassa-493	282	19	n.	n.	PROPN
ijassa-493	282	20	,	,	PUNCT
ijassa-493	282	21	mora	mora	PROPN
ijassa-493	282	22	,	,	PUNCT
ijassa-493	282	23	r.	r.	PROPN
ijassa-493	282	24	,	,	PUNCT
ijassa-493	282	25	daeffler	daeffler	PROPN
ijassa-493	282	26	,	,	PUNCT
ijassa-493	282	27	l.	l.	PROPN
ijassa-493	282	28	,	,	PUNCT
ijassa-493	282	29	zentgraf	zentgraf	PROPN
ijassa-493	282	30	h.	h.	PROPN
ijassa-493	282	31	,	,	PUNCT
ijassa-493	282	32	rommelaere	rommelaere	ADV
ijassa-493	282	33	j.	j.	PROPN
ijassa-493	282	34	,	,	PUNCT
ijassa-493	282	35	marchini	marchini	PROPN
ijassa-493	282	36	,	,	PUNCT
ijassa-493	282	37	a.	a.	NOUN
ijassa-493	282	38	(	(	PUNCT
ijassa-493	282	39	2010	2010	NUM
ijassa-493	282	40	)	)	PUNCT
ijassa-493	282	41	through	through	ADP
ijassa-493	282	42	its	its	PRON
ijassa-493	282	43	nonstructural	nonstructural	ADJ
ijassa-493	282	44	protein	protein	NOUN
ijassa-493	282	45	ns1	ns1	NOUN
ijassa-493	282	46	,	,	PUNCT
ijassa-493	282	47	parvovirus	parvovirus	NOUN
ijassa-493	282	48	h-1	h-1	NOUN
ijassa-493	282	49	induces	induce	VERB
ijassa-493	282	50	apoptosis	apoptosis	NOUN
ijassa-493	282	51	via	via	ADP
ijassa-493	282	52	accumulation	accumulation	NOUN
ijassa-493	282	53	of	of	ADP
ijassa-493	282	54	reactive	reactive	ADJ
ijassa-493	282	55	oxygen	oxygen	NOUN
ijassa-493	282	56	species	specie	NOUN
ijassa-493	282	57	.	.	PUNCT
ijassa-493	283	1	journal	journal	PROPN
ijassa-493	283	2	of	of	ADP
ijassa-493	283	3	virology	virology	NOUN
ijassa-493	283	4	,	,	PUNCT
ijassa-493	283	5	84(12	84(12	NUM
ijassa-493	283	6	)	)	PUNCT
ijassa-493	283	7	,	,	PUNCT
ijassa-493	283	8	5909	5909	NUM
ijassa-493	283	9	-	-	SYM
ijassa-493	283	10	5922	5922	NUM
ijassa-493	283	11	.	.	PUNCT
ijassa-493	284	1	[	[	X
ijassa-493	284	2	18	18	NUM
ijassa-493	284	3	]	]	PUNCT
ijassa-493	284	4	rommelaere	rommelaere	NOUN
ijassa-493	284	5	j.	j.	PROPN
ijassa-493	284	6	,	,	PUNCT
ijassa-493	284	7	geletneky	geletneky	PROPN
ijassa-493	284	8	k.	k.	PROPN
ijassa-493	284	9	,	,	PUNCT
ijassa-493	284	10	angelova	angelova	PROPN
ijassa-493	284	11	a.l	a.l	PROPN
ijassa-493	284	12	.	.	PROPN
ijassa-493	284	13	,	,	PUNCT
ijassa-493	284	14	daeffler	daeffler	PROPN
ijassa-493	284	15	l.	l.	PROPN
ijassa-493	284	16	,	,	PUNCT
ijassa-493	284	17	dinsart	dinsart	PROPN
ijassa-493	284	18	c.	c.	PROPN
ijassa-493	284	19	,	,	PUNCT
ijassa-493	284	20	kiprianova	kiprianova	PROPN
ijassa-493	284	21	i.	i.	PROPN
ijassa-493	284	22	,	,	PUNCT
ijassa-493	284	23	schlehofer	schlehofer	VERB
ijassa-493	284	24	j.r	j.r	PROPN
ijassa-493	284	25	.	.	PROPN
ijassa-493	284	26	,	,	PUNCT
ijassa-493	284	27	raykov	raykov	PROPN
ijassa-493	284	28	z.	z.	PROPN
ijassa-493	284	29	(	(	PUNCT
ijassa-493	284	30	2010	2010	NUM
ijassa-493	284	31	)	)	PUNCT
ijassa-493	284	32	oncolytic	oncolytic	ADJ
ijassa-493	284	33	parvoviruses	parvovirus	NOUN
ijassa-493	284	34	as	as	ADP
ijassa-493	284	35	cancer	cancer	NOUN
ijassa-493	284	36	therapeutics	therapeutic	NOUN
ijassa-493	284	37	.	.	PUNCT
ijassa-493	285	1	cytokine	cytokine	VERB
ijassa-493	285	2	&	&	CCONJ
ijassa-493	285	3	growth	growth	NOUN
ijassa-493	285	4	factor	factor	NOUN
ijassa-493	285	5	reviews	review	NOUN
ijassa-493	285	6	,	,	PUNCT
ijassa-493	285	7	21(2	21(2	NUM
ijassa-493	285	8	)	)	PUNCT
ijassa-493	285	9	,	,	PUNCT
ijassa-493	285	10	185	185	NUM
ijassa-493	285	11	-	-	SYM
ijassa-493	285	12	195	195	NUM
ijassa-493	285	13	.	.	PUNCT
ijassa-493	286	1	[	[	X
ijassa-493	286	2	19	19	NUM
ijassa-493	286	3	]	]	PUNCT
ijassa-493	286	4	cotmore	cotmore	PROPN
ijassa-493	286	5	s.	s.	PROPN
ijassa-493	286	6	f.	f.	PROPN
ijassa-493	286	7	&	&	CCONJ
ijassa-493	286	8	tattersall	tattersall	PROPN
ijassa-493	286	9	p.	p.	PROPN
ijassa-493	286	10	(	(	PUNCT
ijassa-493	286	11	2007	2007	NUM
ijassa-493	286	12	)	)	PUNCT
ijassa-493	286	13	parvoviral	parvoviral	ADJ
ijassa-493	286	14	host	host	NOUN
ijassa-493	286	15	range	range	NOUN
ijassa-493	286	16	and	and	CCONJ
ijassa-493	286	17	cell	cell	NOUN
ijassa-493	286	18	entry	entry	NOUN
ijassa-493	286	19	mechanisms	mechanism	NOUN
ijassa-493	286	20	.	.	PUNCT
ijassa-493	287	1	advances	advance	NOUN
ijassa-493	287	2	in	in	ADP
ijassa-493	287	3	virus	virus	NOUN
ijassa-493	287	4	research	research	NOUN
ijassa-493	287	5	,	,	PUNCT
ijassa-493	287	6	70	70	NUM
ijassa-493	287	7	,	,	PUNCT
ijassa-493	287	8	183	183	NUM
ijassa-493	287	9	-	-	SYM
ijassa-493	287	10	232	232	NUM
ijassa-493	287	11	.	.	PUNCT
ijassa-493	288	1	[	[	X
ijassa-493	288	2	20	20	NUM
ijassa-493	288	3	]	]	X
ijassa-493	288	4	moehler	moehler	PROPN
ijassa-493	288	5	m.	m.	PROPN
ijassa-493	288	6	h.	h.	PROPN
ijassa-493	288	7	,	,	PUNCT
ijassa-493	288	8	zeidler	zeidler	NOUN
ijassa-493	288	9	m.	m.	NOUN
ijassa-493	288	10	,	,	PUNCT
ijassa-493	288	11	wilsberg	wilsberg	PROPN
ijassa-493	288	12	v.	v.	PROPN
ijassa-493	288	13	,	,	PUNCT
ijassa-493	288	14	cornelis	cornelis	PROPN
ijassa-493	288	15	j.	j.	PROPN
ijassa-493	288	16	j.	j.	PROPN
ijassa-493	288	17	,	,	PUNCT
ijassa-493	288	18	woelfel	woelfel	PROPN
ijassa-493	288	19	t.	t.	PROPN
ijassa-493	288	20	,	,	PUNCT
ijassa-493	288	21	rommelaere	rommelaere	ADJ
ijassa-493	288	22	j.	j.	PROPN
ijassa-493	288	23	,	,	PUNCT
ijassa-493	288	24	gallep	gallep	PROPN
ijassa-493	288	25	.	.	PUNCT
ijassa-493	289	1	r.	r.	PROPN
ijassa-493	289	2	,	,	PUNCT
ijassa-493	289	3	heike	heike	PROPN
ijassa-493	289	4	m.	m.	PROPN
ijassa-493	289	5	(	(	PUNCT
ijassa-493	289	6	2005	2005	NUM
ijassa-493	289	7	)	)	PUNCT
ijassa-493	289	8	parvovirus	parvovirus	NOUN
ijassa-493	289	9	h-1	h-1	NOUN
ijassa-493	289	10	-	-	PUNCT
ijassa-493	289	11	induced	induce	VERB
ijassa-493	289	12	tumor	tumor	NOUN
ijassa-493	289	13	cell	cell	NOUN
ijassa-493	289	14	death	death	NOUN
ijassa-493	289	15	enhances	enhance	VERB
ijassa-493	289	16	human	human	ADJ
ijassa-493	289	17	immune	immune	ADJ
ijassa-493	289	18	response	response	NOUN
ijassa-493	289	19	in	in	ADP
ijassa-493	289	20	vitro	vitro	X
ijassa-493	289	21	via	via	ADP
ijassa-493	289	22	increased	increase	VERB
ijassa-493	289	23	phagocytosis	phagocytosis	NOUN
ijassa-493	289	24	,	,	PUNCT
ijassa-493	289	25	maturation	maturation	NOUN
ijassa-493	289	26	,	,	PUNCT
ijassa-493	289	27	and	and	CCONJ
ijassa-493	289	28	cross	cross	NOUN
ijassa-493	289	29	-	-	NOUN
ijassa-493	289	30	presentation	presentation	NOUN
ijassa-493	289	31	by	by	ADP
ijassa-493	289	32	dendritic	dendritic	ADJ
ijassa-493	289	33	cells	cell	NOUN
ijassa-493	289	34	.	.	PUNCT
ijassa-493	290	1	human	human	ADJ
ijassa-493	290	2	gene	gene	NOUN
ijassa-493	290	3	therapy	therapy	NOUN
ijassa-493	290	4	,	,	PUNCT
ijassa-493	290	5	16(8	16(8	NUM
ijassa-493	290	6	)	)	PUNCT
ijassa-493	290	7	,	,	PUNCT
ijassa-493	290	8	996	996	NUM
ijassa-493	290	9	-	-	SYM
ijassa-493	290	10	1005	1005	NUM
ijassa-493	290	11	.	.	PUNCT
ijassa-493	291	1	[	[	X
ijassa-493	291	2	21	21	NUM
ijassa-493	291	3	]	]	PUNCT
ijassa-493	291	4	grekova	grekova	PROPN
ijassa-493	291	5	s.	s.	PROPN
ijassa-493	291	6	p.	p.	PROPN
ijassa-493	291	7	,	,	PUNCT
ijassa-493	291	8	aprahamian	aprahamian	ADJ
ijassa-493	291	9	m.	m.	NOUN
ijassa-493	291	10	,	,	PUNCT
ijassa-493	291	11	daeffler	daeffler	PROPN
ijassa-493	291	12	l.	l.	PROPN
ijassa-493	291	13	,	,	PUNCT
ijassa-493	291	14	leuchs	leuch	NOUN
ijassa-493	291	15	b.	b.	PROPN
ijassa-493	291	16	,	,	PUNCT
ijassa-493	291	17	angelova	angelova	PROPN
ijassa-493	291	18	a.	a.	PROPN
ijassa-493	291	19	,	,	PUNCT
ijassa-493	291	20	giese	giese	ADJ
ijassa-493	291	21	t.	t.	NOUN
ijassa-493	291	22	,	,	PUNCT
ijassa-493	291	23	galabov	galabov	PROPN
ijassa-493	291	24	a.	a.	PROPN
ijassa-493	291	25	,	,	PUNCT
ijassa-493	291	26	helle	helle	PROPN
ijassa-493	291	27	ra	ra	PROPN
ijassa-493	291	28	.	.	PROPN
ijassa-493	291	29	,	,	PUNCT
ijassa-493	291	30	giese	giese	ADJ
ijassa-493	291	31	n.	n.	NOUN
ijassa-493	291	32	a.	a.	PROPN
ijassa-493	291	33	,	,	PUNCT
ijassa-493	291	34	rommelaere	rommelaere	ADV
ijassa-493	291	35	j.	j.	PROPN
ijassa-493	291	36	,	,	PUNCT
ijassa-493	291	37	raykov	raykov	PROPN
ijassa-493	291	38	z.	z.	PROPN
ijassa-493	291	39	(	(	PUNCT
ijassa-493	291	40	2011	2011	NUM
ijassa-493	291	41	)	)	PUNCT
ijassa-493	291	42	interferon	interferon	PROPN
ijassa-493	291	43	γ	γ	PROPN
ijassa-493	291	44	improves	improve	VERB
ijassa-493	291	45	the	the	DET
ijassa-493	291	46	vaccination	vaccination	NOUN
ijassa-493	291	47	potential	potential	NOUN
ijassa-493	291	48	of	of	ADP
ijassa-493	291	49	oncolytic	oncolytic	ADJ
ijassa-493	291	50	parvovirus	parvovirus	NOUN
ijassa-493	291	51	h-1pv	h-1pv	NOUN
ijassa-493	291	52	for	for	ADP
ijassa-493	291	53	the	the	DET
ijassa-493	291	54	treatment	treatment	NOUN
ijassa-493	291	55	of	of	ADP
ijassa-493	291	56	peritoneal	peritoneal	ADJ
ijassa-493	291	57	carcinomatosis	carcinomatosis	NOUN
ijassa-493	291	58	in	in	ADP
ijassa-493	291	59	pancreatic	pancreatic	ADJ
ijassa-493	291	60	cancer	cancer	NOUN
ijassa-493	291	61	.	.	PUNCT
ijassa-493	292	1	cancer	cancer	NOUN
ijassa-493	292	2	biology	biology	NOUN
ijassa-493	292	3	&	&	CCONJ
ijassa-493	292	4	therapy	therapy	NOUN
ijassa-493	292	5	,	,	PUNCT
ijassa-493	292	6	12(10	12(10	NUM
ijassa-493	292	7	)	)	PUNCT
ijassa-493	292	8	,	,	PUNCT
ijassa-493	292	9	888–895	888–895	NUM
ijassa-493	292	10	.	.	PUNCT
ijassa-493	293	1	[	[	X
ijassa-493	293	2	22	22	NUM
ijassa-493	293	3	]	]	PUNCT
ijassa-493	293	4	raykov	raykov	PROPN
ijassa-493	293	5	z.	z.	PROPN
ijassa-493	293	6	,	,	PUNCT
ijassa-493	293	7	grekova	grekova	PROPN
ijassa-493	293	8	s.	s.	PROPN
ijassa-493	293	9	,	,	PUNCT
ijassa-493	293	10	galabov	galabov	PROPN
ijassa-493	293	11	a.s	a.s	PROPN
ijassa-493	293	12	.	.	PROPN
ijassa-493	293	13	,	,	PUNCT
ijassa-493	293	14	balboni	balboni	PROPN
ijassa-493	293	15	g.	g.	PROPN
ijassa-493	293	16	,	,	PUNCT
ijassa-493	293	17	koch	koch	PROPN
ijassa-493	293	18	u.	u.	PROPN
ijassa-493	293	19	,	,	PUNCT
ijassa-493	293	20	aprahamian	aprahamian	ADJ
ijassa-493	293	21	m.	m.	NOUN
ijassa-493	293	22	,	,	PUNCT
ijassa-493	293	23	rommelaere	rommelaere	ADV
ijassa-493	293	24	j.	j.	PROPN
ijassa-493	293	25	(	(	PUNCT
ijassa-493	293	26	2007	2007	NUM
ijassa-493	293	27	)	)	PUNCT
ijassa-493	293	28	combined	combined	ADJ
ijassa-493	293	29	oncolytic	oncolytic	NOUN
ijassa-493	293	30	and	and	CCONJ
ijassa-493	293	31	vaccination	vaccination	NOUN
ijassa-493	293	32	activities	activity	NOUN
ijassa-493	293	33	of	of	ADP
ijassa-493	293	34	parvovirus	parvovirus	NOUN
ijassa-493	293	35	h-1	h-1	NOUN
ijassa-493	293	36	in	in	ADP
ijassa-493	293	37	a	a	DET
ijassa-493	293	38	metastatic	metastatic	ADJ
ijassa-493	293	39	tumor	tumor	NOUN
ijassa-493	293	40	model	model	NOUN
ijassa-493	293	41	.	.	PUNCT
ijassa-493	294	1	oncology	oncology	NOUN
ijassa-493	294	2	reports	report	NOUN
ijassa-493	294	3	,	,	PUNCT
ijassa-493	294	4	17(6	17(6	NUM
ijassa-493	294	5	)	)	PUNCT
ijassa-493	294	6	,	,	PUNCT
ijassa-493	294	7	1493	1493	NUM
ijassa-493	294	8	-	-	SYM
ijassa-493	294	9	1500	1500	NUM
ijassa-493	294	10	.	.	PUNCT
ijassa-493	295	1	[	[	X
ijassa-493	295	2	23	23	NUM
ijassa-493	295	3	]	]	PUNCT
ijassa-493	295	4	angelova	angelova	PROPN
ijassa-493	295	5	a.	a.	PROPN
ijassa-493	295	6	l.	l.	PROPN
ijassa-493	295	7	,aprahamian	,aprahamian	PUNCT
ijassa-493	295	8	m.	m.	NOUN
ijassa-493	295	9	,	,	PUNCT
ijassa-493	295	10	balboni	balboni	PROPN
ijassa-493	295	11	g.	g.	PROPN
ijassa-493	295	12	,delecluse	,delecluse	PUNCT
ijassa-493	295	13	h.	h.	PROPN
ijassa-493	295	14	j.	j.	PROPN
ijassa-493	295	15	,	,	PUNCT
ijassa-493	295	16	feederle	feederle	PROPN
ijassa-493	295	17	r.	r.	PROPN
ijassa-493	295	18	,	,	PUNCT
ijassa-493	295	19	kiprianova	kiprianova	PROPN
ijassa-493	295	20	i.	i.	PROPN
ijassa-493	295	21	,	,	PUNCT
ijassa-493	295	22	grekova	grekova	PROPN
ijassa-493	295	23	s.	s.	PROPN
ijassa-493	295	24	,	,	PUNCT
ijassa-493	295	25	galabov	galabov	PROPN
ijassa-493	295	26	a.	a.	NOUN
ijassa-493	295	27	,	,	PUNCT
ijassa-493	295	28	witzens	witzen	VERB
ijassa-493	295	29	-	-	PUNCT
ijassa-493	295	30	harig	harig	ADJ
ijassa-493	295	31	m.	m.	NOUN
ijassa-493	295	32	,	,	PUNCT
ijassa-493	295	33	ho	ho	PROPN
ijassa-493	295	34	a.	a.	PROPN
ijassa-493	295	35	d.	d.	PROPN
ijassa-493	295	36	,	,	PUNCT
ijassa-493	295	37	rommelaere	rommelaere	PROPN
ijassa-493	295	38	,	,	PUNCT
ijassa-493	295	39	j.	j.	PROPN
ijassa-493	295	40	,	,	PUNCT
ijassa-493	295	41	raykov	raykov	PROPN
ijassa-493	295	42	z.	z.	PROPN
ijassa-493	295	43	(	(	PUNCT
ijassa-493	295	44	2009	2009	NUM
ijassa-493	295	45	)	)	PUNCT
ijassa-493	295	46	74	74	NUM
ijassa-493	295	47	n.a	n.a	PROPN
ijassa-493	295	48	.	.	PROPN
ijassa-493	295	49	babushkina	babushkina	PROPN
ijassa-493	295	50	,	,	PUNCT
ijassa-493	295	51	e.a	e.a	PROPN
ijassa-493	295	52	.	.	PROPN
ijassa-493	295	53	kuzina	kuzina	PROPN
ijassa-493	295	54	oncolytic	oncolytic	PROPN
ijassa-493	295	55	rat	rat	NOUN
ijassa-493	295	56	parvovirus	parvovirus	NOUN
ijassa-493	295	57	h-1pv	h-1pv	NOUN
ijassa-493	295	58	,	,	PUNCT
ijassa-493	295	59	a	a	DET
ijassa-493	295	60	candidate	candidate	NOUN
ijassa-493	295	61	for	for	ADP
ijassa-493	295	62	the	the	DET
ijassa-493	295	63	treatment	treatment	NOUN
ijassa-493	295	64	of	of	ADP
ijassa-493	295	65	human	human	ADJ
ijassa-493	295	66	lymphoma	lymphoma	NOUN
ijassa-493	295	67	:	:	PUNCT
ijassa-493	295	68	in	in	ADP
ijassa-493	295	69	vitro	vitro	X
ijassa-493	295	70	and	and	CCONJ
ijassa-493	295	71	in	in	ADP
ijassa-493	295	72	vivo	vivo	ADJ
ijassa-493	295	73	studies	study	NOUN
ijassa-493	295	74	.	.	PUNCT
ijassa-493	296	1	molecular	molecular	ADJ
ijassa-493	296	2	therapy	therapy	NOUN
ijassa-493	296	3	,	,	PUNCT
ijassa-493	296	4	17(7	17(7	NUM
ijassa-493	296	5	)	)	PUNCT
ijassa-493	296	6	,	,	PUNCT
ijassa-493	296	7	1164–1172	1164–1172	NUM
ijassa-493	296	8	.	.	PUNCT
ijassa-493	297	1	[	[	X
ijassa-493	297	2	24	24	NUM
ijassa-493	297	3	]	]	X
ijassa-493	297	4	marchuk	marchuk	PROPN
ijassa-493	297	5	g.i	g.i	PROPN
ijassa-493	297	6	.	.	PUNCT
ijassa-493	298	1	(	(	PUNCT
ijassa-493	298	2	1991	1991	NUM
ijassa-493	298	3	)	)	PUNCT
ijassa-493	298	4	matematicheskie	matematicheskie	NOUN
ijassa-493	298	5	modeli	modeli	PROPN
ijassa-493	298	6	v	v	ADP
ijassa-493	298	7	immunologii	immunologii	PROPN
ijassa-493	298	8	.	.	PUNCT
ijassa-493	299	1	vychislitel'nye	vychislitel'nye	ADV
ijassa-493	299	2	metody	metody	ADJ
ijassa-493	300	1	i	i	PRON
ijassa-493	300	2	jeksperimenty	jeksperimenty	VERB
ijassa-493	300	3	[	[	X
ijassa-493	300	4	mathematical	mathematical	ADJ
ijassa-493	300	5	models	model	NOUN
ijassa-493	300	6	in	in	ADP
ijassa-493	300	7	immunology	immunology	NOUN
ijassa-493	300	8	.	.	PUNCT
ijassa-493	301	1	computational	computational	ADJ
ijassa-493	301	2	methods	method	NOUN
ijassa-493	301	3	and	and	CCONJ
ijassa-493	301	4	experiments	experiment	NOUN
ijassa-493	301	5	]	]	PUNCT
ijassa-493	301	6	.	.	PUNCT
ijassa-493	302	1	moscow	moscow	PROPN
ijassa-493	302	2	:	:	PUNCT
ijassa-493	302	3	nauka	nauka	PROPN
ijassa-493	302	4	,	,	PUNCT
ijassa-493	303	1	[	[	X
ijassa-493	303	2	in	in	ADP
ijassa-493	303	3	russian	russian	PROPN
ijassa-493	303	4	]	]	PUNCT
ijassa-493	304	1	[	[	X
ijassa-493	304	2	25	25	NUM
ijassa-493	304	3	]	]	X
ijassa-493	304	4	romanyukha	romanyukha	PROPN
ijassa-493	304	5	a.a	a.a	PROPN
ijassa-493	304	6	.	.	PROPN
ijassa-493	304	7	(	(	PUNCT
ijassa-493	304	8	2011	2011	NUM
ijassa-493	304	9	)	)	PUNCT
ijassa-493	304	10	matematicheskie	matematicheskie	NOUN
ijassa-493	304	11	modeli	modeli	PROPN
ijassa-493	304	12	v	v	NUM
ijassa-493	304	13	immunologii	immunologii	PROPN
ijassa-493	305	1	i	i	PRON
ijassa-493	305	2	jepidemiologii	jepidemiologii	PROPN
ijassa-493	305	3	infekcionnyh	infekcionnyh	PROPN
ijassa-493	305	4	zabolevanij	zabolevanij	PROPN
ijassa-493	306	1	[	[	X
ijassa-493	306	2	mathematical	mathematical	ADJ
ijassa-493	306	3	models	model	NOUN
ijassa-493	306	4	in	in	ADP
ijassa-493	306	5	immunology	immunology	NOUN
ijassa-493	306	6	and	and	CCONJ
ijassa-493	306	7	epidemiology	epidemiology	NOUN
ijassa-493	306	8	of	of	ADP
ijassa-493	306	9	infectious	infectious	ADJ
ijassa-493	306	10	diseases	disease	NOUN
ijassa-493	306	11	]	]	PUNCT
ijassa-493	306	12	.	.	PUNCT
ijassa-493	307	1	moscow	moscow	PROPN
ijassa-493	307	2	:	:	PUNCT
ijassa-493	307	3	binom	binom	PROPN
ijassa-493	307	4	.	.	PROPN
ijassa-493	307	5	laboratorija	laboratorija	PROPN
ijassa-493	307	6	znanij	znanij	PROPN
ijassa-493	307	7	,	,	PUNCT
ijassa-493	307	8	[	[	X
ijassa-493	307	9	in	in	ADP
ijassa-493	307	10	russian	russian	NOUN
ijassa-493	307	11	]	]	PUNCT
ijassa-493	308	1	[	[	X
ijassa-493	308	2	26	26	NUM
ijassa-493	308	3	]	]	X
ijassa-493	308	4	bolodurina	bolodurina	PROPN
ijassa-493	308	5	i.p	i.p	PROPN
ijassa-493	308	6	.	.	PROPN
ijassa-493	308	7	,	,	PUNCT
ijassa-493	308	8	lugovskova	lugovskova	PROPN
ijassa-493	308	9	yu.p	yu.p	PROPN
ijassa-493	308	10	.	.	PUNCT
ijassa-493	309	1	(	(	PUNCT
ijassa-493	309	2	2009	2009	NUM
ijassa-493	309	3	)	)	PUNCT
ijassa-493	309	4	optimal'noe	optimal'noe	PROPN
ijassa-493	309	5	upravlenie	upravlenie	PROPN
ijassa-493	309	6	immunologicheskimi	immunologicheskimi	PROPN
ijassa-493	309	7	reakcijami	reakcijami	PROPN
ijassa-493	309	8	organizma	organizma	PROPN
ijassa-493	309	9	cheloveka	cheloveka	VERB
ijassa-493	309	10	[	[	X
ijassa-493	309	11	optimum	optimum	ADJ
ijassa-493	309	12	management	management	NOUN
ijassa-493	309	13	of	of	ADP
ijassa-493	309	14	immunological	immunological	ADJ
ijassa-493	309	15	responses	response	NOUN
ijassa-493	309	16	of	of	ADP
ijassa-493	309	17	the	the	DET
ijassa-493	309	18	human	human	ADJ
ijassa-493	309	19	body	body	NOUN
ijassa-493	309	20	]	]	PUNCT
ijassa-493	309	21	.	.	PUNCT
ijassa-493	310	1	problemy	problemy	PROPN
ijassa-493	310	2	upravlenija	upravlenija	ADJ
ijassa-493	310	3	[	[	X
ijassa-493	310	4	control	control	NOUN
ijassa-493	310	5	sciences	science	NOUN
ijassa-493	310	6	]	]	PUNCT
ijassa-493	310	7	,	,	PUNCT
ijassa-493	310	8	5	5	NUM
ijassa-493	310	9	,	,	PUNCT
ijassa-493	310	10	44–52	44–52	NUM
ijassa-493	310	11	,	,	PUNCT
ijassa-493	310	12	[	[	X
ijassa-493	310	13	in	in	ADP
ijassa-493	310	14	russian	russian	NOUN
ijassa-493	310	15	]	]	PUNCT
ijassa-493	311	1	[	[	X
ijassa-493	311	2	27	27	NUM
ijassa-493	311	3	]	]	PUNCT
ijassa-493	311	4	rusakov	rusakov	PROPN
ijassa-493	311	5	s.v	s.v	PROPN
ijassa-493	311	6	.	.	PROPN
ijassa-493	311	7	,	,	PUNCT
ijassa-493	311	8	chirkov	chirkov	PROPN
ijassa-493	311	9	m.v	m.v	PROPN
ijassa-493	311	10	.	.	PUNCT
ijassa-493	312	1	(	(	PUNCT
ijassa-493	312	2	2012	2012	NUM
ijassa-493	312	3	)	)	PUNCT
ijassa-493	312	4	matematicheskaja	matematicheskaja	PROPN
ijassa-493	312	5	model	model	PROPN
ijassa-493	312	6	'	'	PART
ijassa-493	312	7	vlijanija	vlijanija	NOUN
ijassa-493	312	8	immunoterapii	immunoterapii	NOUN
ijassa-493	312	9	na	na	PART
ijassa-493	312	10	dinamiku	dinamiku	VERB
ijassa-493	312	11	immunnogo	immunnogo	PROPN
ijassa-493	312	12	otveta	otveta	PROPN
ijassa-493	313	1	[	[	X
ijassa-493	313	2	the	the	DET
ijassa-493	313	3	mathematical	mathematical	ADJ
ijassa-493	313	4	model	model	NOUN
ijassa-493	313	5	of	of	ADP
ijassa-493	313	6	the	the	DET
ijassa-493	313	7	effect	effect	NOUN
ijassa-493	313	8	of	of	ADP
ijassa-493	313	9	immunotherapy	immunotherapy	NOUN
ijassa-493	313	10	on	on	ADP
ijassa-493	313	11	the	the	DET
ijassa-493	313	12	immune	immune	ADJ
ijassa-493	313	13	response	response	NOUN
ijassa-493	313	14	dynamics	dynamic	NOUN
ijassa-493	313	15	]	]	PUNCT
ijassa-493	313	16	.	.	PUNCT
ijassa-493	314	1	problemy	problemy	PROPN
ijassa-493	314	2	upravlenija	upravlenija	ADJ
ijassa-493	314	3	[	[	X
ijassa-493	314	4	control	control	NOUN
ijassa-493	314	5	sciences	science	NOUN
ijassa-493	314	6	]	]	PUNCT
ijassa-493	314	7	,	,	PUNCT
ijassa-493	314	8	6	6	NUM
ijassa-493	314	9	,	,	PUNCT
ijassa-493	314	10	45–50	45–50	NUM
ijassa-493	314	11	,	,	PUNCT
ijassa-493	314	12	[	[	X
ijassa-493	314	13	in	in	ADP
ijassa-493	314	14	russian	russian	NOUN
ijassa-493	314	15	]	]	PUNCT
ijassa-493	315	1	[	[	X
ijassa-493	315	2	28	28	NUM
ijassa-493	315	3	]	]	X
ijassa-493	315	4	kogan	kogan	PROPN
ijassa-493	315	5	,	,	PUNCT
ijassa-493	315	6	y.	y.	PROPN
ijassa-493	315	7	,	,	PUNCT
ijassa-493	315	8	halevi	halevi	PROPN
ijassa-493	315	9	–	–	PUNCT
ijassa-493	315	10	tobias	tobias	PROPN
ijassa-493	315	11	,	,	PUNCT
ijassa-493	315	12	k.	k.	PROPN
ijassa-493	315	13	,	,	PUNCT
ijassa-493	315	14	elishmereni	elishmereni	NOUN
ijassa-493	315	15	,	,	PUNCT
ijassa-493	315	16	m.	m.	NOUN
ijassa-493	315	17	,	,	PUNCT
ijassa-493	315	18	vuk	vuk	NOUN
ijassa-493	315	19	-	-	PUNCT
ijassa-493	315	20	pavlović	pavlović	NOUN
ijassa-493	315	21	,	,	PUNCT
ijassa-493	315	22	s.	s.	PROPN
ijassa-493	315	23	,	,	PUNCT
ijassa-493	315	24	&	&	CCONJ
ijassa-493	315	25	agur	agur	PROPN
ijassa-493	315	26	,	,	PUNCT
ijassa-493	315	27	z.	z.	PROPN
ijassa-493	315	28	(	(	PUNCT
ijassa-493	315	29	2012	2012	NUM
ijassa-493	315	30	)	)	PUNCT
ijassa-493	315	31	reconsidering	reconsider	VERB
ijassa-493	315	32	the	the	DET
ijassa-493	315	33	paradigm	paradigm	NOUN
ijassa-493	315	34	of	of	ADP
ijassa-493	315	35	cancer	cancer	NOUN
ijassa-493	315	36	immunotherapy	immunotherapy	NOUN
ijassa-493	315	37	by	by	ADP
ijassa-493	315	38	computationally	computationally	ADV
ijassa-493	315	39	aided	aid	VERB
ijassa-493	315	40	real	real	ADJ
ijassa-493	315	41	-	-	PUNCT
ijassa-493	315	42	time	time	NOUN
ijassa-493	315	43	personalization	personalization	NOUN
ijassa-493	315	44	.	.	PUNCT
ijassa-493	316	1	cancer	cancer	NOUN
ijassa-493	316	2	research	research	NOUN
ijassa-493	316	3	,	,	PUNCT
ijassa-493	316	4	72(9	72(9	NUM
ijassa-493	316	5	)	)	PUNCT
ijassa-493	316	6	,	,	PUNCT
ijassa-493	316	7	2218	2218	NUM
ijassa-493	316	8	2227	2227	NUM
ijassa-493	316	9	.	.	PUNCT
ijassa-493	317	1	[	[	X
ijassa-493	317	2	29	29	NUM
ijassa-493	317	3	]	]	X
ijassa-493	317	4	de	de	X
ijassa-493	317	5	pillis	pillis	PROPN
ijassa-493	317	6	,	,	PUNCT
ijassa-493	317	7	l.	l.	PROPN
ijassa-493	317	8	g.	g.	PROPN
ijassa-493	317	9	,	,	PUNCT
ijassa-493	317	10	radunskaya	radunskaya	PROPN
ijassa-493	317	11	,	,	PUNCT
ijassa-493	317	12	a.	a.	PROPN
ijassa-493	317	13	e.	e.	PROPN
ijassa-493	317	14	,	,	PUNCT
ijassa-493	317	15	&	&	CCONJ
ijassa-493	317	16	wiseman	wiseman	PROPN
ijassa-493	317	17	,	,	PUNCT
ijassa-493	317	18	c.	c.	PROPN
ijassa-493	317	19	l.	l.	PROPN
ijassa-493	317	20	(	(	PUNCT
ijassa-493	317	21	2005	2005	NUM
ijassa-493	317	22	)	)	PUNCT
ijassa-493	317	23	a	a	DET
ijassa-493	317	24	validated	validate	VERB
ijassa-493	317	25	mathematical	mathematical	ADJ
ijassa-493	317	26	model	model	NOUN
ijassa-493	317	27	of	of	ADP
ijassa-493	317	28	cell	cell	NOUN
ijassa-493	317	29	-	-	PUNCT
ijassa-493	317	30	mediated	mediate	VERB
ijassa-493	317	31	immune	immune	ADJ
ijassa-493	317	32	response	response	NOUN
ijassa-493	317	33	to	to	ADP
ijassa-493	317	34	tumor	tumor	NOUN
ijassa-493	317	35	growth	growth	NOUN
ijassa-493	317	36	.	.	PUNCT
ijassa-493	318	1	cancer	cancer	NOUN
ijassa-493	318	2	research	research	NOUN
ijassa-493	318	3	,	,	PUNCT
ijassa-493	318	4	65(17	65(17	NUM
ijassa-493	318	5	)	)	PUNCT
ijassa-493	318	6	,	,	PUNCT
ijassa-493	318	7	7950	7950	NUM
ijassa-493	318	8	-	-	SYM
ijassa-493	318	9	7958	7958	NUM
ijassa-493	318	10	.	.	PUNCT
ijassa-493	319	1	[	[	X
ijassa-493	319	2	30	30	NUM
ijassa-493	319	3	]	]	X
ijassa-493	319	4	palladini	palladini	NOUN
ijassa-493	319	5	,	,	PUNCT
ijassa-493	319	6	a.	a.	NOUN
ijassa-493	319	7	,	,	PUNCT
ijassa-493	319	8	nicoletti	nicoletti	NOUN
ijassa-493	319	9	,	,	PUNCT
ijassa-493	319	10	g.	g.	PROPN
ijassa-493	319	11	,	,	PUNCT
ijassa-493	319	12	pappalardo	pappalardo	PROPN
ijassa-493	319	13	,	,	PUNCT
ijassa-493	319	14	f.	f.	PROPN
ijassa-493	319	15	,	,	PUNCT
ijassa-493	319	16	murgo	murgo	PROPN
ijassa-493	319	17	,	,	PUNCT
ijassa-493	319	18	a.	a.	PROPN
ijassa-493	319	19	,	,	PUNCT
ijassa-493	319	20	grosso	grosso	PROPN
ijassa-493	319	21	,	,	PUNCT
ijassa-493	319	22	v.	v.	PROPN
ijassa-493	319	23	,	,	PUNCT
ijassa-493	319	24	stivani	stivani	PROPN
ijassa-493	319	25	,	,	PUNCT
ijassa-493	319	26	v.	v.	PROPN
ijassa-493	319	27	,	,	PUNCT
ijassa-493	319	28	ianzano	ianzano	PROPN
ijassa-493	319	29	,	,	PUNCT
ijassa-493	319	30	m.l	m.l	PROPN
ijassa-493	319	31	.	.	PROPN
ijassa-493	319	32	,	,	PUNCT
ijassa-493	319	33	antognoli	antognoli	PROPN
ijassa-493	319	34	,	,	PUNCT
ijassa-493	319	35	a.	a.	NOUN
ijassa-493	319	36	,	,	PUNCT
ijassa-493	319	37	croci	croci	PROPN
ijassa-493	319	38	,	,	PUNCT
ijassa-493	319	39	s.	s.	PROPN
ijassa-493	319	40	,	,	PUNCT
ijassa-493	319	41	landuzzi	landuzzi	NOUN
ijassa-493	319	42	,	,	PUNCT
ijassa-493	319	43	l.	l.	PROPN
ijassa-493	319	44	,	,	PUNCT
ijassa-493	319	45	de	de	X
ijassa-493	319	46	giovanni	giovanni	PROPN
ijassa-493	319	47	,	,	PUNCT
ijassa-493	319	48	c.	c.	PROPN
ijassa-493	319	49	,	,	PUNCT
ijassa-493	319	50	nanni	nanni	PROPN
ijassa-493	319	51	,	,	PUNCT
ijassa-493	319	52	p.	p.	PROPN
ijassa-493	319	53	,	,	PUNCT
ijassa-493	319	54	motta	motta	PROPN
ijassa-493	319	55	,	,	PUNCT
ijassa-493	319	56	s.	s.	PROPN
ijassa-493	319	57	,	,	PUNCT
ijassa-493	319	58	lollini	lollini	PROPN
ijassa-493	319	59	,	,	PUNCT
ijassa-493	319	60	p.-l	p.-l	NOUN
ijassa-493	319	61	.	.	PUNCT
ijassa-493	320	1	(	(	PUNCT
ijassa-493	320	2	2010	2010	NUM
ijassa-493	320	3	)	)	PUNCT
ijassa-493	320	4	in	in	ADP
ijassa-493	320	5	silico	silico	NOUN
ijassa-493	320	6	modeling	modeling	NOUN
ijassa-493	320	7	and	and	CCONJ
ijassa-493	320	8	in	in	ADP
ijassa-493	320	9	vivo	vivo	ADJ
ijassa-493	320	10	efficacy	efficacy	NOUN
ijassa-493	320	11	of	of	ADP
ijassa-493	320	12	cancer	cancer	NOUN
ijassa-493	320	13	-	-	PUNCT
ijassa-493	320	14	preventive	preventive	ADJ
ijassa-493	320	15	vaccinations	vaccination	NOUN
ijassa-493	320	16	.	.	PUNCT
ijassa-493	321	1	cancer	cancer	NOUN
ijassa-493	321	2	research	research	NOUN
ijassa-493	321	3	,	,	PUNCT
ijassa-493	321	4	70(20	70(20	NUM
ijassa-493	321	5	)	)	PUNCT
ijassa-493	321	6	,	,	PUNCT
ijassa-493	321	7	7755	7755	NUM
ijassa-493	321	8	-	-	SYM
ijassa-493	321	9	7763	7763	NUM
ijassa-493	321	10	.	.	PUNCT
ijassa-493	322	1	[	[	X
ijassa-493	322	2	31	31	NUM
ijassa-493	322	3	]	]	PUNCT
ijassa-493	322	4	skipper	skipper	PROPN
ijassa-493	322	5	,	,	PUNCT
ijassa-493	322	6	h.e	h.e	PROPN
ijassa-493	322	7	.	.	PROPN
ijassa-493	322	8	(	(	PUNCT
ijassa-493	322	9	1971	1971	NUM
ijassa-493	322	10	)	)	PUNCT
ijassa-493	322	11	kinetics	kinetic	NOUN
ijassa-493	322	12	of	of	ADP
ijassa-493	322	13	mammary	mammary	ADJ
ijassa-493	322	14	tumor	tumor	NOUN
ijassa-493	322	15	cell	cell	NOUN
ijassa-493	322	16	growth	growth	NOUN
ijassa-493	322	17	and	and	CCONJ
ijassa-493	322	18	implications	implication	NOUN
ijassa-493	322	19	for	for	ADP
ijassa-493	322	20	therapy	therapy	NOUN
ijassa-493	322	21	.	.	PUNCT
ijassa-493	323	1	cancer	cancer	NOUN
ijassa-493	323	2	,	,	PUNCT
ijassa-493	323	3	28(6	28(6	NUM
ijassa-493	323	4	)	)	PUNCT
ijassa-493	323	5	,	,	PUNCT
ijassa-493	323	6	1479	1479	NUM
ijassa-493	323	7	-	-	SYM
ijassa-493	323	8	1499	1499	NUM
ijassa-493	323	9	.	.	PUNCT
ijassa-493	324	1	[	[	X
ijassa-493	324	2	32	32	NUM
ijassa-493	324	3	]	]	X
ijassa-493	324	4	monichev	monichev	PROPN
ijassa-493	324	5	a.y	a.y	PROPN
ijassa-493	324	6	.	.	PUNCT
ijassa-493	325	1	(	(	PUNCT
ijassa-493	325	2	1984	1984	NUM
ijassa-493	325	3	)	)	PUNCT
ijassa-493	325	4	dinamika	dinamika	PROPN
ijassa-493	325	5	krovetvorenija	krovetvorenija	PROPN
ijassa-493	326	1	[	[	NOUN
ijassa-493	326	2	dynamics	dynamic	NOUN
ijassa-493	326	3	of	of	ADP
ijassa-493	326	4	hematopoiesis	hematopoiesis	NOUN
ijassa-493	326	5	]	]	PUNCT
ijassa-493	326	6	.	.	PUNCT
ijassa-493	327	1	moscow	moscow	PROPN
ijassa-493	327	2	:	:	PUNCT
ijassa-493	327	3	medizina	medizina	ADJ
ijassa-493	327	4	,	,	PUNCT
ijassa-493	328	1	[	[	X
ijassa-493	328	2	in	in	ADP
ijassa-493	328	3	russian	russian	NOUN
ijassa-493	328	4	]	]	PUNCT
ijassa-493	329	1	[	[	X
ijassa-493	329	2	33	33	NUM
ijassa-493	329	3	]	]	X
ijassa-493	329	4	monichev	monichev	NOUN
ijassa-493	329	5	,	,	PUNCT
ijassa-493	329	6	a.	a.	PROPN
ijassa-493	329	7	y.	y.	PROPN
ijassa-493	329	8	(	(	PUNCT
ijassa-493	329	9	1987	1987	NUM
ijassa-493	329	10	)	)	PUNCT
ijassa-493	329	11	a	a	DET
ijassa-493	329	12	mathematical	mathematical	ADJ
ijassa-493	329	13	model	model	NOUN
ijassa-493	329	14	of	of	ADP
ijassa-493	329	15	the	the	DET
ijassa-493	329	16	spatial	spatial	ADJ
ijassa-493	329	17	structure	structure	NOUN
ijassa-493	329	18	of	of	ADP
ijassa-493	329	19	bone	bone	NOUN
ijassa-493	329	20	marrow	marrow	NOUN
ijassa-493	329	21	in	in	ADP
ijassa-493	329	22	hemopoietic	hemopoietic	ADJ
ijassa-493	329	23	dynamics	dynamic	NOUN
ijassa-493	329	24	.	.	PUNCT
ijassa-493	330	1	cybernetics	cybernetic	NOUN
ijassa-493	330	2	and	and	CCONJ
ijassa-493	330	3	systems	system	NOUN
ijassa-493	330	4	analysis	analysis	NOUN
ijassa-493	330	5	,	,	PUNCT
ijassa-493	330	6	23(2	23(2	NOUN
ijassa-493	330	7	)	)	PUNCT
ijassa-493	330	8	,	,	PUNCT
ijassa-493	330	9	274	274	NUM
ijassa-493	330	10	-	-	SYM
ijassa-493	330	11	280	280	NUM
ijassa-493	330	12	.	.	PUNCT
ijassa-493	331	1	[	[	X
ijassa-493	331	2	34	34	NUM
ijassa-493	331	3	]	]	X
ijassa-493	331	4	kuzina	kuzina	PROPN
ijassa-493	331	5	e.a	e.a	PROPN
ijassa-493	331	6	.	.	PROPN
ijassa-493	331	7	,	,	PUNCT
ijassa-493	331	8	babushkina	babushkina	PROPN
ijassa-493	331	9	n.a	n.a	PROPN
ijassa-493	331	10	.	.	PROPN
ijassa-493	332	1	(	(	PUNCT
ijassa-493	332	2	2016	2016	NUM
ijassa-493	332	3	)	)	PUNCT
ijassa-493	332	4	programmnaja	programmnaja	PROPN
ijassa-493	332	5	realizacija	realizacija	PROPN
ijassa-493	332	6	metoda	metoda	PROPN
ijassa-493	332	7	prognozirovanija	prognozirovanija	PROPN
ijassa-493	332	8	jeffektivnosti	jeffektivnosti	PROPN
ijassa-493	332	9	vakcinoterapii	vakcinoterapii	PROPN
ijassa-493	332	10	ot	ot	PROPN
ijassa-493	332	11	jeksperimenta	jeksperimenta	PROPN
ijassa-493	332	12	v	v	PROPN
ijassa-493	332	13	kliniku	kliniku	PROPN
ijassa-493	333	1	[	[	X
ijassa-493	333	2	software	software	NOUN
ijassa-493	333	3	implementation	implementation	NOUN
ijassa-493	333	4	of	of	ADP
ijassa-493	333	5	the	the	DET
ijassa-493	333	6	method	method	NOUN
ijassa-493	333	7	for	for	ADP
ijassa-493	333	8	predicting	predict	VERB
ijassa-493	333	9	the	the	DET
ijassa-493	333	10	efficacy	efficacy	NOUN
ijassa-493	333	11	of	of	ADP
ijassa-493	333	12	vaccine	vaccine	NOUN
ijassa-493	333	13	therapy	therapy	NOUN
ijassa-493	333	14	from	from	ADP
ijassa-493	333	15	experiment	experiment	NOUN
ijassa-493	333	16	to	to	ADP
ijassa-493	333	17	the	the	DET
ijassa-493	333	18	clinic	clinic	NOUN
ijassa-493	333	19	]	]	PUNCT
ijassa-493	333	20	.	.	PUNCT
ijassa-493	334	1	proceedings	proceeding	NOUN
ijassa-493	334	2	of	of	ADP
ijassa-493	334	3	the	the	DET
ijassa-493	334	4	xii	xii	PROPN
ijassa-493	334	5	int	int	NOUN
ijassa-493	334	6	.	.	PUNCT
ijassa-493	335	1	conf	conf	NOUN
ijassa-493	335	2	.	.	PUNCT
ijassa-493	336	1	“	"	PUNCT
ijassa-493	336	2	physics	physics	NOUN
ijassa-493	336	3	and	and	CCONJ
ijassa-493	336	4	radioelectronics	radioelectronic	NOUN
ijassa-493	336	5	in	in	ADP
ijassa-493	336	6	medicine	medicine	NOUN
ijassa-493	336	7	and	and	CCONJ
ijassa-493	336	8	ecology	ecology	NOUN
ijassa-493	336	9	”	"	PUNCT
ijassa-493	336	10	phreme-2016	phreme-2016	NOUN
ijassa-493	336	11	.	.	PUNCT
ijassa-493	336	12	vladimir	vladimir	PROPN
ijassa-493	336	13	,	,	PUNCT
ijassa-493	336	14	russia	russia	PROPN
ijassa-493	336	15	,	,	PUNCT
ijassa-493	336	16	1	1	NUM
ijassa-493	336	17	,	,	PUNCT
ijassa-493	336	18	125	125	NUM
ijassa-493	336	19	-	-	SYM
ijassa-493	336	20	130	130	NUM
ijassa-493	336	21	,	,	PUNCT
ijassa-493	336	22	[	[	X
ijassa-493	336	23	in	in	ADP
ijassa-493	336	24	russian	russian	PROPN
ijassa-493	336	25	]	]	PUNCT
ijassa-493	336	26	analytical	analytical	ADJ
ijassa-493	336	27	study	study	NOUN
ijassa-493	336	28	of	of	ADP
ijassa-493	336	29	antitumor	antitumor	PROPN
ijassa-493	336	30	viral	viral	ADJ
ijassa-493	336	31	vaccine	vaccine	NOUN
ijassa-493	336	32	75	75	NUM
ijassa-493	336	33	appendix	appendix	NOUN
ijassa-493	336	34	1	1	NUM
ijassa-493	336	35	.	.	PUNCT
ijassa-493	336	36	values	value	NOUN
ijassa-493	336	37	of	of	ADP
ijassa-493	336	38	the	the	DET
ijassa-493	336	39	models	model	NOUN
ijassa-493	336	40	'	'	PART
ijassa-493	336	41	parameters	parameter	NOUN
ijassa-493	336	42	after	after	ADP
ijassa-493	336	43	a	a	DET
ijassa-493	336	44	single	single	ADJ
ijassa-493	336	45	introduction	introduction	NOUN
ijassa-493	336	46	of	of	ADP
ijassa-493	336	47	the	the	DET
ijassa-493	336	48	viral	viral	ADJ
ijassa-493	336	49	vaccine	vaccine	NOUN
ijassa-493	336	50	on	on	ADP
ijassa-493	336	51	the	the	DET
ijassa-493	336	52	first	first	ADJ
ijassa-493	336	53	day	day	NOUN
ijassa-493	336	54	of	of	ADP
ijassa-493	336	55	the	the	DET
ijassa-493	336	56	tumor	tumor	NOUN
ijassa-493	336	57	growth	growth	NOUN
ijassa-493	336	58	equation	equation	NOUN
ijassa-493	336	59	parameter	parameter	NOUN
ijassa-493	336	60	description	description	NOUN
ijassa-493	336	61	(	(	PUNCT
ijassa-493	336	62	)	)	PUNCT
ijassa-493	336	63	dn	dn	PROPN
ijassa-493	336	64	t	t	PROPN
ijassa-493	336	65	dt	dt	PROPN
ijassa-493	336	66	–	–	PUNCT
ijassa-493	336	67	(	(	PUNCT
ijassa-493	336	68	9	9	X
ijassa-493	336	69	)	)	PUNCT
ijassa-493	336	70	n	n	ADV
ijassa-493	336	71	=	=	SYM
ijassa-493	336	72	3.3613	3.3613	NUM
ijassa-493	336	73	,	,	PUNCT
ijassa-493	336	74	n	n	X
ijassa-493	336	75	=	=	NOUN
ijassa-493	336	76	0.0332	0.0332	NUM
ijassa-493	336	77	n=	n=	NUM
ijassa-493	336	78	23	23	NUM
ijassa-493	336	79	0n	0n	NOUN
ijassa-493	336	80	=	=	SYM
ijassa-493	336	81	0.75	0.75	NUM
ijassa-493	336	82	parameters	parameter	NOUN
ijassa-493	336	83	of	of	ADP
ijassa-493	336	84	the	the	DET
ijassa-493	336	85	gompertz	gompertz	NOUN
ijassa-493	336	86	function	function	NOUN
ijassa-493	336	87	approximating	approximate	VERB
ijassa-493	336	88	the	the	DET
ijassa-493	336	89	experimental	experimental	ADJ
ijassa-493	336	90	growth	growth	NOUN
ijassa-493	336	91	curves	curve	NOUN
ijassa-493	336	92	of	of	ADP
ijassa-493	336	93	the	the	DET
ijassa-493	336	94	tumor	tumor	NOUN
ijassa-493	336	95	cell	cell	NOUN
ijassa-493	336	96	population	population	NOUN
ijassa-493	336	97	without	without	ADP
ijassa-493	336	98	the	the	DET
ijassa-493	336	99	vaccine	vaccine	NOUN
ijassa-493	336	100	administration	administration	NOUN
ijassa-493	336	101	(	(	PUNCT
ijassa-493	336	102	control	control	NOUN
ijassa-493	336	103	sample	sample	NOUN
ijassa-493	336	104	)	)	PUNCT
ijassa-493	336	105	(	(	PUNCT
ijassa-493	336	106	)	)	PUNCT
ijassa-493	336	107	vdn	vdn	PROPN
ijassa-493	336	108	t	t	X
ijassa-493	336	109	dt	dt	PROPN
ijassa-493	336	110	–	–	PUNCT
ijassa-493	336	111	(	(	PUNCT
ijassa-493	336	112	1	1	X
ijassa-493	336	113	)	)	PUNCT
ijassa-493	336	114	1	1	NUM
ijassa-493	336	115	=	=	SYM
ijassa-493	336	116	1	1	NUM
ijassa-493	336	117	moment	moment	NOUN
ijassa-493	336	118	of	of	ADP
ijassa-493	336	119	the	the	DET
ijassa-493	336	120	first	first	ADJ
ijassa-493	336	121	introduction	introduction	NOUN
ijassa-493	336	122	of	of	ADP
ijassa-493	336	123	the	the	DET
ijassa-493	336	124	viral	viral	ADJ
ijassa-493	336	125	vaccine	vaccine	NOUN
ijassa-493	336	126	cvz	cvz	NOUN
ijassa-493	336	127	=	=	SYM
ijassa-493	336	128	4.5	4.5	NUM
ijassa-493	336	129	time	time	NOUN
ijassa-493	336	130	lag	lag	NOUN
ijassa-493	336	131	of	of	ADP
ijassa-493	336	132	the	the	DET
ijassa-493	336	133	immune	immune	ADJ
ijassa-493	336	134	response	response	NOUN
ijassa-493	336	135	against	against	ADP
ijassa-493	336	136	the	the	DET
ijassa-493	336	137	virus	virus	NOUN
ijassa-493	336	138	cnz	cnz	NOUN
ijassa-493	336	139	=	=	NOUN
ijassa-493	336	140	10.5	10.5	NUM
ijassa-493	336	141	time	time	NOUN
ijassa-493	336	142	lag	lag	NOUN
ijassa-493	336	143	of	of	ADP
ijassa-493	336	144	the	the	DET
ijassa-493	336	145	immune	immune	ADJ
ijassa-493	336	146	response	response	NOUN
ijassa-493	336	147	against	against	ADP
ijassa-493	336	148	the	the	DET
ijassa-493	336	149	infected	infected	ADJ
ijassa-493	336	150	tumor	tumor	NOUN
ijassa-493	336	151	cells	cell	NOUN
ijassa-493	336	152	1v	1v	NUM
ijassa-493	336	153	cvt	cvt	PROPN
ijassa-493	336	154	z=	z=	PROPN
ijassa-493	336	155	+	+	CCONJ
ijassa-493	336	156	starting	start	VERB
ijassa-493	336	157	moment	moment	NOUN
ijassa-493	336	158	of	of	ADP
ijassa-493	336	159	the	the	DET
ijassa-493	336	160	immune	immune	ADJ
ijassa-493	336	161	response	response	NOUN
ijassa-493	336	162	against	against	ADP
ijassa-493	336	163	the	the	DET
ijassa-493	336	164	virus	virus	NOUN
ijassa-493	336	165	1n	1n	PROPN
ijassa-493	336	166	cnt	cnt	PROPN
ijassa-493	336	167	z=	z=	PROPN
ijassa-493	336	168	+	+	CCONJ
ijassa-493	336	169	starting	start	VERB
ijassa-493	336	170	moment	moment	NOUN
ijassa-493	336	171	of	of	ADP
ijassa-493	336	172	the	the	DET
ijassa-493	336	173	immune	immune	ADJ
ijassa-493	336	174	response	response	NOUN
ijassa-493	336	175	against	against	ADP
ijassa-493	336	176	infected	infected	ADJ
ijassa-493	336	177	tumor	tumor	NOUN
ijassa-493	336	178	cells	cell	NOUN
ijassa-493	336	179	(	(	PUNCT
ijassa-493	336	180	)	)	PUNCT
ijassa-493	336	181	dv	dv	PROPN
ijassa-493	336	182	t	t	PROPN
ijassa-493	336	183	dt	dt	PROPN
ijassa-493	336	184	–	–	PUNCT
ijassa-493	336	185	(	(	PUNCT
ijassa-493	336	186	3	3	X
ijassa-493	336	187	)	)	PUNCT
ijassa-493	336	188	v	v	NOUN
ijassa-493	336	189	=	=	SYM
ijassa-493	336	190	0.1	0.1	NUM
ijassa-493	336	191	rate	rate	NOUN
ijassa-493	336	192	of	of	ADP
ijassa-493	336	193	virus	virus	NOUN
ijassa-493	336	194	replication	replication	NOUN
ijassa-493	336	195	v	v	NOUN
ijassa-493	336	196	=	=	SYM
ijassa-493	336	197	15	15	NUM
ijassa-493	336	198	death	death	NOUN
ijassa-493	336	199	rate	rate	NOUN
ijassa-493	336	200	of	of	ADP
ijassa-493	336	201	viruses	virus	NOUN
ijassa-493	336	202	due	due	ADP
ijassa-493	336	203	to	to	ADP
ijassa-493	336	204	their	their	PRON
ijassa-493	336	205	interaction	interaction	NOUN
ijassa-493	336	206	with	with	ADP
ijassa-493	336	207	antibodies	antibody	NOUN
ijassa-493	336	208	0v	0v	NOUN
ijassa-493	336	209	=	=	NOUN
ijassa-493	336	210	0.015	0.015	NUM
ijassa-493	336	211	dosage	dosage	NOUN
ijassa-493	336	212	of	of	ADP
ijassa-493	336	213	the	the	DET
ijassa-493	336	214	viral	viral	ADJ
ijassa-493	336	215	vaccine	vaccine	NOUN
ijassa-493	336	216	–	–	PUNCT
ijassa-493	336	217	the	the	DET
ijassa-493	336	218	initial	initial	ADJ
ijassa-493	336	219	condition	condition	NOUN
ijassa-493	336	220	of	of	ADP
ijassa-493	336	221	equation	equation	NOUN
ijassa-493	336	222	(	(	PUNCT
ijassa-493	336	223	2	2	NUM
ijassa-493	336	224	)	)	PUNCT
ijassa-493	336	225	(	(	PUNCT
ijassa-493	336	226	)	)	PUNCT
ijassa-493	336	227	vda	vda	PROPN
ijassa-493	336	228	t	t	NOUN
ijassa-493	336	229	dt	dt	PROPN
ijassa-493	336	230	–	–	PUNCT
ijassa-493	336	231	(	(	PUNCT
ijassa-493	336	232	4	4	X
ijassa-493	336	233	)	)	PUNCT
ijassa-493	337	1	a	a	ADV
ijassa-493	337	2	=	=	SYM
ijassa-493	337	3	100	100	NUM
ijassa-493	337	4	rate	rate	NOUN
ijassa-493	337	5	of	of	ADP
ijassa-493	337	6	antibodies	antibody	NOUN
ijassa-493	337	7	’	'	PUNCT
ijassa-493	337	8	formation	formation	NOUN
ijassa-493	337	9	from	from	ADP
ijassa-493	337	10	a	a	DET
ijassa-493	337	11	single	single	ADJ
ijassa-493	337	12	plasma	plasma	NOUN
ijassa-493	337	13	cell	cell	NOUN
ijassa-493	337	14	av	av	NOUN
ijassa-493	337	15	=	=	SYM
ijassa-493	337	16	70	70	NUM
ijassa-493	337	17	rate	rate	NOUN
ijassa-493	337	18	of	of	ADP
ijassa-493	337	19	decrease	decrease	NOUN
ijassa-493	337	20	in	in	ADP
ijassa-493	337	21	the	the	DET
ijassa-493	337	22	number	number	NOUN
ijassa-493	337	23	of	of	ADP
ijassa-493	337	24	antibodies	antibody	NOUN
ijassa-493	337	25	due	due	ADP
ijassa-493	337	26	to	to	ADP
ijassa-493	337	27	interaction	interaction	NOUN
ijassa-493	337	28	with	with	ADP
ijassa-493	337	29	viruses	virus	NOUN
ijassa-493	337	30	a	a	X
ijassa-493	337	31	=	=	SYM
ijassa-493	337	32	5	5	NUM
ijassa-493	337	33	rate	rate	NOUN
ijassa-493	337	34	of	of	ADP
ijassa-493	337	35	decrease	decrease	NOUN
ijassa-493	337	36	in	in	ADP
ijassa-493	337	37	the	the	DET
ijassa-493	337	38	number	number	NOUN
ijassa-493	337	39	of	of	ADP
ijassa-493	337	40	antibodies	antibody	NOUN
ijassa-493	337	41	due	due	ADP
ijassa-493	337	42	to	to	ADP
ijassa-493	337	43	natural	natural	ADJ
ijassa-493	337	44	destruction	destruction	NOUN
ijassa-493	337	45	max	max	PROPN
ijassa-493	337	46	va	va	PROPN
ijassa-493	337	47	=	=	NOUN
ijassa-493	337	48	1.05	1.05	NUM
ijassa-493	337	49	maximum	maximum	ADJ
ijassa-493	337	50	calculated	calculate	VERB
ijassa-493	337	51	number	number	NOUN
ijassa-493	337	52	of	of	ADP
ijassa-493	337	53	antibodies	antibody	NOUN
ijassa-493	337	54	(	(	PUNCT
ijassa-493	337	55	)	)	PUNCT
ijassa-493	337	56	vdc	vdc	PROPN
ijassa-493	337	57	t	t	PROPN
ijassa-493	337	58	dt	dt	PROPN
ijassa-493	337	59	–	–	PUNCT
ijassa-493	337	60	(	(	PUNCT
ijassa-493	337	61	5	5	X
ijassa-493	337	62	)	)	PUNCT
ijassa-493	337	63	c	c	NOUN
ijassa-493	337	64	=	=	SYM
ijassa-493	337	65	100	100	NUM
ijassa-493	337	66	rate	rate	NOUN
ijassa-493	337	67	of	of	ADP
ijassa-493	337	68	antibodies	antibody	NOUN
ijassa-493	337	69	’	'	PUNCT
ijassa-493	337	70	formation	formation	NOUN
ijassa-493	337	71	from	from	ADP
ijassa-493	337	72	a	a	DET
ijassa-493	337	73	single	single	ADJ
ijassa-493	337	74	plasma	plasma	NOUN
ijassa-493	337	75	cell	cell	NOUN
ijassa-493	337	76	cv	cv	ADV
ijassa-493	337	77	=	=	SYM
ijassa-493	337	78	4.5	4.5	NUM
ijassa-493	337	79	dimension	dimension	NOUN
ijassa-493	337	80	factor	factor	NOUN
ijassa-493	337	81	vnc	vnc	NOUN
ijassa-493	337	82	=	=	SYM
ijassa-493	337	83	0.001	0.001	NUM
ijassa-493	337	84	initial	initial	ADJ
ijassa-493	337	85	number	number	NOUN
ijassa-493	337	86	of	of	ADP
ijassa-493	337	87	plasma	plasma	NOUN
ijassa-493	337	88	cells	cell	NOUN
ijassa-493	337	89	(	(	PUNCT
ijassa-493	337	90	)	)	PUNCT
ijassa-493	337	91	nda	nda	PROPN
ijassa-493	337	92	t	t	PROPN
ijassa-493	337	93	dt	dt	PROPN
ijassa-493	337	94	–	–	PUNCT
ijassa-493	337	95	(	(	PUNCT
ijassa-493	337	96	6	6	NUM
ijassa-493	337	97	)	)	PUNCT
ijassa-493	337	98	an	an	NOUN
ijassa-493	337	99	=	=	SYM
ijassa-493	337	100	30	30	NUM
ijassa-493	337	101	rate	rate	NOUN
ijassa-493	337	102	of	of	ADP
ijassa-493	337	103	antibodies	antibody	NOUN
ijassa-493	337	104	’	'	PUNCT
ijassa-493	337	105	formation	formation	NOUN
ijassa-493	337	106	from	from	ADP
ijassa-493	337	107	a	a	DET
ijassa-493	337	108	single	single	ADJ
ijassa-493	337	109	plasma	plasma	NOUN
ijassa-493	337	110	cell	cell	NOUN
ijassa-493	337	111	an	an	NOUN
ijassa-493	337	112	=	=	NOUN
ijassa-493	337	113	6.2	6.2	NUM
ijassa-493	337	114	rate	rate	NOUN
ijassa-493	337	115	of	of	ADP
ijassa-493	337	116	decrease	decrease	NOUN
ijassa-493	337	117	in	in	ADP
ijassa-493	337	118	the	the	DET
ijassa-493	337	119	number	number	NOUN
ijassa-493	337	120	of	of	ADP
ijassa-493	337	121	antibodies	antibody	NOUN
ijassa-493	337	122	due	due	ADP
ijassa-493	337	123	to	to	ADP
ijassa-493	337	124	interaction	interaction	NOUN
ijassa-493	337	125	with	with	ADP
ijassa-493	337	126	tumor	tumor	NOUN
ijassa-493	337	127	cells	cell	NOUN
ijassa-493	337	128	nn	nn	NOUN
ijassa-493	338	1	=	=	SYM
ijassa-493	338	2	6.3	6.3	NUM
ijassa-493	338	3	rate	rate	NOUN
ijassa-493	338	4	of	of	ADP
ijassa-493	338	5	decrease	decrease	NOUN
ijassa-493	338	6	in	in	ADP
ijassa-493	338	7	the	the	DET
ijassa-493	338	8	number	number	NOUN
ijassa-493	338	9	of	of	ADP
ijassa-493	338	10	antibodies	antibody	NOUN
ijassa-493	338	11	due	due	ADP
ijassa-493	338	12	to	to	PART
ijassa-493	338	13	76	76	NUM
ijassa-493	338	14	n.a	n.a	PROPN
ijassa-493	338	15	.	.	PROPN
ijassa-493	338	16	babushkina	babushkina	PROPN
ijassa-493	338	17	,	,	PUNCT
ijassa-493	338	18	e.a	e.a	PROPN
ijassa-493	338	19	.	.	PROPN
ijassa-493	338	20	kuzina	kuzina	PROPN
ijassa-493	338	21	natural	natural	PROPN
ijassa-493	338	22	destruction	destruction	PROPN
ijassa-493	338	23	max	max	NOUN
ijassa-493	338	24	na	na	ADP
ijassa-493	338	25	=	=	SYM
ijassa-493	338	26	4.6445	4.6445	NUM
ijassa-493	338	27	maximum	maximum	ADJ
ijassa-493	338	28	calculated	calculate	VERB
ijassa-493	338	29	number	number	NOUN
ijassa-493	338	30	of	of	ADP
ijassa-493	338	31	antibodies	antibody	NOUN
ijassa-493	338	32	(	(	PUNCT
ijassa-493	338	33	)	)	PUNCT
ijassa-493	338	34	ndc	ndc	PROPN
ijassa-493	338	35	t	t	PROPN
ijassa-493	338	36	dt	dt	PROPN
ijassa-493	338	37	–	–	PUNCT
ijassa-493	338	38	(	(	PUNCT
ijassa-493	338	39	7	7	X
ijassa-493	338	40	)	)	PUNCT
ijassa-493	338	41	cn	cn	NOUN
ijassa-493	338	42	=	=	SYM
ijassa-493	338	43	76.677	76.677	NUM
ijassa-493	338	44	rate	rate	NOUN
ijassa-493	338	45	of	of	ADP
ijassa-493	338	46	formation	formation	NOUN
ijassa-493	338	47	of	of	ADP
ijassa-493	338	48	plasma	plasma	NOUN
ijassa-493	338	49	cells	cell	NOUN
ijassa-493	338	50	cn	cn	VERB
ijassa-493	338	51	=	=	SYM
ijassa-493	338	52	38	38	NUM
ijassa-493	338	53	dimension	dimension	NOUN
ijassa-493	338	54	factor	factor	NOUN
ijassa-493	338	55	nnc	nnc	PROPN
ijassa-493	339	1	=	=	NOUN
ijassa-493	339	2	0.0001	0.0001	NUM
ijassa-493	339	3	initial	initial	ADJ
ijassa-493	339	4	number	number	NOUN
ijassa-493	339	5	of	of	ADP
ijassa-493	339	6	plasma	plasma	NOUN
ijassa-493	339	7	cells	cell	NOUN
ijassa-493	339	8	(	(	PUNCT
ijassa-493	339	9	)	)	PUNCT
ijassa-493	339	10	vdn	vdn	PROPN
ijassa-493	339	11	t	t	X
ijassa-493	339	12	dt	dt	PROPN
ijassa-493	339	13	–	–	PUNCT
ijassa-493	339	14	(	(	PUNCT
ijassa-493	339	15	1	1	X
ijassa-493	339	16	)	)	PUNCT
ijassa-493	339	17	vk	vk	NOUN
ijassa-493	339	18	=	=	SYM
ijassa-493	339	19	0.25	0.25	NUM
ijassa-493	339	20	avk	avk	NOUN
ijassa-493	339	21	=	=	PUNCT
ijassa-493	339	22	0.8	0.8	NUM
ijassa-493	339	23	ank	ank	X
ijassa-493	339	24	=	=	NOUN
ijassa-493	339	25	0.8	0.8	NUM
ijassa-493	339	26	constant	constant	ADJ
ijassa-493	339	27	coefficients	coefficient	NOUN
ijassa-493	339	28	of	of	ADP
ijassa-493	339	29	the	the	DET
ijassa-493	339	30	dynamic	dynamic	ADJ
ijassa-493	339	31	equation	equation	NOUN
ijassa-493	339	32	for	for	ADP
ijassa-493	339	33	infected	infected	ADJ
ijassa-493	339	34	cells	cell	NOUN
ijassa-493	339	35	after	after	ADP
ijassa-493	339	36	a	a	DET
ijassa-493	339	37	single	single	ADJ
ijassa-493	339	38	introduction	introduction	NOUN
ijassa-493	339	39	of	of	ADP
ijassa-493	339	40	the	the	DET
ijassa-493	339	41	vaccine	vaccine	NOUN
ijassa-493	339	42	(	(	PUNCT
ijassa-493	339	43	)	)	PUNCT
ijassa-493	339	44	p	p	PROPN
ijassa-493	339	45	t	t	PROPN
ijassa-493	339	46	–	–	PUNCT
ijassa-493	339	47	(	(	PUNCT
ijassa-493	339	48	8)	8)	NUM
ijassa-493	339	49	p	p	NOUN
ijassa-493	339	50	=	=	NOUN
ijassa-493	339	51	0.3	0.3	NUM
ijassa-493	339	52	pk	pk	NOUN
ijassa-493	339	53	=	=	NOUN
ijassa-493	339	54	0.95	0.95	NUM
ijassa-493	339	55	p	p	NOUN
ijassa-493	339	56	=	=	SYM
ijassa-493	339	57	1	1	NUM
ijassa-493	339	58	/	/	SYM
ijassa-493	339	59	t	t	PROPN
ijassa-493	339	60	*	*	NOUN
ijassa-493	339	61	parameters	parameter	NOUN
ijassa-493	339	62	of	of	ADP
ijassa-493	339	63	function	function	NOUN
ijassa-493	339	64	p(t	p(t	NOUN
ijassa-493	339	65	)	)	PUNCT
ijassa-493	339	66	,	,	PUNCT
ijassa-493	339	67	describing	describe	VERB
ijassa-493	339	68	the	the	DET
ijassa-493	339	69	dynamic	dynamic	ADJ
ijassa-493	339	70	equation	equation	NOUN
ijassa-493	339	71	for	for	ADP
ijassa-493	339	72	reduction	reduction	NOUN
ijassa-493	339	73	of	of	ADP
ijassa-493	339	74	the	the	DET
ijassa-493	339	75	fast	fast	ADV
ijassa-493	339	76	-	-	PUNCT
ijassa-493	339	77	proliferating	proliferate	VERB
ijassa-493	339	78	fraction	fraction	NOUN
ijassa-493	339	79	of	of	ADP
ijassa-493	339	80	tumor	tumor	NOUN
ijassa-493	339	81	cells	cell	NOUN
ijassa-493	339	82	t*=	t*=	PROPN
ijassa-493	339	83	35	35	NUM
ijassa-493	339	84	days	day	NOUN
ijassa-493	339	85	moment	moment	NOUN
ijassa-493	339	86	when	when	SCONJ
ijassa-493	339	87	the	the	DET
ijassa-493	339	88	number	number	NOUN
ijassa-493	339	89	of	of	ADP
ijassa-493	339	90	fractions	fraction	NOUN
ijassa-493	339	91	of	of	ADP
ijassa-493	339	92	rapidly	rapidly	ADV
ijassa-493	339	93	proliferating	proliferate	VERB
ijassa-493	339	94	cells	cell	NOUN
ijassa-493	339	95	is	be	AUX
ijassa-493	339	96	equal	equal	ADJ
ijassa-493	339	97	to	to	ADP
ijassa-493	339	98	the	the	DET
ijassa-493	339	99	number	number	NOUN
ijassa-493	339	100	of	of	ADP
ijassa-493	339	101	fractions	fraction	NOUN
ijassa-493	339	102	of	of	ADP
ijassa-493	339	103	slowly	slowly	ADV
ijassa-493	339	104	proliferating	proliferate	VERB
ijassa-493	339	105	cells	cell	NOUN
ijassa-493	339	106	(	(	PUNCT
ijassa-493	339	107	)	)	PUNCT
ijassa-493	339	108	dn	dn	PROPN
ijassa-493	339	109	t	t	PROPN
ijassa-493	339	110	dt	dt	X
ijassa-493	339	111	–	–	PUNCT
ijassa-493	339	112	(	(	PUNCT
ijassa-493	339	113	10	10	NUM
ijassa-493	339	114	)	)	PUNCT
ijassa-493	339	115	v	v	X
ijassa-493	339	116	=	=	PUNCT
ijassa-493	339	117	4.3	4.3	NUM
ijassa-493	339	118	days	day	NOUN
ijassa-493	339	119	length	length	NOUN
ijassa-493	339	120	of	of	ADP
ijassa-493	339	121	the	the	DET
ijassa-493	339	122	tumor	tumor	NOUN
ijassa-493	339	123	cells	cell	NOUN
ijassa-493	339	124	’	'	PUNCT
ijassa-493	339	125	growth	growth	NOUN
ijassa-493	339	126	delay	delay	NOUN
ijassa-493	339	127	after	after	ADP
ijassa-493	339	128	their	their	PRON
ijassa-493	339	129	death	death	NOUN
ijassa-493	339	130	at	at	ADP
ijassa-493	339	131	1st	1st	ADJ
ijassa-493	339	132	stage	stage	NOUN
ijassa-493	339	133	of	of	ADP
ijassa-493	339	134	immune	immune	ADJ
ijassa-493	339	135	system	system	NOUN
ijassa-493	339	136	stimulation	stimulation	NOUN
ijassa-493	339	137	cn	cn	X
ijassa-493	339	138	=	=	SYM
ijassa-493	339	139	9.8	9.8	NUM
ijassa-493	339	140	days	day	NOUN
ijassa-493	339	141	length	length	NOUN
ijassa-493	339	142	of	of	ADP
ijassa-493	339	143	the	the	DET
ijassa-493	339	144	tumor	tumor	NOUN
ijassa-493	339	145	cells	cell	NOUN
ijassa-493	339	146	’	'	PUNCT
ijassa-493	339	147	growth	growth	NOUN
ijassa-493	339	148	delay	delay	NOUN
ijassa-493	339	149	after	after	ADP
ijassa-493	339	150	their	their	PRON
ijassa-493	339	151	death	death	NOUN
ijassa-493	339	152	at	at	ADP
ijassa-493	339	153	2nd	2nd	ADJ
ijassa-493	339	154	stage	stage	NOUN
ijassa-493	339	155	of	of	ADP
ijassa-493	339	156	immune	immune	ADJ
ijassa-493	339	157	system	system	NOUN
ijassa-493	339	158	stimulation	stimulation	NOUN
ijassa-493	339	159	sum	sum	PROPN
ijassa-493	339	160	=	=	PUNCT
ijassa-493	339	161	14.1	14.1	NUM
ijassa-493	339	162	days	day	NOUN
ijassa-493	339	163	total	total	ADJ
ijassa-493	339	164	length	length	NOUN
ijassa-493	339	165	of	of	ADP
ijassa-493	339	166	the	the	DET
ijassa-493	339	167	tumor	tumor	NOUN
ijassa-493	339	168	cells	cell	NOUN
ijassa-493	339	169	’	'	PUNCT
ijassa-493	339	170	growth	growth	NOUN
ijassa-493	339	171	delay	delay	NOUN
ijassa-493	339	172	(	(	PUNCT
ijassa-493	339	173	1st	1st	ADJ
ijassa-493	339	174	and	and	CCONJ
ijassa-493	339	175	2nd	2nd	ADJ
ijassa-493	339	176	stage	stage	NOUN
ijassa-493	339	177	of	of	ADP
ijassa-493	339	178	immune	immune	ADJ
ijassa-493	339	179	system	system	NOUN
ijassa-493	339	180	stimulation	stimulation	NOUN
ijassa-493	339	181	)	)	PUNCT
ijassa-493	339	182	1	1	NUM
ijassa-493	339	183	vt	vt	NOUN
ijassa-493	339	184	=	=	NOUN
ijassa-493	339	185	5.82	5.82	NUM
ijassa-493	339	186	1	1	NUM
ijassa-493	339	187	nt	not	PART
ijassa-493	339	188	=	=	NOUN
ijassa-493	339	189	12.32	12.32	NUM
ijassa-493	339	190	starting	start	VERB
ijassa-493	339	191	moments	moment	NOUN
ijassa-493	339	192	of	of	ADP
ijassa-493	339	193	the	the	DET
ijassa-493	339	194	1st	1st	NOUN
ijassa-493	339	195	and	and	CCONJ
ijassa-493	339	196	the	the	DET
ijassa-493	339	197	2nd	2nd	ADJ
ijassa-493	339	198	stage	stage	NOUN
ijassa-493	339	199	of	of	ADP
ijassa-493	339	200	immune	immune	ADJ
ijassa-493	339	201	response	response	NOUN
ijassa-493	339	202	2	2	NUM
ijassa-493	339	203	vt	vt	NOUN
ijassa-493	339	204	=	=	NOUN
ijassa-493	339	205	7.13	7.13	NUM
ijassa-493	339	206	2	2	NUM
ijassa-493	339	207	nt	not	PART
ijassa-493	339	208	=	=	NOUN
ijassa-493	339	209	14.288	14.288	NUM
ijassa-493	339	210	ending	end	VERB
ijassa-493	339	211	moments	moment	NOUN
ijassa-493	339	212	of	of	ADP
ijassa-493	339	213	the	the	DET
ijassa-493	339	214	1st	1st	NOUN
ijassa-493	339	215	and	and	CCONJ
ijassa-493	339	216	the	the	DET
ijassa-493	339	217	2nd	2nd	ADJ
ijassa-493	339	218	stages	stage	NOUN
ijassa-493	339	219	of	of	ADP
ijassa-493	339	220	immune	immune	ADJ
ijassa-493	339	221	response	response	NOUN
ijassa-493	339	222	1	1	NUM
ijassa-493	339	223	(	(	PUNCT
ijassa-493	339	224	)	)	PUNCT
ijassa-493	339	225	v	v	NOUN
ijassa-493	339	226	v	v	NUM
ijassa-493	339	227	vn	vn	PROPN
ijassa-493	339	228	t	t	PROPN
ijassa-493	340	1	=	=	NOUN
ijassa-493	340	2	1.3125	1.3125	NUM
ijassa-493	340	3	1	1	NUM
ijassa-493	340	4	(	(	PUNCT
ijassa-493	340	5	)	)	PUNCT
ijassa-493	340	6	n	n	CCONJ
ijassa-493	340	7	n	n	PROPN
ijassa-493	340	8	vn	vn	NOUN
ijassa-493	340	9	t	t	PROPN
ijassa-493	340	10	=	=	SYM
ijassa-493	340	11	1.1458	1.1458	NUM
ijassa-493	340	12	maximal	maximal	ADJ
ijassa-493	340	13	numbers	number	NOUN
ijassa-493	340	14	of	of	ADP
ijassa-493	340	15	infected	infected	ADJ
ijassa-493	340	16	tumor	tumor	NOUN
ijassa-493	340	17	cells	cell	NOUN
ijassa-493	340	18	before	before	ADP
ijassa-493	340	19	the	the	DET
ijassa-493	340	20	start	start	NOUN
ijassa-493	340	21	of	of	ADP
ijassa-493	340	22	the	the	DET
ijassa-493	340	23	1st	1st	NOUN
ijassa-493	340	24	and	and	CCONJ
ijassa-493	340	25	the	the	DET
ijassa-493	340	26	2nd	2nd	ADJ
ijassa-493	340	27	stages	stage	NOUN
ijassa-493	340	28	of	of	ADP
ijassa-493	340	29	immune	immune	ADJ
ijassa-493	340	30	response	response	NOUN
ijassa-493	340	31	2	2	NUM
ijassa-493	340	32	(	(	PUNCT
ijassa-493	340	33	)	)	PUNCT
ijassa-493	340	34	v	v	NOUN
ijassa-493	340	35	v	v	INTJ
ijassa-493	340	36	vn	vn	PROPN
ijassa-493	340	37	t	t	PROPN
ijassa-493	341	1	=	=	PUNCT
ijassa-493	341	2	0.84	0.84	NUM
ijassa-493	341	3	2	2	NUM
ijassa-493	341	4	(	(	PUNCT
ijassa-493	341	5	)	)	PUNCT
ijassa-493	341	6	n	n	CCONJ
ijassa-493	342	1	n	n	PROPN
ijassa-493	342	2	vn	vn	NOUN
ijassa-493	342	3	t	t	NOUN
ijassa-493	343	1	=	=	NOUN
ijassa-493	343	2	0.1031	0.1031	NUM
ijassa-493	343	3	minimal	minimal	ADJ
ijassa-493	343	4	numbers	number	NOUN
ijassa-493	343	5	of	of	ADP
ijassa-493	343	6	infected	infected	ADJ
ijassa-493	343	7	tumor	tumor	NOUN
ijassa-493	343	8	cells	cell	NOUN
ijassa-493	343	9	before	before	ADP
ijassa-493	343	10	the	the	DET
ijassa-493	343	11	end	end	NOUN
ijassa-493	343	12	of	of	ADP
ijassa-493	343	13	the	the	DET
ijassa-493	343	14	1st	1st	NOUN
ijassa-493	343	15	and	and	CCONJ
ijassa-493	343	16	the	the	DET
ijassa-493	343	17	2nd	2nd	ADJ
ijassa-493	343	18	stages	stage	NOUN
ijassa-493	343	19	of	of	ADP
ijassa-493	343	20	immune	immune	ADJ
ijassa-493	343	21	response	response	NOUN
ijassa-493	343	22	1	1	NUM
ijassa-493	343	23	(	(	PUNCT
ijassa-493	343	24	)	)	PUNCT
ijassa-493	343	25	v	v	NOUN
ijassa-493	343	26	v	v	NOUN
ijassa-493	343	27	vn	vn	NOUN
ijassa-493	343	28	t	t	NOUN
ijassa-493	343	29	=	=	NOUN
ijassa-493	343	30	0.472	0.472	NUM
ijassa-493	343	31	,	,	PUNCT
ijassa-493	343	32	1	1	NUM
ijassa-493	343	33	(	(	PUNCT
ijassa-493	343	34	)	)	PUNCT
ijassa-493	343	35	n	n	CCONJ
ijassa-493	343	36	n	n	NUM
ijassa-493	343	37	vn	vn	NOUN
ijassa-493	343	38	t	t	NOUN
ijassa-493	343	39	=	=	NOUN
ijassa-493	343	40	1.043	1.043	NUM
ijassa-493	343	41	number	number	NOUN
ijassa-493	343	42	of	of	ADP
ijassa-493	343	43	dead	dead	ADJ
ijassa-493	343	44	infected	infected	ADJ
ijassa-493	343	45	cells	cell	NOUN
ijassa-493	343	46	at	at	ADP
ijassa-493	343	47	the	the	DET
ijassa-493	343	48	1st	1st	NOUN
ijassa-493	343	49	and	and	CCONJ
ijassa-493	343	50	the	the	DET
ijassa-493	343	51	2nd	2nd	ADJ
ijassa-493	343	52	stages	stage	NOUN
ijassa-493	343	53	of	of	ADP
ijassa-493	343	54	immune	immune	ADJ
ijassa-493	343	55	response	response	NOUN
ijassa-493	343	56	analytical	analytical	ADJ
ijassa-493	343	57	study	study	NOUN
ijassa-493	343	58	of	of	ADP
ijassa-493	343	59	antitumor	antitumor	PROPN
ijassa-493	343	60	viral	viral	ADJ
ijassa-493	343	61	vaccine	vaccine	NOUN
ijassa-493	343	62	77	77	NUM
ijassa-493	343	63	appendix	appendix	NOUN
ijassa-493	343	64	2	2	NUM
ijassa-493	343	65	.	.	PUNCT
ijassa-493	343	66	kinetic	kinetic	ADJ
ijassa-493	343	67	curves	curve	NOUN
ijassa-493	343	68	of	of	ADP
ijassa-493	343	69	tumor	tumor	NOUN
ijassa-493	343	70	growth	growth	NOUN
ijassa-493	343	71	kinetic	kinetic	NOUN
ijassa-493	343	72	curves	curve	NOUN
ijassa-493	343	73	are	be	AUX
ijassa-493	343	74	calculated	calculate	VERB
ijassa-493	343	75	for	for	ADP
ijassa-493	343	76	varying	vary	VERB
ijassa-493	343	77	dosages	dosage	NOUN
ijassa-493	343	78	on	on	ADP
ijassa-493	343	79	two	two	NUM
ijassa-493	343	80	moments	moment	NOUN
ijassa-493	343	81	of	of	ADP
ijassa-493	343	82	introduction	introduction	NOUN
ijassa-493	343	83	:	:	PUNCT
ijassa-493	343	84	1	1	NUM
ijassa-493	343	85	=	=	SYM
ijassa-493	343	86	day	day	NOUN
ijassa-493	343	87	1	1	NUM
ijassa-493	343	88	(	(	PUNCT
ijassa-493	343	89	figures	figure	NOUN
ijassa-493	343	90	(	(	PUNCT
ijassa-493	343	91	a	a	NOUN
ijassa-493	343	92	)	)	PUNCT
ijassa-493	343	93	–	–	PUNCT
ijassa-493	343	94	(	(	PUNCT
ijassa-493	343	95	b	b	NOUN
ijassa-493	343	96	)	)	PUNCT
ijassa-493	343	97	)	)	PUNCT
ijassa-493	343	98	and	and	CCONJ
ijassa-493	343	99	1	1	NUM
ijassa-493	343	100	=	=	SYM
ijassa-493	343	101	day	day	NOUN
ijassa-493	343	102	25	25	NUM
ijassa-493	343	103	(	(	PUNCT
ijassa-493	343	104	figures	figure	NOUN
ijassa-493	343	105	(	(	PUNCT
ijassa-493	343	106	c	c	NOUN
ijassa-493	343	107	)	)	PUNCT
ijassa-493	343	108	–	–	PUNCT
ijassa-493	343	109	(	(	PUNCT
ijassa-493	343	110	d	d	NOUN
ijassa-493	343	111	)	)	PUNCT
ijassa-493	343	112	)	)	PUNCT
ijassa-493	343	113	.	.	PUNCT
ijassa-493	344	1	for	for	ADP
ijassa-493	344	2	each	each	DET
ijassa-493	344	3	dosage	dosage	NOUN
ijassa-493	344	4	,	,	PUNCT
ijassa-493	344	5	figure	figure	NOUN
ijassa-493	344	6	(	(	PUNCT
ijassa-493	344	7	a	a	PRON
ijassa-493	344	8	)	)	PUNCT
ijassa-493	344	9	shows	show	VERB
ijassa-493	344	10	the	the	DET
ijassa-493	344	11	dynamics	dynamic	NOUN
ijassa-493	344	12	of	of	ADP
ijassa-493	344	13	tumor	tumor	NOUN
ijassa-493	344	14	growth	growth	NOUN
ijassa-493	344	15	(	(	PUNCT
ijassa-493	344	16	)	)	PUNCT
ijassa-493	344	17	n	n	CCONJ
ijassa-493	344	18	t	t	NOUN
ijassa-493	344	19	after	after	ADP
ijassa-493	344	20	viral	viral	ADJ
ijassa-493	344	21	vaccine	vaccine	NOUN
ijassa-493	344	22	administration	administration	NOUN
ijassa-493	344	23	(	(	PUNCT
ijassa-493	344	24	dotted	dot	VERB
ijassa-493	344	25	line	line	NOUN
ijassa-493	344	26	denotes	denote	VERB
ijassa-493	344	27	the	the	DET
ijassa-493	344	28	dynamics	dynamic	NOUN
ijassa-493	344	29	of	of	ADP
ijassa-493	344	30	the	the	DET
ijassa-493	344	31	number	number	NOUN
ijassa-493	344	32	of	of	ADP
ijassa-493	344	33	infected	infected	ADJ
ijassa-493	344	34	tumor	tumor	NOUN
ijassa-493	344	35	cells	cell	NOUN
ijassa-493	344	36	(	(	PUNCT
ijassa-493	344	37	)	)	PUNCT
ijassa-493	344	38	vn	vn	PROPN
ijassa-493	344	39	t	t	PROPN
ijassa-493	344	40	)	)	PUNCT
ijassa-493	344	41	,	,	PUNCT
ijassa-493	344	42	figure	figure	NOUN
ijassa-493	344	43	(	(	PUNCT
ijassa-493	344	44	b	b	NOUN
ijassa-493	344	45	)	)	PUNCT
ijassa-493	344	46	shows	show	VERB
ijassa-493	344	47	the	the	DET
ijassa-493	344	48	dynamics	dynamic	NOUN
ijassa-493	344	49	of	of	ADP
ijassa-493	344	50	the	the	DET
ijassa-493	344	51	number	number	NOUN
ijassa-493	344	52	of	of	ADP
ijassa-493	344	53	antibodies	antibody	NOUN
ijassa-493	344	54	(	(	PUNCT
ijassa-493	344	55	)	)	PUNCT
ijassa-493	344	56	va	va	PROPN
ijassa-493	344	57	t	t	PROPN
ijassa-493	344	58	against	against	ADP
ijassa-493	344	59	the	the	DET
ijassa-493	344	60	virus	virus	NOUN
ijassa-493	344	61	(	(	PUNCT
ijassa-493	344	62	red	red	ADJ
ijassa-493	344	63	line	line	NOUN
ijassa-493	344	64	)	)	PUNCT
ijassa-493	344	65	,	,	PUNCT
ijassa-493	344	66	and	and	CCONJ
ijassa-493	344	67	(	(	PUNCT
ijassa-493	344	68	)	)	PUNCT
ijassa-493	344	69	na	na	NOUN
ijassa-493	344	70	t	t	NOUN
ijassa-493	344	71	against	against	ADP
ijassa-493	344	72	infected	infect	VERB
ijassa-493	344	73	tumor	tumor	NOUN
ijassa-493	344	74	cells	cell	NOUN
ijassa-493	344	75	(	(	PUNCT
ijassa-493	344	76	black	black	ADJ
ijassa-493	344	77	line	line	NOUN
ijassa-493	344	78	)	)	PUNCT
ijassa-493	344	79	at	at	ADP
ijassa-493	344	80	two	two	NUM
ijassa-493	344	81	stages	stage	NOUN
ijassa-493	344	82	of	of	ADP
ijassa-493	344	83	the	the	DET
ijassa-493	344	84	immune	immune	ADJ
ijassa-493	344	85	response	response	NOUN
ijassa-493	344	86	.	.	PUNCT
ijassa-493	345	1	dosage	dosage	NOUN
ijassa-493	345	2	0v	0v	NOUN
ijassa-493	345	3	=	=	SYM
ijassa-493	345	4	0,015	0,015	NUM
ijassa-493	345	5	а	а	NOUN
ijassa-493	345	6	)	)	PUNCT
ijassa-493	345	7	c	c	NOUN
ijassa-493	345	8	)	)	PUNCT
ijassa-493	345	9	b	b	NOUN
ijassa-493	345	10	)	)	PUNCT
ijassa-493	345	11	d	d	NOUN
ijassa-493	345	12	)	)	PUNCT
ijassa-493	345	13	78	78	NUM
ijassa-493	345	14	n.a	n.a	PROPN
ijassa-493	345	15	.	.	PROPN
ijassa-493	345	16	babushkina	babushkina	PROPN
ijassa-493	345	17	,	,	PUNCT
ijassa-493	345	18	e.a	e.a	PROPN
ijassa-493	345	19	.	.	PROPN
ijassa-493	345	20	kuzina	kuzina	PROPN
ijassa-493	345	21	dosage	dosage	NOUN
ijassa-493	345	22	0v	0v	NOUN
ijassa-493	345	23	=	=	SYM
ijassa-493	345	24	0,024	0,024	NUM
ijassa-493	345	25	а	а	PROPN
ijassa-493	345	26	)	)	PUNCT
ijassa-493	345	27	c	c	NOUN
ijassa-493	345	28	)	)	PUNCT
ijassa-493	345	29	b	b	NOUN
ijassa-493	345	30	)	)	PUNCT
ijassa-493	345	31	d	d	NOUN
ijassa-493	345	32	)	)	PUNCT
ijassa-493	345	33	analytical	analytical	ADJ
ijassa-493	345	34	study	study	NOUN
ijassa-493	345	35	of	of	ADP
ijassa-493	345	36	antitumor	antitumor	PROPN
ijassa-493	345	37	viral	viral	ADJ
ijassa-493	345	38	vaccine	vaccine	NOUN
ijassa-493	345	39	79	79	NUM
ijassa-493	345	40	dosage	dosage	NOUN
ijassa-493	345	41	0v	0v	NOUN
ijassa-493	345	42	=	=	PROPN
ijassa-493	345	43	0,03	0,03	NUM
ijassa-493	345	44	а	а	PROPN
ijassa-493	345	45	)	)	PUNCT
ijassa-493	345	46	c	c	NOUN
ijassa-493	345	47	)	)	PUNCT
ijassa-493	345	48	b	b	NOUN
ijassa-493	345	49	)	)	PUNCT
ijassa-493	345	50	d	d	NOUN
ijassa-493	345	51	)	)	PUNCT
ijassa-493	345	52	80	80	NUM
ijassa-493	345	53	n.a	n.a	PROPN
ijassa-493	345	54	.	.	PROPN
ijassa-493	345	55	babushkina	babushkina	PROPN
ijassa-493	345	56	,	,	PUNCT
ijassa-493	345	57	e.a	e.a	PROPN
ijassa-493	345	58	.	.	PROPN
ijassa-493	345	59	kuzina	kuzina	PROPN
ijassa-493	345	60	dosage	dosage	NOUN
ijassa-493	345	61	0v	0v	NOUN
ijassa-493	345	62	=	=	PROPN
ijassa-493	345	63	0,04	0,04	NUM
ijassa-493	345	64	а	а	PROPN
ijassa-493	345	65	)	)	PUNCT
ijassa-493	345	66	c	c	NOUN
ijassa-493	345	67	)	)	PUNCT
ijassa-493	345	68	b	b	NOUN
ijassa-493	345	69	)	)	PUNCT
ijassa-493	345	70	d	d	NOUN
ijassa-493	345	71	)	)	PUNCT
ijassa-493	345	72	analytical	analytical	ADJ
ijassa-493	345	73	study	study	NOUN
ijassa-493	345	74	of	of	ADP
ijassa-493	345	75	antitumor	antitumor	PROPN
ijassa-493	345	76	viral	viral	ADJ
ijassa-493	345	77	vaccine	vaccine	NOUN
ijassa-493	345	78	81	81	NUM
ijassa-493	345	79	dosage	dosage	NOUN
ijassa-493	345	80	0v	0v	NOUN
ijassa-493	345	81	=	=	PUNCT
ijassa-493	345	82	0,045	0,045	NUM
ijassa-493	345	83	а	а	NOUN
ijassa-493	345	84	)	)	PUNCT
ijassa-493	345	85	c	c	NOUN
ijassa-493	345	86	)	)	PUNCT
ijassa-493	345	87	b	b	NOUN
ijassa-493	345	88	)	)	PUNCT
ijassa-493	346	1	d	d	NOUN
ijassa-493	346	2	)	)	PUNCT
ijassa-493	346	3	82	82	NUM
ijassa-493	346	4	n.a	n.a	PROPN
ijassa-493	346	5	.	.	PROPN
ijassa-493	346	6	babushkina	babushkina	PROPN
ijassa-493	346	7	,	,	PUNCT
ijassa-493	346	8	e.a	e.a	PROPN
ijassa-493	346	9	.	.	PROPN
ijassa-493	346	10	kuzina	kuzina	PROPN
ijassa-493	346	11	dosage	dosage	NOUN
ijassa-493	346	12	0v	0v	NOUN
ijassa-493	346	13	=	=	SYM
ijassa-493	346	14	0,06	0,06	PROPN
ijassa-493	346	15	а	а	PROPN
ijassa-493	346	16	)	)	PUNCT
ijassa-493	346	17	c	c	NOUN
ijassa-493	346	18	)	)	PUNCT
ijassa-493	346	19	b	b	NOUN
ijassa-493	346	20	)	)	PUNCT
ijassa-493	346	21	d	d	NOUN
ijassa-493	346	22	)	)	PUNCT
ijassa-493	346	23	analytical	analytical	ADJ
ijassa-493	346	24	study	study	NOUN
ijassa-493	346	25	of	of	ADP
ijassa-493	346	26	antitumor	antitumor	PROPN
ijassa-493	346	27	viral	viral	ADJ
ijassa-493	346	28	vaccine	vaccine	NOUN
ijassa-493	346	29	83	83	NUM
ijassa-493	346	30	dosage	dosage	NOUN
ijassa-493	346	31	0v	0v	NOUN
ijassa-493	346	32	=	=	SYM
ijassa-493	346	33	0,075	0,075	NUM
ijassa-493	346	34	а	а	X
ijassa-493	346	35	)	)	PUNCT
ijassa-493	346	36	c	c	NOUN
ijassa-493	346	37	)	)	PUNCT
ijassa-493	346	38	b	b	NOUN
ijassa-493	346	39	)	)	PUNCT
ijassa-493	346	40	d	d	NOUN
ijassa-493	346	41	)	)	PUNCT
ijassa-493	346	42	84	84	NUM
ijassa-493	346	43	n.a	n.a	PROPN
ijassa-493	346	44	.	.	PROPN
ijassa-493	346	45	babushkina	babushkina	PROPN
ijassa-493	346	46	,	,	PUNCT
ijassa-493	346	47	e.a	e.a	PROPN
ijassa-493	346	48	.	.	PROPN
ijassa-493	346	49	kuzina	kuzina	PROPN
ijassa-493	346	50	dosage	dosage	NOUN
ijassa-493	346	51	0v	0v	NOUN
ijassa-493	346	52	=	=	SYM
ijassa-493	346	53	0,1	0,1	NUM
ijassa-493	346	54	а	а	PROPN
ijassa-493	346	55	)	)	PUNCT
ijassa-493	346	56	c	c	NOUN
ijassa-493	346	57	)	)	PUNCT
ijassa-493	346	58	b	b	NOUN
ijassa-493	346	59	)	)	PUNCT
ijassa-493	346	60	d	d	NOUN
ijassa-493	346	61	)	)	PUNCT